Go to
JCI Insight
Citations to this article
Mark Ayers, … , Antoni Ribas, Terrill K. McClanahan
Published June 26, 2017
Citation Information: J Clin Invest. 2017;127(8):2930-2940. https://doi.org/10.1172/JCI91190.
Citation Information: J Clin Invest. 2017;127(8):2930-2940. https://doi.org/10.1172/JCI91190.
Abstract
Programmed death-1–directed (PD-1–directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti–PD-1 therapies, including pembrolizumab. However, whether quantifying T cell–inflamed microenvironment is a useful pan-tumor determinant of PD-1–directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell–inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell–inflamed GEP contained IFN-γ–responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell–inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.
Authors
Mark Ayers, Jared Lunceford, Michael Nebozhyn, Erin Murphy, Andrey Loboda, David R. Kaufman, Andrew Albright, Jonathan D. Cheng, S. Peter Kang, Veena Shankaran, Sarina A. Piha-Paul, Jennifer Yearley, Tanguy Y. Seiwert, Antoni Ribas, Terrill K. McClanahan
Total citations by year
Citation information
Citations to this article (2106)
| Title and authors | Publication | Year |
|---|---|---|
|
A microRNA-regulated transcriptional state defines intratumoral CD8+ T cells that respond to immunotherapy
William Tang, Ben Battistone, Kaylyn Bauer, Allison Weis, Cindy Barba, Muhammad Fadlullah, Arevik Ghazaryan, Van Tran, Soh-Hyun Lee, Busra Agir, Morgan Nelson, Amber Thibeaux, Colton Hernandez, Aik Choon Tan, Dinesh Rao, Matthew Williams, Micah Drummond, Ellen Beswick, June Round, H. Atakan Ekiz, Warren Voth, Ryan O'Connell |
Cell reports | 2025 |
|
A myeloid IFN gamma response gene signature correlates with cancer prognosis
Yuchao Zhang, Asma Khanniche, Yizhe Li, Zhenchuan Wu, Hailong Wang, Hongyu Zhang, Xiaoxue Li, Landian Hu, Xiangyin Kong |
Clinical and translational medicine | 2025 |
|
CBX2 suppresses interferon signaling to diminish tumor immunogenicity via a novel corepressor complex
Yanxun Lin, Huan Jin, Yong She, Yiqun Zhang, Lei Cui, Chunyuan Xie, Yongxiang Liu, Huanling Zhang, Hui Guo, Jiaxin Wu, Lin Li, Zixuan Guo, Xiaojuan Wang, Wu Jiang, Xu Chen, Shuai He, Penghui Zhou, Jing Tan, Jin-Xin Bei, Peng Huang, Jinyun Liu, Yan-Xing Chen, Qi Zhao, Xiaojun Xia, Zining Wang |
Proceedings of the National Academy of Sciences of the United States of America | 2025 |
|
Targeting HMGB2 Acts as Dual Immunomodulator by Bolstering CD8+ T cell Effector Function and Inhibiting Cancer Growth in Hepatocellular Carcinoma
Wei-Feng Qu, Gui-Qi Zhu, Rui Yang, Tian-Hao Chu, Zhi-Qi Guan, Run Huang, Meng-Xin Tian, Xi-Fei Jiang, Chen-Yang Tao, Yuan Fang, Jun Gao, Xiao-Ling Wu, Jia-Feng Chen, Qian-Fu Zhao, Yi wang, Yi-Chao Bu, Jian Zhou, Jia Fan, Wei-Ren Liu, Zheng Tang, Ying-Hong Shi |
Science advances | 2025 |
|
Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge
Tingting Qin, Austin K Mattox, Jean S. Campbell, Jong Chul Park, Kee-Young Shin, Shiting Li, Peter M. Sadow, William Faquin, Goran Micevic, Andrew Daniels, Robert Haddad, Christopher Garris, Mikael Pittet, Thorsten R. Mempel, Anne ONeill, Maureen A Sartor, Sara I. Pai |
Journal of Clinical Investigation | 2025 |
|
Remodelling of the immune landscape by IFNγ counteracts IFNγ-dependent tumour escape in mouse tumour models
Lau VW, Mead GJ, Varyova Z, Mazet JM, Krishnan A, Roberts EW, Prota G, Gileadi U, Midwood KS, Cerundolo V, Gérard A |
Nature Communications | 2025 |
|
Systematic identification of pathological mechanisms, prognostic biomarkers and therapeutic targets by integrating lncRNA expression variation in salivary gland mucoepidermoid carcinoma
Zou YP, Shan XF, Qiu JX, Geng Y, Xie S, Xiang RL, Cai ZG |
Scientific Reports | 2025 |
|
Recurrent and Metastatic Head and Neck Cancer: Mechanisms of Treatment Failure, Treatment Paradigms, and New Horizons
Barham WT, Stagg MP, Mualla R, DiLeo M, Kansara S |
Cancers | 2025 |
|
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
Cesano A, Augustin R, Barrea L, Bedognetti D, Bruno TC, Carturan A, Hammer C, Ho WS, Kather JN, Kirchhoff T, Lu RO, McQuade J, Najjar YG, Pietrobon V, Ruella M, Shen R, Soldati L, Spencer C, Betof Warner A, Warren S, Ziv E, Marincola FM |
Journal for Immunotherapy of Cancer | 2025 |
|
Predictive value of ENLIGHT-DP in patients with metastatic lung adenocarcinoma treated with immune checkpoint inhibitors and platinum chemotherapy directly from histopathology slides using inferred transcriptomics
Arnon J, Dinstag G, Tirosh O, Gugel L, Kinar Y, Gottlieb T, Elia A, Rottenberg Y, Nechushtan H, Tabi M, Blumenfeld P, Pikarsky E, Beker T, Aharonov R, Popovtzer A |
Journal for Immunotherapy of Cancer | 2025 |
|
Radiomics signature for dynamic monitoring of tumor inflamed microenvironment and immunotherapy response prediction
Bernatowicz K, Amat R, Prior O, Frigola J, Ligero M, Grussu F, Zatse C, Serna G, Nuciforo P, Toledo R, Escobar M, Garralda E, Felip E, Perez-Lopez R |
Journal for Immunotherapy of Cancer | 2025 |
|
Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9
Fan T, Xiao C, Deng Z, Li S, Tian H, Zheng Y, Zheng B, Li C, He J |
Respiratory Research | 2025 |
|
Nationwide multi-centric prospective study for the identification of biomarkers to predict the treatment responses of nivolumab through comprehensive analyses of pretreatment plasma exosome mRNAs from head and neck cancer patients (BIONEXT study)
Sato K, Toh S, Murakami T, Nakano T, Hongo T, Matsuo M, Hashimoto K, Sugasawa M, Yamazaki K, Ueki Y, Nakashima T, Uryu H, Ono T, Umeno H, Ueda T, Kano S, Tsukahara K, Watanabe A, Ota I, Monden N, Iwae S, Maruo T, Asada Y, Hanai N, Sano D, Ozawa H, Asakage T, Fukusumi T, Masuda M |
Frontiers in Immunology | 2025 |
|
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial
Dummer R, Robert C, Scolyer RA, Taube JM, Tetzlaff MT, Menzies AM, Hill A, Grob JJ, Portnoy DC, Lebbe C, Khattak MA, Cohen J, Bar-Sela G, Mehmi I, Shapira-Frommer R, Meyer N, Webber AL, Ren Y, Fukunaga-Kalabis M, Krepler C, Long GV |
Nature Medicine | 2025 |
|
Nanostructured lipid carriers based mRNA vaccine leads to a T cell–inflamed tumour microenvironment favourable for improving PD-1/PD-L1 blocking therapy and long-term immunity in a cold tumour model
Fournier C, Mercey-Ressejac M, Derangère V, Al Kadi A, Rageot D, Charrat C, Leroy A, Vollaire J, Josserand V, Escudé M, Escaich S, Ghiringhelli F, Decaens T, Navarro FP, Jouvin-Marche E, Marche PN |
eBioMedicine | 2025 |
|
TBX3 shapes an immunosuppressive microenvironment and induces immunotherapy resistance
Liu Z, Zhang C, Xiao J, He Y, Liang H, Huang J, Cai Z, Yi Z, Chen M, Li Y, Zhang J, liu F, Ren P, Li H, Chen J, Fan B, Hu J, Zu X, Deng D |
Theranostics | 2025 |
|
Artificial intelligence-based spatial analysis of tertiary lymphoid structures and clinical significance for endometrial cancer
Suzuki H, Hamada K, Hamanishi J, Ueda A, Murakami R, Taki M, Mizuno R, Watanabe K, Sato H, Hosoe Y, Ito H, Yamanoi K, Yoshitomi H, Kakiuchi N, Yamaguchi K, Matsumura N, Ogawa S, Ueno H, Mandai M |
Cancer Immunology, Immunotherapy : CII | 2025 |
|
Identification of a novel immunogenic cell death-related classifier to predict prognosis and optimize precision treatment in hepatocellular carcinoma
Zhang D, Lu B, Ma Q, Xu W, Zhang Q, Xiao Z, Li Y, Chen R, Wang AJ |
Heliyon | 2025 |
|
Lysosomal NKG7 restrains mTORC1 activity to promote CD8+ T cell durability and tumor control
Ham H, Hirdler JB, Bihnam DT, Mao Z, Gicobi JK, Macedo BG, Rodriguez-Quevedo MF, Schultz DF, Correia C, Zhong J, Martinez KE, Banuelos A, Ashton DS, Lagnado AB, Guo R, Pessoa R, Pandey A, Li H, Lucien F, Borges da Silva H, Dong H, Billadeau DD |
Nature Communications | 2025 |
|
DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy
Lofiego MF, Tufano R, Bello E, Solmonese L, Marzani F, Piazzini F, Celesti F, Caruso FP, Noviello TM, Mortarini R, Anichini A, Ceccarelli M, Calabrò L, Maio M, Coral S, Di Giacomo AM, Covre A |
Journal of Experimental & Clinical Cancer Research : CR | 2025 |
|
Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses
Turpin R, Peltonen K, Rannikko JH, Liu R, Kumari AN, Nicorici D, Lee MH, Mutka M, Kovanen PE, Niinikoski L, Meretoja T, Mattson J, Järvinen P, Lahdensuo K, Järvinen R, Tornberg S, Mirtti T, Boström P, Koskivuo I, Thotakura A, Pouwels J, Hollmén M, Mustjoki S, Klefström J |
Oncoimmunology | 2025 |
|
Molecular subtyping combined with multiomics analysis to study correlation between TACE refractoriness and tumor stemness in hepatocellular carcinoma
He Q, Xiong Y, Yang X, Yu Y, Chen Z |
Discover Oncology | 2025 |
|
Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation
Sun F, Yao F, Zeng C, Zhao Y, Liang B, Li S, Wang Y, Wu Q, Shi Y, Yao Z, Wang J, Jiang Y, Gu C, Huang Q, Liao W, Huang N, Wang C, Rong X, Wu J, Tan Y, Peng J, Li Y, Shi M |
Journal for Immunotherapy of Cancer | 2025 |
|
Dynamic changes in peripheral blood immunophenotyping and its prognostic value in cervical cancer patients undergoing immune checkpoint blockade therapy
Gong W, Wang Z, Wei Y, Wang M, Li K, Chen X, Huang X, Zhou L, Gan Q, Xu X, Huang Z, Yao H, Wu N, Huang L, Yan B, Zhao B, Yang Z |
Discover Oncology | 2025 |
|
Temporal and spatial composition of the tumor microenvironment predicts response to immune checkpoint inhibition
Greenwald NF, Nederlof I, Sowers C, Ding DY, Park S, Kong A, Houlahan KE, Varra SR, de Graaf M, Geurts V, Liu CC, Ranek JS, Voorwerk L, de Maaker M, Kagel A, McCaffrey E, Khan A, Yeh CY, Fullaway CC, Khair Z, Bai Y, Piyadasa H, Risom T, Delmastro A, Hartmann FJ, Mangiante L, Sotomayor-Vivas C, Schumacher TN, Ma Z, Bosse M, van de Vijver MJ, Tibshirani R, Horlings HM, Curtis C, Kok M, Angelo M |
bioRxiv | 2025 |
|
Candidate approaches for predicting vitiligo recurrence: an effective model and biomarkers
Liu B, Shen J, Li J, Tian B, Zhou B, Gui J, Li Z, Zhang Y, Hu W, Li Q |
Frontiers in Immunology | 2025 |
|
Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It
Zielińska MK, Ciążyńska M, Sulejczak D, Rutkowski P, Czarnecka AM |
Biomolecules | 2025 |
|
Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial
Goswami S, Gao J, Basu S, Shapiro DD, Karam JA, Tidwell RS, Ahrar K, Campbell MT, Shen Y, Trevino AE, Mayer AT, Espejo AB, Seua C, Macaluso MD, Chen Y, Liu W, He Z, Yadav SS, Wang Y, Rao P, Zhao L, Zhang J, Jindal S, Tannir NM, Futreal A, Wang L, Sharma P |
Nature Communications | 2025 |
|
Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts
Boll LM, Vázquez Montes de Oca S, Camarena ME, Castelo R, Bellmunt J, Perera-Bel J, Albà MM |
Nature Communications | 2025 |
|
Senescence-specific molecular subtypes stratify the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
Yan L, Liang H, Qi T, Deng D, Liu J, He Y, Chen J, Fan B, Yao Y, Wang K, Zu X, Chen M, Dai Y, Hu J |
BMC Cancer | 2025 |
|
Hypomethylation of GCNT2 isoform A correlates with transcriptional expression and is associated with poor survival in acute myeloid leukemia
Wu DH, Qiu HC, Xu J, Lin J, Qian J |
Frontiers in Immunology | 2025 |
|
Prognostic and Therapeutic Significance of Cancer‐Associated Fibroblasts Genes in Osteosarcoma Based on Bulk and Single‐Cell RNA Sequencing Data
Que Y, Ding T, Wang H, Xu S, He P, Shen Q, Cao K, Luo Y, Hu Y |
Journal of Cellular and Molecular Medicine | 2025 |
|
Development of a Microvessel Density Gene Signature and Its Application in Precision Medicine
Kuronishi M, Ozawa Y, Kimura T, Li SD, Kato Y |
Cancer Research Communications | 2025 |
|
Preclinical evaluation of an anchored immunotherapy strategy with aluminum hydroxide-tethered interleukin-12 in dogs with advanced malignant melanoma
Barbosa MM, Kamerer RL, Schmit J, Lopez AJ, Uyehara R, Tighe R, Battula S, Kaufman HL, Fan TM |
Molecular cancer therapeutics | 2025 |
|
Ancestral differences in anti-cancer treatment efficacy and their underlying genomic and molecular alterations
Luo M, Yang J, Schäffer AA, Chen C, Liu Y, Chen Y, Lin C, Diao L, Zang Y, Lou Y, Salman H, Mills GB, Ruppin E, Han L |
Cancer discovery | 2025 |
|
Structurally Oriented Classification of FOXA1 Alterations Identifies Prostate Cancers with Opposing Clinical Outcomes and Distinct Molecular and Immunologic Subtypes
Hwang J, Likasitwatanakul P, Deshmukh SK, Wu S, Kwon JJ, Toye E, Moline D, Evans MG, Elliott A, Passow R, Luo C, John E, Gandhi N, McKay RR, Heath EI, Nabhan C, Reizine N, Orme JJ, Domingo Domenech JM, Sartor O, Baca SC, Dehm SM, Antonarakis ES |
Clinical Cancer Research | 2025 |
|
High-dimensional deconstruction of HNSC reveals clinically distinct cellular states and ecosystems that are associated with prognosis and therapy response
Xiao L, Shen Z, Pan Z, Qiu Y, Huang D, Liu Y, Liu C, Zhang X |
Journal of Translational Medicine | 2025 |
|
Immunogenic cell death signature predicts survival and reveals the role of VEGFA + Mast cells in lung adenocarcinoma
Zhang M, Zhou G, Xu Y, Wei B, Liu Q, Zhang G, Chang R |
Scientific Reports | 2025 |
|
Integration of multiple machine learning approaches develops a gene mutation-based classifier for accurate immunotherapy outcomes
Shi R, Sun J, Zhou Z, Shi M, Wang X, Gao Z, Zhao T, Li M, Shu Y |
NPJ Precision Oncology | 2025 |
|
Targeting Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer: Beyond PD-1/PD-L1 Monoclonal Antibodies
Roussot N, Kaderbhai C, Ghiringhelli F |
Cancers | 2025 |
|
The Emerging Role of CD8+ T Cells in Shaping Treatment Outcomes of Patients with MDS and AML
Tasis A, Spyropoulos T, Mitroulis I |
Cancers | 2025 |
|
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
Demir T, Moloney C, Mahalingam D |
Cancers | 2025 |
|
Predicting Survival Rates in Brain Metastases Patients from Non‐Small Cell Lung Cancer Using Radiomic Signatures Associated with Tumor Immune Heterogeneity
Deng F, Xiao G, Tanzhu G, Chu X, Ning J, Lu R, Chen L, Zhang Z, Zhou R |
Advanced Science | 2025 |
|
AI Model for Predicting Anti-PD1 Response in Melanoma Using Multi-Omics Biomarkers
Gschwind A, Ossowski S |
Cancers | 2025 |
|
Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
Cottrell TR, Lotze MT, Ali A, Bifulco CB, Capitini CM, Chow LQ, Cillo AR, Collyar D, Cope L, Deutsch JS, Dubrovsky G, Gnjatic S, Goh D, Halabi S, Kohanbash G, Maecker HT, Maleki Vareki S, Mullin S, Seliger B, Taube J, Vos W, Yeong J, Anderson KG, Bruno TC, Chiuzan C, Diaz-Padilla I, Garrett-Mayer E, Glitza Oliva IC, Grandi P, Hill EG, Hobbs BP, Najjar YG, Pettit Nassi P, Simons VH, Subudhi SK, Sullivan RJ, Takimoto CH |
Journal for Immunotherapy of Cancer | 2025 |
|
Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors
Wawrzyniak P, Hartman ML |
Molecular Cancer | 2025 |
|
Upregulation of RIG‐I is Critical for Responsiveness to IFN‐α Plus Anti‐PD‐1 in Colorectal Cancer
Nie H, Fang S, Zhou R, Jia Y, Zhou J, Ning Y, Yu Y, Hong Y, Xu F, Zhao Q, Nie J, Wang F |
Cancer Medicine | 2025 |
|
Opportunities for Discovery Using Neoadjuvant Immune Checkpoint Blockade in Melanoma
Nair U, Rakestraw E, Beasley GM, O\u2019Connor MH |
International Journal of Molecular Sciences | 2025 |
|
Dynamic Change of PD‐L2 on Circulating Plasma Extracellular Vesicles as a Predictor of Treatment Response in Melanoma Patients Receiving Anti‐PD‐1 Therapy
Sun L, Wei X, Zhao Q, Mao L, Bai X, Li C, Gu J, Kong Y, Cui C, Chi Z, Sheng X, Lian B, Wang X, Li S, Yan X, Tang B, Zhou L, Li J, Guo J, Si L, Dai J |
Journal of Extracellular Vesicles | 2025 |
|
Relative expression orderings based prediction of treatment response to Anti-PD-1 immunotherapy in advanced melanoma
Gao Y, Huo Y, Wang L, Ruan J, Chen L, Li H, Hong G |
Scientific Reports | 2025 |
|
Overview on biomarkers for immune oncology drugs
Imyanitov EN, Preobrazhenskaya EV, Mitiushkina NV |
Exploration of Targeted Anti-tumor Therapy | 2025 |
|
NCBP2 predicts the prognosis and the immunotherapy response of cancers: a pan-cancer analysis
Li S, Wang Y, Yang X, Li M, Li G, Song Q, Liu J |
PeerJ | 2025 |
|
Comprehensive immunophenotyping of gastric adenocarcinoma identifies an inflamed class of tumors amenable to immunotherapies
Veas Rodriguez J, Piñol M, Sorolla MA, Parisi E, Sorolla A, Santacana M, Ruiz M, Parra G, Bernabeu M, Iglesias M, Aracil C, Escartin A, Vilardell F, Matias-Guiu X, Salud A, Montal R |
Journal for Immunotherapy of Cancer | 2025 |
|
CD161, a promising prognostic biomarker in hepatocellular carcinoma, correlates with immune infiltration
Wang J, Wang X, Shi J, Wang Y, Mi L, Zhao M, Han G, Yin F |
PeerJ | 2025 |
|
Novel immune checkpoint inhibitor strategies in advanced non-small cell lung cancer: towards biomarker-driven therapies?
Muntinghe-Wagenaar MB, Hiltermann TJ |
Translational Lung Cancer Research | 2025 |
|
TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinoma
Jin K, Xu J, Zhang L, Liu Z, Su X, Xu Z, Ding Y, Liu H, Chang Y, Xu L, Wang Z, Zhu Y, Xu J |
BMJ Oncology | 2025 |
|
Spatial genomics reveals cholesterol metabolism as a key factor in colorectal cancer immunotherapy resistance
Kavran AJ, Bai Y, Rabe B, Kreshock A, Fisher A, Cheng Y, Lewin A, Dai C, Meyer MJ, Mavrakis KJ, Lyubetskaya A, Drokhlyansky E |
Frontiers in Oncology | 2025 |
|
Dendritic cell maturation in cancer
Moon CY, Belabed M, Park MD, Mattiuz R, Puleston D, Merad M |
Nature reviews. Cancer | 2025 |
|
STAT3/TGFBI signaling promotes the temozolomide resistance of glioblastoma through upregulating glycolysis by inducing cellular senescence
Zhang Y, Xiao X, Yang G, Jiang X, Jiao S, Nie Y, Zhang T |
Cancer Cell International | 2025 |
|
Genome-wide CRISPR/Cas9 screen reveals factors that influence the susceptibility of tumor cells to NK cell-mediated killing
Guia S, Fenis A, Baudesson De Chanville C, Galluso J, Medjouel H, Escaliere B, Modelska A, Vienne M, Lopes N, Pouchin A, Rossi B, Gauthier L, Roulland S, Vivier E, Narni-Mancinelli E |
Journal for Immunotherapy of Cancer | 2025 |
|
Multimodal diagnostic models and subtype analysis for neoadjuvant therapy in breast cancer
Ye Z, Yuan J, Hong D, Xu P, Liu W |
Frontiers in Immunology | 2025 |
|
Unravelling Cancer Immunity: Coagulation.Sig and BIRC2 as Predictive Immunotherapeutic Architects
Yao Z, Fan J, Bai Y, He J, Zhang X, Zhang R, Xue L |
Journal of Cellular and Molecular Medicine | 2025 |
|
Inflammatory reprogramming of the solid tumor microenvironment by infiltrating clonal hematopoiesis is associated with adverse outcomes
Buttigieg MM, Vlasschaert C, Bick AG, Vanner RJ, Rauh MJ |
Cell Reports Medicine | 2025 |
|
Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer
Adams S, Demaria S, Rinchai D, Wang E, Novik Y, Oratz R, Fenton-Kerimian M, Levine PG, Li X, Marincola F, Jin P, Stroncek D, Goldberg J, Bedognetti D, Formenti SC |
Journal for Immunotherapy of Cancer | 2025 |
|
TCGEx: a powerful visual interface for exploring and analyzing cancer gene expression data
Kus ME, Sahin C, Kilic E, Askin A, Ozgur MM, Karahanogullari G, Aksit A, O\u2019Connell RM, Ekiz HA |
EMBO Reports | 2025 |
|
Transcriptomic miRNA and mRNA signatures in primary prostate cancer that are associated with lymph‐node invasion
Bustos MA, Chong KK, Koh Y, Kim S, Ziarnik E, Ramos RI, Jimenez G, Krasne DL, Allen WM, Wilson TG, Hoon DS |
Clinical and Translational Medicine | 2025 |
|
Comprehensive bioinformatics analysis identified HMGB3 as a promising immunotherapy target for glioblastoma multiforme
Wang L, Xu P, Li X, Zhang Q |
Discover Oncology | 2025 |
|
Integrated analysis of molecular and clinical features associated with overall survival in melanoma patients with brain metastasis
Kumar S, Pelster MS, Hasanov M, Guerrieri RA, Hudgens CW, Ledesma DA, Wang F, Fischer GM, Simon JM, Haydu LE, Katlowitz KV, Gopal YN, McQuade JL, Kwong LN, Huse JT, Lazar AJ, Tetzlaff MT, Gershenwald JE, Joon AY, Chen K, Li Z, Ram PT, Ferguson SD, Davies MA |
Acta Neuropathologica Communications | 2025 |
|
Adeno-associated virus-clustered regularly interspaced short palindromic repeats/cas9‑mediated ovarian cancer treatment targeting PD-L1
Yahata T, Toujima S, Sasaki I, Iwahashi N, Fujino M, Nishioka K, Noguchi T, Tanizaki-Horiuchi Y, Kaisho T, Ino K |
BMC Cancer | 2025 |
|
Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal
Morris VK, Liu S, Lin K, Zhu H, Prasad S, Mahvash A, Bhosale P, Sun B, Parra ER, Wistuba I, Peddireddy A, Yao J, Mendoza-Perez J, Knafl M, Woodman SE, Eng C, Halperin D |
Clinical Cancer Research | 2025 |
|
Identification of SURF4 and RALGAPA1 as promising therapeutic targets in glioblastoma and pan-cancer through integrative multi-omics, CRISPR-Cas9 screening and prognostic meta-analysis
Wang F, Chen Y, Huang R, Lu D, Zhang J, Yang Y, Dang H, Liu M, Chen Z, Sun X, Wang Z |
Cancer Immunology, Immunotherapy : CII | 2025 |
|
Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial
Aronson SL, Thijssen B, Lopez-Yurda M, Koole SN, van der Leest P, León-Castillo A, Harkes R, Seignette IM, Sanders J, Alkemade M, Kemper I, Holtkamp MJ, Mandjes IA, Broeks A, Lahaye MJ, Rijlaarsdam MA, van den Broek D, Wessels LF, Horlings HM, van Driel WJ, Sonke GS |
Nature Communications | 2025 |
|
iMLGAM: Integrated Machine Learning and Genetic Algorithm‐driven Multiomics analysis for pan‐cancer immunotherapy response prediction
Ye B, Fan J, Xue L, Zhuang Y, Luo P, Jiang A, Xie J, Li Q, Liang X, Tan J, Zhao S, Zhou W, Ren C, Lin H, Zhang P |
iMeta | 2025 |
|
Integrated radiomics and immune infiltration analysis to decipher immunotherapy efficacy in lung adenocarcinoma
Lei Y, Fan W, Liu B, Liao Y, Liu C, Xue S, Zhou D, Wang H, Zhang Q |
Quantitative Imaging in Medicine and Surgery | 2025 |
|
ATF3 Within the Interferon Signaling Pathway: A Potential Biomarker for Predicting Pathological Response to Neoadjuvant Chemoimmunotherapy
He C, Han R, Zhang T, Zhong P, Huang D, Lu C, Zhang Y, Li J, Deng Y, He Y |
Thoracic Cancer | 2025 |
|
Genetic and transcriptional insights into immune checkpoint blockade response and survival: lessons from melanoma and beyond
Wen J, Wang Y, Wang S, Liang Y, Hu X, Ou Q, Bao H, Zhao K, Wang Y |
Journal of Translational Medicine | 2025 |
|
VDAC2 loss elicits tumour destruction and inflammation for cancer therapy
Yuan S, Sun R, Shi H, Chapman NM, Hu H, Guy C, Rankin S, KC A, Palacios G, Meng X, Sun X, Zhou P, Yang X, Gottschalk S, Chi H |
Nature | 2025 |
|
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach.
Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA |
Nature reviews. Clinical oncology | 2025 |
|
Biomarker-informed care for patients with renal cell carcinoma.
McKinnon MB, Rini BI, Haake SM |
Nature cancer | 2025 |
|
Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
Alsaafeen BH, Ali BR, Elkord E |
Frontiers in Immunology | 2025 |
|
Progress on liposome delivery systems in the treatment of bladder cancer
Guo X, Zhang Y, Liu Q, Xu M, Pang J, Yang B, Rong S, Yang X |
RSC Advances | 2025 |
|
Single-cell and bulk transcriptome sequencing identifies circadian rhythm disruption and cluster-specific clinical insights in colorectal tumorigenesis
Liu C, Liu J, Shao J, Zhao X, Xie L, Shang M, Li Y, Li W |
Discover Oncology | 2025 |
|
PathNetDRP: a novel biomarker discovery framework using pathway and protein–protein interaction networks for immune checkpoint inhibitor response prediction
Lee D, Ahn J, Choi J |
BMC Bioinformatics | 2025 |
|
Novel prognostic biomarkers in small cell lung cancer reveal mutational signatures, genomic mutations, and immune implications
Li Y, Song C, Wang H, Di W, Chen Y, Hu Y, Li P, Chen J, Ren Y, Gong J, Wang Q |
Scientific Reports | 2025 |
|
A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours
Price T, Lugowska I, Chawla SP, Falchook G, Subbiah V, Monzon JG, Arkenau HT, Hui M, Kuboki Y, Dziadziuszko R, Shibaki R, Hong MH, Tan D, Rocha Lima CM, Wang K, Hindoyan A, Shi W, Wong H, Kistler M, Prenen H |
BMJ Open | 2025 |
|
Intratumoral IL12 mRNA administration activates innate and adaptive pathways in checkpoint inhibitor resistant tumors resulting in complete responses
Lakshmipathi J, Santha S, Li M, Qian Y, Roy SF, Luheshi N, Politi K, Bosenberg M, Eyles J, Muthusamy V |
Research Square | 2025 |
|
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
Plummer R, Sodergren MH, Hodgson R, Ryan BM, Raulf N, Nicholls JP, Reebye V, Voutila J, Sinigaglia L, Meyer T, Pinato DJ, Sarker D, Basu B, Blagden S, Cook N, Jeffrey Evans TR, Yachnin J, Chee CE, Li D, El-Khoueiry A, Diab M, Huang KW, Pai M, Spalding D, Talbot T, Noel MS, Keenan B, Mahalingam D, Song MS, Grosso M, Arnaud D, Auguste A, Zacharoulis D, Storkholm J, McNeish I, Habib R, Rossi JJ, Habib NA |
Cell Reports Medicine | 2025 |
|
Multi‑omics analysis identifies different molecular subtypes with unique outcomes in early-stage poorly differentiated lung adenocarcinoma
Liu B, Tao W, Zhou X, Xu LD, Luo Y, Yang X, Min Q, Huang M, Zhu Y, Cui X, Wang Y, Gong T, Zhang E, Huang YS, Chen W, Yan S, Wu N |
Molecular Cancer | 2025 |
|
Systemic rewiring of dendritic cells by melanoma-secreted midkine impairs immune surveillance and response to immune checkpoint blockade.
Catena X, Contreras-Alcalde M, Juan-Larrea N, Cerezo-Wallis D, Calvo TG, Mucientes C, Olmeda D, Suárez J, Oterino-Sogo S, Martínez L, Megías D, Sancho D, Tejedo C, Frago S, Dudziak D, Seretis A, Stoitzner P, Soengas MS |
Nature cancer | 2025 |
|
[Biomarkers in adjuvant and neoadjuvant treatment of melanoma].
Kött J, Gebhardt C |
Dermatologie (Heidelberg, Germany) | 2025 |
|
CD24, NFIL3, FN1, and KLRK1 signature predicts melanoma immunotherapy response and survival.
Sorroche BP, de Jesus Teixeira R, de Souza VG, Tosi IC, Tostes K, Laus AC, Santana IVV, de Lima Vazquez V, Arantes LMRB |
Journal of molecular medicine (Berlin, Germany) | 2025 |
|
Cytokine-mediated regulation of immune cell metabolic pathways in the tumor microenvironment.
Soleimani Mamalo A, Pashaei M, Valilo M, Ojarudi M |
Naunyn-Schmiedeberg's archives of pharmacology | 2025 |
|
Targeting GDF-15 in cancer cachexia and immunity.
Cheng LY, Desai J, Neeson PJ |
Nature medicine | 2025 |
|
Immunogenomic determinants of exceptional response to immune checkpoint inhibition in renal cell carcinoma.
Jammihal T, Saliby RM, Labaki C, Soulati H, Gallegos J, Peris A, McCurry D, Yu C, Shah V, Poduval D, El Zarif T, El Ahmar N, Laimon YN, Eid M, Sheshdeh AB, Krajewski KM, Büttner FA, Schwab M, Heng D, Casellas RC, Rai K, Zacharias Millward NM, Msaouel P, Karam J, Signoretti S, Van Allen E, Choueiri TK, Braun DA, Shukla SA |
Nature cancer | 2025 |
|
Reciprocal Modulation of Tumour and Immune Cell Motility: Uncovering Dynamic Interplays and Therapeutic Approaches.
Aquino A, Franzese O |
Cancers | 2025 |
|
Clinical Applications of the Molecular Landscape of Melanoma: Integration of Research into Diagnostic and Therapeutic Strategies
Szabó IL, Emri G, Ladányi A, Tímár J |
Cancers | 2025 |
|
Macrophage sensitivity to bexmarilimab-induced reprogramming is shaped by the tumor microenvironment
Rannikko JH, Turpin R, Boström P, Virtakoivu R, Harth C, Takeda A, Tamminen A, Koskivuo I, Hollmén M |
Journal for Immunotherapy of Cancer | 2025 |
|
Effect of prior and first-line immunotherapy on baseline immune biomarkers and modulation of the tumor microenvironment in response to nivolumab and relatlimab combination therapy in patients with melanoma from RELATIVITY-020
Ascierto PA, Tang H, Dolfi S, Nyakas M, Marie Svane I, Muñoz-Couselo E, Grob JJ, Gomez-Roca CA, Chiarion-Sileni V, Peltola K, Larkin J, Melero I, Callahan M, Dummer R, Djidel P, Warad D, Reusser-Wolf D, Lipson EJ, Garnett-Benson C |
Journal for Immunotherapy of Cancer | 2025 |
|
Elevated HDAC4 Expression Is Associated with Reduced T-Cell Inflamed Tumor Microenvironment Gene Signatures and Immune Checkpoint Inhibitor Effectiveness in Melanoma
Alamoudi MK, Alsaleh AA, Thyagarajan A, Alkholifi FK, Raza ML, Sahu RP |
Cancers | 2025 |
|
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial.
Luke JJ, Bever K, Hodi FS, Taube J, Massey A, Yao D, Neely J, Tam R, Lee G, Gupta A, Dutta S, Szabo P, Bao R, Reilly T |
Journal for immunotherapy of cancer | 2025 |
|
High-Sensitivity PD-L1 Staining Using Clone 73-10 Antibody and Spatial Transcriptomics for Precise Expression Analysis in Non-Tumorous, Intraepithelial Neoplasia, and Squamous Cell Carcinoma of Head and Neck.
Noda Y, Atsumi N, Nakaya T, Iwai H, Tsuta K |
Head and neck pathology | 2025 |
|
Comprehensive Profiling of Acral Lentiginous Melanoma Reveals Downregulated Immune Activation Compared to Cutaneous Melanoma
Wang SJ, Xiu J, Butcher KM, DeClerck BK, Kim GH, Moser J, Gibney GT, Hernandez\u2010Aya LF, Lutzky J, Abdulla F, Margolin KA, Possik PA, Robles\u2010Espinoza CD, Ito F, In GK |
Pigment Cell & Melanoma Research | 2025 |
|
Recent advances in biomarkers for predicting the efficacy of immunotherapy in non-small cell lung cancer
Zhang J, Song Z, Zhang Y, Zhang C, Xue Q, Zhang G, Tan F |
Frontiers in Immunology | 2025 |
|
Generalizable AI predicts immunotherapy outcomes across cancers and treatments
Shen W, Nguyen TH, Li MM, Huang Y, Moon I, Nair N, Marbach D, Zitnik M |
medRxiv | 2025 |
|
Cross-tissue multicellular coordination and its rewiring in cancer.
Shi Q, Chen Y, Li Y, Qin S, Yang Y, Gao Y, Zhu L, Wang D, Zhang Z |
Nature | 2025 |
|
Ferroptosis-related gene signature-based subtype identification of triple-negative breast cancer to prioritize treatment strategies
Chen Y, Huang X, Wang J, Hu C, Zheng Y, Wang Y, Zheng S, Ji G, You Q |
Frontiers in Oncology | 2025 |
|
Development of a cuproptosis-related prognostic signature to reveal heterogeneity of the immune microenvironment and drug sensitivity in acute lymphoblastic leukemia
Zhang B, Zhu S, Zheng D, Zhang X, Xie W, Zhou S, Zheng S, Wang Q, Lin Z, Zheng Z, Chen Z, Lan E, Cui L, Ying H, Zhang Y, Lin X, Zhuang Q, Qian H, Hu X, Zhuang Y, Zhang Q, Jin Z, Jiang S, Ma Y |
European Journal of Medical Research | 2025 |
|
Co-targeting of VEGFR2 and PD-L1 promotes survival and vasculature normalization in pleural mesothelioma
Rovers S, Van Audenaerde J, Verloy R, De Waele J, Brants L, Hermans C, Lau HW, Merlin C, Möller Ribas M, Ponsaerts P, Van Laere S, Lardon F, Wouters A, Fisher SA, van Meerbeeck J, Marcq E, Smits E |
Oncoimmunology | 2025 |
|
Cell Death and Senescence‐Based Molecular Classification and an Individualized Prediction Model for Lung Adenocarcinoma
Wang P, Zhang C, Wu P, Zhao Z, Sun N, Xue Q, Gao S, He J |
MedComm | 2025 |
|
Basic rules to respond to PD-1 blockade cancer immunotherapy
Ribas A |
Journal for Immunotherapy of Cancer | 2025 |
|
PD-1 and CTLA-4 blockade promote CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer
Elselien Frijlink, Douwe M.T. Bosma, Thomas W. Battaglia, Julia Busselaar, Mo D. Staal, Inge Verbrugge, Jannie Borst |
Journal of Clinical Investigation | 2024 |
|
T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC
Ling Yi, Ziwei Xu, Tianyu Ma, Chong Wang, Panjian Wei, Bo Xiao, Hongtao Zhang, Nanying Che, Zhidong Liu, Yi Han |
Cancer Immunology, Immunotherapy | 2024 |
|
Nilotinib boosts the efficacy of anti-PDL1 therapy in colorectal cancer by restoring the expression of MHC-I
Haiyan Dong, Chuangyu Wen, Lu He, Jingdan Zhang, Nanlin Xiang, Liumei Liang, Limei Hu, Weiqian Li, Jiaqi Liu, Mengchen Shi, Yijia Hu, Siyu Chen, Huanliang Liu, Xiangling Yang |
Journal of Translational Medicine | 2024 |
|
A phase 2 study of spartalizumab (PDR001) among patients with recurrent or metastatic esophageal squamous cell carcinoma (KCSG HN18-17, K-MASTER project 12)
Dong Ki Lee, Sook Ryun Park, Yeul-Hong Kim, Yun-Gyoo Lee, Su-Jin Shin, Beung-Chul Ahn, Sung Sook Lee, Sun Min Lim, Hye Ryun Kim, Byoung Chul Cho, Min-Hee Hong |
OncoImmunology | 2024 |
|
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Ascierto PA, Casula M, Bulgarelli J, Pisano M, Piccinini C, Piccin L, Cossu A, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, Richtig E, Fierro MT, Lebbe C, Helgadottir H, Queirolo P, Spagnolo F, Tucci M, Del Vecchio M, Cao MG, Minisini AM, De Placido S, Sanmamed MF, Mallardo D, Paone M, Vitale MG, Melero I, Grimaldi AM, Giannarelli D, Dummer R, Sileni VC, Palmieri G |
Nature Communications | 2024 |
|
Identification of TTC21A as a Potential Prognostic Marker in Head and Neck Squamous Cell Carcinoma: In Silico Analysis.
Wang L, Yin Y, Liu P, Chen H, Xu M |
Cancer genomics & proteomics | 2024 |
|
Multiomics characterization of pyroptosis in the tumor microenvironment and therapeutic relevance in metastatic melanoma
Chen W, He Y, Zhou G, Chen X, Ye Y, Zhang G, Liu H |
BMC Medicine | 2024 |
|
Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8+ clonal effector and CAR T-cell function while promoting a senescence-associated phenotype
Towers R, Trombello L, Fusenig M, Tunger A, Baumann AL, Savoldelli R, Wehner R, Fasslrinner F, Arndt C, Dazzi F, Von Bonin M, Feldmann A, Bachmann MP, Wobus M, Schmitz M, Bornhäuser M |
Cancer Immunology, Immunotherapy | 2024 |
|
Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.
Verschoor YL, van de Haar J, van den Berg JG, van Sandick JW, Kodach LL, van Dieren JM, Balduzzi S, Grootscholten C, IJsselsteijn ME, Veenhof AAFA, Hartemink KJ, Vollebergh MA, Jurdi A, Sharma S, Spickard E, Owers EC, Bartels-Rutten A, den Hartog P, de Miranda NFCC, van Leerdam ME, Haanen JBAG, Schumacher TN, Voest EE, Chalabi M |
Nature Medicine | 2024 |
|
Development of a stemness-related prognostic index to provide therapeutic strategies for bladder cancer.
Fu S, Tan Z, Shi H, Chen J, Zhang Y, Guo C, Feng W, Xu H, Wang J, Wang H |
npj Precision Oncology | 2024 |
|
Identification and validation of the association of Janus kinase 2 mutations with the response to immune checkpoint inhibitor therapy.
Chen P, Long J, Zhang J, Xie F, Wu W, Tian Z, Zhang S, Yu K |
Inflammation research : official journal of the European Histamine Research Society ... [et al.] | 2024 |
|
LOXL1 promotes tumor cell malignancy and restricts CD8 + T cell infiltration in colorectal cancer
Li C, Chen S, Fang X, Du Y, Guan XY, Lin R, Xu L, Lan P, Yan Q |
Cell Biology and Toxicology | 2024 |
|
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial
Andresen NK, Røssevold AH, Quaghebeur C, Gilje B, Boge B, Gombos A, Falk RS, Mathiesen RR, Julsrud L, Garred Ø, Russnes HG, Lereim RR, Chauhan SK, Lingjærde OC, Dunn C, Naume B, Kyte JA |
Journal for ImmunoTherapy of Cancer | 2024 |
|
Short-course neoadjuvant radiotherapy combined with chemotherapy and toripalimab for locally advanced esophageal squamous cell carcinoma (SCALE-1): a single-arm phase Ib clinical trial
Jiang N, Zhang J, Guo Z, Wu Y, Zhao L, Kong C, Song X, Gu L, Zhao Y, Li S, He X, Ren B, Zhu X, Jiang M |
Journal for ImmunoTherapy of Cancer | 2024 |
|
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
Makker V, Taylor MH, Aghajanian C, Cohn AL, Brose MS, Simone CD, Cao ZA, Suttner L, Loboda A, Cristescu R, Jelinic P, Orlowski R, Dutta L, Matsui J, Dutcus CE, Minoshima Y, Messing MJ |
Journal for ImmunoTherapy of Cancer | 2024 |
|
Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancer
Guler GD, Ning Y, Coruh C, Mognol GP, Phillips T, Nabiyouni M, Hazen K, Scott A, Volkmuth W, Levy S |
Journal for ImmunoTherapy of Cancer | 2024 |
|
NKG2A(+)CD8(+) T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma.
Qiu Y, Liu L, Jiang W, Xu Z, Wang J, Dai S, Guo J, Xu J |
Journal for ImmunoTherapy of Cancer | 2024 |
|
Inhibition of anti-tumor immunity by melanoma cell-derived Activin-A depends on STING
Pinjusic K, Ambrosini G, Lourenco J, Fournier N, Iseli C, Guex N, Egorova O, Nassiri S, Constam DB |
Frontiers in immunology | 2024 |
|
Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
Serafini MS, Cavalieri S, Licitra L, Pistore F, Lenoci D, Canevari S, Airoldi M, Cossu Rocca M, Strojan P, Kuhar CG, Merlano M, Perrone F, Vingiani A, Denaro N, Perri F, Argiris A, Gurizzan C, Ghi MG, Cassano A, Allegrini G, Bossi P, De Cecco L |
Journal for ImmunoTherapy of Cancer | 2024 |
|
Historical perspective and future directions: computational science in immuno-oncology
Ricker CA, Meli K, Van Allen EM |
Journal for ImmunoTherapy of Cancer | 2024 |
|
Tumor characteristics of dissociated response to immune checkpoint inhibition in advanced melanoma
Versluis JM, Hoefsmit EP, Shehwana H, Dimitriadis P, Sanders J, Broeks A, Blank CU |
Cancer Immunology, Immunotherapy | 2024 |
|
Integrating bulk-RNA sequencing and single-cell sequencing analyses to characterize adenosine-enriched tumor microenvironment landscape and develop an adenosine-related prognostic signature predicting immunotherapy in lung adenocarcinoma.
Han T, Wu J, Liu Y, Zhou J, Miao R, Guo J, Xu Z, Xing Y, Bai Y, Hu D, Han T, Wu J, Liu Y, Zhou J, Miao R, Guo J, Xu Z, Xing Y, Bai Y, Hu D |
Functional & Integrative Genomics | 2024 |
|
ARID2 mutations may relay a distinct subset of cutaneous melanoma patients with different outcomes
Akinjiyan FA, Nassief G, Phillipps J, Adeyelu T, Elliott A, Abdulla F, Zhou AY, Souroullas G, Kim KB, Vanderwalde A, Park SJ, Ansstas G |
Scientific Reports | 2024 |
|
Diversity of the immune microenvironment and response to checkpoint inhibitor immunotherapy in mucosal melanoma
Joris Vos, Joleen Traets, Xiaohang Qiao, Iris Seignette, Dennis Peters, Michel Wouters, Erik Hooijberg, Annegien Broeks, Jacqueline van der Wal, M. Baris Karakullukcu, Martin Klop, Arash Navran, Marc Beurden, Oscar Brouwer, Luc Morris, Mariette Poelgeest, Ellen Kapiteijn, John Haanen, Christian Blank, Charlotte Zuur |
JCI insight | 2024 |
|
Interferon-stimulated neutrophils as a predictor of immunotherapy response
Benguigui M, Cooper TJ, Kalkar P, Schif-Zuck S, Halaban R, Bacchiocchi A, Kamer I, Deo A, Manobla B, Menachem R, Haj-Shomaly J, Vorontsova A, Raviv Z, Buxbaum C, Christopoulos P, Bar J, Lotem M, Sznol M, Ariel A, Shen-Orr SS, Shaked Y |
Cancer Cell | 2024 |
|
Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types.
Shen J, Choi YL, Lee T, Kim H, Chae YK, Dulken BW, Bogdan S, Huang M, Fisher GA, Park S, Lee SH, Hwang JE, Chung JH, Kim L, Song H, Pereira S, Shin S, Lim Y, Ahn CH, Kim S, Oum C, Kim S, Park G, Song S, Jung W, Kim S, Bang YJ, Mok TSK, Ali SM, Ock CY |
Journal for ImmunoTherapy of Cancer | 2024 |
|
A robust primary liver cancer subtype related to prognosis and drug response based on a multiple combined classifying strategy.
Deng J, Lai G, Zhang C, Li K, Zhu W, Xie B, Zhong X |
Heliyon | 2024 |
|
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B, Pons-Tostivint E, Park K, Hartl S, Forde PM, Hochmair MJ, Awad MM, Thomas M, Goss G, Wheatley-Price P, Shepherd FA, Florescu M, Cheema P, Chu QSC, Kim SW, Morgensztern D, Johnson ML, Cousin S, Kim DW, Moskovitz MT, Vicente D, Aronson B, Hobson R, Ambrose HJ, Khosla S, Reddy A, Russell DL, Keddar MR, Conway JP, Barrett JC, Dean E, Kumar R, Dressman M, Jewsbury PJ, Iyer S, Barry ST, Cosaert J, Heymach JV |
Nature Medicine | 2024 |
|
Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner.
Tilsed CM, Morales MLO, Zemek RM, Gordon BA, Piggott MJ, Nowak AK, Fisher SA, Lake RA, Lesterhuis WJ |
BMC Cancer | 2024 |
|
Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors.
Zhou W, Yeerkenbieke G, Zhang Y, Zhou M, Li J |
Journal of Cancer Research and Clinical Oncology | 2024 |
|
Comprehensive analysis of single cell and bulk data develops a promising prognostic signature for improving immunotherapy responses in ovarian cancer.
Ding H, Hu B, Guo R |
PloS one | 2024 |
|
Assessment of human leukocyte antigen-based neoantigen presentation to determine pan-cancer response to immunotherapy.
Han J, Dong Y, Zhu X, Reuben A, Zhang J, Xu J, Bai H, Duan J, Wan R, Zhao J, Bai J, Xia X, Yi X, Cheng C, Wang J, Wang Z |
Nature Communications | 2024 |
|
Combined Immunotherapy Improves Outcome for Replication-Repair-Deficient (RRD) High-Grade Glioma Failing Anti-PD-1 Monotherapy: A Report from the International RRD Consortium.
Das A, Fernandez NR, Levine A, Bianchi V, Stengs LK, Chung J, Negm L, Dimayacyac JR, Chang Y, Nobre L, Ercan AB, Sanchez-Ramirez S, Sudhaman S, Edwards M, Larouche V, Samuel D, Van Damme A, Gass D, Ziegler DS, Bielack SS, Koschmann C, Zelcer S, Yalon-Oren M, Campino GA, Sarosiek T, Nichols KE, Loret De Mola R, Bielamowicz K, Sabel M, Frojd CA, Wood MD, Glover JM, Lee YY, Vanan M, Adamski JK, Perreault S, Chamdine O, Hjort MA, Zapotocky M, Carceller F, Wright E, Fedorakova I, Lossos A, Tanaka R, Osborn M, Blumenthal DT, Aronson M, Bartels U, Huang A, Ramaswamy V, Malkin D, Shlien A, Villani A, Dirks PB, Pugh TJ, Getz G, Maruvka YE, Tsang DS, Ertl-Wagner B, Hawkins C, Bouffet E, Morgenstern DA, Tabori U |
Cancer Discovery | 2024 |
|
Soluble immune-checkpoint factors: a potential immunotherapy biomarker
Aaron C. Tan, Sarah L. Cook, Mustafa Khasraw |
Journal of Clinical Investigation | 2024 |
|
Machine learning-based investigation of regulated cell death for predicting prognosis and immunotherapy response in glioma patients
Zhang W, Dang R, Liu H, Dai L, Liu H, Adegboro AA, Zhang Y, Li W, Peng K, Hong J, Li X |
Scientific Reports | 2024 |
|
Converging and evolving immuno-genomic routes toward immune escape in breast cancer.
Blanco-Heredia J, Souza CA, Trincado JL, Gonzalez-Cao M, Gonçalves-Ribeiro S, Gil SR, Pravdyvets D, Cedeño S, Callari M, Marra A, Gazzo AM, Weigelt B, Pareja F, Vougiouklakis T, Jungbluth AA, Rosell R, Brander C, Tresserra F, Reis-Filho JS, Tiezzi DG, de la Iglesia N, Heyn H, De Mattos-Arruda L |
Nature Communications | 2024 |
|
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort
Saeed A, Park R, Pathak H, Al-Bzour AN, Dai J, Phadnis M, Al-Rajabi R, Kasi A, Baranda J, Sun W, Williamson S, Chiu YC, Osmanbeyoglu HU, Madan R, Abushukair H, Mulvaney K, Godwin AK, Saeed A |
Nature Communications | 2024 |
|
Differentially Expressed Genes Involved in Primary Resistance to Immunotherapy in Patients with Advanced-Stage Pulmonary Cancer
Chinchilla-Tábora LM, Montero JC, Corchete LA, González-Morais I, del Barco Morillo E, Olivares-Hernández A, Rodríguez González M, Sayagués JM, Ludeña MD |
International journal of molecular sciences | 2024 |
|
Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers
Meci A, Goyal N, Slonimsky G |
Cancers | 2024 |
|
An integrative pan-cancer bioinformatics analysis of MSRB1 and its association with tumor immune microenvironment, prognosis, and immunotherapy
Jiang S, Yang S, Gao Z, Yin C, Zhang M, Wu Q, Li Y |
Heliyon | 2024 |
|
Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 in head and neck cancer
Basak NP, Jaganathan K, Das B, Muthusamy O, M R, Malhotra R, Samal A, Nath M, MS G, Shankar AP, BV P, Pillai V, BV M, C J, K V, K GS, Govindan S, V S, Juby, R K, Bhowal C, Kumar U, K G, Malhotra M, Sankaran S |
Nature Communications | 2024 |
|
Nasopharyngeal and Peripheral Blood Type II Interferon Signature Evaluation in Infants during Respiratory Syncytial Virus Infection.
Savino F, Dini M, Clemente A, Calvi C, Pau A, Galliano I, Gambarino S, Bergallo M |
2024 | |
|
Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series
Kournoutas I, Monga V, Davick J, Rieth J |
Case reports in oncology | 2024 |
|
When inflammatory stressors dramatically change, disease phenotypes may transform between autoimmune hematopoietic failure and myeloid neoplasms.
Zhao XC, Ju B, Xiu NN, Sun XY, Meng FJ |
Frontiers in immunology | 2024 |
|
Oncolytic alphavirus replicons mediated recruitment and activation of T cells.
Bhatt DK, Meuleman SL, Hoogeboom BN, Daemen T |
iScience | 2024 |
|
Immune microenvironment heterogeneity of concurrent adenocarcinoma and squamous cell carcinoma in multiple primary lung cancers.
Zhang J, Huang Y, Han Y, Dong D, Cao Y, Chen X, Liu D, Cheng X, Sun D, Li H, Zhang Y |
npj Precision Oncology | 2024 |
|
Immune checkpoint inhibitors in metastatic melanoma therapy (Review).
Shah V, Panchal V, Shah A, Vyas B, Agrawal S, Bharadwaj S |
2024 | |
|
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma.
Augustin RC, Luke JJ |
American Journal of Clinical Dermatology | 2024 |
|
Tumor-localized interleukin-2 and interleukin-12 combine with radiation therapy to safely potentiate regression of advanced malignant melanoma in pet dogs.
Stinson JA, Barbosa MMP, Sheen A, Momin N, Fink E, Hampel J, Selting K, Kamerer R, Bailey KL, Wittrup KD, Fan TM |
bioRxiv : the preprint server for biology | 2024 |
|
STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity.
Tan J, Egelston CA, Guo W, Stark JM, Lee PP |
EBioMedicine | 2024 |
|
Increased CD8+ tissue resident memory T cells, regulatory T cells and activated natural killer cells in systemic sclerosis lungs.
Padilla CM, Valenzi E, Tabib T, Nazari B, Sembrat J, Rojas M, Fuschiotti P, Lafyatis R |
Rheumatology (Oxford, England) | 2024 |
|
Identification of a CpG-based signature coupled with gene expression as prognostic indicators for melanoma: a preliminary study.
Lin Z, Yang L |
Scientific Reports | 2024 |
|
Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer.
Wang Y, Yang X, Ma J, Chen S, Gong P, Dai P |
Heliyon | 2024 |
|
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Freyer G, Floquet A, Tredan O, Carrot A, Langlois-Jacques C, Lopez J, Selle F, Abdeddaim C, Leary A, Dubot-Poitelon C, Fabbro M, Gladieff L, Lamuraglia M |
Nature Communications | 2024 |
|
Integrating molecular subtype and CD8(+) T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer.
Li B, Jin K, Liu Z, Su X, Xu Z, Liu G, Xu J, Liu H, Chang Y, Wang Y, Zhu Y, Wang Z, Xu L, Zhang W |
Cancer Immunology, Immunotherapy | 2024 |
|
Risk model based on genes regulating the response of tumor cells to T-cell-mediated killing in esophageal squamous cell carcinoma.
Zhang X, Yu C, Zhou S, Zhang Y, Tian B, Bian Y, Wang W, Lin H, Wang LW |
Aging | 2024 |
|
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.
Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, Pikarsky E, Kudo M, Finn RS |
Nature reviews. Clinical oncology | 2024 |
|
Shifting the paradigm: engaging multicellular networks for cancer therapy
Hu J, Ascierto P, Cesano A, Herrmann V, Marincola FM |
Journal of Translational Medicine | 2024 |
|
Objective analysis and clinical significance of the spatial tumor infiltrating lymphocyte patterns in non-small cell lung cancer.
de Rodas ML, Wang Y, Peng G, Gu J, Mino-Kenudson M, Riess JW, Velcheti V, Hellmann M, Gainor JF, Zhao H, Schalper KA |
Clinical cancer research | 2024 |
|
POLQ identifies a better response subset to immunotherapy in muscle‐invasive bladder cancer with high PD‐L1
Liu G, Jin K, Liu Z, Su X, Xu Z, Li B, Xu J, Chang Y, Wang Y, Zhu Y, Xu L, Xu J, Wang Z, Liu H, Zhang W |
Cancer Medicine | 2024 |
|
Bulk anda single-cell transcriptome profiling reveals the molecular characteristics of T cell-mediated tumor killing in pancreatic cancer
Dai YW, Pan YT, Lin DF, Chen XH, Zhou X, Wang WM |
Heliyon | 2024 |
|
The Use of Immune Regulation in Treating Head and Neck Squamous Cell Carcinoma (HNSCC)
Wang CW, Biswas PK, Islam A, Chen MK, Chueh PJ |
Cells | 2024 |
|
Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma
Błoński PJ, Czarnecka AM, Ostaszewski K, Szumera-Ciećkiewicz A, Rutkowski P |
Biomedicines | 2024 |
|
rs822336 binding to C/EBPβ and NFIC modulates induction of PD-L1 expression and predicts anti-PD-1/PD-L1 therapy in advanced NSCLC
Polcaro G, Liguori L, Manzo V, Chianese A, Donadio G, Caputo A, Scognamiglio G, Dell\u2019Annunziata F, Langella M, Corbi G, Ottaiano A, Cascella M, Perri F, De Marco M, Col JD, Nassa G, Giurato G, Zeppa P, Filippelli A, Franci G, Piaz FD, Conti V, Pepe S, Sabbatino F |
Molecular Cancer | 2024 |
|
PERP May Affect the Prognosis of Lung Adenocarcinoma by Inhibiting Apoptosis
Liu Z, Han S, Luo Y, Zhao Z, Ni L, Chai L, Tang H |
Cancer management and research | 2024 |
|
Non-tumor-related prognostic factors for immunotherapy–chemotherapy or immunotherapy alone as first-line in advanced non-small cell lung cancer (NSCLC)
Guo Z, Wei X, Tang C, Liang J |
Clinical and Experimental Medicine | 2024 |
|
The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial
Hsiehchen D, Beg MS, Kainthla R, Lohrey J, Kazmi SM, Khosama L, Maxwell MC, Kline H, Katz C, Hassan A, Kubota N, Siglinsky E, Pillai AK, Youssoufian H, Mockbee C, Culm K, Uhlik M, Benjamin L, Brekken RA, Ahn C, Singal AG, Zhu H, Hoshida Y, Yopp AC |
Nature Communications | 2024 |
|
PTEN loss in glioma cell lines leads to increased extracellular vesicles biogenesis and PD-L1 cargo in a PI3K-dependent manner
Sanchez JC, Pierpont TM, Argueta-Zamora D, Wilson K, August A, Cerione RA |
2024 | |
|
Machine learning framework develops neutrophil extracellular traps model for clinical outcome and immunotherapy response in lung adenocarcinoma.
Han AX, Long BY, Li CY, Huang DD, Xiong EQ, Li FJ, Wu GL, Liu Q, Yang GB, Hu HY |
Apoptosis : an international journal on programmed cell death | 2024 |
|
Integrating transcriptomics and machine learning for immunotherapy assessment in colorectal cancer.
Xiang J, Liu S, Chang Z, Li J, Liu Y, Wang H, Zhang H, Wang C, Yu L, Tang Q, Wang G |
Cell Death Discovery | 2024 |
|
Multi-omics and artificial intelligence predict clinical outcomes of immunotherapy in non-small cell lung cancer patients.
Mei T, Wang T, Zhou Q |
Clinical and Experimental Medicine | 2024 |
|
Pan-cancer evaluation of regulated cell death to predict overall survival and immune checkpoint inhibitor response.
Zhang W, Zhu Y, Liu H, Zhang Y, Liu H, Adegboro AA, Dang R, Dai L, Wanggou S, Li X |
npj Precision Oncology | 2024 |
|
Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy.
Chen JH, Nieman LT, Spurrell M, Jorgji V, Elmelech L, Richieri P, Xu KH, Madhu R, Parikh M, Zamora I, Mehta A, Nabel CS, Freeman SS, Pirl JD, Lu C, Meador CB, Barth JL, Sakhi M, Tang AL, Sarkizova S, Price C, Fernandez NF, Emanuel G, He J, Van Raay K, Reeves JW, Yizhak K, Hofree M, Shih A, Sade-Feldman M, Boland GM, Pelka K, Aryee MJ, Mino-Kenudson M, Gainor JF, Korsunsky I, Hacohen N |
Nature Immunology | 2024 |
|
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
Chénard-Poirier M, Hansen AR, Gutierrez ME, Rasco D, Xing Y, Chen LC, Zhou H, Webber AL, Freshwater T, Sharma MR |
Investigational New Drugs | 2024 |
|
Discovery of a novel ROS-based signature for predicting prognosis and immunosuppressive tumor microenvironment in lung adenocarcinoma
Guo Y, Chang G, Wan R, Zhang X, Ma Z, Bai H, Wang J |
Journal of Cancer | 2024 |
|
BCG as an Innovative Option for HCC Treatment: Repurposing and Mechanistic Insights
Vaziri F, Setayesh T, Hu Y, Ravindran R, Wei D, Wan YY |
Advanced Science | 2024 |
|
Strategies for improving the performance of prediction models for response to immune checkpoint blockade therapy in cancer
Zeng T, Zhang JZ, Stromberg A, Chen J, Wang C |
BMC Research Notes | 2024 |
|
Molecular patterns of resistance to immune checkpoint blockade in melanoma
Lauss M, Phung B, Borch TH, Harbst K, Kaminska K, Ebbesson A, Hedenfalk I, Yuan J, Nielsen K, Ingvar C, Carneiro A, Isaksson K, Pietras K, Svane IM, Donia M, Jönsson G |
Nature Communications | 2024 |
|
Non-invasive prediction for pathologic complete response to neoadjuvant chemoimmunotherapy in lung cancer using CT-based deep learning: a multicenter study
Qu W, Chen C, Cai C, Gong M, Luo Q, Song Y, Yang M, Shi M |
Frontiers in immunology | 2024 |
|
Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma
Bai X, Attrill GH, Gide TN, Ferguson PM, Nahar KJ, Shang P, Vergara IA, Palendira U, da Silva IP, Carlino MS, Menzies AM, Long GV, Scolyer RA, Wilmott JS, Quek C |
Nature Communications | 2024 |
|
Gene features of tumor-specific T cells relevant to immunotherapy, targeted therapy and chemotherapy in lung cancer
Luo Z, Liu X, Chen Y, Shen L, Qin H, Zha Q, Hu F, Wang Y |
Heliyon | 2024 |
|
Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma
Makawita S, Lee S, Kong E, Kwong LN, Abouelfetouh Z, Danner De Armas A, Xiao L, Murugesan K, Danziger N, Pavlick D, Korkut A, Ross JS, Javle M |
JCO Precision Oncology | 2024 |
|
Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio: Markers predicting immune-checkpoint inhibitor efficacy and immune-related adverse events
Jiang QY, Xue RY |
World journal of gastrointestinal oncology | 2024 |
|
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications.
Xiao T, Lee J, Gauntner TD, Velegraki M, Lathia JD, Li Z |
Nature reviews. Cancer | 2024 |
|
Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer.
Hosseinzadeh S, Imani M, Pourfarzi F, Jafari N, AbedianKenari S, Safarzadeh E |
Medical Oncology | 2024 |
|
Integration of CD4(+) T cells and molecular subtype predicts benefit from PD-L1 blockade in muscle-invasive bladder cancer.
Liu G, Jin K, Liu Z, Su X, Xu Z, Li B, Xu J, Liu H, Chang Y, Zhu Y, Xu L, Wang Z, Wang Y, Zhang W |
Cancer Science | 2024 |
|
Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events?
Riondino S, Rosenfeld R, Formica V, Morelli C, Parisi G, Torino F, Mariotti S, Roselli M |
Cancers | 2024 |
|
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.
Liefaard MC, van der Voort A, van Seijen M, Thijssen B, Sanders J, Vonk S, Mittempergher L, Bhaskaran R, de Munck L, van Leeuwen-Stok AE, Salgado R, Horlings HM, Lips EH, Sonke GS |
npj Breast Cancer | 2024 |
|
Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility.
Leonard-Murali S, Bhaskarla C, Yadav GS, Maurya SK, Galiveti CR, Tobin JA, Kann RJ, Ashwat E, Murphy PS, Chakka AB, Soman V, Cantalupo PG, Zhuo X, Vyas G, Kozak DL, Kelly LM, Smith E, Chandran UR, Hsu YS, Kammula US |
Nature Communications | 2024 |
|
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma.
Aggen DH, Rosenberg JE |
Nature reviews. Clinical oncology | 2024 |
|
Clinicopathologic characteristics of HPV-associated head and neck squamous cell carcinoma in Southern China: long-term retrospective study of 400 cases.
Du M, Lin Q, Yan S, Gao X, Yang C, Li Z, Liao W, Yang A, Chen S |
Therapeutic advances in medical oncology | 2024 |
|
Integrative analysis of single-cell and bulk transcriptome data reveal the significant role of macrophages in lupus nephritis.
Wei S, Shen H, Zhang Y, Liu C, Li S, Yao J, Jin Z, Yu H |
Arthritis Research & Therapy | 2024 |
|
Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in Hepatocellular Carcinoma.
Liu X, Zhang K, Kaya NA, Jia Z, Wu D, Chen T, Liu Z, Zhu S, Hillmer AM, Wuestefeld T, Liu J, Chan YS, Hu Z, Ma L, Jiang L, Zhai W |
Nature Communications | 2024 |
|
Identification of tumor heterogeneity associated with KRAS/TP53 co-mutation status in lung adenocarcinoma based on single-cell RNA sequencing.
Ye YH, Zhang YT, Luo YL, Xu AP, Ji L |
American journal of cancer research | 2024 |
|
CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer
Lim RJ, Salehi-Rad R, Tran LM, Oh MS, Dumitras C, Crosson WP, Li R, Patel TS, Man S, Yean CE, Abascal J, Huang Z, Ong SL, Krysan K, Dubinett SM, Liu B |
Cell reports. Medicine | 2024 |
|
Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses
Tian J, Quek C |
International journal of molecular sciences | 2024 |
|
Subtyping of triple-negative breast cancers: its prognostication and implications in diagnosis of breast origin.
Hu H, Tong K, Tsang JY, Ko CW, Tam F, Loong TC, Tse GM |
ESMO Open | 2024 |
|
Early Immune Remodeling Steers Clinical Response to First-Line Chemoimmunotherapy in Advanced Gastric Cancer.
An M, Mehta A, Min BH, Heo YJ, Wright SJ, Parikh M, Bi L, Lee H, Kim TJ, Lee SY, Moon J, Park RJ, Strickland MR, Park WY, Kang WK, Kim KM, Kim ST, Klempner SJ, Lee J |
Cancer Discovery | 2024 |
|
A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101)
Lakhani N, Cosman R, Banerji U, Rasco D, Tomaszewska-Kiecana M, Garralda E, Kornacki D, Li J, Tian C, Bourayou N, Powderly J |
ESMO Open | 2024 |
|
KRAS Allelic Variants in Biliary Tract Cancers
Moffat GT, Hu ZI, Meric-Bernstam F, Kong EK, Pavlick D, Ross JS, Murugesan K, Kwong L, De Armas AD, Korkut A, Javle M, Knox JJ |
2024 | |
|
PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD‐1 blockade
De Wispelaere W, Annibali D, Tuyaerts S, Messiaen J, Antoranz A, Shankar G, Dubroja N, Herreros\u2010Pomares A, Baiden\u2010Amissah RE, Orban M, Delfini M, Berardi E, Van Brussel T, Schepers R, Philips G, Boeckx B, Baietti MF, Congedo L, HoWangYin KY, Bayon E, Van Rompuy A, Leucci E, Tabruyn SP, Bosisio F, Mazzone M, Lambrechts D, Amant F |
Clinical and Translational Medicine | 2024 |
|
BAP1 Deficiency Inflames the Tumor Immune Microenvironment and Is a Candidate Biomarker for Immunotherapy Response in Malignant Pleural Mesothelioma
Xu D, Gao Y, Yang H, Spils M, Marti TM, Losmanová T, Su M, Wang W, Zhou Q, Dorn P, Shu Y, Peng RW |
2024 | |
|
Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer
Lautert-Dutra W, M. Melo C, Chaves LP, Crozier C, P. Saggioro F, B. dos Reis R, Bayani J, Bonatto SL, Squire JA |
Molecular cytogenetics | 2024 |
|
Molecular characterization of the evolution of premalignant lesions in the upper aerodigestive tract
Lechner A, Kumbrink J, Walz C, Jung A, Baumeister P, Flach S |
Frontiers in Oncology | 2024 |
|
Predictability of B cell clonal persistence and immunosurveillance in breast cancer
Sammut SJ, Galson JD, Minter R, Sun B, Chin SF, De Mattos-Arruda L, Finch DK, Schätzle S, Dias J, Rueda OM, Seoane J, Osbourn J, Caldas C, Bashford-Rogers RJ |
Nature Immunology | 2024 |
|
Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non‐small cell lung cancer
Zhao J, Zhuang W, Sun B, Bai H, Wang Z, Zhong J, Wan R, Liu L, Duan J, Wang J |
Thoracic Cancer | 2024 |
|
Facts and hopes in using omics to advance combined immunotherapy strategies
Augustin RC, Cai WL, Luke JJ, Bao R |
Clinical cancer research | 2024 |
|
Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma
Versluis JM, Blankenstein SA, Dimitriadis P, Wilmott JS, Elens R, Blokx WA, van Houdt W, Menzies AM, Schrage YM, Wouters MW, Sanders J, Broeks A, Scolyer RA, Suijkerbuijk KP, Long GV, van Akkooi AC, Blank CU |
Journal for ImmunoTherapy of Cancer | 2024 |
|
A Retrospective Review and Comprehensive Tumour Profiling of Advanced Non-Melanomatous Cutaneous Spindle Cell Neoplasms Treated with Immune-Checkpoint Inhibitors
McLean LS, Lim AM, Angel C, Young RJ, Pizzolla A, Archer S, Solomon BJ, Thai AA, Lewin J, Rischin D |
Cancers | 2024 |
|
A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations
Rodon J, Rodriguez E, Maitland ML, Tsai FY, Socinski MA, Berlin JD, Thomas JS, Al Baghdadi T, Wang IM, Guo C, Golmakani M, Clark LN, Gazdoiu M, Li M, Tolcher AW |
ESMO Open | 2024 |
|
Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication
Chen D, Liu P, Lu X, Li J, Qi D, Zang L, Lin J, Liu Y, Zhai S, Fu D, Weng Y, Li H, Shen B |
Journal of experimental & clinical cancer research : CR | 2024 |
|
Tumor-agnostic transcriptome-based classifier identifies spatial infiltration patterns of CD8+T cells in the tumor microenvironment and predicts clinical outcome in early-phase and late-phase clinical trials
Roller A, Davydov II, Schwalie PC, Serrano-Serrano ML, Heller A, Staedler N, Ferreira CS, Dietmann G, Klaman I, Valdeolivas A, Korski K, Cannarile MA |
Journal for ImmunoTherapy of Cancer | 2024 |
|
Deciphering the heterogeneity dominated by tumor-associated macrophages for survival prognostication and prediction of immunotherapy response in lung adenocarcinoma
Sun J, Guo H, Nie Y, Zhou S, Zeng Y, Sun Y |
Scientific Reports | 2024 |
|
Clustering of HR + /HER2− breast cancer in an Asian cohort is driven by immune phenotypes
Pan JW, Ragu M, Chan WQ, Hasan SN, Islam T, Teoh LY, Jamaris S, See MH, Yip CH, Rajadurai P, Looi LM, Taib NA, Rueda OM, Caldas C, Chin SF, Lim J, Teo SH |
Breast Cancer Research | 2024 |
|
Single-cell RNA-seq reveals T cell exhaustion and immune response landscape in osteosarcoma
Fan Q, Wang Y, Cheng J, Pan B, Zang X, Liu R, Deng Y |
Frontiers in immunology | 2024 |
|
NK cell transfer overcomes resistance to PD-(L)1 therapy in aged mice.
Hou J, Xie S, Gao J, Jiang T, Zhu E, Yang X, Jin Z, Long H, Zhang A, Yang F, Wang L, Zha H, Jia Q, Zhu B, Wang X |
Experimental Hematology and Oncology | 2024 |
|
Therapeutic Targeting of DNA Repair Pathways in Pediatric Extracranial Solid Tumors: Current State and Implications for Immunotherapy.
Zhao SJ, Prior D, Heske CM, Vasquez JC |
Cancers | 2024 |
|
Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy
Verner JM, Arbuthnott HF, Ramachandran R, Bharadwaj M, Chaudhury N, Jou E |
2024 | |
|
IFN-α/β/IFN-γ/IL-15 pathways identify GBP1-expressing tumors with an immune-responsive phenotype
Wang L, Wei Y, Jin Z, Liu F, Li X, Zhang X, Bai X, Jia Q, Zhu B, Chu Q |
Clinical and Experimental Medicine | 2024 |
|
HLA-A(+) tertiary lymphoid structures with reactivated tumor infiltrating lymphocytes are associated with a positive immunotherapy response in esophageal squamous cell carcinoma.
Zhang D, Jiang D, Jiang L, Ma J, Wang X, Xu X, Chen Z, Jiang M, Ye W, Wang J, Meng W, Qiu W, Hou Y, Huang J, Jiao Y, Liu Y, Liu Z |
British Journal of Cancer | 2024 |
|
Immune profiling of dedifferentiated liposarcoma and identification of novel antigens for targeted immunotherapy.
Jirovec A, Flaman A, Godbout E, Serrano D, Werier J, Purgina B, Diallo JS |
Scientific Reports | 2024 |
|
Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM, Notohardjo JCL, de Joode K, Velker EL, Haanen JBAG, Suijkerbuijk KPM, Aarts MJB, de Groot JWB, Kapiteijn E, van den Berkmortel FWPJ, Westgeest HM, de Gruijl TD, Retel VP, Cuppen E, van der Veldt AAM, Labots M, Voest EE, van de Haar J, van den Eertwegh AJM |
Scientific Reports | 2024 |
|
Molecular features and prognostic factors of locally advanced microsatellite instability-high gastric cancer.
Furukawa K, Hatakeyama K, Terashima M, Urakami K, Koseki Y, Fujiya K, Tanizawa Y, Bando E, Yamaguchi K |
2024 | |
|
PCDH11X mutation as a potential biomarker for immune checkpoint therapies in lung adenocarcinoma.
Liu M, Yang M, Zhang B, Xia S, Zhao J, Yan L, Ren Y, Guo H, Zhao J |
Journal of Molecular Medicine | 2024 |
|
Kinetics of IFNγ-Induced Cytokines and Development of Immune-Related Adverse Events in Patients Receiving PD-(L)1 Inhibitors.
Alserawan L, Mulet M, Anguera G, Riudavets M, Zamora C, Osuna-Gómez R, Serra-López J, Barba Joaquín A, Sullivan I, Majem M, Vidal S |
Cancers | 2024 |
|
An investigation of the clinical impact and therapeutic relevance of a DNA damage immune response (DDIR) signature in patients with advanced gastroesophageal adenocarcinoma
Baxter MA, Spender LC, Cairns D, Walsh S, Oparka R, Porter RJ, Bray S, Skinner G, King S, Turbitt J, Collinson D, Miedzybrodzka ZH, Jellema G, Logan G, Kennedy RD, Turkington RC, McLean MH, Swinson D, Grabsch HI, Lord S, Seymour MJ, Hall PS, Petty RD |
ESMO Open | 2024 |
|
Multi-omics analysis for ferroptosis-related genes as prognostic factors in cutaneous melanoma
|
2024 | |
|
Challenges and opportunities in the immunotherapy era: balancing expectations with hope in small-cell lung cancer
Khan R, Coleman N |
Therapeutic advances in medical oncology | 2024 |
|
DRG2 is required for surface localization of PD-L1 and the efficacy of anti-PD-1 therapy
Choi SH, Mani M, Kim J, Cho WJ, Martin TF, Kim JH, Chu HS, Jeong WJ, Won YW, Lee BJ, Ahn B, Kim J, Jeon DY, Park JW |
Cell Death Discovery | 2024 |
|
SLC7A5 correlated with malignancies and immunotherapy response in bladder cancer
Zhang C, Wang Y, Guo X, Wang Z, Xiao J, Liu Z |
Cancer Cell International | 2024 |
|
Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer
Beckabir W, Zhou M, Lee JS, Vensko SP, Woodcock MG, Wang HH, Wobker SE, Atassi G, Wilkinson AD, Fowler K, Flick LM, Damrauer JS, Harrison MR, McKinnon KP, Rose TL, Milowsky MI, Serody JS, Kim WY, Vincent BG |
Nature Communications | 2024 |
|
Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications
Ho M, Bonavida B |
Cells | 2024 |
|
Metabolic pathway-based subtypes associate glycan biosynthesis and treatment response in head and neck cancer
Dankó B, Hess J, Unger K, Samaga D, Walz C, Walch A, Sun N, Baumeister P, Zeng PY, Walter F, Marschner S, Späth R, Gires O, Herkommer T, Dazeh R, Matos T, Kreutzer L, Matschke J, Eul K, Klauschen F, Pflugradt U, Canis M, Ganswindt U, Mymryk JS, Wollenberg B, Nichols AC, Belka C, Zitzelsberger H, Lauber K, Selmansberger M |
npj Precision Oncology | 2024 |
|
Machine learning-based integration develops an immunogenic cell death-derived lncRNA signature for predicting prognosis and immunotherapy response in lung adenocarcinoma
Sun J, Guo H, Zhang S, Nie Y, Zhou S, Zeng Y, Sun Y |
Scientific Reports | 2024 |
|
Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response.
Li S, Zhao J, Wang G, Yao Q, Leng Z, Liu Q, Jiang J, Wang W |
Archives of Dermatological Research | 2024 |
|
Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
Xie M, Vuko M, Rodriguez-Canales J, Zimmermann J, Schick M, O'Brien C, Paz-Ares L, Goldman JW, Garassino MC, Gay CM, Heymach JV, Jiang H, Barrett JC, Stewart RA, Lai Z, Byers LA, Rudin CM, Shrestha Y |
Molecular Cancer | 2024 |
|
Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineages.
Hu YM, Zhao F, Graff JN, Chen C, Zhao X, Thomas GV, Wu H, Kardosh A, Mills GB, Alumkal JJ, Moran AE, Xia Z |
bioRxiv : the preprint server for biology | 2024 |
|
Unleashing Natural IL18 Activity Using an Anti-IL18BP Blocker Induces Potent Immune Stimulation and Antitumor Effects
Menachem A, Alteber Z, Cojocaru G, Fridman Kfir T, Blat D, Leiderman O, Galperin M, Sever L, Cohen N, Cohen K, Granit RZ, Vols S, Frenkel M, Soffer L, Meyer K, Menachem K, Galon Tilleman H, Morein D, Borukhov I, Toporik A, Perpinial Shahor M, Tatirovsky E, Mizrachi A, Levy-Barda A, Sadot E, Strenov Y, Eitan R, Jakobson-Setton A, Yanichkin N, Ferre P, Ophir E |
Cancer immunology research | 2024 |
|
The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers
Seema Mustafa, Jansen CS, Jani Y, Evans S, Zhuang TZ, Brown J, Nazha B, Master V, Bilen MA |
Biomarker insights | 2024 |
|
The combination of tumor mutational burden and T‐cell receptor repertoire predicts the response to immunotherapy in patients with advanced non–small cell lung cancer
Li Y, Ji L, Zhang Y, Zhang J, Reuben A, Zeng H, Huang Q, Wei Q, Tan S, Xia X, Li W, Zhang J, Tian P |
2024 | |
|
DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers
Pineda JM, Bradley RK |
eLife | 2024 |
|
Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis
Chen Y, Han H, Cheng J, Cheng Q, Zhu S, Zhan P, Liu H, Song Y, Lv T |
Cancer Immunology, Immunotherapy | 2024 |
|
The role of CD4+ T cells in visceral leishmaniasis; new and emerging roles for NKG7 and TGFβ
Na J, Engwerda C |
Frontiers in Cellular and Infection Microbiology | 2024 |
|
IFIT1 + neutrophil is a causative factor of immunosuppressive features of poorly cohesive carcinoma (PCC)
Liu YJ, Li JP, Han M, Li JX, Ye QW, Lin ST, Zhou JY, Liu SL, Zou X |
Journal of Translational Medicine | 2024 |
|
Pan‐Cancer Single‐Cell and Spatial‐Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy
Liu C, Xie J, Lin B, Tian W, Wu Y, Xin S, Hong L, Li X, Liu L, Jin Y, Tang H, Deng X, Zou Y, Zheng S, Fang W, Cheng J, Dai X, Bao X, Zhao P |
Advanced Science | 2024 |
|
Tumor-Infiltrating T Cells in Skin Basal Cell Carcinomas and Squamous Cell Carcinomas: Global Th1 Preponderance with Th17 Enrichment—A Cross-Sectional Study
Cunha D, Neves M, Silva D, Silvestre AR, Nunes PB, Arrobas F, Ribot JC, Ferreira F, Moita LF, Soares-de-Almeida L, Silva JM, Filipe P, Ferreira J |
Cells | 2024 |
|
Protein tyrosine phosphatases: emerging role in cancer therapy resistance
Zhao M, Shuai W, Su Z, Xu P, Wang A, Sun Q, Wang G |
2024 | |
|
Comprehensive pan‐cancer analysis of mitochondrial outer membrane permeabilisation activity reveals positive immunomodulation and assists in identifying potential therapeutic targets for immunotherapy resistance
Chen Q, Gao F, Wu J, Zhang K, Du T, Chen Y, Cai R, Zhao D, Deng R, Tang J |
Clinical and Translational Medicine | 2024 |
|
Targeting SUMOylation with an injectable nanocomposite hydrogel to optimize radiofrequency ablation therapy for hepatocellular carcinoma
Liu J, Li X, Chen J, Guo J, Guo H, Zhang X, Fan J, Zhang K, Mao J, Zhou B |
Journal of nanobiotechnology | 2024 |
|
IL4I1: a novel molecular biomarker represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer
Peng X, Liu C, Zhang L, Chen Y, Mao L, Gao S, Shi X, Zuo L |
Frontiers in pharmacology | 2024 |
|
Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients
Dalle S, Verronese E, N\u2019Kodia A, Bardin C, Rodriguez C, Andrieu T, Eberhardt A, Chemin G, Hasan U, Le-Bouar M, Caramel J, Amini-Adle M, Bendriss-Vermare N, Dubois B, Caux C, Ménétrier-Caux C |
OncoImmunology | 2024 |
|
Chemokines and Cytokines in Immunotherapy of Melanoma and Other Tumors: From Biomarkers to Therapeutic Targets
Reschke R, Enk AH, Hassel JC |
International journal of molecular sciences | 2024 |
|
The impact of CDCA5 expression on the immune microenvironment and its potential utility as a biomarker for PD-L1/PD-1 inhibitors in lung adenocarcinoma
Koh YW, Hwang Y, Lee SK, Han JH, Haam S, Lee HW |
Translational oncology | 2024 |
|
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With Chemotherapy
Geurts VC, Balduzzi S, Steenbruggen TG, Linn SC, Siesling S, Badve SS, DeMichele A, Ignatiadis M, Leon-Ferre RA, Goetz MP, Wolff AC, Klar N, Michiels S, Loi S, Adams S, Horlings HM, Sonke GS, Salgado R, Kok M |
JAMA Oncology | 2024 |
|
Transcriptome Deconvolution Reveals Absence of Cancer Cell Expression Signature in Immune Checkpoint Blockade Response
Guo YA, Kulshrestha T, Chang MM, Kassam I, Revkov E, Rizzetto S, Tan AC, Tan DS, Tan IB, Skanderup AJ |
Cancer research communications | 2024 |
|
Activation of CD14+ Monocytes via the IFN-γ Signaling Pathway Is Associated with Immune-Related Adverse Events in Hepatocellular Carcinoma Patients Receiving PD-1 Inhibition Combination Therapy
Song Y, Pan S, Tian J, Yu Y, Wang S, Qiu Q, Shen Y, Yang L, Liu X, Luan J, Wang Y, Wang J, Fan X, Meng F, Wang FS |
Biomedicines | 2024 |
|
Immuno-oncologic profiling of pediatric brain tumors reveals major clinical significance of the tumor immune microenvironment
Levine AB, Nobre L, Das A, Milos S, Bianchi V, Johnson M, Fernandez NR, Stengs L, Ryall S, Ku M, Rana M, Laxer B, Sheth J, Sbergio SG, Fedoráková I, Ramaswamy V, Bennett J, Siddaway R, Tabori U, Hawkins C |
Nature Communications | 2024 |
|
Molecular subtyping of skin cutaneous melanoma based on inflammatory response
Liu Q, Ma F, Zhang G |
Heliyon | 2024 |
|
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
Monette A, Warren S, Barrett JC, Garnett-Benson C, Schalper KA, Taube JM, Topp B, Snyder A |
Journal for ImmunoTherapy of Cancer | 2024 |
|
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K, Dai Z |
Signal Transduction and Targeted Therapy | 2024 |
|
The Role of Natural Killer Cells in Oncolytic Virotherapy: Friends or Foes?
Franks ML, An JH, Leavenworth JW |
Human vaccines | 2024 |
|
Collagen 1 Fiber Volume Predicts for Recurrence of Stage 1 Non-Small Cell Lung Cancer
Kakkad S, Krishnamachary B, Fackche N, Garner M, Brock M, Huang P, Bhujwalla ZM |
Tomography | 2024 |
|
Mime: A flexible machine-learning framework to construct and visualize models for clinical characteristics prediction and feature selection
Liu H, Zhang W, Zhang Y, Adegboro AA, Fasoranti DO, Dai L, Pan Z, Liu H, Xiong Y, Li W, Peng K, Wanggou S, Li X |
Computational and Structural Biotechnology Journal | 2024 |
|
Deciphering the interplay of HPV infection, MHC-II expression, and CXCL13+ CD4+ T cell activation in oropharyngeal cancer: implications for immunotherapy
Yan S, Zhang X, Lin Q, Du M, Li Y, He S, Chen J, Li X, Bei J, Chen S, Song M |
Cancer Immunology, Immunotherapy | 2024 |
|
Tumor-Intrinsic Activity of Chromobox 2 Remodels the Tumor Microenvironment in High-grade Serous Carcinoma
Iwanaga R, Yamamoto TM, Gomez K, Nguyen LL, Woodruff ER, Post MD, Mikeska RG, Danis E, Danhorn T, Boorgula MP, Mitra SS, Marjon NA, Bitler BG, Brubaker LW |
Cancer research communications | 2024 |
|
Advances and prospects of biomarkers for immune checkpoint inhibitors
Yamaguchi H, Hsu JM, Sun L, Wang SC, Hung MC |
Cell reports. Medicine | 2024 |
|
Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma
Luo D, Luo A, Hu S, Ye G, Li D, Zhao H, Peng B |
Scientific Reports | 2024 |
|
Head-to-head comparison of composite and individual biomarkers to predict clinical benefit to PD-1 blockade in non-small cell lung cancer
Hummelink K, van der Noort V, Muller M, Schouten RD, van den Heuvel MM, Thommen DS, Smit EF, Meijer GA, Monkhorst K |
PloS one | 2024 |
|
Reshaping tumor microenvironment by regulating local cytokines expression with a portable smart blue-light controlled device
Wang HR, Zhang Y, Mo YJ, Zhang Z, Chen R, Lu XB, Huang W |
Communications biology | 2024 |
|
Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response in mice and humans
Skelly DA, Graham JP, Cheng M, Furuta M, Walter A, Stoklasek TA, Yang H, Stearns TM, Poirion O, Zhang JG, Grassmann JD, Luo D, Flynn WF, Courtois ET, Chang CH, Serreze DV, Menghi F, Reinholdt LG, Liu ET |
2024 | |
|
Tumor-associated macrophage clusters linked to immunotherapy in a pan-cancer census.
Wei C, Ma Y, Wang M, Wang S, Yu W, Dong S, Deng W, Bie L, Zhang C, Shen W, Xia Q, Luo S, Li N |
npj Precision Oncology | 2024 |
|
Recent developments in immunotherapy for gastrointestinal tract cancers.
Chong X, Madeti Y, Cai J, Li W, Cong L, Lu J, Mo L, Liu H, He S, Yu C, Zhou Z, Wang B, Cao Y, Wang Z, Shen L, Wang Y, Zhang X |
Journal of Hematology & Oncology | 2024 |
|
Measuring the composition of the tumor microenvironment with transcriptome analysis: past, present and future
Zhang H, Lu X, Lu B, Gullo G, Chen L |
Future Oncology | 2024 |
|
Toxoplasma gondii infection supports the infiltration of T cells into brain tumors
Nguyen YT, Sibley L, Przanowski P, Zhao XY, Kovacs M, Wang S, Jones MK, Cowan M, Liu W, Merchak AR, Gaultier A, Janes K, Zang C, Harris T, Ewald SE, Zong H |
Journal of Neuroimmunology | 2024 |
|
DNA methylation profiling deciphers three EMT subtypes with distinct prognoses and therapeutic vulnerabilities in breast cancer
Sun S, Chen S, Wang N, Hong Z, Sun Y, Xu Y, Chi J, Wang X, Li L |
Journal of Cancer | 2024 |
|
The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Dravillas CE, Coleman SS IV, Hoyd R, Caryotakis G, Denko L, Chan CH, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AE, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC |
Cancer research communications | 2024 |
|
The crosstalk between lung cancer and the bone marrow niche fuels emergency myelopoiesis.
Calderon-Espinosa E, De Ridder K, Benoot T, Jansen Y, Vanhonacker D, Heestermans R, De Becker A, Van Riet I, Decoster L, Goyvaerts C |
Frontiers in immunology | 2024 |
|
A prognostic model constructed by ferroptosis-associated genes (FAGs) in papillary renal cell carcinoma (PRCC) and its association with tumor mutation burden (TMB) and immune infiltration.
Chen YB, Yang X, Lv D, Tang LY, Liu YW |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2024 |
|
Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma.
Aung TN, Warrell J, Martinez-Morilla S, Gavrielatou N, Vathiotis I, Yaghoobi V, Kluger HM, Gerstein M, Rimm DL |
Clinical cancer research | 2024 |
|
Gene panel predicts neoadjuvant chemoimmunotherapy response and benefit from immunotherapy in HER2-negative breast cancer
Lu X, Gou Z, Chen H, Li L, Chen F, Bao C, Bu H |
Journal for Immunotherapy of Cancer | 2024 |
|
A pan-cancer cuproptosis signature predicting immunotherapy response and prognosis
Zhu X, Zhang Z, Xiao Y, Wang H, Zhang J, Wang M, Jiang M, Xu Y |
Heliyon | 2024 |
|
Multimodal analysis unveils tumor microenvironment heterogeneity linked to immune activity and evasion
Lapuente-Santana Ó, Sturm G, Kant J, Ausserhofer M, Zackl C, Zopoglou M, McGranahan N, Rieder D, Trajanoski Z, da Cunha Carvalho de Miranda NF, Eduati F, Finotello F |
iScience | 2024 |
|
CD24 affects the immunosuppressive effect of tumor-infiltrating cells and tumor resistance in a variety of cancers
Zhao C, Huang Y, Zhang H, Liu H |
Discover Oncology | 2024 |
|
Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study
Feng T, Li Q, Zhu R, Yu C, Xu L, Ying L, Wang C, Xu W, Wang J, Zhu J, Huang M, Xu C, Jin J, Zhang X, Lu T, Yang Y, Zhu C, Chen Q, Su D |
Journal for Immunotherapy of Cancer | 2024 |
|
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation
Jin Y, Huang RJ, Guan WL, Wang ZQ, Mai ZJ, Li YH, Xiao J, Zhang X, Zhao Q, Chen SF, Liu M, Shi YX, Wang F, Xu RH |
Signal Transduction and Targeted Therapy | 2024 |
|
Predictive Signatures for Responses to Checkpoint Blockade in Small-Cell Lung Cancer in Second-Line Therapy Do Not Predict Responses in First-Line Patients
Thompson JC, Tilsed C, Davis C, Gupta A, Melidosian B, Sun C, Kallen ME, Timmers C, Langer CJ, Albelda SM |
Cancers | 2024 |
|
Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade
Holzgruber J, Martins C, Kulcsar Z, Duplaine A, Rasbach E, Migayron L, Singh P, Statham E, Landsberg J, Boniface K, Seneschal J, Hoetzenecker W, Berdan EL, Ho Sui S, Ramsey MR, Barthel SR, Schatton T |
Nature Communications | 2024 |
|
Tumor immune microenvironmental characteristics in Human Epidermal Growth Factor-2 (HER2) positive esophageal adenocarcinoma: A comparative analysis and biomarker study
Stroes CI, Meijer SL, Creemers GJ, Hooijer GK, Mohammad NH, Los M, Slingerland M, Hospers GA, Cats A, Beerepoot LV, Bijlsma MF, van Laarhoven HW |
Translational Oncology | 2024 |
|
Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors.
Malhotra J, De S, Nguyen K, Lee P, Villaflor V |
Cancer immunology, immunotherapy : CII | 2024 |
|
Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer.
Chen T, Wang M, Chen Y, Cao Y, Liu Y |
Cell & bioscience | 2024 |
|
Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma.
Lee K, Cha H, Kim J, Jang Y, Son Y, Joe CY, Kim J, Kim J, Lee SH, Lee S |
Scientific reports | 2024 |
|
Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non–Small Cell Lung Cancer. An Official American Thoracic Society Research Statement
Moghaddam SJ, Savai R, Salehi-Rad R, Sengupta S, Kammer MN, Massion P, Beane JE, Ostrin EJ, Priolo C, Tennis MA, Stabile LP, Bauer AK, Sears CR, Szabo E, Rivera MP, Powell CA, Kadara H, Jenkins BJ, Dubinett SM, Houghton AM, Kim CF, Keith RL |
American Journal of Respiratory and Critical Care Medicine | 2024 |
|
Tumor-localized interleukin-2 and interleukin-12 combine with radiation therapy to safely potentiate regression of advanced malignant melanoma in pet dogs
Stinson JA, Barbosa MM, Sheen A, Momin N, Fink E, Hampel J, Selting KA, Kamerer RL, Bailey KL, Wittrup KD, Fan TM |
Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 |
|
Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist’s Perspective on Current Knowledge
Martínez-Vila C, González-Navarro EA, Teixido C, Martin R, Aya F, Juan M, Arance A |
International Journal of Molecular Sciences | 2024 |
|
Checkpoint therapy in cancer treatment: progress, challenges, and future directions
Bicak M, Cimen Bozkus C, Bhardwaj N |
The Journal of Clinical Investigation | 2024 |
|
Exploring the molecular and immune landscape of cellular senescence in lung adenocarcinoma.
Ru K, Cui L, Wu C, Tan XX, An WT, Wu Q, Ma YT, Hao Y, Xiao X, Bai J, Liu X, Xia XF, Zhao MQ |
Frontiers in immunology | 2024 |
|
Neutrophil extracellular trap genes predict immunotherapy response in gastric cancer
Sun N, Jiang J, Chen B, Chen Y, Wu H, Wang H, Chen J |
Heliyon | 2024 |
|
Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial
Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, Wilky BA, Pimentel A, Mahadevan D, Balmanoukian AS, Sanborn RE, Schwartz GK, Abou-Alfa GK, Segal NH, Bockorny B, Moser JC, Sharma S, Patel JM, Wu W, Chand D, Rosenthal K, Mednick G, Delepine C, Curiel TJ, Stebbing J, Lenz HJ, O\u2019Day SJ, El-Khoueiry AB |
Nature Medicine | 2024 |
|
Integrated multiomics revealed adenosine signaling predict immunotherapy response and regulate tumor ecosystem of melanoma
Xu Y, Lau P, Chen X, Zhao S, He Y, Jiang Z, Chen X, Zhang G, Liu H |
Human Genomics | 2024 |
|
Integrative analysis of pan-cancer single-cell data reveals a tumor ecosystem subtype predicting immunotherapy response
Zeng S, Chen L, Tian J, Liu Z, Liu X, Tang H, Wu H, Liu C |
NPJ Precision Oncology | 2024 |
|
A Combined Proteomic and Transcriptomic Signature Is Predictive of Response to Anti-PD-1 Treatment: A Retrospective Study in Metastatic Melanoma Patients
Mallardo D, Fordellone M, White A, Vowinckel J, Bailey M, Sparano F, Sorrentino A, Mallardo M, Facchini BA, De Filippi R, Ferrara G, Vanella V, Beeler K, Chiodini P, Cesano A, Warren S, Ascierto PA |
International Journal of Molecular Sciences | 2024 |
|
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial.
Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, Garner H, Boeckx B, Traets JJH, Mandjes IAM, de Maaker M, van Brussel T, Chelushkin M, Champanhet E, Lopez-Yurda M, van de Vijver K, van den Berg JG, Hofland I, Klioueva N, Mann RM, Loo CE, van Duijnhoven FH, Skinner V, Luykx S, Kerver E, Kalashnikova E, van Dongen MGJ, Sonke GS, Linn SC, Blank CU, de Visser KE, Salgado R, Wessels LFA, Drukker CA, Schumacher TN, Horlings HM, Lambrechts D, Kok M |
Nature medicine | 2024 |
|
A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses
Seligson ND, Chen JL, Goodrich AC, Van Tine BA, Campbell JD, Richards AL, Antonescu CR, Liebner DA, Milhem MM, Streicher H, Tap WD, Schwartz GK, George S, D'Angelo SP |
Journal for Immunotherapy of Cancer | 2024 |
|
Comparison of Tumor Microenvironments between Primary Tumors and Lymph Node Metastases in Head and Neck Squamous Cell Carcinoma and Their Predictive Role in Immune Checkpoint Inhibitor Treatment
Kim DH, Ahn JS, Kang M, Park G, Lim Y, Hwang S, Ock CY, Koh J, Chung EJ, Kwon SK, Jeon YK, Jung KC, Ahn SH, Keam B |
Cells | 2024 |
|
Hyperactivation of mTOR/eIF4E Signaling Pathway Promotes the Production of Tryptophan‐To‐Phenylalanine Substitutants in EBV‐Positive Gastric Cancer
Zheng Z, Zhong C, Wei C, Chen X, Chen G, Nie R, Chen Z, Zhang F, Li Y, Zhou Z, Chen Y, Liang Y |
Advanced Science | 2024 |
|
T lymphocyte‑related immune response and immunotherapy in gastric cancer (Review)
Zhang Z, Zhang W, Liu X, Yan Y, Fu W |
Oncology Letters | 2024 |
|
Unraveling the regulatory cell death pathways in gastric cancer: a multi-omics study
Sun J, Rao L, Zhou S, Zeng Y, Sun Y |
Frontiers in Pharmacology | 2024 |
|
The central role of transfer RNAs in mistranslation
Schuntermann DB, Jaskolowski M, Reynolds NM, Vargas-Rodriguez O |
The Journal of Biological Chemistry | 2024 |
|
Salivary biomarkers: a promising approach for predicting immunotherapy response in head and neck cancers.
Nejat Dehkordi A, Maddahi M, Vafa P, Ebrahimi N, Aref AR |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2024 |
|
Exploring public cancer gene expression signatures across bulk, single-cell and spatial transcriptomics data with signifinder Bioconductor package.
Pirrotta S, Masatti L, Bortolato A, Corrà A, Pedrini F, Aere M, Esposito G, Martini P, Risso D, Romualdi C, Calura E |
NAR genomics and bioinformatics | 2024 |
|
Immunogenic cell death signatures from on-treatment tumor specimens predict immune checkpoint therapy response in metastatic melanoma.
Zeng H, Jiang Q, Zhang R, Zhuang Z, Wu J, Li Y, Fang Y |
Scientific reports | 2024 |
|
Cancer cell-intrinsic biosynthesis of itaconate promotes tumor immunogenicity.
Wang Z, Cui L, Lin Y, Huo B, Zhang H, Xie C, Zhang H, Liu Y, Jin H, Guo H, Li M, Wang X, Zhou P, Huang P, Liu J, Xia X |
The EMBO journal | 2024 |
|
Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity.
Cuyàs E, Pedarra S, Verdura S, Pardo MA, Espin Garcia R, Serrano-Hervás E, Llop-Hernández À, Teixidor E, Bosch-Barrera J, López-Bonet E, Martin-Castillo B, Lupu R, Pujana MA, Sardanyès J, Alarcón T, Menendez JA |
Cell death discovery | 2024 |
|
Cold and hot tumors: from molecular mechanisms to targeted therapy.
Wu B, Zhang B, Li B, Wu H, Jiang M |
Signal transduction and targeted therapy | 2024 |
|
Size matters: integrating tumour volume and immune activation signatures predicts immunotherapy response.
Lim SY, da Silva IP, Adegoke NA, Lo SN, Menzies AM, Carlino MS, Scolyer RA, Long GV, Lee JH, Rizos H |
Molecular cancer | 2024 |
|
Triple-Negative Breast Cancer: Tumor Immunogenicity and Beyond.
Ibrahim E, Diab E, Hayek R, Hoyek K, Kourie H |
International journal of breast cancer | 2024 |
|
Revolutionizing prognostic predictions in colorectal cancer: Macrophage‑driven transcriptional insights from single‑cell RNA sequencing and gene co‑expression network analysis.
Feng Y, Cheng Z, Gao J, Huang T, Wang J, Tang Q, Pu K, Liu C |
Oncology letters | 2024 |
|
Glioblastoma and Immune Checkpoint Inhibitors: A Glance at Available Treatment Options and Future Directions.
Rodriguez SMB, Tataranu LG, Kamel A, Turliuc S, Rizea RE, Dricu A |
International journal of molecular sciences | 2024 |
|
Exploring Molecular Drivers of PARPi Resistance in BRCA1-Deficient Ovarian Cancer: The Role of LY6E and Immunomodulation.
Petta TB, Carlson J |
International journal of molecular sciences | 2024 |
|
Targeting IRE1α reprograms the tumor microenvironment and enhances anti-tumor immunity in prostate cancer.
Unal B, Kuzu OF, Jin Y, Osorio D, Kildal W, Pradhan M, Kung SHY, Oo HZ, Daugaard M, Vendelbo M, Patterson JB, Thomsen MK, Kuijjer ML, Saatcioglu F |
Nature communications | 2024 |
|
Prognostic biomarkers for immunotherapy in esophageal cancer.
Tong X, Jin M, Wang L, Zhang D, Yin Y, Shen Q |
Frontiers in immunology | 2024 |
|
A machine learning model reveals expansive downregulation of ligand-receptor interactions that enhance lymphocyte infiltration in melanoma with developed resistance to immune checkpoint blockade.
Sahni S, Wang B, Wu D, Dhruba SR, Nagy M, Patkar S, Ferreira I, Day CP, Wang K, Ruppin E |
Nature communications | 2024 |
|
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy
Saini KS, Somara S, Ko HC, Thatai P, Quintana A, Wallen ZD, Green MF, Mehrotra R, McGuigan S, Pang L, Das S, Yadav K, Neric D, Cantini L, Joshi C, Iwamoto K, Dubbewar S, Vidal L, Chico I, Severson E, Lorini L, Badve S, Bossi P |
Frontiers in Oncology | 2024 |
|
Personalized Treatment Strategies via Integration of Gene Expression Biomarkers in Molecular Profiling of Laryngeal Cancer.
Maniaci A, Giurdanella G, Chiesa Estomba C, Mauramati S, Bertolin A, Lionello M, Mayo-Yanez M, Rizzo PB, Lechien JR, Lentini M |
Journal of personalized medicine | 2024 |
|
Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer.
Wang Y, Ju X, Hua R, Chen J, Dai X, Liu L, Wang G, Bai Y, Hu H, Li X |
British journal of cancer | 2024 |
|
Construction of a tumor mutational burden-derived LncRNA prognostic computational framework associated with therapy sensitivity in skin cutaneous melanoma.
Li G, Wu T, Li H, Wei C, Sun Y, Gao P, Huang X, Liu Z, Li J, Wang Y, Li G, Fan L |
Journal of translational medicine | 2024 |
|
Second-line monotherapy with a PD-1/CTLA-4 inhibitor effectively treated multiple brain and lung metastases of cervical cancer: a case report
Ni J, Dong X, Shou H, Xu Q, Yin Z, Lou H |
Frontiers in Immunology | 2024 |
|
Notch1 blockade by a novel, selective anti-Notch1 neutralizing antibody improves immunotherapy efficacy in melanoma by promoting an inflamed TME.
de Freitas JT, Thakur V, LaPorte KM, Thakur VS, Flores B, Caicedo V, Ajaegbu CGE, Ingrasci G, Lipman ZM, Zhang K, Qiu H, Malek TR, Bedogni B |
Journal of experimental & clinical cancer research : CR | 2024 |
|
Stratifying hepatocellular carcinoma based on immunophenotypes for immunotherapy response and prognosis.
Liu Y, Ji H, Wu LH, Wang XX, Yang Y, Zhang Q, Zhang HM |
Molecular therapy. Oncology | 2024 |
|
MFAP3L predicts tumor microenvironment status, molecular subtypes and clinical benefit in patients with bladder cancer.
Xie G, Qi T, Yao Y, Feng D, Zhou W |
Scientific reports | 2024 |
|
Biomarkers to predict the benefits of immune‑checkpoint blockade‑based therapy in patients with malignant peritoneal mesothelioma (Review).
Wang C, Zhao Y, Liang W |
Oncology letters | 2024 |
|
Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).
Hao W, Rajendran BK, Cui T, Sun J, Zhao Y, Palaniyandi T, Selvam M |
International journal of molecular medicine | 2024 |
|
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.
Dugo M, Huang CS, Egle D, Bermejo B, Zamagni C, Seitz RS, Nielsen TJ, Thill M, Antón-Torres A, Russo S, Ciruelos EM, Schweitzer BL, Ross DT, Galbardi B, Greil R, Semiglazov V, Gyorffy B, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Blasi O, Callari M, Pusztai L, Valagussa P, Viale G, Gianni L, Bianchini G |
Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 |
|
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours.
Holder AM, Dedeilia A, Sierra-Davidson K, Cohen S, Liu D, Parikh A, Boland GM |
Nature reviews. Cancer | 2024 |
|
DDR1 is identified as an immunotherapy target for microsatellite stable colon cancer by CRISPR screening
Wu M, Ma W, Lv G, Wang X, Li C, Chen X, Peng X, Tang C, Pan Z, Liu R, Chen G, Zhang R |
NPJ Precision Oncology | 2024 |
|
Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors
Malhotra J, Huang A, Amini A, Lee P |
Cancers | 2024 |
|
Predictive biomarkers for immune checkpoint efficacy: is multi-omics breaking the deadlock?
Mogenet A, Greillier L, Tomasini P |
Translational Lung Cancer Research | 2024 |
|
Expression of PD-L1, PD-L2, and inflammatory gene expression profile in locally advanced head and neck squamous cell carcinoma
Hong MH, Park S, Vo T, Cho J, Jung HA, Lee SH, Kim SH, Zhou H, Chirovsky D, Koh YW, Yoon SO, Webber AL, Gumuscu B, Cho BC, Ahn MJ |
ESMO Open | 2024 |
|
SpottedPy quantifies relationships between spatial transcriptomic hotspots and uncovers environmental cues of epithelial-mesenchymal plasticity in breast cancer.
Withnell E, Secrier M |
Genome biology | 2024 |
|
Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma.
Wang Z, Zou X, Wang H, Hao Z, Li G, Wang S |
Frontiers in immunology | 2024 |
|
A Novel Natural Killer Cell-related Gene Signature for Improving the Prediction of Prognosis and Immunotherapy Response in Bladder Cancer.
Ma X, Wei X, Yang G, Li S, Liu R |
Combinatorial chemistry & high throughput screening | 2024 |
|
Cabozantinib inhibits tumor growth in mice with ovarian cancer
Stiff PJ, Kertowidjojo E, Potkul RK, Banerjee S, Mehrotra S, Small W Jr, Stack MS, Drakes ML |
American Journal of Cancer Research | 2024 |
|
Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma: A Prospective Phase II trial
Davar D, Morrison RM, Dzutsev AK, Karunamurthy A, Chauvin JM, Amatore F, Deutsch JS, Das Neves RX, Rodrigues RR, McCulloch JA, Wang H, Hartman DJ, Badger JH, Fernandes MR, Bai Y, Sun J, Cole AM, Aggarwal P, Fang JR, Deitrick C, Bao R, Duvvuri U, Sridharan SS, Kim SW, Choudry MH, Holtzman MP, Pingpank JF, O\u2019Toole JP, DeBlasio R, Jin Y, Ding Q, Gao W, Groetsch C, Pagliano O, Rose A, Urban C, Singh J, Divarkar P, Mauro D, Bobilev D, Wooldridge J, Krieg AM, Fury MG, Whiteaker JR, Zhao L, Paulovich AG, Najjar YG, Luke JJ, Kirkwood JM, Taube JM, Park HJ, Trinchieri G, Zarour HM |
Cancer cell | 2024 |
|
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors
Davar D, Carneiro BA, Dy GK, Sheth S, Borad MJ, Harrington KJ, Patel SP, Galanis E, Samson A, Agrawal S, Chen Z, Fan C, Gong M, Burton J, Tu E, Durham N, Laubscher K, Arnaldez F, Zamarin D |
Journal for Immunotherapy of Cancer | 2024 |
|
Mapping in silico genetic networks of the KMT2D tumour suppressor gene to uncover novel functional associations and cancer cell vulnerabilities.
Takemon Y, Pleasance ED, Gagliardi A, Hughes CS, Csizmok V, Wee K, Trinh DL, Huff RD, Mungall AJ, Moore RA, Chuah E, Mungall KL, Lewis E, Nelson J, Lim HJ, Renouf DJ, Jones SJ, Laskin J, Marra MA |
Genome medicine | 2024 |
|
A patient stratification signature mirrors the immunogenic potential of high grade serous ovarian cancers.
Berry LK, Pullikuth AK, Stearns KL, Wang Y, Wagner CJ, Chou JW, Darby JP, Kelly MG, Mall R, Leung M, Chifman J, Miller LD |
Journal of translational medicine | 2024 |
|
Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors.
Kim DH, Kang M, Park G, Mostafavi M, Lim Y, Ock CY, Koh J, Jeon YK, Jung KC, Ahn SH, Chung EJ, Kwon SK, Keam B |
Discover oncology | 2024 |
|
Stratified analysis identifies HIF-2α as a therapeutic target for highly immune-infiltrated melanomas.
Huang AY, Burke KP, Porter R, Meiger L, Fatouros P, Yang J, Robitschek E, Vokes N, Ricker C, Rosado V, Tarantino G, Chen J, Aprati TJ, Glettig MC, He Y, Wang C, Fu D, Ho LL, Galani K, Freeman GJ, Buchbinder EI, Stephen Hodi F, Kellis M, Boland GM, Sharpe AH, Liu D |
bioRxiv : the preprint server for biology | 2024 |
|
Development of mutated β-catenin gene signature to identify CTNNB1 mutations from whole and spatial transcriptomic data in patients with HCC
Lehrich BM, Tao J, Liu S, Hirsch TZ, Yasaka TM, Cao C, Delgado ER, Guan X, Lu S, Pan L, Liu Y, Singh S, Poddar M, Bell A, Singhi AD, Zucman-Rossi J, Wang Y, Monga SP |
JHEP Reports | 2024 |
|
Harnessing Bacterial Agents to Modulate the Tumor Microenvironment and Enhance Cancer Immunotherapy
Thomas CJ, Delgado K, Sawant K, Roy J, Gupta U, Song CS, Poojary R, de Figueiredo P, Song J |
Cancers | 2024 |
|
Gene Expression Profiling of the Peritumoral Immune Cell Infiltrate of Penile Squamous Cell Carcinomas
Winkelmann R, Becker N, Leichner R, Wild PJ, Demes M, Banek S, Döring C, Bein J |
International Journal of Molecular Sciences | 2024 |
|
Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma
Zhou Q, Dian Y, He Y, Yao L, Su H, Meng Y, Sun Y, Li D, Xiong Y, Zeng F, Liang X, Liu H, Chen X, Deng G |
Journal for Immunotherapy of Cancer | 2024 |
|
An immune scoring system predicts prognosis and immune characteristics in lung adenocarcinoma brain metastases by RNA sequencing
Xiao G, Tanzhu G, Gao X, Li L, Liu Z, Xia X, Zhou R |
Acta Neuropathologica Communications | 2024 |
|
Identification of Cuproptosis-Related Genes for Molecular Subtyping: Predicting Prognostic and Therapeutic Response in Glioma
Xia X, Huang X, Wu L, Xu P, Li P |
OncoTargets and Therapy | 2024 |
|
TET2 promotes tumor antigen presentation and T cell IFN-γ, which is enhanced by vitamin C
Cheng M, Chu AK, Li Z, Yang S, Smith MD, Zhang Q, Brown NG, Marzluff WF, Bardeesy N, Milner JJ, Welch JD, Xiong Y, Baldwin AS |
JCI Insight | 2024 |
|
Local CpG-Stat3 siRNA treatment improves antitumor effects of immune checkpoint inhibitors
Zhang C, Huang R, Ren L, Martincuks A, Song J, Kortylewski M, Swiderski P, Forman SJ, Yu H |
Molecular Therapy. Nucleic Acids | 2024 |
|
PD-1/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies
Jin M, Fang J, Peng J, Wang X, Xing P, Jia K, Hu J, Wang D, Ding Y, Wang X, Li W, Chen Z |
Molecular Cancer | 2024 |
|
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer
Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM, Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L |
Cell Reports Medicine | 2024 |
|
Powerful microscopy technologies decode spatially organized cellular networks that drive response to immunotherapy in humans
Chen JH, Elmelech L, Tang AL, Hacohen N |
Current opinion in immunology | 2024 |
|
Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy
Chand D, Savitsky DA, Krishnan S, Mednick G, Delepine C, Garcia-Broncano P, Soh KT, Wu W, Wilkens MK, Udartseva O, Vincent S, Joshi B, Keith JG, Manrique M, Marques M, Tanne A, Levey DL, Han H, Ng S, Ridpath J, Huber O, Morin B, Galand C, Bourdelais S, Gombos RB, Ward R, Qin Y, Waight JD, Costa MR, Sebastian-Yague A, Rudqvist NP, Pupecka-Swider M, Venkatraman V, Slee A, Patel JM, Grossman JE, Wilson NS, Von Hoff DD, Stebbing J, Curiel TJ, Buell JS, O\u2019Day SJ, Stein RB |
Cancer Discovery | 2024 |
|
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
Robles-Oteíza C, Hastings K, Choi J, Sirois I, Ravi A, Expósito F, de Miguel F, Knight JR, López-Giráldez F, Choi H, Socci ND, Merghoub T, Awad M, Getz G, Gainor J, Hellmann MD, Caron É, Kaech SM, Politi K |
The Journal of Experimental Medicine | 2024 |
|
Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinoma
Goswami S, Gao J, Basu S, Shapiro DD, Karam JA, Tidwell RS, Ahrar K, Campbell MT, Shen Y, Trevino AE, Mayer AT, Espejo AB, Seua C, Macaluso MD, Chen Y, Liu W, He Z, Yadav SS, Wang Y, Rao P, Zhao L, Zhang J, Jindal S, Futreal A, Wang L, Tannir NM, Sharma P |
Research Square | 2024 |
|
Hyper-Interferon Sensitive Influenza Induces Adaptive Immune Responses and Overcomes Resistance to Anti–PD-1 in Murine Non–Small Cell Lung Cancer
Du Y, Salehi-Rad R, Zhang TH, Crosson WP, Abascal J, Chen D, Shi Y, Jiang H, Tseng YW, Ma X, Hong M, Wang S, Wang X, Tang K, Hu S, Li Y, Ni S, Cai Y, Tappuni S, Shen Y, Liu B, Sun R |
Cancer Immunology Research | 2024 |
|
Single‐cell transcriptomic analysis of glioblastoma reveals pericytes contributing to the blood–brain–tumor barrier and tumor progression
Li Y, Wu C, Long X, Wang X, Gao W, Deng K, Xie B, Zhang S, Wu M, Liu Q |
MedComm | 2024 |
|
Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer
Connor AE, Lyons PM, Kilgallon AM, Simpson JC, Perry AS, Lysaght J |
Heliyon | 2024 |
|
Integrative analysis of a novel immunogenic PANoptosis‑related gene signature in diffuse large B-cell lymphoma for prognostication and therapeutic decision-making
Xu M, Ruan M, Zhu W, Xu J, Lin L, Li W, Zhu W |
Scientific Reports | 2024 |
|
Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy
Yin X, Song Y, Deng W, Blake N, Luo X, Meng J |
Frontiers in Oncology | 2024 |
|
Identification of gene signatures relevant to the efficacy of immune checkpoint inhibitors in non-small cell lung cancer
Liu M, Li Q, Meng X, Cui Y, Sun W, Wang H, Gao Q |
Medicine | 2024 |
|
Integrated immunogenomic analyses of high-grade serous ovarian cancer reveal vulnerability to combination immunotherapy
Gronauer R, Madersbacher L, Monfort-Lanzas P, Floriani G, Sprung S, Zeimet AG, Marth C, Fiegl H, Hackl H |
Frontiers in Immunology | 2024 |
|
Evaluating the Safety of Immune Checkpoint Inhibitors and Combination Therapies in the Management of Brain Metastases: A Comprehensive Review
Podder V, Ranjan T, Margolin K, Maharaj A, Ahluwalia MS |
Cancers | 2024 |
|
Polyfunctional IL-21+ IFNG+ T follicular helper cells contribute to checkpoint inhibitor diabetes mellitus and can be targeted by JAK inhibitor therapy
Huang N, Ortega J, Kimbrell K, Lee J, Scott LN, Peluso EM, Wang SJ, Kao E, Kim K, Olay J, Quandt Z, Angell TE, Su MA, Lechner MG |
bioRxiv | 2024 |
|
Circulating immune landscape in melanoma patients undergoing anti-PD1 therapy reveals key immune features according to clinical response to treatment
Sosa Cuevas E, Mouret S, Vayssière G, Kerboua S, Girard P, Molens JP, Manceau M, Charles J, Saas P, Aspord C |
Frontiers in Immunology | 2024 |
|
Tumor microenvironment assessment-based signatures for predicting response to immunotherapy in non-small cell lung cancer
Wu J, Wang Y, Huang Z, Wu J, Sun H, Zhou R, Qiu W, Ye Z, Fang Y, Huang X, Wu J, Bin J, Liao Y, Shi M, Wang J, Liao W, Zeng D |
iScience | 2024 |
|
CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II
Chang Y, Wu L |
Briefings in Bioinformatics | 2024 |
|
Spatial transcriptomics in breast cancer reveals tumour microenvironment-driven drug responses and clonal therapeutic heterogeneity
Jiménez-Santos MJ, García-Martín S, Rubio-Fernández M, Gómez-López G, Al-Shahrour F |
NAR Cancer | 2024 |
|
Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images
Patkar S, Chen A, Basnet A, Bixby A, Rajendran R, Chernet R, Faso S, Kumar PA, Desai D, El-Zammar O, Curtiss C, Carello SJ, Nasr MR, Choyke P, Harmon S, Turkbey B, Jamaspishvili T |
NPJ Precision Oncology | 2024 |
|
Artificial neural network systems to predict the response to sintilimab in squamous-cell non-small-cell lung cancer based on data of ORIENT-3 study
Xie T, Fan G, Tang L, Xing P, Shi Y |
Cancer Immunology, Immunotherapy : CII | 2024 |
|
Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment
Gao Y, Chen S, Li L |
Frontiers in Immunology | 2024 |
|
Immunoadjuvant therapy in the regulation of cell death in sepsis: recent advances and future directions
Islam MM, Watanabe E, Salma U, Ozaki M, Irahara T, Tanabe S, Katsuki R, Oishi D, Takeyama N |
Frontiers in Immunology | 2024 |
|
Tumor-Infiltrating Immune Cells and HLA Expression as Potential Biomarkers Predicting Response to PD-1 Inhibitor Therapy in Stage IV Melanoma Patients
Hegyi B, Csikó KG, Balatoni T, Fröhlich G, Bőcs K, Tóth E, Mohos A, Neumark AR, Menyhárt CD, Ferrone S, Ladányi A |
Biomolecules | 2024 |
|
Tumor microenvironment and immunotherapy for triple-negative breast cancer
Guo Z, Zhu Z, Lin X, Wang S, Wen Y, Wang L, Zhi L, Zhou J |
Biomarker Research | 2024 |
|
Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort
McFaline-Figueroa JR, Sun L, Youssef GC, Huang R, Li G, Kim J, Lee EQ, Nayak L, Chukwueke U, Beroukhim R, Batchelor TT, Chiocca EA, Everson RG, Doherty L, Stefanik J, Partridge K, Spearman A, Myers A, Westergaard C, Russ A, Lavallee M, Smokovich A, LaForest-Roys C, Garcia Fox R, McCluskey C, Bi WL, Arnaout O, Peruzzi P, Cosgrove GR, Ligon KL, Arrillaga-Romany I, Clarke JL, Reardon DA, Cloughesy TF, Prins RM, Wen PY |
Nature Communications | 2024 |
|
Deciphering the Role of SLFN12: A Novel Biomarker for Predicting Immunotherapy Outcomes in Glioma Patients Through Artificial Intelligence
Chen Z, Liu C, Zheng W, Fang Y, Zhang H, Luo J, Li J, Qiu Y, Peng J, Xia Y, Miao C, Luo Q |
Journal of Cellular and Molecular Medicine | 2024 |
|
Optimizing T cell inflamed signature through a combination biomarker approach for predicting immunotherapy response in NSCLC
Chen YC, Chen AY, Hong R, Huang BE, Pirooznia M |
Scientific Reports | 2024 |
|
Association of PD-1 + Treg/PD-1 + CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment
Liu X, Xu D, Zhou C, Zhong Y, Geng H, Huang C, Shen Y, Xia X, Wang C, Zhu C, Cao H |
Journal of Translational Medicine | 2024 |
|
Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients
Poddubskaya E, Suntsova M, Lyadova M, Luppov D, Guryanova A, Lyadov V, Garazha A, Sorokin M, Semenova A, Shatalov V, Biakhova M, Simonov A, Moisseev A, Buzdin A |
Frontiers in Immunology | 2024 |
|
Advances in biomarkers for immunotherapy in small-cell lung cancer
Li H, Zhao P, Tian L, Lu Y, Wang X, Shao W, Cheng Y |
Frontiers in Immunology | 2024 |
|
Identification and Validation of Epithelial Cell Centre Regulatory Transcription Factors in the Gastric Cancer Microenvironment
Su G, Wang J, Liu S, Fu X, Li Y, Pan G |
International Journal of General Medicine | 2024 |
|
Integrating T-cell inflammation features for prognosis in hepatocellular carcinoma: a novel predictive model
Tang P, Wang T, Song F, Zhang Y, Zhao Y, Yarmohammadi H, Donadon M, Chen Z |
Journal of Gastrointestinal Oncology | 2024 |
|
DNA Methyltransferase Inhibition Upregulates the Costimulatory Molecule ICAM-1 and the Immunogenic Phenotype of Melanoma Cells
Cereghetti AS, Turko P, Cheng P, Benke S, Al Hrout A, Dzung A, Dummer R, Hottiger MO, Chahwan R, Ferretti LP, Levesque MP |
JID Innovations | 2024 |
|
“Leaving no one behind”: digital empathy and inclusive media literacy education for young adults on the autism spectrum
Rajagopal T, Chandrashekaran V |
International Journal of Developmental Disabilities | 2024 |
|
PTEN loss in glioma cell lines leads to increased extracellular vesicle biogenesis and PD-L1 cargo in a PI3K-dependent manner
Sanchez JC, Pierpont TM, Argueta-Zamora D, Wilson K, August A, Cerione RA |
The Journal of Biological Chemistry | 2024 |
|
Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer
Chibaya L, DeMarco KD, Lusi CF, Kane GI, Brassil ML, Parikh CN, Murphy KC, Chowdury SR, Li J, Ma B, Naylor TE, Cerrutti J, Mori H, Diaz-Infante M, Peura J, Pitarresi JR, Zhu LJ, Fitzgerald KA, Atukorale PU, Ruscetti M |
Science translational medicine | 2024 |
|
A Distinguished Roadmap of Fibroblast Senescence in Predicting Immunotherapy Response and Prognosis Across Human Cancers
Chen D, Liu P, Lin J, Zang L, Liu Y, Zhai S, Lu X, Weng Y, Li H |
Advanced Science | 2024 |
|
Chemoprevention of head and neck cancer: a review of current approaches and future perspectives
Han S, Bommireddy R, Kim P, Selvaraj P, Shin DM |
Cancer prevention research (Philadelphia, Pa.) | 2024 |
|
Prognostic Biomarkers in Evolving Melanoma Immunotherapy
Reschke R, Enk AH, Hassel JC |
American Journal of Clinical Dermatology | 2024 |
|
Tumor and Blood B Cell Abundance Outperforms Established Immune Checkpoint Blockade Response Prediction Signatures in Head and Neck Cancer
Chang TG, Spathis A, Schäffer AA, Gavrielatou N, Kuo F, Jia D, Mukherjee S, Sievers C, Economopoulou P, Anastasiou M, Moutafi M, Pal LR, Vos J, Lee AS, Lam S, Zhao K, Jiang P, Allen CT, Foukas P, Gomatou G, Altan-Bonnet G, Morris LG, Psyrri A, Ruppin E |
Annals of oncology : official journal of the European Society for Medical Oncology | 2024 |
|
Androgen Deprivation Therapy Drives a Distinct Immune Phenotype in Localized Prostate Cancer
Dallos MC, Obradovic AZ, McCann P, Chowdhury N, Pratapa A, Aggen DH, Gaffney C, Autio KA, Virk RK, De Marzo AM, Antonarakis ES, Scher HI, Drake CG, Rathkopf DE |
Clinical cancer research : an official journal of the American Association for Cancer Research | 2024 |
|
P-stalk ribosomes act as master regulators of cytokine-mediated processes
Dopler A, Alkan F, Malka Y, van der Kammen R, Hoefakker K, Taranto D, Kocabay N, Mimpen I, Ramirez C, Malzer E, Isaeva OI, Kerkhoff M, Gangaev A, Silva J, Ramalho S, Hoekman L, Altelaar M, Beijersbergen R, Akkari L, Yewdell JW, Kvistborg P, Faller WJ |
Cell | 2024 |
|
Programmable bacteria synergize with PD-1 blockade to overcome cancer cell–intrinsic immune resistance mechanisms
Li F, Yang Z, Savage TM, Vincent RL, de los Santos-Alexis K, Ahn A, Rouanne M, Mariuzza DL, Danino T, Arpaia N |
Science immunology | 2024 |
|
Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy
Ryba-Stanisławowska M |
Cellular Oncology (Dordrecht, Netherlands) | 2024 |
|
Single-cell RNA sequencing-derived signatures define response patterns to atezolizumab + bevacizumab in advanced hepatocellular carcinoma.
Cappuyns S, Piqué-Gili M, Esteban-Fabró R, Philips G, Balaseviciute U, Pinyol R, Gris-Oliver A, Vandecaveye V, Abril-Fornaguera J, Montironi C, Bassaganyas L, Peix J, Zeitlhoefler M, Mesropian A, Huguet-Pradell J, Haber PK, Figueiredo I, Ioannou G, Gonzalez-Kozlova E, D'Alessio A, Mohr R, Meyer T, Lachenmayer A, Marquardt JU, Reeves HL, Edeline J, Finkelmeier F, Trojan J, Galle PR, Foerster F, Mínguez B, Montal R, Gnjatic S, Pinato DJ, Heikenwalder M, Verslype C, Van Cutsem E, Lambrechts D, Villanueva A, Dekervel J, Llovet JM |
Journal of hepatology | 2024 |
|
Evolution route in nasopharyngeal carcinoma metastasis and its clinical significance
Zhi-Xiang Zuo, Xiao-long Zhang, Rui You, Mei Lin, You-ping Liu, Hong-min Cai, Li-zhi Liu, Xiong Zou, Yu-long Xie, Ru-hai Zou, Yi-nuan Zhang, Rui Sun, Wei-yi Feng, Hai-yan Wang, Gui-hua Tao, Hao-jiang Li, Wen-jie Huang, Chao Zhang, Pei-yu Huang, Jin Wang, Qi Zhao, Qi Yang, Hong-wan Zhang, Ting Liu, Xiao-bing Jiang, Jun Tang, Yang-kui Gu, Tao Yu, Zhi-Qiang Wang, Lin Feng, Tiebang Kang, Ming-yuan Chen |
Nature Communications | 2023 |
|
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases
Benjamin Onderdonk, Mark Korpics, Rebekah E Dadey, Jared H Hara, Lilit Karapetyan, Yuanyuan Zha, Theodore Karrison, Adam C Olson, Gini Fleming, Ralph Weichselbaum, Riyue Bao, Steven Chmura, Jason Luke |
Journal of Clinical Investigation | 2023 |
|
Tumor immunophenotyping-derived signature identifies prognosis and neoadjuvant immunotherapeutic responsiveness in gastric cancer
Jia-Bin Wang, Qing-Zhu Qiu, Qiao-Ling Zheng, Ya-Jun Zhao, Yu Xu, Tao Zhang, Shuan-Hu Wang, Quan Wang, Qin-Wen Jin, Yin-Hua Ye, Ping Li, Jian-Wei Xie, Jian-Xian Lin, Jun Lu, Qi-Yue Chen, Long-Long Cao, Ying-Hong Yang, Chao-Hui Zheng, Chang-Ming Huang |
Advanced Science | 2023 |
|
Biomarkers for immune checkpoint blockade in glioblastoma: making sense of tumor heterogeneity to personalize treatment
Víctor A. Arrieta1,2,3, Daniel J. McGrail4,5, Daniel J. Brat6, Catalina Lee-Chang1,3, Amy B. Heimberger1,3, Dhan Chand7, Roger Stupp1,3,8, Adam M. Sonabend1,3* |
Journal of Clinical Investigation | 2023 |
|
PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity
Yan Gu, Xiaozeng Lin, Ying Dong, Geoffrey Wood, Nabil Seidah, Geoff Werstuck, Pierre Major, Michael Bonert, Anil Kapoor, Damu Tang |
Journal of experimental & clinical cancer research : CR | 2023 |
|
Single-cell characterization of anti-LAG3+anti-PD1 treatment in melanoma patients
Jani Huuhtanen, Henna Kasanen, Katriina Peltola, Tapio Lönnberg, Virpi Glumoff, Oscar Brück, Olli Dufva, Karita Peltonen, Johanna Vikkula, Emmi Jokinen, Mette Ilander, Moon Lee, Siru Mäkelä, Marta Nyakas, Bin Li, Micaela Hernberg, Petri Bono, Harri Lähdesmäki, Anna Kreutzman, Satu Mustjoki |
Journal of Clinical Investigation | 2023 |
|
Clinical importance of the lncRNA NEAT1 in cancer patients treated with immune checkpoint inhibitors
Joseph Toker, J. Iorgulescu, Alexander L. Ling, Genaro R. Villa, Laxmi Parida, Gad Getz, Catherine J. Wu, David Reardon, E. Antonino Chiocca, Marco Mineo |
Clinical cancer research | 2023 |
|
Suppression of cytosolic DNA degradation promotes breast cancer immunogenicity via a STING-independent pathway
Jing Zhang, Hui Dai, Lei Huo, Jared Burks, Daniel McGrail, Shiaw-Yih Lin |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Intimate communications within the tumor microenvironment: stromal factors function as an orchestra
Cheng B, Yu Q, Wang W |
Journal of biomedical science | 2023 |
|
The immune microenvironment shapes transcriptional and genetic heterogeneity in chronic lymphocytic leukemia.
Sun C, Chen YC, Martinez Zurita A, Baptista MJ, Pittaluga S, Liu D, Rosebrock D, Gohil SH, Saba NS, Davies-Hill T, Herman SEM, Getz G, Pirooznia M, Wu CJ, Wiestner A |
Blood Advances | 2023 |
|
Battles against aberrant KEAP1-NRF2 signaling in lung cancer: intertwined metabolic and immune networks
Xu K, Ma J, Hall SR, Peng RW, Yang H, Yao F |
Theranostics | 2023 |
|
Sorting Transcriptomics Immune Information from Tumor Molecular Features Allows Prediction of Response to Anti-PD1 Therapy in Patients with Advanced Melanoma
Trilla-Fuertes L, Gámez-Pozo A, Prado-Vázquez G, López-Vacas R, Zapater-Moros A, López-Camacho E, Lumbreras-Herrera MI, Soriano V, Garicano F, Lecumberri MJ, Rodríguez de la Borbolla M, Majem M, Pérez-Ruiz E, González-Cao M, Oramas J, Magdaleno A, Fra J, Martín-Carnicero A, Corral M, Puértolas T, Ramos R, Fresno Vara JÁ, Espinosa E |
International journal of molecular sciences | 2023 |
|
Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity
Lin J, Sun S, Zhao K, Gao F, Wang R, Li Q, Zhou Y, Zhang J, Li Y, Wang X, Du L, Wang S, Li Z, Lu H, Lan Y, Song D, Guo W, Chen Y, Gao F, Zhao Y, Fan R, Guan J, He W |
Nature Communications | 2023 |
|
Caspase-8 contributes to an immuno-hot microenvironment by promoting phagocytosis via an ecto-calreticulin-dependent mechanism
Gong Z, Jia Q, Guo J, Li C, Xu S, Jin Z, Chu H, Wan YY, Zhu B, Zhou Y |
Experimental Hematology and Oncology | 2023 |
|
A high interferon gamma signature of CD8+ T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer
Li S, Li K, Tian F, Li H, Xia Q, Li T, Dong B, Li D, Yu J, Zhang J, Wang L, Zhang C, Xu S, Zhao Y, Liu Y |
Frontiers in immunology | 2023 |
|
PVRIG Expression Is an Independent Prognostic Factor and a New Potential Target for Immunotherapy in Hepatocellular Carcinoma
Birnbaum DJ, Picard M, Da Costa Q, Delayre T, Finetti P, Cabaud O, Agavnian E, De Rauglaudre B, Denicolaï E, Bertucci F, Mamessier E |
Cancers | 2023 |
|
Immunologic Signatures across Molecular Subtypes and Potential Biomarkers for Sub-Stratification in Endometrial Cancer
Jiang F, Jiang S, Cao D, Mao M, Xiang Y |
International journal of molecular sciences | 2023 |
|
Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers
Spiliopoulou P, Vornicova O, Genta S, Spreafico A |
International journal of molecular sciences | 2023 |
|
Canine oral squamous cell carcinoma as a spontaneous, translational model for radiation and immunology research
Boss MK, Harrison LG, Gold A, Karam SD, Regan DP |
Frontiers in Oncology | 2023 |
|
Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer
Wu W, Wang X, Le W, Lu C, Li H, Zhu Y, Chen X, An W, Xu C, Wu Q, Wang L |
Frontiers in immunology | 2023 |
|
Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy
Hua H, He W, Chen N, He Y, Wu G, Ye F, Zhou X, Li Y, Ding Y, Zhong W, Teng L, Jiang W, Sheng Q |
Frontiers in immunology | 2023 |
|
Conserved angio-immune subtypes of the tumor microenvironment predict response to immune checkpoint blockade therapy
Subramanian M, Kabir AU, Barisas D, Krchma K, Choi K |
Cell reports. Medicine | 2023 |
|
Exploring the role of tumor stemness and the potential of stemness-related risk model in the prognosis of intrahepatic cholangiocarcinoma
Yue Y, Tao J, An D, Shi L |
Frontiers in Genetics | 2023 |
|
Molecular characterization based on tumor microenvironment-related signatures for guiding immunotherapy and therapeutic resistance in lung adenocarcinoma
Jie Y, Wu J, An D, Li M, He H, Wang D, Gu A, E M |
Frontiers in pharmacology | 2023 |
|
Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients
Akbar S, Raza A, Mohsin R, Kanbour A, Qadri S, Parray A, Zar Gul AR, Philip A, Vijayakumar S, Merhi M, Hydrose S, Inchakalody VP, Al-Abdulla R, Abualainin W, Sirriya SA, Al-Bozom I, Uddin S, Khan OM, Mohamed Ibrahim MI, Al Homsi U, Dermime S |
Frontiers in immunology | 2023 |
|
LncRNA TINCR impairs the efficacy of immunotherapy against breast cancer by recruiting DNMT1 and downregulating MiR-199a-5p via the STAT1–TINCR-USP20-PD-L1 axis
Wang Q, Li G, Ma X, Liu L, Liu J, Yin Y, Li H, Chen Y, Zhang X, Zhang L, Sun L, Ai J, Xu S |
Cell Death and Disease | 2023 |
|
Therapeutic cancer vaccination against telomerase: clinical developments in melanoma
Ellingsen EB, Bjørheim J, Gaudernack G |
Current Opinion in Oncology | 2023 |
|
Whole-Transcriptome Sequencing Combined with High-Dimensional Proteomic Technologies Reveals the Potential Value of miR-135b-5p as a Biomarker for Hepatocellular Carcinoma
Zhang Y, He L, Pan L, Feng C, Wang X, Tao Y, Li T, Wang Q, Ullah H |
BioMed Research International | 2023 |
|
Pan-cancer analysis of chromothripsis-related gene expression patterns indicates an association with tumor immune and therapeutic agent responses
Zhang Q, Yang L, Xiao H, Dang Z, Kuang X, Xiong Y, Zhu J, Huang Z, Li M |
Frontiers in Oncology | 2023 |
|
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma
Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Ohkawa K, Oshita M, Miyazaki M, Yakushijin T, Nozaki Y, Matsumoto K, Tanaka S, Kaneko A, Iio S, Nawa T, Yamada Y, Morishita N, Usui T, Hiramatsu N, Doi Y, Sakakibara M, Imanaka K, Yoshida Y, Kodama T, Hikita H, Tatsumi T, Takehara T |
PloS one | 2023 |
|
Distinct mechanisms of mismatch repair deficiency delineate two modes of response to PD-1 immunotherapy in endometrial carcinoma
Chow RD, Michaels T, Bellone S, Hartwich TM, Bonazzoli E, Iwasaki A, Song E, Santin AD |
Cancer Discovery | 2023 |
|
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
Tomlins SA, Khazanov NA, Bulen BJ, Hovelson DH, Shreve MJ, Lamb LE, Matrana MR, Burkard ME, Yang ES, Edenfield WJ, Dees EC, Onitilo AA, Thompson M, Buchschacher GL Jr, Miller AM, Menter A, Parsons B, Wassenaar T, Hwang LC, Suga JM, Siegel R, Irvin W Jr, Nair S, Slim JN, Misleh J, Khatri J, Masters G, Thomas S, Safa M, Anderson DM, Kwiatkowski K, Mitchell K, Hu-Seliger T, Drewery S, Fischer A, Plouffe K, Czuprenski E, Hipp J, Reeder T, Vakil H, Johnson DB, Rhodes DR |
2023 | |
|
Targeting Cbl-b in cancer immunotherapy
Augustin RC, Bao R, Luke JJ |
Journal for ImmunoTherapy of Cancer | 2023 |
|
DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects
Ota Y, Nagai Y, Hirose Y, Hori S, Koga-Yamakawa E, Eguchi K, Sumida K, Murata M, Umehara H, Yamamoto S |
Frontiers in immunology | 2023 |
|
Efficacy and Safety of PD-1/PD-L1 Checkpoint Inhibitors versus Anti-PD-1/PD-L1 Combined with Other Therapies for Tumors: A Systematic Review
Zhang Y, Yao Q, Pan Y, Fang X, Xu H, Zhao T, Zhu G, Jiang T, Li S, Cao H |
Cancers | 2023 |
|
IFN-γ-STAT1-mediated CD8+ T-cell-neural stem cell cross talk controls astrogliogenesis after spinal cord injury
Wang J, Xu L, Peng D, Zhu Y, Gu Z, Yao Y, Li H, Cao X, Fu CY, Zheng M, Song X, Ding Y, Shen Y, Zhong J, Chen YY, Hu J, Wang LL |
Ensho Saisei | 2023 |
|
A novel prognostic model related to oxidative stress for treatment prediction in lung adenocarcinoma
Peng H, Li X, Luan Y, Wang C, Wang W |
Frontiers in Oncology | 2023 |
|
Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer
Lin Z, Wang Q, Jiang T, Wang W, Zhao JJ |
Frontiers in immunology | 2023 |
|
Analysis of immunotherapeutic response-related signatures in esophageal squamous-cell carcinoma
Zheng B, Li J, Zhang M, Zhang P, Deng W, Pu Y |
Frontiers in immunology | 2023 |
|
Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
Sisler DJ, Hinz TK, Le AT, Kleczko EK, Nemenoff RA, Heasley LE |
Frontiers in Oncology | 2023 |
|
Cancer-associated fibroblasts are the main contributors to epithelial-to-mesenchymal signatures in the tumor microenvironment
Szabo PM, Vajdi A, Kumar N, Tolstorukov MY, Chen BJ, Edwards R, Ligon KL, Chasalow SD, Chow KH, Shetty A, Bolisetty M, Holloway JL, Golhar R, Kidd BA, Hull PA, Houser J, Vlach L, Siemers NO, Saha S |
Scientific Reports | 2023 |
|
Multi-omics analysis unravels the underlying mechanisms of poor prognosis and differential therapeutic responses of solid predominant lung adenocarcinoma
Li F, Wang S, Wang Y, Lv Z, Jin D, Yi H, Fu L, Zhai S, Xiao T, Mao Y |
Frontiers in immunology | 2023 |
|
A composite score based on immune-related gene prognostic index and m6A risk score of head and neck squamous cell carcinoma
Yang Y, Cai Z, Huang K, Li M, Wang X, Lin Y, Chen S, Yang Z, Lin Z |
Frontiers in Genetics | 2023 |
|
Research into the characteristic molecules significantly affecting liver cancer immunotherapy
Chen J, Jin H, Zhou H, Hei X, Liu K |
Frontiers in immunology | 2023 |
|
Review of biomarkers for response to immunotherapy in HNSCC microenvironment
Chen S, Yang Y, He S, Lian M, Wang R, Fang J |
Frontiers in Oncology | 2023 |
|
Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer.
Hargadon KM |
Cellular and molecular life sciences : CMLS | 2023 |
|
Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha.
Sahu A, Wang X, Munson P, Klomp JPG, Wang X, Gu SS, Han Y, Qian G, Nicol P, Zeng Z, Wang C, Tokheim C, Zhang W, Fu J, Wang J, Nair NU, Rens JAP, Bourajjaj M, Jansen B, Leenders I, Lemmers J, Musters M, van Zanten S, van Zelst L, Worthington J, Liu JS, Juric D, Meyer CA, Oubrie A, Liu XS, Fisher DE, Flaherty KT |
Cancer Discovery | 2023 |
|
An adverse tumor-protective effect of IDO1 inhibition.
Kenski JCN, Huang X, Vredevoogd DW, de Bruijn B, Traets JJH, Ibáñez-Molero S, Schieven SM, van Vliet A, Krijgsman O, Kuilman T, Pozniak J, Loayza-Puch F, Terry AM, Müller J, Logtenberg MEW, de Bruijn M, Levy P, Körner PR, Goding CR, Schumacher TN, Marine JC, Agami R, Peeper DS |
Cell reports. Medicine | 2023 |
|
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
Geurts BS, Battaglia TW, van Berge Henegouwen JM, Zeverijn LJ, de Wit GF, Hoes LR, van der Wijngaart H, van der Noort V, Roepman P, de Leng WWJ, Jansen AML, Opdam FL, de Jonge MJA, Cirkel GA, Labots M, Hoeben A, Kerver ED, Bins AD, Erdkamp FGL, van Rooijen JM, Houtsma D, Hendriks MP, de Groot JB, Verheul HMW, Gelderblom H, Voest EE |
BMC Cancer | 2023 |
|
VISTA expression and patient selection for immune-based anticancer therapy
Martin AS, Molloy M, Ugolkov A, von Roemeling RW, Noelle RJ, Lewis LD, Johnson M, Radvanyi L, Martell RE |
Frontiers in immunology | 2023 |
|
Consensus Clustering and Survival-Related Genes of Cuproptosis in Cutaneous Melanoma
Qin W, Gan F, Jike Y, Jiang M, Li A |
Mediators of Inflammation | 2023 |
|
Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma
Xiao G, Li L, Tanzhu G, Liu Z, Gao X, Wan X, Xiao D, Chen L, Xia X, Zhou R |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma.
Meliante PG, Zoccali F, de Vincentiis M, Ralli M, Petrella C, Fiore M, Minni A, Barbato C |
2023 | |
|
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity.
Cai Z, Chen J, Yu Z, Li H, Liu Z, Deng D, Liu J, Chen C, Zhang C, Ou Z, Chen M, Hu J, Zu X |
2023 | |
|
Combinatorial Blood Platelets-Derived circRNA and mRNA Signature for Early-Stage Lung Cancer Detection.
D'Ambrosi S, Giannoukakos S, Antunes-Ferreira M, Pedraz-Valdunciel C, Bracht JWP, Potie N, Gimenez-Capitan A, Hackenberg M, Fernandez Hilario A, Molina-Vila MA, Rosell R, Würdinger T, Koppers-Lalic D |
International journal of molecular sciences | 2023 |
|
Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer.
Zeng TM, Yang G, Lou C, Wei W, Tao CJ, Chen XY, Han Q, Cheng Z, Shang PP, Dong YL, Xu HM, Guo LP, Chen DS, Song YJ, Qi C, Deng WL, Yuan ZG |
Nature Communications | 2023 |
|
Development and validation of a mutation-based model to predict immunotherapeutic efficacy in NSCLC.
He P, Liu J, Xu Q, Ma H, Niu B, Huang G, Wu W |
Frontiers in Oncology | 2023 |
|
Multiancestry genomic and transcriptomic analysis of gastric cancer.
Totoki Y, Saito-Adachi M, Shiraishi Y, Komura D, Nakamura H, Suzuki A, Tatsuno K, Rokutan H, Hama N, Yamamoto S, Ono H, Arai Y, Hosoda F, Katoh H, Chiba K, Iida N, Nagae G, Ueda H, Shihang C, Sekine S, Abe H, Nomura S, Matsuura T, Sakai E, Ohshima T, Rino Y, Yeoh KG, So J, Sanghvi K, Soong R, Fukagawa A, Yachida S, Kato M, Seto Y, Ushiku T, Nakajima A, Katai H, Tan P, Ishikawa S, Aburatani H, Shibata T |
Nature Genetics | 2023 |
|
Chromothripsis is correlated with reduced cytotoxic immune infiltration and diminished responsiveness to checkpoint blockade immunotherapy.
Chu H, Jin Z, Cheng JN, Jia Q, Zhu B, Cai H |
Theranostics | 2023 |
|
Characterization of pancreatic cancer with ultra-low tumor mutational burden.
Imamura T, Ashida R, Ohshima K, Uesaka K, Sugiura T, Ohgi K, Yamada M, Otsuka S, Hatakeyama K, Nagashima T, Sugino T, Urakami K, Akiyama Y, Yamaguchi K |
Scientific Reports | 2023 |
|
Multi-omics profiling of papillary thyroid microcarcinoma reveals different somatic mutations and a unique transcriptomic signature
Li Q, Feng T, Zhu T, Zhang W, Qian Y, Zhang H, Zheng X, Li D, Yun X, Zhao J, Li Y, Yu H, Gao M, Qian B |
Journal of Translational Medicine | 2023 |
|
ACER2 forms a cold tumor microenvironment and predicts the molecular subtype in bladder cancer: Results from real-world cohorts
Liu J, Cheng C, Qi T, Xiao J, Zhou W, Deng D, Dai Y |
Frontiers in Genetics | 2023 |
|
T lymphocyte characteristics and immune repertoires in the epicardial adipose tissue of heart failure patients
Zhang XZ, Chen XL, Tang TT, Zhang S, Li QL, Xia N, Nie SF, Zhang M, Zhu ZF, Zhou ZH, Dong NG, Cheng X |
Frontiers in immunology | 2023 |
|
Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.
Yan ZJ, Yu CT, Chen L, Wang HY |
Briefings in Bioinformatics | 2023 |
|
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.
Reijers ILM, Rao D, Versluis JM, Menzies AM, Dimitriadis P, Wouters MW, Spillane AJ, Klop WMC, Broeks A, Bosch LJW, Lopez-Yurda M, van Houdt WJ, Rawson RV, Grijpink-Ongering LG, Gonzalez M, Cornelissen S, Bouwman J, Sanders J, Plasmeijer E, Elshot YS, Scolyer RA, van de Wiel BA, Peeper DS, van Akkooi ACJ, Long GV, Blank CU |
Journal of Experimental Medicine | 2023 |
|
A transcriptomic pan-cancer signature for survival prognostication and prediction of immunotherapy response based on endothelial senescence
Wu Z, Uhl B, Gires O, Reichel CA |
Journal of biomedical science | 2023 |
|
Association of DNA Promoter Methylation and BRAF Mutation in Thyroid Cancer
Jasmine F, Aschebrook-Kilfoy B, Rahman MM, Zaagman G, Grogan RH, Kamal M, Ahsan H, Kibriya MG |
Current Oncology | 2023 |
|
PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
Sorroche BP, Teixeira RD, Pereira CA, Santana IV, Vujanovic L, Vazquez VD, Arantes LM |
Diagnostics | 2023 |
|
A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy
Lin J, Cai Y, Ma Y, Pan J, Wang Z, Zhang J, Liu Y, Zhao Z |
International journal of molecular sciences | 2023 |
|
Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype.
de Nonneville A, Finetti P, Boudin L, Denicolaï E, Birnbaum D, Mamessier E, Bertucci F |
Pharmaceutics | 2023 |
|
Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti-PD-1 Antibody.
Niwa Y, Adachi K, Tabata K, Ishida R, Hotta K, Ishida T, Mano Y, Ozawa Y, Minoshima Y, Funahashi Y, Semba T |
Molecular cancer therapeutics | 2023 |
|
Identification of immune related molecular subtypes and prognosis model for predicting prognosis, drug resistance in cervical squamous cell carcinoma
Hu D, Zhang Z, Zhang Y, Huang K, Li X |
Frontiers in Genetics | 2023 |
|
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer
Licata L, Mariani M, Rossari F, Viale G, Notini G, Naldini MM, Bosi C, Piras M, Dugo M, Bianchini G |
2023 | |
|
An artificial intelligence network-guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms.
Zhang N, Zhang H, Liu Z, Dai Z, Wu W, Zhou R, Li S, Wang Z, Liang X, Wen J, Zhang X, Zhang B, Ouyang S, Zhang J, Luo P, Li X, Cheng Q |
Cell Proliferation | 2023 |
|
Characterization of tumor microenvironment and programmed death-related genes to identify molecular subtypes and drug resistance in pancreatic cancer
Yu L, He R, Cui Y |
Frontiers in pharmacology | 2023 |
|
Comprehensive Explorations of CCL28 in Lung Adenocarcinoma Immunotherapy and Experimental Validation
Su X, Wang G, Zheng S, Ge C, Kong F, Wang C |
Journal of inflammation research | 2023 |
|
B cell‐dependent subtypes and treatment‐based immune correlates to survival in stage 3 and 4 lung adenocarcinomas
Raju Paul S, Valiev I, Korek SE, Zyrin V, Shamsutdinova D, Gancharova O, Zaitsev A, Nuzhdina E, Davies DL, Dagogo\u2010Jack I, Frenkel F, Brown JH, Hess JM, Viet S, Petersen JL, Wright CD, Ott HC, Auchincloss HG, Muniappan A, Shioda T, Lanuti M, Davis CM, Ehli EA, Hung YP, Mino\u2010Kenudson M, Tsiper M, Sluder AE, Reeves PM, Kotlov N, Bagaev A, Ataullakhanov R, Poznansky MC |
FASEB bioAdvances | 2023 |
|
A novel transcriptional signature identifies T-cell infiltration in high-risk paediatric cancer
Mayoh C, Gifford AJ, Terry R, Lau LM, Wong M, Rao P, Shai-Hee T, Saletta F, Khuong-Quang DA, Qin V, Mateos MK, Meyran D, Miller KE, Yuksel A, Mould EV, Bowen-James R, Govender D, Senapati A, Zhukova N, Omer N, Dholaria H, Alvaro F, Tapp H, Diamond Y, Pozza LD, Moore AS, Nicholls W, Gottardo NG, McCowage G, Hansford JR, Khaw SL, Wood PJ, Catchpoole D, Cottrell CE, Mardis ER, Marshall GM, Tyrrell V, Haber M, Ziegler DS, Vittorio O, Trapani JA, Cowley MJ, Neeson PJ, Ekert PG |
Genome Medicine | 2023 |
|
The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating.
Mao Y, Xie H, Lv M, Yang Q, Shuang Z, Gao F, Li S, Zhu L, Wang W |
Cancer Immunology, Immunotherapy | 2023 |
|
ANGPTL2 promotes immune checkpoint inhibitor-related autoimmune myocarditis
Haruki Horiguchi, Tsuyoshi Kadomatsu, Tomoya Yamashita, Shinsei Yumoto, Kazutoyo Terada, Michio Sato, Jun Morinaga, Keishi Miyata, Yuichi Oike |
Communications biology | 2023 |
|
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab.
Nabbi A, Danesh A, Espin-Garcia O, Pedersen S, Wellum J, Fu LH, Paulson JN, Geoerger B, Marshall LV, Trippett T, Rossato G, Pugh TJ, Hutchinson KE |
Nature cancer | 2023 |
|
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.
Ravi A, Hellmann MD, Arniella MB, Holton M, Freeman SS, Naranbhai V, Stewart C, Leshchiner I, Kim J, Akiyama Y, Griffin AT, Vokes NI, Sakhi M, Kamesan V, Rizvi H, Ricciuti B, Forde PM, Anagnostou V, Riess JW, Gibbons DL, Pennell NA, Velcheti V, Digumarthy SR, Mino-Kenudson M, Califano A, Heymach JV, Herbst RS, Brahmer JR, Schalper KA, Velculescu VE, Henick BS, Rizvi N, Jänne PA, Awad MM, Chow A, Greenbaum BD, Luksza M, Shaw AT, Wolchok J, Hacohen N, Getz G, Gainor JF |
Nature Genetics | 2023 |
|
Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases—Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway
Massa C, Wang Y, Marr N, Seliger B |
International journal of molecular sciences | 2023 |
|
An OMA1 redox site controls mitochondrial homeostasis, sarcoma growth, and immunogenicity.
Miallot R, Millet V, Groult Y, Modelska A, Crescence L, Roulland S, Henri S, Malissen B, Brouilly N, Panicot-Dubois L, Vincentelli R, Sulzenbacher G, Finetti P, Dutour A, Blay JY, Bertucci F, Galland F, Naquet P |
Life science alliance | 2023 |
|
A narrative review of genetic biomarkers in non-small cell lung cancer: an update and future perspectives.
Workman S, Jabbour SK, Deek MP |
2023 | |
|
Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.
Ao YQ, Gao J, Wang S, Jiang JH, Deng J, Wang HK, Xu B, Ding JY |
Molecular Cancer | 2023 |
|
Immune profiles according to EGFR mutant subtypes and correlation with PD-1/PD-L1 inhibitor therapies in lung adenocarcinoma.
Koh YW, Park B, Jung SH, Han JH, Haam S, Lee HW |
Frontiers in immunology | 2023 |
|
A novel natural killer cell-related signatures to predict prognosis and chemotherapy response of pancreatic cancer patients.
Lan Y, Jia Q, Feng M, Zhao P, Zhu M |
Frontiers in Genetics | 2023 |
|
PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial.
Voorwerk L, Isaeva OI, Horlings HM, Balduzzi S, Chelushkin M, Bakker NAM, Champanhet E, Garner H, Sikorska K, Loo CE, Kemper I, Mandjes IAM, de Maaker M, van Geel JJL, Boers J, de Boer M, Salgado R, van Dongen MGJ, Sonke GS, de Visser KE, Schumacher TN, Blank CU, Wessels LFA, Jager A, Tjan-Heijnen VCG, Schröder CP, Linn SC, Kok M |
Nature cancer | 2023 |
|
Palmitoyl transferases act as novel drug targets for pancreatic cancer.
Lin Z, Lv Z, Liu X, Huang K |
Journal of Translational Medicine | 2023 |
|
Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach.
Mao Y, Gide TN, Adegoke NA, Quek C, Maher N, Potter A, Patrick E, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Carlino MS, Lo SN, Menzies AM, da Silva IP, Long GV, Scolyer RA, Wilmott JS |
Journal of Translational Medicine | 2023 |
|
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
Posner A, Sivakumaran T, Pattison A, Etemadmoghadam D, Thio N, Wood C, Fisher K, Webb S, DeFazio A, Wilcken N, Gao B, Karapetis CS, Singh M, Collins IM, Richardson G, Steer C, Warren M, Karanth N, Fellowes A, Fox SB, Hicks RJ, Schofield P, Bowtell D, Prall OW, Tothill RW, Mileshkin L |
Journal for ImmunoTherapy of Cancer | 2023 |
|
CD86 Is Associated with Immune Infiltration and Immunotherapy Signatures in AML and Promotes Its Progression
Zhang Q, Ma R, Chen H, Guo W, Li Z, Xu K, Chen W |
Journal of Oncology | 2023 |
|
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
Li B, Chen H, Yang S, Chen F, Xu L, Li Y, Li M, Zhu C, Shao F, Zhang X, Deng C, Zeng L, He Y, Zhang C |
Molecular Cancer | 2023 |
|
Mathematical modeling suggests cytotoxic T lymphocytes control growth of B16 tumor cells in collagin-fibrin gels by cytolytic and non-lytic mechanisms
Majumder B, Budhu S, Ganusov VV |
2023 | |
|
Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
Pulanco MC, Madsen AT, Tanwar A, Corrigan DT, Zang X |
Cellular & molecular immunology | 2023 |
|
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.
Luke JJ, Fakih M, Schneider C, Chiorean EG, Bendell J, Kristeleit R, Kurzrock R, Blagden SP, Brana I, Goff LW, O'Hayer K, Geschwindt R, Smith M, Zhou F, Naing A |
British Journal of Cancer | 2023 |
|
Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
Zhou S, Yang H |
Frontiers in immunology | 2023 |
|
Tumor and immune remodeling following radiotherapy in human renal cell carcinoma
Chow J, Khan A, Gaudieri M, Wasik BJ, Conway A, Soh KT, Repasky EA, Schwaab T, Wallace PK, Abrams SI, Singh AK, Muhitch JB |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer
Corr BR, Moroney MR, Woodruff E, Watson ZL, Jordan KR, Danhorn T, Bailey C, Wolsky RJ, Bitler BG |
2023 | |
|
By using machine learning and in vitro testing, SERPINH1 functions as a novel tumorigenic and immunogenic gene and predicts immunotherapy response in osteosarcoma
Xia G, Wu S, Luo K, Cui X |
Frontiers in Oncology | 2023 |
|
Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study
Fakih M, Raghav KP, Chang DZ, Larson T, Cohn AL, Huyck TK, Cosgrove D, Fiorillo JA, Tam R, D'Adamo D, Sharma N, Brennan BJ, Wang YA, Coppieters S, Zebger-Gong H, Weispfenning A, Seidel H, Ploeger BA, Mueller U, Oliveira CS, Paulson AS |
2023 | |
|
Early Changes of Serum Interleukin 14α Levels Predicts the Response to Anti-PD-1 Therapy in Cancer
Wang B, Chen C, Jiang S, Huang Y, Zeng Y, Li L, Wang M, Guo J, Li Q, Cao J, Shen L, Gu JJ, Liang Y |
Clinical Medicine Insights. Oncology | 2023 |
|
The Emerging Role of IL-9 in the Anticancer Effects of Anti-PD-1 Therapy
Vinokurova D, Apetoh L |
Biomolecules | 2023 |
|
Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma
Loh JW, Lee JY, Lim AH, Guan P, Lim BY, Kannan B, Lee EC, Gu NX, Ko TK, Ng CC, Lim JC, Yeong J, Lim JQ, Ong CK, Teh BT, Chan JY |
Communications biology | 2023 |
|
Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
Pabst L, Lopes S, Bertrand B, Creusot Q, Kotovskaya M, Pencreach E, Beau-Faller M, Mascaux C |
International journal of molecular sciences | 2023 |
|
EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
Masamoto Y, Chiba A, Mizuno H, Hino T, Hayashida H, Sato T, Bando M, Shirahige K, Kurokawa M |
Blood Advances | 2023 |
|
Mapping the functional interactions at the tumor-immune checkpoint interface
Bozorgui B, Kong EK, Luna A, Korkut A |
Communications biology | 2023 |
|
MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer
Alburquerque-Bejar JJ, Navajas-Chocarro P, Saigi M, Ferrero-Andres A, Morillas JM, Vilarrubi A, Gomez A, Mate JL, Munoz-Marmol AM, Romero OA, Blecua P, Davalos V, Esteller M, Pros E, Llabata P, Torres-Diz M, Esteve-Codina A, Sanchez-Cespedes M |
Cell reports. Medicine | 2023 |
|
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma
Ji JH, Ha SY, Lee D, Sankar K, Koltsova EK, Abou-Alfa GK, Yang JD |
International journal of molecular sciences | 2023 |
|
Screening prognostic markers for hepatocellular carcinoma based on pyroptosis-related lncRNA pairs
Wu T, Li N, Luo F, Chen Z, Ma L, Hu T, Hong G, Li H |
BMC bioinformatics | 2023 |
|
Identification and validation of fatty acid metabolism-related lncRNA signatures as a novel prognostic model for clear cell renal cell carcinoma
Shen C, Chen Z, Jiang J, Zhang Y, Chen X, Xu W, Peng R, Zuo W, Jiang Q, Fan Y, Fang X, Zheng B |
Scientific Reports | 2023 |
|
Identification of CircRNA signature associated with tumor immune infiltration to predict therapeutic efficacy of immunotherapy
Dong Y, Gao Q, Chen Y, Zhang Z, Du Y, Liu Y, Zhang G, Li S, Wang G, Chen X, Liu H, Han L, Ye Y |
Nature Communications | 2023 |
|
Identification and validation of a novel cuproptosis-related gene signature in multiple myeloma
Zhang B, Wang Q, Zhang T, Zheng Z, Lin Z, Zhou S, Zheng D, Chen Z, Zheng S, Zhang Y, Lin X, Dong R, Chen J, Qian H, Hu X, Zhuang Y, Zhang Q, Jin Z, Jiang S, Ma Y |
Frontiers in Cell and Developmental Biology | 2023 |
|
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma.
Lucas MW, Versluis JM, Rozeman EA, Blank CU |
Nature reviews. Clinical oncology | 2023 |
|
TSPO acts as an immune resistance gene involved in the T cell mediated immune control of glioblastoma.
Menevse AN, Ammer LM, Vollmann-Zwerenz A, Kupczyk M, Lorenz J, Weidner L, Hussein A, Sax J, Mühlbauer J, Heuschneider N, Rohrmus C, Mai LS, Jachnik B, Stamova S, Volpin V, Durst FC, Sorrentino A, Xydia M, Milenkovic VM, Bader S, Braun FK, Wetzel C, Albert NL, Tonn JC, Bartenstein P, Proescholdt M, Schmidt NO, Linker RA, Riemenschneider MJ, Beckhove P, Hau P |
Acta Neuropathologica Communications | 2023 |
|
Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.
Pagadala M, Sears TJ, Wu VH, Pérez-Guijarro E, Kim H, Castro A, Talwar JV, Gonzalez-Colin C, Cao S, Schmiedel BJ, Goudarzi S, Kirani D, Au J, Zhang T, Landi T, Salem RM, Morris GP, Harismendy O, Patel SP, Alexandrov LB, Mesirov JP, Zanetti M, Day CP, Fan CC, Thompson WK, Merlino G, Gutkind JS, Vijayanand P, Carter H |
Nature Communications | 2023 |
|
Role of the gut microbiota in anticancer therapy: from molecular mechanisms to clinical applications
Zhao LY, Mei JX, Yu G, Lei L, Zhang WH, Liu K, Chen XL, Kołat D, Yang K, Hu JK |
Signal Transduction and Targeted Therapy | 2023 |
|
Harnessing immune checkpoint trial data in pediatric cancer.
Neeson PJ, Ekert PG |
Nature cancer | 2023 |
|
Immune landscape of breast tumors with low and intermediate estrogen receptor expression
Voorwerk L, Sanders J, Keusters MS, Balduzzi S, Cornelissen S, Duijst M, Lips EH, Sonke GS, Linn SC, Horlings HM, Kok M |
npj Breast Cancer | 2023 |
|
GBP5 Identifies Immuno-Hot Tumors and Predicts the Therapeutic Response to Immunotherapy in NSCLC
Fan H, Shi Y, Wang H, Li Y, Mei J, Xu J, Liu C |
International journal of general medicine | 2023 |
|
Molecular vasculogenic mimicry–Related signatures predict clinical outcomes and therapeutic responses in bladder cancer: Results from real-world cohorts
Zhang C, Xiao J, Yuan T, He Y, Deng D, Xiao Z, Chen J, Zu X, Liu P, Liu Z |
Frontiers in pharmacology | 2023 |
|
The characteristics and clinical relevance of tumor fusion burden in non-EBV (+) gastric cancer with MSS
Zhu Y, Wu W, Qiao L, Ji J, Duan L, Gong L, Ren D, Li F, Wei L, Pan K |
BMC Gastroenterology | 2023 |
|
Protocol to identify novel immunotherapy biomarkers based on transcriptomic data in human cancers
Mei J, Cai Y, Xu R, Zhu Y, Zhao X, Zhang Y, Mao W, Xu J, Yin Y |
2023 | |
|
Construction of an interferon regulatory factors-related risk model for predicting prognosis, immune microenvironment and immunotherapy in clear cell renal cell carcinoma
Pan H, Lu W, Zhang M, Liu C |
Frontiers in Oncology | 2023 |
|
Phenotypic plasticity and reduced tissue retention of exhausted tumor-infiltrating T cells following neoadjuvant immunotherapy in head and neck cancer
Sievers C, Craveiro M, Friedman J, Robbins Y, Yang X, Bai K, Nguyen A, Redman JM, Chari R, Soon-Shiong P, Schlom J, Gulley J, Allen CT |
Cancer Cell | 2023 |
|
Immune desert in MMR-deficient tumors predicts poor responsiveness of immune checkpoint inhibition
Zheng G, Lu Y, Yang Z, Chen H, Liang Q, Zhu Q, Li Y, Xiao X, He Z, Zhu Y, Li B, Huang L, Dong N, Hu S, Pan Y, Zhang C, Zhu C |
Frontiers in immunology | 2023 |
|
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.
Campbell KM, Amouzgar M, Pfeiffer SM, Howes TR, Medina E, Travers M, Steiner G, Weber JS, Wolchok JD, Larkin J, Hodi FS, Boffo S, Salvador L, Tenney D, Tang T, Thompson MA, Spencer CN, Wells DK, Ribas A |
Cancer Cell | 2023 |
|
Clinical efficacy and biomarker analysis of dual PD-1/CTLA-4 blockade in recurrent/metastatic EBV-associated nasopharyngeal carcinoma.
Lim DW, Kao HF, Suteja L, Li CH, Quah HS, Tan DS, Tan SH, Tan EH, Tan WL, Lee JN, Wee FY, Jain A, Goh BC, Chua MLK, Liao BC, Ng QS, Hong RL, Ang MK, Yeong JP, Iyer NG |
Nature Communications | 2023 |
|
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G |
Nature Medicine | 2023 |
|
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma.
Naghavian R, Faigle W, Oldrati P, Wang J, Toussaint NC, Qiu Y, Medici G, Wacker M, Freudenmann LK, Bonté PE, Weller M, Regli L, Amigorena S, Rammensee HG, Walz JS, Brugger SD, Mohme M, Zhao Y, Sospedra M, Neidert MC, Martin R |
Nature | 2023 |
|
Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes.
Lee SE, Wang F, Grefe M, Trujillo-Ocampo A, Ruiz-Vasquez W, Takahashi K, Abbas HA, Borges P, Antunes DA, Al-Atrash G, Daver N, Molldrem JJ, Futreal A, Garcia-Manero G, Im JS |
Clinical cancer research | 2023 |
|
Leveraging various extracellular matrix levels to assess prognosis and sensitivity to immunotherapy in patients with ovarian cancer
Huang Y, Lei X, Sun L, Liu Y, Yang J |
Frontiers in Oncology | 2023 |
|
Multi-institutional study of pathologist reading of the PD-L1 combined positive score (CPS) immunohistochemistry assay in gastric or gastroesophageal junction cancer
Fernandez AI, Robbins CJ, Gaule P, Agostini-Vulaj D, Anders RA, Bellizi A, Chen W, Chen ZE, Gopal P, Zhao L, Lisovsky M, Liu X, Shia J, Wang H, Yang Z, McCann L, Chan YG, Weidler J, Bates M, Zhang X, Rimm DL |
Modern Pathology | 2023 |
|
Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations
Wu L, Zhang Z, Bai M, Yan Y, Yu J, Xu Y |
Cell communication and signaling : CCS | 2023 |
|
Senescence-induced immune remodeling facilitates metastatic adrenal cancer in a sex-dimorphic manner.
Warde KM, Smith LJ, Liu L, Stubben CJ, Lohman BK, Willett PW, Ammer JL, Castaneda-Hernandez G, Imodoye SO, Zhang C, Jones KD, Converso-Baran K, Ekiz HA, Barry M, Clay MR, Kiseljak-Vassiliades K, Giordano TJ, Hammer GD, Basham KJ |
2023 | |
|
Xerna™ TME Panel is a machine learning-based transcriptomic biomarker designed to predict therapeutic response in multiple cancers
Uhlik M, Pointing D, Iyer S, Ausec L, Štajdohar M, Cvitkovič R, Žganec M, Culm K, Santos VC, Pytowski B, Malafa M, Liu H, Krieg AM, Lee J, Rosengarten R, Benjamin L |
Frontiers in Oncology | 2023 |
|
Dysregulation in IFN-γ signaling and response: the barricade to tumor immunotherapy
Han J, Wu M, Liu Z |
Frontiers in immunology | 2023 |
|
Potential non-invasive biomarkers in tumor immune checkpoint inhibitor therapy: response and prognosis prediction
Song R, Liu F, Ping Y, Zhang Y, Wang L |
Biomarker Research | 2023 |
|
Genomic analysis of immunogenic cell death-related subtypes for predicting prognosis and immunotherapy outcomes in glioblastoma multiforme
Liu Z, Li W, You G, Hu Z, Liu Y, Zheng N |
Open Medicine | 2023 |
|
Cancer immune exclusion: breaking the barricade for a successful immunotherapy
Bruni S, Mercogliano MF, Mauro FL, Cordo Russo RI, Schillaci R |
Frontiers in Oncology | 2023 |
|
Collagen-anchored interleukin-2 and interleukin-12 safely reprogram the tumor microenvironment in canine soft tissue sarcomas
Stinson JA, Sheen A, Momin N, Hampel J, Bernstein R, Kamerer R, Fadl-Alla B, Samuelson J, Fink E, Fan TM, Wittrup KD |
Clinical cancer research | 2023 |
|
Mechanistic insights into the interactions between cancer drivers and the tumour immune microenvironment.
Misetic H, Keddar MR, Jeannon JP, Ciccarelli FD |
Genome Medicine | 2023 |
|
An immune-related biomarker index for predicting the effectiveness of immunotherapy and prognosis in hepatocellular carcinoma.
Wu X, Jin B, Liu X, Mao Y, Wan X, Du S |
Journal of Cancer Research and Clinical Oncology | 2023 |
|
The tumor microbiome as a predictor of outcomes in patients with metastatic melanoma treated with immune checkpoint inhibitors
Wheeler CE, Coleman SS IV, Hoyd R, Denko L, Chan CH, Churchman ML, Denko N, Dodd RD, Eljilany I, Hardikar S, Husain M, Ikeguchi AP, Jin N, Ma Q, McCarter MD, Osman AE, Robinson LA, Singer EA, Tinoco G, Ulrich CM, Zakharia Y, Spakowicz D, Tarhini AA, Tan AC |
2023 | |
|
Immune-related adverse events of immune checkpoint inhibitors: a review
Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, Bai L, Bian Y |
Frontiers in immunology | 2023 |
|
Crosstalk between ILC3s and Microbiota: Implications for Colon Cancer Development and Treatment with Immune Check Point Inhibitors
Drommi F, Calabrò A, Vento G, Pezzino G, Cavaliere R, Omero F, Muscolino P, Granata B, D\u2019Anna F, Silvestris N, De Pasquale C, Ferlazzo G, Campana S |
Cancers | 2023 |
|
Prognostic and predictive impact of gene expression in node‐positive early breast cancer patients receiving dose‐dense versus standard‐dose adjuvant chemotherapy
Reinisch M, Bruzas S, Gluz O, Ataseven B, Schmid P, Cortés J, Blohmer J, Shenoy S, Dyson MH, Dittmer\u2010Grabowski C, Chiari O, Harrach H, Gebauer D, Traut A, Kuemmel S |
Molecular Oncology | 2023 |
|
Identification of fatty acid-related subtypes, the establishment of a prognostic signature, and immune infiltration characteristics in lung adenocarcinoma
Wang Y, Huang X, Fan H, Xu Y, Qi Z, Zhang Y, Huang Y |
Aging | 2023 |
|
Immunology and immunotherapy in gastric cancer.
Xu X, Chen J, Li W, Feng C, Liu Q, Gao W, He M |
Clinical and Experimental Medicine | 2023 |
|
Type I interferon signature and cycling lymphocytes in macrophage activation syndrome
Zhengping Huang, Kailey Brodeur, Liang Chen, Yan Du, Holly Wobma, Evan Hsu, Meng Liu, Joyce Chang, Margaret Chang, Janet Chou, Megan Day-Lewis, Fatma Dedeoglu, Olha Halyabar, James Lederer, Tianwang Li, Mindy Lo, Meiping Lu, Esra Meidan, Jane Newburger, Adrienne Randolph, Mary Son, Robert Sundel, Maria L Taylor, Huaxiang Wu, Qing Zhou, Scott Canna, Kevin Wei, Lauren Henderson, Peter Nigrovic, Pui Lee |
Journal of Clinical Investigation | 2023 |
|
Immune-related genetic prognostic index to predict prognosis and immune checkpoint inhibitor therapy efficiency in acute myeloid leukemia
Cao X, Huang X, Zhao X |
Chinese Medical Journal | 2023 |
|
Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma
Cheung CC, Seah YH, Fang J, Orpilla NH, Lau MC, Lim CJ, Lim X, Lee JN, Lim JC, Lim S, Cheng Q, Toh HC, Choo SP, Lee SY, Lee JJ, Liu J, Lim TK, Tai D, Yeong J |
Frontiers in immunology | 2023 |
|
Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multicenter cohort study based on super-enhancer profiling
Chen D, Cao Y, Tang H, Zang L, Yao N, Zhu Y, Jiang Y, Zhai S, Liu Y, Shi M, Zhao S, Wang W, Wen C, Peng C, Chen H, Deng X, Jiang L, Shen B |
Theranostics | 2023 |
|
Nivolumab plus chemoradiotherapy in locally-advanced cervical cancer: the NICOL phase 1 trial.
Rodrigues M, Vanoni G, Loap P, Dubot C, Timperi E, Minsat M, Bazire L, Durdux C, Fourchotte V, Laas E, Pouget N, Castel-Ajgal Z, Marret G, Lesage L, Meseure D, Vincent-Salomon A, Lecompte L, Servant N, Vacher S, Bieche I, Malhaire C, Huchet V, Champion L, Kamal M, Amigorena S, Lantz O, Chevrier M, Romano E |
Nature Communications | 2023 |
|
Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network.
Nigon E, Lefeuvre-Plesse C, Martinez A, Chauleur C, Lortholary A, Favier L, Bats AS, Guille A, AdélaÏde J, Finetti P, de Casteljac V, Provansal M, Mamessier E, Bertucci F, Ray-Coquard I, Sabatier R |
Journal of Translational Medicine | 2023 |
|
YTHDF2 negatively correlates with tumor immune infiltration in small cell lung cancer.
Chen G, Ren D, Wang Y, Wang H, Zhang J, Yang S |
Journal Of Molecular Histology | 2023 |
|
A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations.
Thavaneswaran S, Kansara M, Lin F, Espinoza D, Grady JP, Lee CK, Ballinger ML, Sebastian L, Corpuz T, Qiu MR, Mundra P, Bailey CG, Schmitz U, Simes J, Joshua AM, Thomas DM |
British Journal of Cancer | 2023 |
|
PD-1Hi CAR-T cells provide superior protection against solid tumors
Sailer CJ, Hong Y, Dahal A, Ryan AT, Mir S, Gerber SA, Reagan PM, Kim M |
Frontiers in immunology | 2023 |
|
Dissecting molecular, pathological, and clinical features associated with tumor neural/neuroendocrine heterogeneity
Cai L, DeBerardinis RJ, Xiao G, Minna JD, Xie Y |
iScience | 2023 |
|
Prediction of Disease Progression to Upfront Pembrolizumab Monotherapy in Advanced Non-Small-Cell Lung Cancer with High PD-L1 Expression Using Baseline CT Disease Quantification and Smoking Pack Years
Silver A, Ho C, Ye Q, Zhang J, Janzen I, Li J, Martin M, Wu L, Wang Y, Lam S, MacAulay C, Melosky B, Yuan R |
Current Oncology | 2023 |
|
Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy
Pickering C, Aiyetan P, Xu G, Mitchell A, Rice R, Najjar YG, Markowitz J, Ebert LM, Brown MP, Tapia-Rico G, Frederick D, Cong X, Serie D, Lindpaintner K, Schwarz F, Boland GM |
Frontiers in immunology | 2023 |
|
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
Shitara K, Di Bartolomeo M, Mandala M, Ryu MH, Caglevic C, Olesinski T, Chung HC, Muro K, Goekkurt E, McDermott RS, Mansoor W, Wainberg ZA, Shih CS, Kobie J, Nebozhyn M, Cristescu R, Cao ZA, Loboda A, Özgüroğlu M |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Features of metabolism associated molecular patterns in pancreatic ductal adenocarcinoma.
Chen J, Wang Y, Jiang H |
Cancer Gene Therapy | 2023 |
|
Tutorial: integrative computational analysis of bulk RNA-sequencing data to characterize tumor immunity using RIMA.
Yang L, Wang J, Altreuter J, Jhaveri A, Wong CJ, Song L, Fu J, Taing L, Bodapati S, Sahu A, Tokheim C, Zhang Y, Zeng Z, Bai G, Tang M, Qiu X, Long HW, Michor F, Liu Y, Liu XS |
Nature Protocols | 2023 |
|
Melanoma-intrinsic NR2F6 activity regulates antitumor immunity.
Kim H, Feng Y, Murad R, Pozniak J, Pelz C, Chen Y, Dalal B, Sears R, Sergienko E, Jackson M, Ruppin E, Herlyn M, Harris C, Marine JC, Klepsch V, Baier G, Ronai ZA |
Science Advances | 2023 |
|
Implications of inflammatory cell death-related IFNG and co-expressed RNAs (AC006369.1 and CCR7) in breast carcinoma prognosis, and anti-tumor immunity
Deng Y, Li Z, Pan M, Wu H, Ni B, Han X |
Frontiers in Genetics | 2023 |
|
ACSM6 overexpression indicates a non-inflammatory tumor microenvironment and predicts treatment response in bladder cancer: results from multiple real-world cohorts
Li Z, Yao Y, Qi T, Wu Z, Deng D, Liu B |
Frontiers in pharmacology | 2023 |
|
Tucatinib promotes immune activation and synergizes with programmed cell death–1 and programmed cell death–ligand 1 inhibition in HER2-positive breast cancer
Li R, Sant S, Brown E, Caramia F, Nikolic B, Clarke K, Byrne A, Lara Gonzalez LE, Savas P, Luen SJ, Teo ZL, Virassamy B, Neeson PJ, Darcy PK, Loi S |
JNCI Journal of the National Cancer Institute | 2023 |
|
Sustained complete response to first-line immunochemotherapy for highly aggressive TP53/MDM2-mutated upper tract urothelial carcinoma with ERBB2 mutations, luminal immune-infiltrated contexture, and non-mesenchymal state: a case report and literature review
Xu T, Guo H, Xie J, He Y, Che J, Peng B, Yang B, Yao X |
Frontiers in Oncology | 2023 |
|
CD16+ macrophages: an emerging biomarker for combined CTLA-4 and PD-1 blockade
Smithy JW, Luke JJ |
Clinical cancer research | 2023 |
|
Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors
Ding L, Sun L, Bu MT, Zhang Y, Scott LN, Prins RM, Su MA, Lechner MG, Hugo W |
Frontiers in immunology | 2023 |
|
Th1 cells inducing IFNγ response improves immunotherapy efficacy in gastric cancer
Cao Q, Xue R, Zhang N |
Chinese Journal of Cancer Research | 2023 |
|
PTPRD/PTPRT mutation correlates to treatment outcomes of immunotherapy and immune landscape in pan-cancers
Wang G, Ji X, Wang H, Tang X, Xing X, Ji J |
Chinese Journal of Cancer Research | 2023 |
|
The Current State of Neoadjuvant Therapy in Resectable Advanced Stage Melanoma.
Bushara O, Tidwell J, Wester JR, Miura J |
Cancers | 2023 |
|
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer.
Liu Y, Liu Z, Yang Y, Cui J, Sun J, Liu Y |
British Journal of Cancer | 2023 |
|
The DNA damage repair-related lncRNAs signature predicts the prognosis and immunotherapy response in gastric cancer
Zhao Z, Mak TK, Shi Y, Huang H, Huo M, Zhang C |
Frontiers in immunology | 2023 |
|
A tumor mutational burden-derived immune computational framework selects sensitive immunotherapy/chemotherapy for lung adenocarcinoma populations with different prognoses
Zhang W, Wei C, Huang F, Huang W, Xu X, Zhu X |
Frontiers in Oncology | 2023 |
|
Hypoxia-based classification and prognostic signature for clinical management of hepatocellular carcinoma
Li K, Yang Y, Ma M, Lu S, Li J |
World journal of surgical oncology | 2023 |
|
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results.
Gutierrez M, Lam WS, Hellmann MD, Gubens MA, Aggarwal C, Tan DSW, Felip E, Chiu JWY, Lee JS, Yang JC, Garon EB, Finocchiaro G, Ahn MJ, Luft A, Landers GA, Basso A, Ma H, Kobie J, Palcza J, Cristescu R, Fong L, Snyder A, Yuan J, Herbst RS |
Nature Medicine | 2023 |
|
IMPemBra: a phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients with melanoma harboring the BRAFV600 mutation.
Rozeman EA, Versluis JM, Sikorska K, Hoefsmit EP, Dimitriadis P, Rao D, Lacroix R, Grijpink-Ongering LG, Lopez-Yurda M, Heeres BC, van de Wiel BA, Flohil C, Sari A, Heijmink SWTPJ, van den Broek D, Broeks A, de Groot JWB, Vollebergh MA, Wilgenhof S, van Thienen JV, Haanen JBAG, Blank CU |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
Mestrallet G, Brown M, Bozkus CC, Bhardwaj N |
Frontiers in immunology | 2023 |
|
Cytotoxic T Lymphocytes Control Growth of B16 Tumor Cells in Collagen–Fibrin Gels by Cytolytic and Non-Lytic Mechanisms
Majumder B, Budhu S, Ganusov VV |
Viruses | 2023 |
|
A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer
Han Y, Liu SY, Jin R, Meng W, Wu YL, Li H |
Frontiers in immunology | 2023 |
|
Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma
Zeng W, Wang J, Yang J, Chen Z, Cui Y, Li Q, Luo G, Ding H, Ju S, Li B, Chen J, Xie Y, Tong X, Liu M, Zhao J |
Frontiers in immunology | 2023 |
|
The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL
Erman A, Ignjatović M, Leskovšek K, Miceska S, Lampreht Tratar U, Bošnjak M, Kloboves Prevodnik V, Čemažar M, Kandolf Sekulovič L, Avguštin G, Ocvirk J, Mesti T |
Biomedicines | 2023 |
|
Comprehensive Immune Profiling Unveils a Subset of Leiomyosarcoma with “Hot” Tumor Immune Microenvironment
Feng X, Tonon L, Li H, Darbo E, Pleasance E, Macagno N, Dufresne A, Brahmi M, Bollard J, Ducimetière F, Karanian M, Meurgey A, Pérot G, Valentin T, Chibon F, Blay JY |
Cancers | 2023 |
|
Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer
O\u2019Meara CH, Jafri Z, Khachigian LM |
International journal of molecular sciences | 2023 |
|
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer
Nadal E, Saleh M, Aix SP, Ochoa-de-Olza M, Patel SP, Antonia S, Zhao Y, Gueorguieva I, Man M, Estrem ST, Liu J, Avsar E, Lin WH, Benhadji KA, Gandhi L, Guba SC, Diaz IA |
BMC Cancer | 2023 |
|
Targeting m6A reader YTHDF1 augments antitumour immunity and boosts anti-PD-1 efficacy in colorectal cancer
Bao Y, Zhai J, Chen H, Wong CC, Liang C, Ding Y, Huang D, Gou H, Chen D, Pan Y, Kang W, To KF, Yu J |
Gut | 2023 |
|
Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study.
Wen C, Zhang L, Yang Y, Jin Y, Ren D, Zhang Z, Zou S, Li F, Sun H, Jin J, Lu X, Xie J, Cheng D, Xu Z, Chen H, Mao B, Zhang J, Wang J, Deng X, Peng C, Li H, Jiang C, Lin L, Zhang H, Chen H, Shen B, Zhan Q |
International journal of surgery (London, England) | 2023 |
|
The GPCR-Gα(s)-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure.
Wu VH, Yung BS, Faraji F, Saddawi-Konefka R, Wang Z, Wenzel AT, Song MJ, Pagadala MS, Clubb LM, Chiou J, Sinha S, Matic M, Raimondi F, Hoang TS, Berdeaux R, Vignali DAA, Iglesias-Bartolome R, Carter H, Ruppin E, Mesirov JP, Gutkind JS |
Nature Immunology | 2023 |
|
Different immune contextures underlie tumor site-specific responses to immune checkpoint blockade in esophageal cancer.
Guo JC, Hsu CL, Hsieh MS, Lin CC, Huang TC, Kuo HY, Shao YY, Hsu CH |
Thoracic Cancer | 2023 |
|
Single-cell dissection of Merkel cell carcinoma heterogeneity unveils transcriptomic plasticity and therapeutic vulnerabilities.
Das BK, Kannan A, Velasco GJ, Kunika MD, Lambrecht N, Nguyen Q, Zhao H, Wu J, Gao L |
Cell reports. Medicine | 2023 |
|
A GPCR checkpoint drives CD8(+) T cell dysfunction and immunotherapy failure in mice.
|
Nature Immunology | 2023 |
|
C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer
Zhang C, Cao K, Yang M, Wang Y, He M, Lu J, Huang Y, Zhang G, Liu H |
OncoImmunology | 2023 |
|
Integrative evaluation and experimental validation of the immune-modulating potential of dysregulated extracellular matrix genes in high-grade serous ovarian cancer prognosis
Wu Q, He X, Liu J, Ou C, Li Y, Fu X |
Cancer Cell International | 2023 |
|
Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response
Kleczko EK, Le AT, Hinz TK, Nguyen TT, Navarro A, Hu CJ, Selman AM, Clambey ET, Merrick DT, Lu S, Weiser-Evans M, Nemenoff RA, Heasley LE |
Cancer Letters | 2023 |
|
Comparison of different predictive biomarker testing assays for PD-1/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis
Shi H, Zhang W, Zhang L, Zheng Y, Dong T |
Frontiers in immunology | 2023 |
|
Development of a CD8+ T cell-based molecular classification for predicting prognosis and heterogeneity in triple-negative breast cancer by integrated analysis of single-cell and bulk RNA-sequencing
Dai YW, Wang WM, Zhou X |
Heliyon | 2023 |
|
Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8+ T cell infiltration and functional transition
Yu A, Hu J, Fu L, Huang G, Deng D, Zhang M, Wang Y, Shu G, Jing L, Li H, Chen X, Yang T, Wei J, Chen Z, Zu X, Luo J |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Combination of multiple omics techniques for a personalized therapy or treatment selection
Massa C, Seliger B |
Frontiers in immunology | 2023 |
|
Characterization of endoplasmic reticulum stress unveils ZNF703 as a promising target for colorectal cancer immunotherapy
Wang H, Li Z, Tao Y, Ou S, Ye J, Ran S, Luo K, Guan Z, Xiang J, Yan G, Wang Y, Ma T, Yu S, Song Y, Huang R |
Journal of Translational Medicine | 2023 |
|
Nanoparticle delivery of innate immune agonists combines with senescence-inducing agents to mediate T cell control of pancreatic cancer
Chibaya L, Lusi CF, DeMarco KD, Kane GI, Brassil ML, Parikh CN, Murphy KC, Li J, Naylor TE, Cerrutti J, Peura J, Pitarresi JR, Zhu LJ, Fitzgerald KA, Atukorale PU, Ruscetti M |
2023 | |
|
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models
Gray E, Ulrich M, Epp A, Younan P, Sahetya D, Hensley K, Allred S, Huang LY, Hahn J, Gahnberg K, Treuting PM, Trueblood ES, Gosink JJ, Thurman R, Wo S, Spahr K, Haass EJ, Snead K, Miller D, Padilla M, Smith AJ, Frantz C, Schrum JP, Nazarenko N, Gardai SJ |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Neoantigen Targetability in Progressive Advanced Melanoma
van den Bulk J, Verdegaal EM, van der Ploeg M, Visser M, Nunes JB, de Ru AH, Tjokrodirijo RT, Ijsselsteijn ME, Janssen NI, van der Breggen R, de Bruin L, de Kok P, Janssen GM, Ruano D, Kapiteijn EH, van Veelen PA, de Miranda NF, van der Burg SH |
Clinical cancer research | 2023 |
|
Pan-cancer spatially resolved single-cell analysis reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment
Ma C, Yang C, Peng A, Sun T, Ji X, Mi J, Wei L, Shen S, Feng Q |
Molecular Cancer | 2023 |
|
Taxifolin Inhibits the Growth of Non-Small-Cell Lung Cancer via Downregulating Genes Displaying Novel and Robust Associations with Immune Evasion Factors
Lin X, Dong Y, Gu Y, Wei F, Peng J, Su Y, Wang Y, Yang C, Neira SV, Kapoor A, Tang D |
Cancers | 2023 |
|
ERK mediates interferon gamma-induced melanoma cell death
Champhekar A, Heymans R, Saco J, Turon Font G, Gonzalez C, Gao A, Pham J, Lee J, Maryoung R, Medina E, Campbell KM, Karin D, Austin D, Damioseaux R, Ribas A |
Molecular Cancer | 2023 |
|
Two bullets in the gun: combining immunotherapy with chemotherapy to defeat neuroblastoma by targeting adrenergic-mesenchymal plasticity
D\u2019Amico S, Tempora P, Gragera P, Król K, Melaiu O, De Ioris MA, Locatelli F, Fruci D |
Frontiers in immunology | 2023 |
|
The coenzyme A precursor pantethine enhances antitumor immunity in sarcoma
Miallot R, Millet V, Roger A, Fenouil R, Tardivel C, Martin JC, Shintu L, Berchard P, Sousa Lanza J, Malissen B, Henri S, Ugolini S, Dutour A, Finetti P, Bertucci F, Blay JY, Galland F, Naquet P |
Life science alliance | 2023 |
|
Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcome
Röhl L, Wellhausen J, Berszin M, Krücken I, Zebralla V, Pirlich M, Wiegand S, Dietz A, Wald T, Wichmann G |
Frontiers in immunology | 2023 |
|
Coordination of Single-cell and Bulk RNA Sequencing to Construct a Cuproptosis-related Gene Prognostic Index for Endometrial Cancer Prognosis, Immune Microenvironment Infiltration, and Immunotherapy Treatment Options
Pang X, Li F, Lu M, Zhu L |
Journal of Cancer | 2023 |
|
Formin protein FMNL1 is a biomarker for tumor-infiltrating immune cells and associated with well immunotherapeutic response
Lu G, Wang H, Xu R, Xu J, An F, Xu H, Nie H, Mei J, Zhan Q, Zhang Q |
Journal of Cancer | 2023 |
|
Targeted Proteomic Quantitation of NRF2 Signaling and Predictive Biomarkers in HNSCC
Wamsley NT, Wilkerson EM, Guan L, LaPak KM, Schrank TP, Holmes BJ, Sprung RW, Gilmore PE, Gerndt SP, Jackson RS, Paniello RC, Pipkorn P, Puram SV, Rich JT, Townsend RR, Zevallos JP, Zolkind P, Le QT, Goldfarb D, Major MB |
Molecular & cellular proteomics : MCP | 2023 |
|
Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-γ signalling
Cao L, Lu H, Soutto M, Bhat N, Chen Z, Peng D, Gomaa A, Wang J, Xie J, Li P, Zheng C, Nomura S, Datta J, Merchant N, Chen Z, Villarino A, Zaika A, Huang C, El-Rifai W |
Gut | 2023 |
|
signifinder enables the identification of tumor cell states and cancer expression signatures in bulk, single-cell and spatial transcriptomic data.
Pirrotta S, Masatti L, Corrà A, Pedrini F, Esposito G, Martini P, Risso D, Romualdi C, Calura E |
bioRxiv : the preprint server for biology | 2023 |
|
DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers.
Pineda JMB, Bradley RK |
bioRxiv : the preprint server for biology | 2023 |
|
Strategies for Improving the Performance of Prediction Models for Response to Immune Checkpoint Blockade Therapy in Cancer.
Zeng T, Zhang J, Stromberg A, Chen J, Wang C |
medRxiv : the preprint server for health sciences | 2023 |
|
Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC, Newman S, Li A, Joy M, Lyons M, Pham MP, Lucas P, Smith K, Sander C, Isett B, Davar D, Najjar YG, Zarour HM, Kirkwood JM, Luke JJ, Bao R |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Pavlick AC, Ariyan CE, Buchbinder EI, Davar D, Gibney GT, Hamid O, Hieken TJ, Izar B, Johnson DB, Kulkarni RP, Luke JJ, Mitchell TC, Mooradian MJ, Rubin KM, Salama AK, Shirai K, Taube JM, Tawbi HA, Tolley JK, Valdueza C, Weiss SA, Wong MK, Sullivan RJ |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Astragaloside IV Attenuates Programmed Death-Ligand 1-Mediated Immunosuppression during Liver Cancer Development via the miR-135b-5p/CNDP1 Axis
Ma Y, Li Y, Wu T, Li Y, Wang Q |
Cancers | 2023 |
|
Tumor-repopulating cell-derived microparticles elicit cascade amplification of chemotherapy-induced antitumor immunity to boost anti-PD-1 therapy
Bie N, Yong T, Wei Z, Liang Q, Zhang X, Li S, Li X, Li J, Gan L, Yang X |
Signal Transduction and Targeted Therapy | 2023 |
|
Artificial intelligence‐powered spatial analysis of tumor‐infiltrating lymphocytes as a biomarker in locally advanced unresectable thymic epithelial neoplasm: A single‐center, retrospective, longitudinal cohort study
Kim DH, Lim Y, Kim S, Ock C, Youk J, Kim M, Kim TM, Kim D, Kim HJ, Koh J, Jung KC, Na KJ, Kang CH, Keam B |
Thoracic Cancer | 2023 |
|
Single-cell morphological and topological atlas reveals the ecosystem diversity of human breast cancer
Zhao S, Chen DP, Fu T, Yang JC, Ma D, Zhu XZ, Wang XX, Jiao YP, Jin X, Xiao Y, Xiao WX, Zhang HY, Lv H, Madabhushi A, Yang WT, Jiang YZ, Xu J, Shao ZM |
Nature Communications | 2023 |
|
RNA-seq RNAaccess identified as the preferred method for gene expression analysis of low quality FFPE samples
Song K, Elboudwarej E, Zhao X, Zhuo L, Pan D, Liu J, Brachmann C, Patterson SD, Yoon OK, Zavodovskaya M |
PloS one | 2023 |
|
Identification of RECK as a protective prognostic indicator and a tumor suppressor through regulation of the ERK/MAPK signaling pathway in gastric cancer
Qi F, Wang Y, Yu B, Li F |
Journal of Translational Medicine | 2023 |
|
Molecular classification of human papilloma virus-negative head and neck squamous cell carcinomas: Cell cycle-based classifier and prognostic signature
Gu H, Li T, Beeraka NM, Zheng Y, Zhang X, Song R, Zhou R, Wang X, Sukocheva O, Fan R, Liu J |
PloS one | 2023 |
|
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA |
Nature Medicine | 2023 |
|
Quantifying the impact of immunotherapy on RNA dynamics in cancer
Usaite I, Biswas D, Dijkstra K, Watkins TB, Pich O, Puttick C, Angelova M, Thakkar K, Hiley C, Birkbak N, Kok M, Zaccaria S, Wu Y, Litchfield K, Swanton C, Kanu N |
Journal for ImmunoTherapy of Cancer | 2023 |
|
IGFBP2 from a novel copper metabolism-associated biomarker promoted glioma progression and response to immunotherapy
Luo Q, Zhuang J, Zheng D, Miao C, Luo H, Peng J, Zheng C, Qin C, Lan C, Chen M, Xia Y, Huang D, Chen Z |
Frontiers in immunology | 2023 |
|
Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy
Zhao J, Dong Y, Bai H, Bai F, Yan X, Duan J, Wan R, Xu J, Fei K, Wang J, Wang Z |
2023 | |
|
Proteogenomics Reveal the Overexpression of HLA-I in Cancer
Wang Y, Fenyö D |
Journal of Proteome Research | 2023 |
|
Metabolic and senescence characteristics associated with the immune microenvironment in non-small cell lung cancer: insights from single-cell RNA sequencing
Liao H, Wan Z, Liang Y, Kang L, Wan R |
Aging | 2023 |
|
Constructing an APOBEC-related gene signature with predictive value in the overall survival and therapeutic sensitivity in lung adenocarcinoma
Luo Y, Wang H, Zhong J, Shi J, Zhang X, Yang Y, Wu R |
Heliyon | 2023 |
|
Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC
De Marchi P, Leal LF, da Silva LS, Cavagna RD, da Silva FA, da Silva VD, da Silva EC, Saito AO, de Lima VC, Reis RM |
Translational oncology | 2023 |
|
Deactivation of ligand-receptor interactions enhancing lymphocyte infiltration drives melanoma resistance to Immune Checkpoint Blockade
Sahni S, Wang B, Wu D, Dhruba SR, Nagy M, Patkar S, Ferreira I, Wang K, Ruppin E |
2023 | |
|
Update of latest data for combined therapy for esophageal cancer using radiotherapy and immunotherapy: A focus on efficacy, safety, and biomarkers
Cheng S, Li B, Yu J, Wang L |
Chinese Journal of Cancer Research | 2023 |
|
A multidimensional analysis reveals distinct immune phenotypes and tertiary lymphoid structure-like aggregates in the bone marrow of pediatric acute myeloid leukemia
Koedijk JB, van der Werf I, Penter L, Vermeulen MA, Barneh F, Perzolli A, Meesters-Ensing JI, Fiocco M, de Groot-Kruseman HA, Moeniralam R, Christensen KB, Porter B, Pfaff K, Garcia JS, Rodig SJ, Wu CJ, Hasle H, Nierkens S, Belderbos ME, Zwaan CM, Heidenreich O |
2023 | |
|
Metabolic predictors of response to immune checkpoint blockade therapy
Shorer O, Yizhak K |
iScience | 2023 |
|
Machine learning endometrial cancer risk prediction model: integrating guidelines of European Society for Medical Oncology with the tumor immune framework
Bruno V, Betti M, D\u2019Ambrosio L, Massacci A, Chiofalo B, Pietropolli A, Piaggio G, Ciliberto G, Nisticò P, Pallocca M, Buda A, Vizza E |
International Journal of Gynecological Cancer | 2023 |
|
Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer
Lv K, Sun M, Fang H, Wang J, Lin C, Liu H, Zhang H, Li H, He H, Gu Y, Li R, Shao F, Xu J |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Single cell dynamics of tumor specificity vs bystander activity in CD8+ T cells define the diverse immune landscapes in colorectal cancer
Borràs DM, Verbandt S, Ausserhofer M, Sturm G, Lim J, Verge GA, Vanmeerbeek I, Laureano RS, Govaerts J, Sprooten J, Hong Y, Wall R, De Hertogh G, Sagaert X, Bislenghi G, D\u2019Hoore A, Wolthuis A, Finotello F, Park WY, Naulaerts S, Tejpar S, Garg AD |
Cell Discovery | 2023 |
|
Gut microbial structural variation associates with immune checkpoint inhibitor response
Liu R, Zou Y, Wang WQ, Chen JH, Zhang L, Feng J, Yin JY, Mao XY, Li Q, Luo ZY, Zhang W, Wang DM |
Nature Communications | 2023 |
|
Nonfucosylation of an anti-TIGIT antibody enhances FcγR engagement, driving innate immune activation and antitumor activity
Smith AJ, Thurman RE, Zeng W, Grogan B, Lucas S, Gutierrez G, Heiser RA, Wo SW, Blackmarr A, Peterson S, Gardai SJ |
Frontiers in immunology | 2023 |
|
Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ
Newey A, Yu L, Barber LJ, Choudhary JS, Bassani-Sternberg M, Gerlinger M |
2023 | |
|
Fusing WGCNA and Machine Learning for Immune-Related Gene Prognostic Index in Lung Adenocarcinoma: Precision Prognosis, Tumor Microenvironment Profiling, and Biomarker Discovery
He J, Luan T, Zhao G, Yang Y |
Journal of inflammation research | 2023 |
|
Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence
Lautert-Dutra W, Melo CM, Chaves LP, Souza FC, Crozier C, Sundby AE, Woroszchuk E, Saggioro FP, Avante FS, dos Reis RB, Squire JA, Bayani J |
Frontiers in Oncology | 2023 |
|
IFN-γ lowers tumor growth by increasing glycolysis and lactate production in a nitric oxide-dependent manner: implications for cancer immunotherapy
Chattopadhyay A, Jagdish S, Karhale AK, Ramteke NS, Zaib A, Nandi D |
Frontiers in immunology | 2023 |
|
Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8+ exhausted-like T cells
Li S, Li K, Wang K, Yu H, Wang X, Shi M, Liang Z, Yang Z, Hu Y, Li Y, Liu W, Li H, Cheng S, Ye L, Yang Y |
Nature Communications | 2023 |
|
Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy
Singh S, Singh N, Baranwal M, Sharma S, Devi SS, Kumar S |
3 Biotech | 2023 |
|
TIGIT+ NK cells in combination with specific gut microbiota features predict response to checkpoint inhibitor therapy in melanoma patients
Tsakmaklis A, Farowski F, Zenner R, Lesker TR, Strowig T, Schlößer H, Lehmann J, von Bergwelt-Baildon M, Mauch C, Schlaak M, Knuever J, Schweinsberg V, Heinzerling LM, Vehreschild MJ |
BMC Cancer | 2023 |
|
Biomarkers and experimental models for cancer immunology investigation
Xu H, Jia Z, Liu F, Li J, Huang Y, Jiang Y, Pu P, Shang T, Tang P, Zhou Y, Yang Y, Su J, Liu J |
2023 | |
|
Construction of a 5-gene prognostic signature based on oxidative stress related genes for predicting prognosis in osteosarcoma.
Hong X, Fu R |
PloS one | 2023 |
|
Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients.
Sacconi A, Muti P, Pulito C, Urbani G, Allegretti M, Pellini R, Mehterov N, Ben-David U, Strano S, Bossi P, Blandino G |
Molecular Cancer | 2023 |
|
MIRS: An AI scoring system for predicting the prognosis and therapy of breast cancer.
Huang C, Deng M, Leng D, Sun B, Zheng P, Zhang XD |
iScience | 2023 |
|
Molecular Networks of Platinum Drugs and Their Interaction with microRNAs in Cancer.
Tanabe S, Boonstra E, Hong T, Quader S, Ono R, Cabral H, Aoyagi K, Yokozaki H, Perkins EJ, Sasaki H |
Genes & development | 2023 |
|
Molecular subtyping based on immune cell marker genes predicts prognosis and therapeutic response in patients with lung adenocarcinoma.
Liu ZT, Shen JT, Lei YJ, Huang YC, Zhao GQ, Zheng CH, Wang X, Wang YT, Chen L, Li ZX, Li SZ, Liao J, Yu TD |
BMC Cancer | 2023 |
|
LEPRE1 shapes a non-flamed tumour immune landscape and predicts the prognosis in esophageal squamous cell carcinoma.
Liu M, Ma Y, Guo Y, Ma Y, Bao X, Lu X |
Clinical and Translational Medicine | 2023 |
|
The cellular trajectories of tumor-associated macrophages decipher the heterogeneity of pancreatic cancer.
Lin J, Lu F, Wu Y, Huang H, Pan Y |
Functional & Integrative Genomics | 2023 |
|
Association between pretreatment emotional distress and neoadjuvant immune checkpoint blockade response in melanoma.
Fraterman I, Reijers ILM, Dimitriadis P, Broeks A, Gonzalez M, Menzies AMM, Lopez-Yurda M, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Hospers GAP, Long GV, Blank CU, van de Poll-Franse LV |
Nature Medicine | 2023 |
|
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy.
Licata L, Barreca M, Galbardi B, Dugo M, Viale G, Győrffy B, Karn T, Pusztai L, Gianni L, Callari M, Bianchini G |
British Journal of Cancer | 2023 |
|
Computational immunogenomic approaches to predict response to cancer immunotherapies.
Addala V, Newell F, Pearson JV, Redwood A, Robinson BW, Creaney J, Waddell N |
Nature reviews. Clinical oncology | 2023 |
|
Unraveling the Intricacies of CD73/Adenosine Signaling: The Pulmonary Immune and Stromal Microenvironment in Lung Cancer
Saigí M, Mesía-Carbonell O, Barbie DA, Guillamat-Prats R |
Cancers | 2023 |
|
Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response
Becker AS, Kluge C, Schofeld C, Zimpfer AH, Schneider B, Strüder D, Redwanz C, Ribbat-Idel J, Idel C, Maletzki C |
Cancers | 2023 |
|
Targeting Proteasomes and the MHC Class I Antigen Presentation Machinery to Treat Cancer, Infections and Age-Related Diseases
Rana PS, Ignatz-Hoover JJ, Driscoll JJ |
Cancers | 2023 |
|
Assessment tool based on fatty acid metabolic signatures for predicting the prognosis and treatment response in bladder cancer
Chen X, Zhang Z, Liao W, Zhao Y |
Heliyon | 2023 |
|
IQGAP3 is relevant to prostate cancer: A detailed presentation of potential pathomechanisms
Mei W, Dong Y, Gu Y, Kapoor A, Lin X, Su Y, Vega Neira S, Tang D |
Journal of Advanced Research | 2023 |
|
Pre-treatment with systemic agents for advanced NSCLC elicits changes in the phenotype of autologous T cell therapy products
O\u2019Brien Gore C, Billman A, Hunjan S, Colebrook J, Choy D, Li W, Haynes J, Wade J, Hobern E, McDonald L, Papa S, Brugman M, Kordasti S, Montiel-Equihua C |
2023 | |
|
Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
Kim CG, Koh JY, Shin SJ, Shin JH, Hong M, Chung HC, Rha SY, Kim HS, Lee CK, Lee JH, Han Y, Kim H, Che X, Yun UJ, Kim H, Kim JH, Lee SY, Park SK, Park S, Kim H, Ahn JY, Jeung HC, Lee JS, Nam YD, Jung M |
Cell reports. Medicine | 2023 |
|
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.
Butterfield LH, Najjar YG |
Nature reviews. Immunology | 2023 |
|
Exploration and validation of a combined Hypoxia and m6A/m5C/m1A regulated gene signature for prognosis prediction of liver cancer.
Ren M, Fan B, Cao G, Zong R, Feng L, Sun H |
BMC Genomics | 2023 |
|
Development and validation of an immune-related gene prognostic index for lung adenocarcinoma
Liu Z, Lei Y, Shen J, Zhao G, Wang X, Wang Y, Kudo Y, Liao J, Huang Y, Yu T |
Journal of Thoracic Disease | 2023 |
|
Comprehensive Single-Cell Immune Profiling Defines the Patient Multiple Myeloma Microenvironment Following Oncolytic Virus Therapy in a Phase Ib Trial
Nawrocki ST, Olea J, Villa Celi C, Dadrastoussi H, Wu K, Tsao-Wei D, Colombo A, Coffey M, Fernandez Hernandez E, Chen X, Nuovo GJ, Carew JS, Mohrbacher AF, Fields P, Kuhn P, Siddiqi I, Merchant A, Kelly KR |
Clinical cancer research | 2023 |
|
Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer
Shi X, Peng X, Chen Y, Shi Z, Yue C, Zuo L, Zhang L, Gao S |
Frontiers in immunology | 2023 |
|
Driver mutations in GNAQ and GNA11 genes as potential targets for precision immunotherapy in uveal melanoma patients.
García-Mulero S, Fornelino R, Punta M, Lise S, Varela M, Del Carpio LP, Moreno R, Costa-García M, Rieder D, Trajanoski Z, Gros A, Alemany R, Piulats JM, Sanz-Pamplona R |
OncoImmunology | 2023 |
|
Predicting T Cell-Inflamed Gene Expression Profile in Hepatocellular Carcinoma Based on Dynamic Contrast-Enhanced Ultrasound Radiomics
Wang Y, Weng W, Liang R, Zhou Q, Hu H, Li M, Chen L, Chen S, Peng S, Kuang M, Xiao H, Wang W |
Journal of Hepatocellular Carcinoma | 2023 |
|
Personalizing Oncolytic Immunovirotherapy Approaches.
Stergiopoulos GM, Iankov I, Galanis E |
Molecular diagnosis & therapy | 2023 |
|
KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance.
Zavitsanou AM, Pillai R, Hao Y, Wu WL, Bartnicki E, Karakousi T, Rajalingam S, Herrera A, Karatza A, Rashidfarrokhi A, Solis S, Ciampricotti M, Yeaton AH, Ivanova E, Wohlhieter CA, Buus TB, Hayashi M, Karadal-Ferrena B, Pass HI, Poirier JT, Rudin CM, Wong KK, Moreira AL, Khanna KM, Tsirigos A, Papagiannakopoulos T, Koralov SB |
Cell Reports | 2023 |
|
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
Lin CC, Garralda E, Schöffski P, Hong DS, Siu LL, Martin M, Maur M, Hui R, Soo RA, Chiu J, Zhang T, Ma B, Kyi C, Tan DS, Cassier PA, Sarantopoulos J, Weickhardt A, Carvajal RD, Spratlin J, Esaki T, Rolland F, Akerley W, Deschler-Baier B, Rispoli L, Samant TS, Chowdhury NR, Gusenleitner D, Kwak EL, Askoxylakis V, De Braud F |
OncoImmunology | 2023 |
|
Promising and Minimally Invasive Biomarkers: Targeting Melanoma
Spiliopoulou P, Holanda Lopes CD, Spreafico A |
Cells | 2023 |
|
Inflammatory response signature score model for predicting immunotherapy response and pan-cancer prognosis
Chen S, Huang M, Zhang L, Huang Q, Wang Y, Liang Y |
Computational and Structural Biotechnology Journal | 2023 |
|
Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
Yoshimoto S, Chester N, Xiong A, Radaelli E, Wang H, Brillantes M, Gulendran G, Glassman P, Siegel DL, Mason NJ |
mAbs | 2023 |
|
Molecular and Genetic Advances in Small Cell Lung Cancer Landscape: From Homogeneity to Diversity
Zullo L, Dall\u2019Olio FG, Rossi G, Dellepiane C, Barletta G, Bennicelli E, Ingaliso M, Tagliamento M, Genova C |
International journal of molecular sciences | 2023 |
|
Predictive Factors in Metastatic Melanoma Treated with Immune Checkpoint Inhibitors: From Clinical Practice to Future Perspective
Poletto S, Paruzzo L, Nepote A, Caravelli D, Sangiolo D, Carnevale-Schianca F |
Cancers | 2023 |
|
Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma
Duan J, Zhang Y, Chen R, Liang L, Huo Y, Lu S, Zhao J, Hu C, Sun Y, Yang K, Chen M, Yu Y, Ying J, Huang R, Ma X, Leaw S, Bai F, Shen Z, Cai S, Gao D, Wang J, Wang Z |
Cell reports. Medicine | 2023 |
|
Predicting patient outcomes after treatment with immune checkpoint blockade: A review of biomarkers derived from diverse data modalities
Liu Y, Altreuter J, Bodapati S, Cristea S, Wong CJ, Wu CJ, Michor F |
2023 | |
|
The exploration of mitochondrial‐related features helps to reveal the prognosis and immunotherapy methods of colorectal cancer
Xie Y, Jiang H |
EMBO reports | 2023 |
|
SCD1 inhibition enhances the effector functions of CD8 + T cells via ACAT1‐dependent reduction of esterified cholesterol
Sugi T, Katoh Y, Ikeda T, Seta D, Iwata T, Nishio H, Sugawara M, Kato D, Katoh K, Kawana K, Yaguchi T, Kawakami Y, Hirai S |
Cancer Science | 2023 |
|
Dual-responsive supramolecular photodynamic nanomedicine with activatable immunomodulation for enhanced antitumor therapy
He S, Wang L, Wu D, Tong F, Zhao H, Li H, Gong T, Gao H, Zhou Y |
Acta pharmaceutica Sinica. B | 2023 |
|
A Dysfunctional T-cell Gene Signature for Predicting Nonresponse to PD-1 Blockade in Non–small Cell Lung Cancer That Is Suitable for Routine Clinical Diagnostics
Hummelink K, Tissier R, Bosch LJ, Krijgsman O, van den Heuvel MM, Theelen WS, Damotte D, Goldwasser F, Leroy K, Smit EF, Meijer GA, Thommen DS, Monkhorst K |
Clinical cancer research | 2023 |
|
Immunosurveillance in clinical cancer management
Kroemer G, Chan TA, Eggermont AM, Galluzzi L |
CA: a cancer journal for clinicians | 2023 |
|
Potential of circulating tumor DNA to refine immunotherapy
Lee RJ, Luke JJ |
Cancer | 2023 |
|
Integration of peripheral blood and tissue-based biomarkers of response to immune checkpoint blockade in urothelial carcinoma
Vanguri RS, Smithy JW, Li Y, Zhuang M, Maher CA, Aleynick N, Peng X, Al-Ahmadie H, Funt SA, Rosenberg JE, Iyer G, Bajorin D, Mathews JC, Nadeem S, Panageas KS, Shen R, Callahan MK, Hollmann TJ |
The Journal of Pathology | 2023 |
|
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Meric-Bernstam F, Sweis RF, Kasper S, Hamid O, Bhatia S, Dummer R, Stradella A, Long GV, Spreafico A, Shimizu T, Steeghs N, Luke JJ, McWhirter SM, Müller T, Nair N, Lewis N, Chen X, Bean A, Kattenhorn L, Pelletier M, Sandhu S |
Clinical cancer research | 2023 |
|
Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
Luke JJ, Piha-Paul SA, Medina T, Verschraegen CF, Varterasian M, Brennan AM, Riese RJ, Sokolovska A, Strauss J, Hava DL, Janku F |
Clinical cancer research | 2023 |
|
COSMIC-312, a disappointing result—is that so surprising?
Adhoute X, Bourlière M, Anty R |
Annals of translational medicine | 2023 |
|
Targeting tumor microenvironment for non-small cell lung cancer immunotherapy.
Wang L, Jia Q, Chu Q, Zhu B |
Chinese medical journal pulmonary and critical care medicine | 2023 |
|
Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.
Pan M, Wei X, Xiang X, Liu Y, Zhou Q, Yang W |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2023 |
|
Vasculitis, CA19–9, and Perineural Invasion Differentially Predict Response and Surgical Outcome in Pancreatic Ductal Adenocarcinoma
Piper M, Ross RB, Hu J, Watanabe S, Knitz M, Mehrotra S, Shulick R, Chiaro MD, Karam SD |
International journal of radiation oncology, biology, physics | 2023 |
|
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma
Carroll TM, Chadwick JA, Owen RP, White MJ, Kaplinsky J, Peneva I, Frangou A, Xie PF, Chang J, Roth A, Amess B, James SA, Rei M, Fuchs HS, McCann KJ, Omiyale AO, Jacobs BA, Lord SR, Norris-Bulpitt S, Dobbie ST, Griffiths L, Ramirez KA, Ricciardi T, Macri MJ, Ryan A, Venhaus RR, Van den Eynde BJ, Karydis I, Schuster-Böckler B, Middleton MR, Lu X |
Cancer Cell | 2023 |
|
Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-γ-stimulated anti-tumor immunity
Jiale Ren, Ni Li, Siyu Pei, Yannan Lian, Li Li, Yuchong Peng, Qiuli Liu, Jiacheng Guo, Xuege Wang, Ying Han, Guoying Zhang, Hanling Wang, Yaqi Li, Jun Jiang, Qintong Li, Minjia Tan, Junjie Peng, Guohong Hu, Yichuan Xiao, Xiong Li, Moubin Lin, Jun Qin |
Journal of Clinical Investigation | 2022 |
|
Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of PD-1 blockade in lung cancer
Kentaro Masuhiro, Motohiro Tamiya, Kosuke Fujimoto, Shohei Koyama, Yujiro Naito, Akio Osa, Takashi Hirai, Hidekazu Suzuki, Norio Okamoto, Takayuki Shiroyama, Kazumi Nishino, Yuichi Adachi, Takuro Nii, Yumi Kinugasa-Katayama, Akiko Kajihara, Takayoshi Morita, Seiya Imoto, Satoshi Uematsu, Takuma Irie, Daisuke Okuzaki, Taiki Aoshi, Yoshito Takeda, Toru Kumagai, Tomonori Hirashima, Atsushi Kumanogoh |
JCI Insight | 2022 |
|
Deciphering the Tumor Cell-infiltrating Landscapes Reveal Microenvironment Subtypes and Therapeutic Potentials for Nonsquamous NSCLC
Hao Chen, Tongchao Zhang, Yuan Zhang, Hao Wu, Zhen Fang, Yang Liu, Yang Chen, Zhe Wang, Shengtao Jia, Xingzhao Ji, Liang Shang, Fengying Du, Jin Liu, Ming Lu, Wei Chong |
JCI Insight | 2022 |
|
Noninvasive interrogation of CD8+ T cell effector function for monitoring tumor early responses to immunotherapy
Haoyi Zhou, Yanpu Wang, Hongchuang Xu, Xiuling Shen, Ting Zhang, Xin Zhou, Yuwen Zeng, Kui Li, Li Zhang, Hua Zhu, Xing Yang, Nan Li, Zhi Yang, Zhaofei Liu |
Journal of Clinical Investigation | 2022 |
|
Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers
S Chen, V Popolizio, R Woolaver, H Ge, A Krinsky, J John, E Danis, Y Ke, Y Kramer, L Bian, A Nicklawsky, D Gao, S Liu, Z Chen, X Wang, J Wang |
Journal of Experimental & Clinical Cancer Research | 2022 |
|
PRC2-mediated epigenetic suppression of type I IFN-STAT2 axis enhances antitumor immunity in luminal breast cancer
Juyeong Hong, Jihoon Lee, Zhao Zhang, Yanming Wu, Mei Yang, Yiji Liao, Richard de la Rosa, Jessica Scheirer, Douglas Pechacek, Nu Zhang, Zhenming Xu, Tyler Curiel, Xi Tan, Tim Huang, Kexin Xu |
Cancer research | 2022 |
|
Integrative genomic analysis reveals low T-cell infiltration as the primary feature of tobacco use in HPV-positive oropharyngeal cancer
B Wahle, P Zolkind, R Ramirez, Z Skidmore, S Anderson, A Mazul, D Hayes, V Sandulache, W Thorstad, D Adkins, O Griffith, M Griffith, J Zevallos |
iScience | 2022 |
|
Association of differential expression of immunoregulatory molecules and presence of targetable mutations may inform rational design of clinical trials
C Szeto, R Kurzrock, S Kato, A Goloubev, S Veerapaneni, A Preble, S Reddy, J Adashek |
ESMO Open | 2022 |
|
Statin shapes inflamed tumor microenvironment and enhances immune checkpoint blockade in non-small cell lung cancer
Wenjun Mao, Yun Cai, Danrong Chen, Guanyu Jiang, Yongrui Xu, Ruo Chen, Fengxu Wang, Xuehai Wang, Mingfeng Zheng, Xinyuan Zhao, Jie Mei |
JCI Insight | 2022 |
|
Novel AnnexinA2--TLR2--MyD88 pathway induces Arginase-1 expression in tumor-associated neutrophils
Huajia Zhang, Xiaodong Zhu, Travis Friesen, Jeff W. Kwak, Tatyana Pisarenko, Surapat Mekvanich, Mark A. Velasco, Julia Kargl, McGarry Houghton |
Journal of Clinical Investigation | 2022 |
|
RAD21 Amplification Epigenetically Suppresses Interferon Signaling to Promote Immune Evasion in Ovarian Cancer
Peng Deng, Zining Wang, Jinghong Chen, Shini Liu, Xiaosai Yao, Shaoyan Liu, Lizhen Liu, Zhaoliang Yu, Yulin Huang, Zhongtang Xiong, Rong Xiao, Jiuping Gao, Weiting Liang, Jieping Chen, Hui Liu, Jinghan Hong, Jason Yongsheng Chan, Peiyong Guan, Jianfeng Chen, Yali Wang, Jiaxin Yin, Tiebang Kang, Bin Teh, Qiang Yu, Zhixiang Zuo, Qingping Jiang, Jihong Liu, Ying Xiong, xiaojuan Xia, Jing Tan |
Journal of Clinical Investigation | 2022 |
|
Metabolic molecular phenotypes in gliomas identifies hyaluronic acids in mediating the infiltration, migration, and polarization of macrophages
Hao Zhang, Nan Zhang, Ziyu Dai, Zeyu Wang, Xun Zhang, Xisong Liang, Li-Yang Zhang, Songshan Feng, Wantao Wu, Weijie Ye, Quan Cheng, Zhi-Xiong Liu |
Molecular Oncology | 2022 |
|
Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
L Yang, Q Ning, S Tang, D Cui |
Journal of Immunology Research | 2022 |
|
Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
A Fedoriw, L Shi, S O'Brien, K Smitheman, Y Wang, J Hou, C Sherk, S Rajapurkar, J Laraio, L Williams, C Xu, G Han, Q Feng, M Bedford, L Wang, O Barbash, R Kruger, P Hwu, H Mohammad, W Peng |
Cancer immunology research | 2022 |
|
Harnessing cytokines and chemokines for cancer therapy
D Propper, F Balkwill |
Nature Reviews Clinical Oncology | 2022 |
|
Cancer Immunotherapies: Solid Tumors and Hematologic Malignancies
P Hays |
2022 | |
|
The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer
Y Fan, S He |
Cancer management and research | 2022 |
|
Immunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
C Ngo, S Postel-Vinay |
Biomedicines | 2022 |
|
Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC
R Arend, C Scalise, E Gordon, A Davis, M Foxall, B Johnston, D Crossman, S Cooper |
Clinical cancer research | 2022 |
|
Non-Canonical NF-κB Signaling Stratifies LGG into Subtypes with Distinct Molecular and Cellular Characteristic and Survival Expectancy
M Lin, T Huang, X Wang, X Li, J Ma, L Su, J Wu |
International journal of general medicine | 2022 |
|
Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer
C Hsieh, C Jian, L Lin, G Low, P Ou, C Hsu, D Ou |
Cancers | 2022 |
|
Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers
A Peña-Romero, E Orenes-Piñero |
Cancers | 2022 |
|
T cell subtype profiling measures exhaustion and predicts anti-PD-1 response
I Schillebeeckx, J Earls, K Flanagan, J Hiken, A Bode, J Armstrong, D Messina, D Adkins, J Ley, I Alborelli, P Jermann, J Glasscock |
Scientific Reports | 2022 |
|
Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression
B Hwang, L Tsao, C Acharya, T Trotter, P Agarwal, J Wei, T Wang, X Yang, G Lei, T Osada, H Lyerly, M Morse, Z Hartman |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Intratumoral therapies and in-situ vaccination for melanoma
L Huppert, A Daud |
Human Vaccines & Immunotherapeutics | 2022 |
|
The role of biomarkers in personalized immunotherapy
K Sankar, J Ye, Z Li, L Zheng, W Song, S Hu-Lieskovan |
Biomarker Research | 2022 |
|
Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance
J Deng, M Zhou, T Liao, W Kuang, H Xia, Z Yin, Q Tan, Y Li, S Song, E Zhou, Y Jin |
Frontiers in Cell and Developmental Biology | 2022 |
|
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4
P Liao, W Wang, W Wang, I Kryczek, X Li, Y Bian, A Sell, S Wei, S Grove, J Johnson, P Kennedy, M Gijón, Y Shah, W Zou |
Cancer Cell | 2022 |
|
An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma
J Yan, X Wu, J Yu, Y Kong, S Cang |
Frontiers in immunology | 2022 |
|
An overview of the crosstalk between YAP and cGAS-STING signaling in non-small cell lung cancer: it takes two to tango
F Hao |
Clinical & Translational Oncology | 2022 |
|
CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors
V Qin, N Haynes, C DSouza, P Neeson, J Zhu |
Frontiers in immunology | 2022 |
|
Harnessing big data to characterize immune-related adverse events
Y Jing, J Yang, D Johnson, J Moslehi, L Han |
Nature Reviews Clinical Oncology | 2022 |
|
Immune priming using DC- and T cell-targeting gene therapy sensitizes both treated and distant B16 tumors to checkpoint inhibition
J Wenthe, S Naseri, A Hellström, R Moreno, G Ullenhag, R Alemany, T Lövgren, E Eriksson, A Loskog |
Molecular Therapy — Oncolytics | 2022 |
|
A blood-based miRNA signature with prognostic value for overall survival in advanced stage non-small cell lung cancer treated with immunotherapy
T Rajakumar, R Horos, J Jehn, J Schenz, T Muley, O Pelea, S Hofmann, P Kittner, M Kahraman, M Heuvelman, T Sikosek, J Feufel, J Skottke, D Nötzel, F Hinkfoth, K Tikk, A Daniel-Moreno, J Ceiler, N Mercaldo, F Uhle, S Uhle, M Weigand, M Elshiaty, F Lusky, H Schindler, Q Ferry, T Sauka-Spengler, Q Wu, K Rabe, M Reck, M Thomas, P Christopoulos, B Steinkraus |
npj Precision Oncology | 2022 |
|
Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma
J Hu, F Mao, L Li, X Wang, D Cai, L He, Q Wu, C Wang, N Zhang, Y Ma, X Wu, K Qu, X Wang, G Chen |
Journal of Oncology | 2022 |
|
MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer
J Lecuelle, L Favier, C Fraisse, A Lagrange, C Kaderbhai, R Boidot, S Chevrier, P Joubert, B Routy, C Truntzer, F Ghiringhelli |
Journal for ImmunoTherapy of Cancer | 2022 |
|
The Prognostic and Predictive Role of Xeroderma Pigmentosum Gene Expression in Melanoma
S Fischer, M Hamed, S Emmert, O Wolkenhauer, G Fuellen, A Thiem |
Frontiers in Oncology | 2022 |
|
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
M van der Heijden, T Powles, D Petrylak, R de Wit, A Necchi, C Sternberg, N Matsubara, H Nishiyama, D Castellano, S Hussain, A Bamias, G Gakis, J Lee, S Tagawa, U Vaishampayan, J Aragon-Ching, B Eigl, R Hozak, E Rasmussen, M Xia, R Rhodes, S Wijayawardana, K Bell-McGuinn, A Aggarwal, A Drakaki |
Nature Communications | 2022 |
|
Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
A Engelsen, M Lotsberg, R Khouzam, J Thiery, J Lorens, S Chouaib, S Terry |
Frontiers in immunology | 2022 |
|
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
A Naimi, R Mohammed, A Raji, S Chupradit, A Yumashev, W Suksatan, M Shalaby, L Thangavelu, S Kamrava, N Shomali, A Sohrabi, A Adili, A Noroozi-Aghideh, E Razeghian |
Cell Communication and Signaling | 2022 |
|
Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
R Haddad, T Seiwert, L Chow, S Gupta, J Weiss, I Gluck, J Eder, B Burtness, M Tahara, B Keam, H Kang, K Muro, A Albright, R Mogg, M Ayers, L Huang, J Lunceford, R Cristescu, J Cheng, R Mehra |
Journal for ImmunoTherapy of Cancer | 2022 |
|
ISA101 and nivolumab for HPV-16 + cancer: updated clinical efficacy and immune correlates of response
L de Sousa, K Rajapakshe, J Canales, R Chin, L Feng, Q Wang, T Barrese, E Massarelli, W William, F Johnson, R Ferrarotto, I Wistuba, C Coarfa, J Lee, J Wang, C Melief, M Curran, B Glisson |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Reveal the Heterogeneity in the Tumor Microenvironment of Pancreatic Cancer and Analyze the Differences in Prognosis and Immunotherapy Responses of Distinct Immune Subtypes
X Wang, L Li, Y Yang, L Fan, Y Ma, F Mao |
Frontiers in Oncology | 2022 |
|
The B7H4-PDL1 classifier stratifies immuno-phenotype in cervical cancer
L Chen, J Dong, Z Li, Y Chen, Y Zhang |
Cancer Cell International | 2022 |
|
Integrated analysis reveals the molecular features of fibrosis in triple-negative breast cancer
J Ding, Y Xiao, S Zhao, Y Xu, Y Xiao, Z Shao, Y Jiang, G Di |
Molecular Therapy — Oncolytics | 2022 |
|
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
H Yamaguchi, J Hsu, W Yang, M Hung |
Nature Reviews Clinical Oncology | 2022 |
|
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
Y Xia, W Tang, X Qian, X Li, F Cheng, K Wang, F Zhang, C Zhang, D Li, J Song, H Zhang, J Zhao, A Yao, X Wu, C Wu, G Ji, X Liu, F Zhu, L Qin, X Xiao, Z Deng, X Kong, S Li, Y Yu, , W Deng, C Qi, H Liu, L Pu, P Wang, X Wang |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non‐small cell lung cancer
J Deng, X Ma, Y Ni, X Li, , M Tian, X Zhang, M Xiang, W Deng, C Song, H Wu |
Cancer Medicine | 2022 |
|
Association between immune-related adverse event timing and treatment outcomes
D Hsiehchen, A Naqash, M Espinoza, M Itzstein, A Cortellini, B Ricciuti, D Owen, M Laharwal, Y Toi, M Burke, Y Xie, D Gerber |
OncoImmunology | 2022 |
|
Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab
S Lambert, C Zhang, C Guo, T Turan, D Masica, S Englert, Y Fang, J Sheridan, R McLaughlin, C Tribouley, G Vosganian, D Afar |
Journal of immunotherapy (Hagerstown, Md. : 1997) | 2022 |
|
An aging‐related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma
W Zhang, Y Li, J Lyu, F Shi, Y Kong, C Sheng, S Wang, Q Wang |
Cancer Science | 2022 |
|
Novel Immune-Related Gene-Based Signature Characterizing an Inflamed Microenvironment Predicts Prognosis and Radiotherapy Efficacy in Glioblastoma
H Ji, H Zhao, J Jin, Z Liu, X Gao, F Wang, J Dong, X Yan, J Zhang, N Wang, J Du, S Hu |
Frontiers in Genetics | 2022 |
|
Adoptive Cell Therapy in Pediatric and Young Adult Solid Tumors: Current Status and Future Directions
J Ligon, K Wessel, N Shah, J Glod |
Frontiers in immunology | 2022 |
|
Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse
P Dobosz, P Stempor, M Moreno, N Bulgakova |
Heredity | 2022 |
|
Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target
H Wang, Y Zhou, Y Zhang, S Fang, M Zhang, H Li, F Xu, L Liu, J Liu, Q Zhao, F Wang |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
C Genova, C Dellepiane, P Carrega, S Sommariva, G Ferlazzo, P Pronzato, R Gangemi, G Filaci, S Coco, M Croce |
Frontiers in immunology | 2022 |
|
Identification of a Tumor Cell Associated Type I IFN Resistance Gene Expression Signature of Human Melanoma, the Components of Which Have a Predictive Potential for Immunotherapy
A Ladányi, E Rásó, T Barbai, L Vízkeleti, L Puskás, S Kovács, B Győrffy, J Tímár |
International journal of molecular sciences | 2022 |
|
High farnesoid X receptor expression predicts favorable clinical outcomes in PD‑L1 low/negative non‑small cell lung cancer patients receiving anti‑PD‑1‑based chemo‑immunotherapy
L Wang, X Xu, B Shang, J Sun, B Liang, X Wang, W You, S Jiang |
International journal of oncology | 2022 |
|
Siglec15 facilitates the progression of non-small cell lung cancer and is correlated with spinal metastasis
H Liang, Q Chen, Z Hu, L Zhou, Q Meng, T Zhang, B Wang, Y Ge, S Lu, W Ding, X Zhou, X Li, H Lin, L Jiang, J Dong |
Annals of translational medicine | 2022 |
|
CTR-DB, an omnibus for patient-derived gene expression signatures correlated with cancer drug response.
Liu Z, Liu J, Liu X, Wang X, Xie Q, Zhang X, Kong X, He M, Yang Y, Deng X, Yang L, Qi Y, Li J, Liu Y, Yuan L, Diao L, He F, Li D |
Nucleic Acids Research | 2022 |
|
Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma.
Nastoupil LJ, Chin CK, Westin JR, Fowler NH, Samaniego F, Cheng X, Ma MCJ, Wang Z, Chu F, Dsouza L, Obi C, Mims J, Feng L, Zhou S, Green M, Davis RE, Neelapu SS |
Blood Advances | 2022 |
|
Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature.
Bertucci F, Niziers V, de Nonneville A, Finetti P, Mescam L, Mir O, Italiano A, Le Cesne A, Blay JY, Ceccarelli M, Bedognetti D, Birnbaum D, Mamessier E |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary.
Tarhini AA, Lee SJ, Tan AC, El Naqa IM, Stephen Hodi F, Butterfield LH, LaFramboise WA, Storkus WJ, Karunamurthy AD, Conejo-Garcia JR, Hwu P, Streicher H, Sondak VK, Kirkwood JM |
Journal for ImmunoTherapy of Cancer | 2022 |
|
[Research Progress of Immunotherapy Biomarkers for Non-small Cell Lung Cancer].
Jiang C, Yi L, Gao X, Zhang H, Zhang S |
Zhongguo fei ai za zhi = Chinese journal of lung cancer | 2022 |
|
Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R, Aurora-Garg D, Albright A, Xu L, Liu XQ, Loboda A, Lang L, Jin F, Rubin EH, Snyder A, Lunceford J |
Journal for ImmunoTherapy of Cancer | 2022 |
|
A Prognostic Model of Colon Cancer Based on the Microenvironment Component Score via Single Cell Sequencing.
Liu Y, Liu X, Xu Q, Gao X, Linghu E |
In vivo (Athens, Greece) | 2022 |
|
Prognostic value of tumor mutation burden and the relationship between tumor mutation burden and immune infiltration in HER2+ breast cancer: a gene expression-based study.
Wen Y, Ouyang D, Chen Q, Zeng L, Luo N, He H, Anwar M, Qu L, Zou Q, Yi W |
Gland Surgery | 2022 |
|
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.
Freeman SS, Sade-Feldman M, Kim J, Stewart C, Gonye ALK, Ravi A, Arniella MB, Gushterova I, LaSalle TJ, Blaum EM, Yizhak K, Frederick DT, Sharova T, Leshchiner I, Elagina L, Spiro OG, Livitz D, Rosebrock D, Aguet F, Carrot-Zhang J, Ha G, Lin Z, Chen JH, Barzily-Rokni M, Hammond MR, Vitzthum von Eckstaedt HC, Blackmon SM, Jiao YJ, Gabriel S, Lawrence DP, Duncan LM, Stemmer-Rachamimov AO, Wargo JA, Flaherty KT, Sullivan RJ, Boland GM, Meyerson M, Getz G, Hacohen N |
Cell reports. Medicine | 2022 |
|
Androgen receptor activity in T cells limits checkpoint blockade efficacy.
Guan X, Polesso F, Wang C, Sehrawat A, Hawkins RM, Murray SE, Thomas GV, Caruso B, Thompson RF, Wood MA, Hipfinger C, Hammond SA, Graff JN, Xia Z, Moran AE |
Nature | 2022 |
|
High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments.
Weiner AB, Yu CY, Kini M, Liu Y, Davicioni E, Mitrofanova A, Lotan TL, Schaeffer EM |
Prostate Cancer and Prostatic Diseases | 2022 |
|
Identification of Novel Prognostic Biomarkers Relevant to Immune Infiltration in Lung Adenocarcinoma.
Xia Z, Rong X, Dai Z, Zhou D |
Frontiers in Genetics | 2022 |
|
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
Schöffski P, Tan DSW, Martín M, Ochoa-de-Olza M, Sarantopoulos J, Carvajal RD, Kyi C, Esaki T, Prawira A, Akerley W, De Braud F, Hui R, Zhang T, Soo RA, Maur M, Weickhardt A, Krauss J, Deschler-Baier B, Lau A, Samant TS, Longmire T, Chowdhury NR, Sabatos-Peyton CA, Patel N, Ramesh R, Hu T, Carion A, Gusenleitner D, Yerramilli-Rao P, Askoxylakis V, Kwak EL, Hong DS |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Clinical Significance and Immune Landscape of a Pyroptosis-Derived LncRNA Signature for Glioblastoma.
Xing Z, Liu Z, Fu X, Zhou S, Liu L, Dang Q, Guo C, Ge X, Lu T, Zheng Y, Dai L, Han X, Wang X |
Frontiers in Cell and Developmental Biology | 2022 |
|
Multi-Omics Characterization of Tumor Microenvironment Heterogeneity and Immunotherapy Resistance Through Cell States-Based Subtyping in Bladder Cancer.
Hu R, Tao T, Yu L, Ding Q, Zhu G, Peng G, Zheng S, Yang L, Wu S |
Frontiers in Cell and Developmental Biology | 2022 |
|
Biomarkers of response to PD-1 pathway blockade.
Li H, van der Merwe PA, Sivakumar S |
British Journal of Cancer | 2022 |
|
IFN-γ activates the tumor cell-intrinsic STING pathway through the induction of DNA damage and cytosolic dsDNA formation.
Xiong H, Xi Y, Yuan Z, Wang B, Hu S, Fang C, Cai Y, Fu X, Li L |
OncoImmunology | 2022 |
|
Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer.
Korentzelos D, Wells A, Clark AM |
Scientific Reports | 2022 |
|
Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
Wong J, Gruber E, Maher B, Waltham M, Sabouri-Thompson Z, Jong I, Luong Q, Levy S, Kumar B, Brasacchio D, Jia W, So J, Skinner H, Lewis A, Hogg SJ, Vervoort S, DiCorleto C, Uhe M, Gamgee J, Opat S, Gregory GP, Polekhina G, Reynolds J, Hawkes EA, Kailainathan G, Gasiorowski R, Kats LM, Shortt J |
Leukemia | 2022 |
|
Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types
Budczies J, Kluck K, Beck S, Ourailidis I, Allgäuer M, Menzel M, Kazdal D, Perkhofer L, Kleger A, Schirmacher P, Seufferlein T, Stenzinger A |
The Journal of Pathology: Clinical Research | 2022 |
|
Epigenetic state determines inflammatory sensing in neuroblastoma.
Wolpaw AJ, Grossmann LD, Dessau JL, Dong MM, Aaron BJ, Brafford PA, Volgina D, Pascual-Pasto G, Rodriguez-Garcia A, Uzun Y, Arsenian-Henriksson M, Powell DJ Jr, Bosse KR, Kossenkov A, Tan K, Hogarty MD, Maris JM, Dang CV |
Proceedings of the National Academy of Sciences | 2022 |
|
Immune subtypes and neoantigen-related immune evasion in advanced colorectal cancer.
Sugawara T, Miya F, Ishikawa T, Lysenko A, Nishino J, Kamatani T, Takemoto A, Boroevich KA, Kakimi K, Kinugasa Y, Tanabe M, Tsunoda T |
iScience | 2022 |
|
Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer.
Kaneda T, Kurata T, Yoshida T, Kibata K, Yoshioka H, Yanagimoto H, Takeda K, Yoshida T, Tsuta K |
BMC Cancer | 2022 |
|
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy.
Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation.
Imamura T, Okamura Y, Ohshima K, Uesaka K, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Otsuka S, Ohnami S, Nagashima T, Hatakeyama K, Kakuda Y, Sugino T, Urakami K, Akiyama Y, Yamaguchi K |
Cancer Medicine | 2022 |
|
Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity.
Kamerkar S, Leng C, Burenkova O, Jang SC, McCoy C, Zhang K, Dooley K, Kasera S, Zi T, Sisó S, Dahlberg W, Sia CL, Patel S, Schmidt K, Economides K, Soos T, Burzyn D, Sathyanarayanan S |
Science Advances | 2022 |
|
Genome-wide aneuploidy detected by mFast-SeqS in circulating cell-free DNA is associated with poor response to pembrolizumab in patients with advanced urothelial cancer.
Mendelaar PAJ, Robbrecht DGJ, Rijnders M, de Wit R, de Weerd V, Deger T, Westgeest HM, Aarts MJB, Voortman J, Martens JWM, van der Veldt AAM, Nakauma-González JA, Wilting SM, Lolkema M |
Molecular Oncology | 2022 |
|
FMO4 shapes immuno-metabolic reconfiguration in hepatocellular carcinoma.
Luo Y, Chen AN, Fu JT, Zhou G, Wang J, Zhou X, Yang J, Shi JP |
Clinical and Translational Medicine | 2022 |
|
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer.
Pan Y, Fu Y, Zeng Y, Liu X, Peng Y, Hu C, Deng C, Qiu Z, Zou J, Liu Y, Wu F |
Biomarker Research | 2022 |
|
Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.
Lee JY, Nguyen B, Mukhopadhyay A, Han M, Zhang J, Gujar R, Salazar J, Hermiz R, Svenson L, Browning E, Lyerly HK, Canton DA, Fisher D, Daud A, Algazi A, Skitzki J, Twitty CG |
2022 | |
|
A Somatic Mutation Signature Predicts the Best Overall Response to Anti-programmed Cell Death Protein-1 Treatment in Epidermal Growth Factor Receptor/Anaplastic Lymphoma Kinase-Negative Non-squamous Non-small Cell Lung Cancer.
Peng J, Xiao L, Zou D, Han L |
Frontiers in Medicine | 2022 |
|
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.
Moreno V, Calvo E, Middleton MR, Barlesi F, Gaudy-Marqueste C, Italiano A, Romano E, Marabelle A, Chartash E, Dobrenkov K, Zhou H, Connors EC, Zhang Y, Wermke M |
Cancer Immunology, Immunotherapy | 2022 |
|
Screening of organoids derived from patients with breast cancer implicates the repressor NCOR2 in cytotoxic stress response and antitumor immunity.
Tsai KK, Huang SS, Northey JJ, Liao WY, Hsu CC, Cheng LH, Werner ME, Chuu CP, Chatterjee C, Lakins JN, Weaver VM |
2022 | |
|
Integrative analysis of immune‐related multi‐omics profiles identifies distinct prognosis and tumor microenvironment patterns in osteosarcoma
Shi D, Mu S, Pu F, Liu J, Zhong B, Hu B, Ni N, Wang H, Luu HH, Haydon RC, Shen L, Zhang Z, He T, Shao Z |
Molecular Oncology | 2022 |
|
Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy.
Jing Y, Chen X, Li K, Liu Y, Zhang Z, Chen Y, Liu Y, Wang Y, Lin SH, Diao L, Wang J, Lou Y, Johnson DB, Chen X, Liu H, Han L |
Journal for ImmunoTherapy of Cancer | 2022 |
|
The Non-N6-Methyladenosine Epitranscriptome Patterns and Characteristics of Tumor Microenvironment Infiltration and Mesenchymal Transition in Glioblastoma.
Xu J, Gao Z, Liu K, Fan Y, Zhang Z, Xue H, Guo X, Zhang P, Deng L, Wang S, Wang H, Wang Q, Zhao R, Li G |
Frontiers in immunology | 2022 |
|
Stemness Refines the Classification of Colorectal Cancer With Stratified Prognosis, Multi-Omics Landscape, Potential Mechanisms, and Treatment Options.
Liu Z, Xu H, Weng S, Ren Y, Han X |
Frontiers in immunology | 2022 |
|
Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment.
Pirš B, Škof E, Smrkolj V, Smrkolj Š |
Cancers | 2022 |
|
Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.
Asleh K, Negri GL, Spencer Miko SE, Colborne S, Hughes CS, Wang XQ, Gao D, Gilks CB, Chia SKL, Nielsen TO, Morin GB |
Nature Communications | 2022 |
|
Urinary Sediment mRNA Level of CREBBP and CYBA in Children With Steroid-Resistant Nephrotic Syndrome.
Li W, Shou X, Xiang W, He L, Li L, Fu H, Mao J |
Frontiers in immunology | 2022 |
|
Integrated Analysis of MATH-Based Subtypes Reveals a Novel Screening Strategy for Early-Stage Lung Adenocarcinoma.
Li C, Tian C, Zeng Y, Liang J, Yang Q, Gu F, Hu Y, Liu L |
Frontiers in Cell and Developmental Biology | 2022 |
|
Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas.
Kerrison WGJ, Lee ATJ, Thway K, Jones RL, Huang PH |
Biomedicines | 2022 |
|
Integrative Analysis of Gene Expression and DNA Methylation Depicting the Impact of Obesity on Breast Cancer.
Xiong Z, Li X, Yang L, Wu L, Xie Y, Xu F, Xie X |
Frontiers in Cell and Developmental Biology | 2022 |
|
Single-Cell Multiomics Reveals Clonal T-Cell Expansions and Exhaustion in Blastic Plasmacytoid Dendritic Cell Neoplasm.
DePasquale EAK, Ssozi D, Ainciburu M, Good J, Noel J, Villanueva MA, Couturier CP, Shalek AK, Aranki SF, Mallidi HR, Griffin GK, Lane AA, van Galen P |
Frontiers in immunology | 2022 |
|
Immune suppressive microenvironment in brain metastatic non-small cell lung cancer: comprehensive immune microenvironment profiling of brain metastases versus paired primary lung tumors (GASTO 1060).
Li M, Hou X, Sai K, Wu L, Chen J, Zhang B, Wang N, Wu L, Zheng H, Zhang J, Mou Y, Chen L |
OncoImmunology | 2022 |
|
Retinoic Acid Induces an IFN-Driven Inflammatory Tumour Microenvironment, Sensitizing to Immune Checkpoint Therapy.
Tilsed CM, Casey TH, de Jong E, Bosco A, Zemek RM, Salmons J, Wan G, Millward MJ, Nowak AK, Lake RA, Lesterhuis WJ |
Frontiers in Oncology | 2022 |
|
Molecular landscape of IDH-mutant astrocytoma and oligodendroglioma grade 2 indicate tumor purity as an underlying genomic factor
Zhao B, Xia Y, Yang F, Wang Y, Wang Y, Wang Y, Dai C, Wang Y, Ma W |
Molecular Medicine | 2022 |
|
Deconvolving clinically relevant cellular immune crosstalk from bulk gene expression using CODEFACS and LIRICS stratifies melanoma patients to anti-PD-1 therapy
Wang K, Patkar S, Lee JS, Gertz EM, Robinson W, Schischlik F, Crawford DR, Schäffer AA, Ruppin E |
Cancer Discovery | 2022 |
|
Type 1 T Helper Cell-Based Molecular Subtypes and Signature Are Associated with Clinical Outcome in Pancreatic Ductal Adenocarcinoma
Wei R, Zhang H, Cao J, Qin D, Deng W, Li S |
Frontiers in Cell and Developmental Biology | 2022 |
|
Genomic landscape and immune-related gene expression profiling of epithelial ovarian cancer after neoadjuvant chemotherapy.
Lodewijk I, Bernardini A, Suárez-Cabrera C, Bernal E, Sánchez R, Garcia JL, Rojas K, Morales L, Wang S, Han X, Dueñas M, Paramio JM, Manso L |
npj Precision Oncology | 2022 |
|
The Inflammatory Status of Soluble Microenvironment Influences the Capacity of Melanoma Cells to Control T-Cell Responses.
Bogéa GMR, Silva-Carvalho AÉ, Filiú-Braga LDC, Neves FAR, Saldanha-Araujo F |
Frontiers in Oncology | 2022 |
|
Tumor microenvironment-aware, single-transcriptome prediction of microsatellite instability in colorectal cancer using meta-analysis.
Seo MK, Kang H, Kim S |
Scientific Reports | 2022 |
|
Integrative Analysis of Multi-Omics Data-Identified Key Genes With KLRC3 as the Core in a Gene Regulatory Network Related to Immune Phenotypes in Lung Adenocarcinoma.
Mao K, Zhao Y, Ding B, Feng P, Li Z, Zhou YL, Xue Q |
Frontiers in Genetics | 2022 |
|
Prognosis and Characterization of Immune Microenvironment in Head and Neck Squamous Cell Carcinoma through a Pyroptosis-Related Signature.
Lu L, Zhang P, Cao X, Guan M |
Journal of Oncology | 2022 |
|
Crosstalk between the gut microbiome and clinical response in locally advanced thoracic esophageal squamous cell carcinoma during neoadjuvant camrelizumab and chemotherapy.
Xu L, Qi Y, Jiang Y, Ji Y, Zhao Q, Wu J, Lu W, Wang Y, Chen Q, Wang C |
Annals of translational medicine | 2022 |
|
Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk.
He BX, Zhong YF, Zhu YB, Deng JJ, Fang MJ, She YL, Wang TT, Yang Y, Sun XW, Belluomini L, Watanabe S, Dong D, Tian J, Xie D |
Translational Lung Cancer Research | 2022 |
|
Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker.
Mansurov A, Hosseinchi P, Chang K, Lauterbach AL, Gray LT, Alpar AT, Budina E, Slezak AJ, Kang S, Cao S, Solanki A, Gomes S, Williford JM, Swartz MA, Mendoza JL, Ishihara J, Hubbell JA |
Nature Biomedical Engineering | 2022 |
|
EphB4 and ephrinB2 act in opposition in the head and neck tumor microenvironment.
Bhatia S, Nguyen D, Darragh LB, Van Court B, Sharma J, Knitz MW, Piper M, Bukkapatnam S, Gadwa J, Bickett TE, Bhuvane S, Corbo S, Wu B, Lee Y, Fujita M, Joshi M, Heasley LE, Ferris RL, Rodriguez O, Albanese C, Kapoor M, Pasquale EB, Karam SD |
Nature Communications | 2022 |
|
Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.
Zhang W, Tang Y, Guo Y, Kong Y, Shi F, Sheng C, Wang S, Wang Q |
npj Precision Oncology | 2022 |
|
Recommendations for the use of biomarkers for head and neck cancer, including salivary gland tumours: a consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology.
Trigo J, García-Cosío M, García-Castaño A, Gomà M, Mesia-Nin R, Ruiz-Bravo E, Soria-Rivas A, Castillo P, Braña-García I, Alberola-Ferranti M |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2022 |
|
Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy.
Li Y, Yang C, Liu Z, Du S, Can S, Zhang H, Zhang L, Huang X, Xiao Z, Li X, Fang J, Qin W, Sun C, Wang C, Chen J, Chen H |
Molecular Cancer | 2022 |
|
Identification of Signature Genes and Characterizations of Tumor Immune Microenvironment and Tumor Purity in Lung Adenocarcinoma Based on Machine Learning.
Feng H, Zhao Y, Yan W, Wei X, Lin J, Jiang P, Wang C, Li B |
Frontiers in Medicine | 2022 |
|
Integrated Analysis of Multi-Omics Alteration, Immune Profile, and Pharmacological Landscape of Pyroptosis-Derived lncRNA Pairs in Gastric Cancer.
Guo C, Liu Z, Yu Y, Liu S, Ma K, Ge X, Xing Z, Lu T, Weng S, Wang L, Liu L, Hua Z, Han X, Li Z |
Frontiers in Cell and Developmental Biology | 2022 |
|
Dishevelled-Associated Activator of Morphogenesis 2 (DAAM2) Predicts the Immuno-Hot Phenotype in Pancreatic Adenocarcinoma.
Zhang Q, Pan J, Nie H, Wang H, An F, Zhan Q |
Frontiers in Molecular Biosciences | 2022 |
|
Cytokine Profiles of Head and Neck Squamous Cell Carcinoma Undergoing Dual Immunotherapy With Cetuximab and Pembrolizumab Identify Interferon Gamma-Induced Protein 10 as Novel Biomarker.
Berszin M, Michaelides I, Siemert J, Röhl L, Wellhausen J, Wald T, Bohr C, Künzel J, Gradistanac T, Dietz A, Zebralla V, Pirlich M, Wiegand S, Wichmann G |
Frontiers in Oncology | 2022 |
|
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
Wise-Draper TM, Gulati S, Palackdharry S, Hinrichs BH, Worden FP, Old MO, Dunlap NE, Kaczmar JM, Patil Y, Riaz MK, Tang A, Mark J, Zender C, Gillenwater AM, Bell D, Kurtzweil N, Mathews M, Allen CL, Mierzwa ML, Casper K, Jandarov R, Medvedovic M, Lee JJ, Harun N, Takiar V, Gillison M |
Clinical cancer research | 2022 |
|
The role of tumor-infiltrating lymphocytes in cholangiocarcinoma.
Liu D, Heij LR, Czigany Z, Dahl E, Lang SA, Ulmer TF, Luedde T, Neumann UP, Bednarsch J |
Journal of experimental & clinical cancer research : CR | 2022 |
|
Ubiquitin ligase STUB1 destabilizes IFNγ-receptor complex to suppress tumor IFNγ signaling.
Apriamashvili G, Vredevoogd DW, Krijgsman O, Bleijerveld OB, Ligtenberg MA, de Bruijn B, Boshuizen J, Traets JJH, D'Empaire Altimari D, van Vliet A, Lin CP, Visser NL, Londino JD, Sanchez-Hodge R, Oswalt LE, Altinok S, Schisler JC, Altelaar M, Peeper DS |
Nature Communications | 2022 |
|
New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis.
Shinohara S, Takahashi Y, Komuro H, Matsui T, Sugita Y, Demachi-Okamura A, Muraoka D, Takahara H, Nakada T, Sakakura N, Masago K, Miyai M, Nishida R, Shomura S, Shigematsu Y, Hatooka S, Sasano H, Watanabe F, Adachi K, Fujinaga K, Kaneda S, Takao M, Ohtsuka T, Yamaguchi R, Kuroda H, Matsushita H |
Journal for ImmunoTherapy of Cancer | 2022 |
|
TcellInflamedDetector: an R package to distinguish T cell inflamed tumor types from non-T cell inflamed tumor types.
Yang SD, Park HS |
Genomics & Informatics | 2022 |
|
Inactivation of Hippo pathway characterizes a poor-prognosis subtype of esophageal cancer
Zihang Mai, Jianye Yuan, Hong Yang, Shuogui Fang, Xiuying Xie, Xinye Wang, Jiaxin Xie, Jing Wen, Jianhua Fu |
JCI Insight | 2022 |
|
CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response
de Nonneville A, Finetti P, Picard M, Monneur A, Pantaleo MA, Astolfi A, Ostrowski J, Birnbaum D, Mamessier E, Bertucci F |
Cancers | 2022 |
|
Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC
Rocha P, Zhang J, Laza-Briviesca R, Cruz-Bermúdez A, Bota-Rabassedas N, Sanchez-Espiridon B, Yoshimura K, Behrens C, Lu W, Tang X, Pataer A, Parra ER, Haymaker C, Fujimoto J, Swisher SG, Heymach JV, Gibbons DL, Lee JJ, Sepesi B, Cascone T, Solis LM, Provencio M, Wistuba II, Kadara H |
Clinical cancer research | 2022 |
|
Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy.
Wessolly M, Stephan-Falkenau S, Streubel A, Wiesweg M, Borchert S, Mairinger E, Kollmeier J, Reis H, Bauer T, Schmid KW, Mairinger T, Schuler M, Mairinger FD |
BMC Cancer | 2022 |
|
Upregulation of IFNɣ-mediated chemokines dominate the immune transcriptome of muscle-invasive urothelial carcinoma.
Olkhov-Mitsel E, Hodgson A, Liu SK, Vesprini D, Bayani J, Bartlett JMS, Xu B, Downes MR |
Scientific Reports | 2022 |
|
Mesenchymal stromal cells equipped by IFNα empower T cells with potent anti-tumor immunity.
Zhang T, Wang Y, Li Q, Lin L, Xu C, Xue Y, Hu M, Shi Y, Wang Y |
Oncogene | 2022 |
|
Machine learning and bioinformatics analysis revealed classification and potential treatment strategy in stage 3-4 NSCLC patients.
Li C, Tian C, Zeng Y, Liang J, Yang Q, Gu F, Hu Y, Liu L |
BMC Medical Genomics | 2022 |
|
Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis.
Li S, Wu X, Yan X, Zhou L, Chi Z, Si L, Cui C, Tang B, Mao L, Lian B, Wang X, Bai X, Dai J, Kong Y, Tang X, Feng H, Yao S, Flaherty KT, Guo J, Sheng X |
Journal for ImmunoTherapy of Cancer | 2022 |
|
A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
Long J, Wang D, Wang A, Chen P, Lin Y, Bian J, Yang X, Zheng M, Zhang H, Zheng Y, Sang X, Zhao H |
Genome Medicine | 2022 |
|
Differential Expression of Genes Involved in Metabolism and Immune Response in Diffuse and Intestinal Gastric Cancers, a Pilot Ptudy.
Perrot-Applanat M, Pimpie C, Vacher S, Bieche I, Pocard M, Baud V |
Biomedicines | 2022 |
|
Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived models.
Lissa D, Takahashi N, Desai P, Manukyan I, Schultz CW, Rajapakse V, Velez MJ, Mulford D, Roper N, Nichols S, Vilimas R, Sciuto L, Chen Y, Guha U, Rajan A, Atkinson D, El Meskini R, Weaver Ohler Z, Thomas A |
Nature Communications | 2022 |
|
Targeting the gut and tumor microbiota in cancer.
Park EM, Chelvanambi M, Bhutiani N, Kroemer G, Zitvogel L, Wargo JA |
Nature Medicine | 2022 |
|
High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC.
Frigola J, Carbonell C, Irazno P, Pardo N, Callejo A, Cedres S, Martinez-Marti A, Navarro A, Soleda M, Jimenez J, Hernandez-Losa J, Vivancos A, Felip E, Amat R |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.
Zhang Z, Wang ZX, Chen YX, Wu HX, Yin L, Zhao Q, Luo HY, Zeng ZL, Qiu MZ, Xu RH |
Genome Medicine | 2022 |
|
A 2-Gene Signature Related to Interferon-Gamma Predicts Prognosis and Responsiveness to Immune Checkpoint Blockade of Glioma.
Li Y, Ji H, Gao X |
Frontiers in Medicine | 2022 |
|
Characterization of a Pyroptosis-Related Signature for Prognosis Prediction and Immune Microenvironment Infiltration in Prostate Cancer.
Zhang G, Luo Y, Dong W, Zhong W |
Computational and mathematical methods in medicine | 2022 |
|
GATA3 Predicts the Tumor Microenvironment Phenotypes and Molecular Subtypes for Bladder Carcinoma
Zhang Q, Qi T, Long Y, Li X, Yao Y, Wu Q, Zou A, Qthmane B, Liu P |
Frontiers in Surgery | 2022 |
|
TIRSF: a web server for screening gene signatures to predict Tumor immunotherapy response
Chen L, Chen T, Zhang Y, Lin H, Wang R, Wang Y, Li H, Zuo Z, Ren J, Xie Y |
Nucleic Acids Research | 2022 |
|
Genome instability is associated with ethnic differences between Asians and Europeans in hepatocellular carcinoma
Kaya NA, Chen J, Lai H, Yang H, Ma L, Liu X, Alvarez JS, Liu J, Hillmer AM, Tai D, Sheng JY, Hu Z, Chan YS, Chow PK, Mu Y, Wuestefeld T, Zhai W |
Theranostics | 2022 |
|
Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy
Deng B, Yang B, Chen J, Wang S, Zhang W, Guo Y, Han Y, Li H, Dang Y, Yuan Y, Dai X, Zang Y, Li Y, Li B |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy
Yao Y, Wang J, Yang F, Gao W |
Frontiers in immunology | 2022 |
|
Novel Inflammasome-Based Risk Score for Predicting Survival and Efficacy to Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
Tsao CC, Wu HH, Wang YF, Shen PC, Wu WT, Chen HY, Dai YH |
Biomedicines | 2022 |
|
The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy
Lee JY, Kannan B, Lim BY, Li Z, Lim AH, Loh JW, Ko TK, Ng CC, Chan JY |
International journal of molecular sciences | 2022 |
|
NOTCH1 mutation associates with impaired immune response and decreased relapse-free survival in patients with resected T1-2N0 laryngeal cancer
Gong XY, Chen HB, Zhang LQ, Chen DS, Li W, Chen DH, Xu J, Zhou H, Zhao LL, Song YJ, Xiao MZ, Deng WL, Qi C, Wang XR, Chen X |
Frontiers in immunology | 2022 |
|
TISMO: syngeneic mouse tumor database to model tumor immunity and immunotherapy response.
Zeng Z, Wong CJ, Yang L, Ouardaoui N, Li D, Zhang W, Gu S, Zhang Y, Liu Y, Wang X, Fu J, Zhou L, Zhang B, Kim S, Yates KB, Brown M, Freeman GJ, Uppaluri R, Manguso R, Liu XS |
Nucleic Acids Research | 2022 |
|
Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody.
Katoh Y, Yaguchi T, Kubo A, Iwata T, Morii K, Kato D, Ohta S, Satomi R, Yamamoto Y, Oyamada Y, Ouchi K, Takahashi S, Ishioka C, Matoba R, Suematsu M, Kawakami Y |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma.
Chen Q, Wang C, Lei X, Huang T, Zhou R, Lu Y |
Journal of Oncology | 2022 |
|
Potential predictive value of comutant LRP1B and FAT for immune response in non-small cell lung cancer: LRP1B and FAT comutation enhance immune response.
Hao F, Ma Q, Zhong D |
Translational oncology | 2022 |
|
THEM6: A Novel Molecular Biomarker Predicts Tumor Microenvironment, Molecular Subtype, and Prognosis in Bladder Cancer.
Zhao X, Hu J, Li J, Gu L, Chen J, Othmane B, Gong G, Yuan J, Deng H |
Disease Markers | 2022 |
|
Genomic Analysis Uncovers the Prognostic and Immunogenetic Feature of Pyroptosis in Gastric Carcinoma: Indication for Immunotherapy.
Zhou J, Nie RC, Yin YX, Wang Y, Yuan SQ, Zhao ZH, Zhang XK, Duan JL, Chen YB, Zhou ZW, Xie D, Li YF, Cai MY |
Frontiers in Cell and Developmental Biology | 2022 |
|
Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade.
Luo H, Liu GL, Jian D, Liang DD, Li XM, Zhong L, Yang B, Jiang J, Wang D, Li MX, Lan WH, Dai N |
Journal of Immunology Research | 2022 |
|
[Immunological biomarker research in uro-oncology-using the example of urothelial cancer].
Eckstein M |
Die Urologie | 2022 |
|
Signatures of immune senescence predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia
Sergio Rutella, Jayakumar Vadakekolathu, Mazziotta Francesco, Stephen Reeder, Tung-On Yau, Rupkatha Mukhopadhyay, Benjamin Dickins, Heidi Altmann, Michael Kramer, Hanna A. Knaus, Bruce R. Blazar, Vedran Radojcic, Joshua F. Zeidner, Andrea Arruda, Bofei Wang, Hussein A Abbas, Mark Minden, Sarah K Tasian, Martin Bornhäuser, Ivana Gojo, Leo Luznik |
Journal of Clinical Investigation | 2022 |
|
Prognostic Ferroptosis-Related lncRNA Signatures Associated With Immunotherapy and Chemotherapy Responses in Patients With Stomach Cancer
Lai D, Tan L, Zuo X, Liu D, Jiao D, Wan G, Lu C, Shen D, Gu X |
Frontiers in Genetics | 2022 |
|
Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects
Kuryk L, Rodella G, Staniszewska M, Pancer KW, Wieczorek M, Salmaso S, Caliceti P, Garofalo M |
Frontiers in Oncology | 2022 |
|
A Metabolism-Related Gene Prognostic Index Bridging Metabolic Signatures and Antitumor Immune Cycling in Head and Neck Squamous Cell Carcinoma
Du K, Zou J, Wang B, Liu C, Khan M, Xie T, Huang X, Shen P, Tian Y, Yuan Y |
Frontiers in immunology | 2022 |
|
Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments.
Roviello G, Catalano M, Santi R, Santoni M, Galli IC, Amorosi A, Polom W, De Giorgi U, Nesi G |
Frontiers in Oncology | 2022 |
|
A Prognostic Model for Breast Cancer Based on Cancer Incidence-Related DNA Methylation Pattern
Xiong Z, Yang L, Ao J, Yi J, Zouxu X, Zhong W, Feng J, Huang W, Wang X, Shuang Z |
Frontiers in Genetics | 2022 |
|
Assessment of POLE and POLD1 mutations as prognosis and immunotherapy biomarkers for stomach adenocarcinoma
Zhu M, Cui H, Zhang L, Zhao K, Jia X, Jin H |
Translational cancer research | 2022 |
|
Comprehensive Characterization of Metabolism-Associated Subtypes of Renal Cell Carcinoma to Aid Clinical Therapy
Yao Z, Zheng Z, Zheng X, Wu H, Zhao W, Mu X, Sun F, Wu K, Zheng J |
Oxidative medicine and cellular longevity | 2022 |
|
Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment
Wang A, Yuan Y, Chu H, Gao Y, Jin Z, Jia Q, Zhu B |
2022 | |
|
Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
Pataskar A, Champagne J, Nagel R, Kenski J, Laos M, Michaux J, Pak HS, Bleijerveld OB, Mordente K, Navarro JM, Blommaert N, Nielsen MM, Lovecchio D, Stone E, Georgiou G, de Gooijer MC, van Tellingen O, Altelaar M, Joosten RP, Perrakis A, Olweus J, Bassani-Sternberg M, Peeper DS, Agami R |
Nature | 2022 |
|
Stemness Subtypes and Scoring System Predict Prognosis and Efficacy of Immunotherapy in Soft Tissue Sarcoma
Gu HY, Qu WQ, Peng HH, Yu YF, Jiang ZZ, Qi BW, Yu AX |
Frontiers in immunology | 2022 |
|
Tumor Microenvironment Profiling Identifies Prognostic Signatures and Suggests Immunotherapeutic Benefits in Neuroblastoma
Feng C, Li T, Xiao J, Wang J, Meng X, Niu H, Jiang B, Huang L, Deng X, Yan X, Wu D, Fang Y, Lin Y, Chen F, Wu X, Zhao X, Feng J |
Frontiers in Cell and Developmental Biology | 2022 |
|
Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Colon Cancer to Immunotherapy
Wang Z, Song J, Azami NL, Sun M |
Frontiers in immunology | 2022 |
|
A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study
Tong H, Sun J, Fang J, Zhang M, Liu H, Xia R, Zhou W, Liu K, Chen X |
Frontiers in immunology | 2022 |
|
Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome
Gorris MA, van der Woude LL, Kroeze LI, Bol K, Verrijp K, Amir AL, Meek J, Textor J, Figdor CG, de Vries IJ |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis
Tu Z, Peng J, Long X, Li J, Wu L, Huang K, Zhu X |
Frontiers in immunology | 2022 |
|
Tumor Microenvironment Evaluation for Gastrointestinal Cancer in the Era of Immunotherapy and Machine Learning
Ye Z, Zeng D, Zhou R, Shi M, Liao W |
Frontiers in immunology | 2022 |
|
A Novel Immune-Prognosis Index Predicts the Benefit of Lung Adenocarcinoma Patients
Bai Y, Pei Y, Xia L, Ma L, Deng S |
Frontiers in pharmacology | 2022 |
|
Extended Application of Genomic Selection to Screen Multi-Omics Data for the Development of Novel Pyroptosis-Immune Signatures and Predicting Immunotherapy of Glioma
Ma S, Wang F, Wang N, Jin J, Yan X, Wang L, Zheng X, Hu S, Du J |
Frontiers in pharmacology | 2022 |
|
CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer
Jin K, Yu Y, Zeng H, Liu Z, You R, Zhang H, Liu C, Su X, Yan S, Chang Y, Xu L, Xu J, Zhu Y, Wang Z |
British Journal of Cancer | 2022 |
|
Identification of Transcriptional Heterogeneity and Construction of a Prognostic Model for Melanoma Based on Single-Cell and Bulk Transcriptome Analysis
Kang Z, Wang J, Huang W, Liu J, Yan W |
Frontiers in Cell and Developmental Biology | 2022 |
|
Immune Checkpoint Inhibitors as a Neoadjuvant/Adjuvant Treatment of Muscle-Invasive Bladder Cancer: A Systematic Review
Barone B, Calogero A, Scafuri L, Ferro M, Lucarelli G, Di Zazzo E, Sicignano E, Falcone A, Romano L, De Luca L, Oliva F, Mirto BF, Capone F, Imbimbo C, Crocetto F |
Cancers | 2022 |
|
Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction
Tímár J, Ladányi A |
International journal of molecular sciences | 2022 |
|
A Risk Model of Eight Immune-Related Genes Predicting Prognostic Response to Immune Therapies for Gastric Cancer
Yu M, Zhang Y, Mao R, Zhu C, Zhao R, Jin L |
Genes & development | 2022 |
|
Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response
Ling C, Zhou X, Gao Y, Sui X |
Pharmaceuticals | 2022 |
|
Verification of genetic differences and immune cell infiltration subtypes in the neuroblastoma tumour microenvironment during immunotherapy
Qian B, Sun J, Zuo P, Da M, Mo X, Fang Y |
World journal of surgical oncology | 2022 |
|
TGFβ-Associated Signature Predicts Prognosis and Tumor Microenvironment Infiltration Characterization in Gastric Carcinoma
Liu S, Li Z, Li H, Wen X, Wang Y, Chen Q, Xu X |
Frontiers in Genetics | 2022 |
|
Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males
Saad M, Lee SJ, Tan AC, El Naqa IM, Hodi FS, Butterfield LH, LaFramboise WA, Storkus W, Karunamurthy AD, Conejo-Garcia J, Hwu P, Streicher H, Sondak VK, Kirkwood JM, Tarhini AA |
Journal of Translational Medicine | 2022 |
|
Multiomics Data Analysis and Identification of Immune-Related Prognostic Signatures With Potential Implications in Prognosis and Immune Checkpoint Blockade Therapy of Glioblastoma
Ma S, Wang F, Wang N, Jin J, Ba Y, Ji H, Du J, Hu S |
Frontiers in neurology | 2022 |
|
APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases
Shi R, Wang X, Wu Y, Xu B, Zhao T, Trapp C, Wang X, Unger K, Zhou C, Lu S, Buchner A, Schulz GB, Cao F, Belka C, Su C, Li M, Shu Y |
Theranostics | 2022 |
|
Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma
Wang Q, Tang H, Luo X, Chen J, Zhang X, Li X, Li Y, Chen Y, Xu Y, Han S |
Frontiers in immunology | 2022 |
|
Artificial Intelligence–Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non–Small-Cell Lung Cancer
Park S, Ock CY, Kim H, Pereira S, Park S, Ma M, Choi S, Kim S, Shin S, Aum BJ, Paeng K, Yoo D, Cha H, Park S, Suh KJ, Jung HA, Kim SH, Kim YJ, Sun JM, Chung JH, Ahn JS, Ahn MJ, Lee JS, Park K, Song SY, Bang YJ, Choi YL, Mok TS, Lee SH |
Journal of Clinical Oncology | 2022 |
|
A Framework to Predict the Molecular Classification and Prognosis of Breast Cancer Patients and Characterize the Landscape of Immune Cell Infiltration
Zheng K, Luo Z, Zhou Y, Zhang L, Wang Y, Chen X, Yao S, Xiong H, Yuan X, Zou Y, Wang Y, Xiong H |
Computational and mathematical methods in medicine | 2022 |
|
DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma
Chen M, Huang B, Zhu L, Wang Q, Pang Y, Cheng M, Lian H, Liu M, Zhao K, Xu S, Zhang J, Zhong C |
Frontiers in immunology | 2022 |
|
A Robust Immuno-Prognostic Model of Non-Muscle-Invasive Bladder Cancer Indicates Dynamic Interaction in Tumor Immune Microenvironment Contributes to Cancer Progression
Sun X, Xu H, Liu G, Chen J, Xu J, Li M, Liu L |
Frontiers in Genetics | 2022 |
|
m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment
Zhang T, Liu H, Gao F, Gong W, Cui Y, He J, Li L, Qiu L, Qian Z, Zhou S, Meng B, Ren X, Zhang H, Wang X |
Frontiers in immunology | 2022 |
|
Multimodal predictors for precision immunotherapy
Roelofsen LM, Kaptein P, Thommen DS |
2022 | |
|
Role of Adenoviruses in Cancer Therapy
Tseha ST |
Frontiers in Oncology | 2022 |
|
A promising Prognostic risk model for advanced renal cell carcinoma (RCC) with immune-related genes
Cao P, Wu JY, Zhang JD, Sun ZJ, Zheng X, Yu BZ, Cao HY, Zhang FL, Gao ZH, Wang W |
BMC Cancer | 2022 |
|
Characterizing HDAC Pathway Copy Number Variation in Pan-Cancer
Yang S, Xie S, Shi X, Su D, He B, Xu Y, Liu Z |
2022 | |
|
Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes
Trigos AS, Pasam A, Banks P, Wallace R, Guo C, Keam S, Thorne H, Mitchell C, Lade S, Clouston D, Hakansson A, Liu Y, Blyth B, Murphy D, Lawrentschuk N, Bolton D, Moon D, Darcy P, Haupt Y, Williams SG, Castro E, Olmos D, Goode D, Neeson P, Sandhu S |
Journal for ImmunoTherapy of Cancer | 2022 |
|
A Pyroptosis-Related Signature Predicts Overall Survival and Immunotherapy Responses in Lung Adenocarcinoma
Zhu K, Yan A, Zhou F, Zhao S, Ning J, Yao L, Shang D, Chen L |
Frontiers in Genetics | 2022 |
|
Chronic exposure to waterpipe smoke elicits immunomodulatory and carcinogenic effects in the lung
Hassane M, Rahal Z, Karaoghlanian N, Zhang J, Sinjab A, Wong JW, Lu W, Scheet P, Lee JJ, Raso MG, Solis LM, Fujimoto J, Chami H, Shihadeh AL, Kadara H |
Cancer prevention research (Philadelphia, Pa.) | 2022 |
|
Hepatic IRF8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-PD-1 therapy
Wu H, Li Y, Shi G, Du S, Wang X, Ye W, Zhang Z, Chu Y, Ma S, Wang D, Li Y, Chen Z, Birnbaumer L, Wang Z, Yang Y |
Hepatology | 2022 |
|
Predicting Chemo-Radiotherapy Sensitivity With Concordant Survival Benefit in Non-Small Cell Lung Cancer via Computed Tomography Derived Radiomic Features
Liu Y, Qi H, Wang C, Deng J, Tan Y, Lin L, Cui Z, Li J, Qi L |
Frontiers in Oncology | 2022 |
|
HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC
Mei J, Jiang G, Chen Y, Xu Y, Wan Y, Chen R, Liu F, Mao W, Zheng M, Xu J |
BMC Cancer | 2022 |
|
IFN-γ induces PD-L1 through p38/JNK/ERK signaling pathways and counteracts the tumor promoting effect mediated by PD-L1 in Glioblastoma
Jia H, Xie X, Wang L, Wang L, Che F |
Computational Intelligence and Neuroscience | 2022 |
|
IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer
Yi X, Zheng X, Xu H, Li J, Zhang T, Ge P, Liao D, Li H, Lyu X, Ai J |
Frontiers in immunology | 2022 |
|
Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
Shui IM, Liu XQ, Zhao Q, Kim ST, Sun Y, Yearley JH, Choudhury T, Webber AL, Krepler C, Cristescu R, Lee J |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Dissecting Immunosuppressive Cell Communication Patterns Reveals JunB Proto-Oncogene (JUNB) Shaping a Non-Inflamed Tumor Microenvironment
Chen H, Chen G |
Frontiers in Genetics | 2022 |
|
Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
Lee CK, Chan SL, Chon HJ |
Cancers | 2022 |
|
A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy
Su X, Jin H, Du N, Wang J, Lu H, Xiao J, Li X, Yi J, Gu T, Dan X, Gao Z, Li M |
Frontiers in Oncology | 2022 |
|
Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma
Lv H, Liu X, Zeng X, Liu Y, Zhang C, Zhang Q, Xu J |
Frontiers in pharmacology | 2022 |
|
Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer
Lau D, Khare S, Stein MM, Jain P, Gao Y, BenTaieb A, Rand TA, Salahudeen AA, Khan AA |
Nature Communications | 2022 |
|
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro Jr G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BG, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Ge J, Swaby RF, Gumuscu B, Harrington K |
Journal of Clinical Oncology | 2022 |
|
A Novel Artificial Neural Network Prognostic Model Based on a Cancer-Associated Fibroblast Activation Score System in Hepatocellular Carcinoma
Luo Y, Tan H, Yu T, Tian J, Shi H |
Frontiers in immunology | 2022 |
|
Establishment of a Necroptosis Related Genes Signature to Predict Prognosis and Therapeutic Response in Colon Cancer
Wang Y, Huang Y, Li C, Wang X, Yang M, Xu D, Liu B, Yuan X |
Frontiers in Cell and Developmental Biology | 2022 |
|
CRISPR activation and interference screens decode stimulation responses in primary human T cells
Schmidt R, Steinhart Z, Layeghi M, Freimer JW, Bueno R, Nguyen VQ, Blaeschke F, Ye CJ, Marson A |
Science (New York, N.Y.) | 2022 |
|
HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer
Zhang W, Lin Z, Shi F, Wang Q, Kong Y, Ren Y, Lyu J, Sheng C, Li Y, Qin H, Wang S, Wang Q |
Cancers | 2022 |
|
CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression
Boudin L, De Nonneville A, Finetti P, Guittard G, Nunes JA, Birnbaum D, Mamessier E, Bertucci F |
Cancers | 2022 |
|
Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
Pedersen JG, Sokac M, Sørensen BS, Luczak AA, Aggerholm-Pedersen N, Birkbak NJ, Øllegaard TH, Jakobsen MR |
Cancers | 2022 |
|
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
Kanemura H, Hayashi H, Tomida S, Tanizaki J, Suzuki S, Kawanaka Y, Tsuya A, Fukuda Y, Kaneda H, Kudo K, Takahama T, Imai R, Haratani K, Chiba Y, Otani T, Ito A, Sakai K, Nishio K, Nakagawa K |
2022 | |
|
CD8+ T cell trajectory subtypes decode tumor heterogeneity and provide treatment recommendations for hepatocellular carcinoma
Liu L, Liu Z, Gao J, Liu X, Weng S, Guo C, Hu B, Wang Z, Zhang J, Shi J, Guo W, Zhang S |
Frontiers in immunology | 2022 |
|
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma
Lu Z, Yang S, Luo X, Shi Y, Lee JS, Deva S, Liu T, Chao Y, Zhang Y, Huang R, Xu Y, Shen Z, Shen L |
Gastric Cancer | 2022 |
|
Analysis of Genomic Alterations Associated with Recurrence in Early Stage HER2-Positive Breast Cancer
Kim YS, Sun DS, Ahn J, Kim Y, Yoon JS, Won HS |
Cancers | 2022 |
|
A Differentiation-Related Gene Prognostic Index Contributes to Prognosis and Immunotherapy Evaluation in Patients with Hepatocellular Carcinoma
Xiao J, Liu T, Liu Z, Xiao C, Du J, Zuo S, Li H, Gu H |
Cells | 2022 |
|
Peripheral Blood Biomarkers Predictive of Efficacy Outcome and Immune-Related Adverse Events in Advanced Gastrointestinal Cancers Treated with Checkpoint Inhibitors
Zhang Z, Xie T, Qi C, Zhang X, Shen L, Peng Z |
Cancers | 2022 |
|
Consensus Molecular Subtypes Efficiently Classify Gastric Adenocarcinomas and Predict the Response to Anti-PD-1 Immunotherapy
Wu X, Ye Y, Vega KJ, Yao J |
Cancers | 2022 |
|
Immunotherapy for the Treatment of Squamous Cell Carcinoma: Potential Benefits and Challenges
Ansary TM, Hossain MR, Komine M, Ohtsuki M |
International journal of molecular sciences | 2022 |
|
The cancer-associated fibroblast-related signature predicts prognosis and indicates immune microenvironment infiltration in gastric cancer
Mak TK, Li X, Huang H, Wu K, Huang Z, He Y, Zhang C |
Frontiers in immunology | 2022 |
|
Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action
Tilsed CM, Fisher SA, Nowak AK, Lake RA, Lesterhuis WJ |
Frontiers in Oncology | 2022 |
|
Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing
Yang L, Wei S, Zhang J, Hu Q, Hu W, Cao M, Zhang L, Wang Y, Wang P, Wang K |
Journal of Translational Medicine | 2022 |
|
Machine learning-based identification of tumor-infiltrating immune cell-associated lncRNAs for improving outcomes and immunotherapy responses in patients with low-grade glioma
Zhang N, Zhang H, Wu W, Zhou R, Li S, Wang Z, Dai Z, Zhang L, Liu F, Liu Z, Zhang J, Luo P, Liu Z, Cheng Q |
Theranostics | 2022 |
|
Inhibition of IL-17A Protects against Thyroid Immune-Related Adverse Events while Preserving Checkpoint Inhibitor Antitumor Efficacy.
Lechner MG, Cheng MI, Patel AY, Hoang AT, Yakobian N, Astourian M, Pioso MS, Rodriguez ED, McCarthy EC, Hugo W, Angell TE, Drakaki A, Ribas A, Su MA |
Journal of immunology (Baltimore, Md. : 1950) | 2022 |
|
Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy.
Boukhaled GM, Gadalla R, Elsaesser HJ, Abd-Rabbo D, Quevedo R, Yang SYC, Guo M, Wang BX, Noamani B, Gray D, Lau SCM, Taylor K, Aung K, Spreafico A, Hansen AR, Saibil SD, Hirano N, Guidos C, Pugh TJ, McGaha TL, Ohashi PS, Sacher AG, Butler MO, Brooks DG |
Nature Immunology | 2022 |
|
Wilms Tumor 1-Associated Protein Expression Is Linked to a T-Cell-Inflamed Phenotype in Pancreatic Cancer.
Xu JL |
Digestive Diseases and Sciences | 2022 |
|
Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood.
Carlisle JW, Jansen CS, Cardenas MA, Sobierajska E, Reyes AM, Greenwald R, Del Balzo L, Prokhnevska N, Kucuk O, Carthon BC, Mullane PC, Osunkoya A, Baumgarten D, Hosseinzadeh F, Wilkinson S, Lake R, Sowalsky AG, Liu Y, Master VA, Bilen MA, Kissick H |
Journal for ImmunoTherapy of Cancer | 2022 |
|
A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma.
Jin C, Zhao JS, Huang XQ, Yang XZ, Niu FY, Lin JR, Ma L, Shi YX, Li XS, Jiang P, Gao S, Li F, Song Y |
Hepatology International | 2022 |
|
The cross-talk of cancer-associated fibroblasts assist in prognosis and immunotherapy in patients with breast carcinoma.
Gu X, Zheng S, Zhang H, Sun X, Zhou Q |
Cancer Gene Therapy | 2022 |
|
Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results.
Palmer CD, Rappaport AR, Davis MJ, Hart MG, Scallan CD, Hong SJ, Gitlin L, Kraemer LD, Kounlavouth S, Yang A, Smith L, Schenk D, Skoberne M, Taquechel K, Marrali M, Jaroslavsky JR, Nganje CN, Maloney E, Zhou R, Navarro-Gomez D, Greene AC, Grotenbreg G, Greer R, Blair W, Cao MD, Chan S, Bae K, Spira AI, Roychowdhury S, Carbone DP, Henick BS, Drake CG, Solomon BJ, Ahn DH, Mahipal A, Maron SB, Johnson B, Rousseau R, Yelensky R, Liao CY, Catenacci DVT, Allen A, Ferguson AR, Jooss K |
Nature Medicine | 2022 |
|
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib.
Zhu Z, Turner NC, Loi S, André F, Martin M, Diéras V, Gelmon KA, Harbeck N, Zhang C, Cao JQ, Yan Z, Lu DR, Wei P, VanArsdale TL, Rejto PA, Huang X, Rugo HS, Loibl S, Cristofanilli M, Finn RS, Liu Y |
npj Precision Oncology | 2022 |
|
STUB1 is an intracellular checkpoint for interferon gamma sensing.
Ng S, Lim S, Sim ACN, Mangadu R, Lau A, Zhang C, Martinez SB, Chandramohan A, Lim UM, Ho SSW, Chang SC, Gopal P, Hong LZ, Schwaid A, Fernandis AZ, Loboda A, Li C, Phan U, Henry B, Partridge AW |
Scientific Reports | 2022 |
|
Immunotherapy in non-small cell lung cancer: Past, present, and future directions
Punekar SR, Shum E, Grello CM, Lau SC, Velcheti V |
Frontiers in Oncology | 2022 |
|
Temporally restricted activation of IFNβ signaling underlies response to immune checkpoint therapy in mice
Zemek RM, Chin WL, Fear VS, Wylie B, Casey TH, Forbes C, Tilsed CM, Boon L, Guo BB, Bosco A, Forrest AR, Millward MJ, Nowak AK, Lake RA, Lassmann T, Joost Lesterhuis W |
Nature Communications | 2022 |
|
NAPSB as a predictive marker for prognosis and therapy associated with an immuno-hot tumor microenvironment in hepatocellular carcinoma
Ning YM, Lin K, Liu XP, Ding Y, Jiang X, Zhang Z, Xuan YT, Dong L, Liu L, Wang F, Zhao Q, Wang HZ, Fang J |
BMC Gastroenterology | 2022 |
|
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades.
Zhao X, Bao Y, Meng B, Xu Z, Li S, Wang X, Hou R, Ma W, Liu D, Zheng J, Shi M |
Frontiers in immunology | 2022 |
|
The rest period between chemotherapy and immunotherapy influences the efficacy of immune checkpoint inhibitors in lung cancer
Kang DH, Choi S, Sun P, Chung C, Park D, Lee S, Koh JS, Kim Y, Lee JE |
Thoracic Cancer | 2022 |
|
Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer
Hong DS, Gopal AK, Shoushtari AN, Patel SP, He AR, Doi T, Ramalingam SS, Patnaik A, Sandhu S, Chen Y, Davis CB, Fisher TS, Huang B, Fly KD, Ribas A |
Frontiers in immunology | 2022 |
|
Development and Validation of a DNA Methylation-related Classifier of Circulating Tumour Cells to Predict Prognosis and to provide a therapeutic strategy in Lung Adenocarcinoma
Gu X, Huang X, Zhang X, Wang C |
International journal of biological sciences | 2022 |
|
Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers
Korlimarla A, PS H, Prabhu J, Ragulan C, Patil Y, VP S, Desai K, Mathews A, Appachu S, Diwakar RB, BS S, Melcher A, Cheang M, Sadanandam A |
Translational oncology | 2022 |
|
Development and validation of a robust necroptosis related classifier for colon adenocarcinoma.
Yang J, Chen H, Wang Y, Chen J |
Frontiers in Genetics | 2022 |
|
Integrative tumour mutation burden with CD39 and PD-L1 for the prediction of response to PD-L1 blockade and adjuvant chemotherapy in muscle-invasive bladder cancer patients.
Liu C, Liu Z, Jin K, Zeng H, Shao F, Chang Y, Wang Y, Xu L, Wang Z, Zhu Y, Zhang W |
British Journal of Cancer | 2022 |
|
Identification and validation of miR-509-5p as a prognosticator for favorable survival in osteosarcoma
Guo J, Fang X, Zhou J, Zeng L, Yu B |
Medicine | 2022 |
|
Recent Advances and Challenges in Cancer Immunotherapy
Peterson C, Denlinger N, Yang Y |
Cancers | 2022 |
|
Impact of cancer evolution on immune surveillance and checkpoint inhibitor response
Wu Y, Biswas D, Swanton C |
Seminars in Cancer Biology | 2022 |
|
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma
Rossi N, Lee KA, Bermudez MV, Visconti A, Thomas AM, Bolte LA, Björk JR, de Ruijter LK, Newton-Bishop J, Harland M, Shaw HM, Harries M, Sacco J, Board R, Lorigan P, de Vries EG, Segata N, Taams L, Papa S, Spector TD, Nathan P, Weersma RK, Hospers GA, Fehrmann RS, Bataille V, Falchi M |
EBioMedicine | 2022 |
|
Tumor Antigenicity and a Pre-Existing Adaptive Immune Response in Advanced BRAF Mutant Colorectal Cancers.
Bolzacchini E, Libera L, Church SE, Sahnane N, Bombelli R, Digiacomo N, Giordano M, Petracco G, Sessa F, Capella C, Furlan D |
Cancers | 2022 |
|
The epiphany derived from T-cell–inflamed profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses
Niu D, Chen Y, Mi H, Mo Z, Pang G |
Frontiers in Genetics | 2022 |
|
Immune microenvironment characteristics in multiple myeloma progression from transcriptome profiling
Wang J, Hu Y, Hamidi H, Dos Santos C, Zhang J, Punnoose E, Li W |
Frontiers in Oncology | 2022 |
|
CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma
Hu ZW, Sun W, Wen YH, Ma RQ, Chen L, Chen WQ, Lei WB, Wen WP |
Frontiers in immunology | 2022 |
|
Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development
Fu J, Chen F, Lin Y, Gao J, Chen A, Yang J |
Journal of Cancer Research and Clinical Oncology | 2022 |
|
An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy
Blaye C, Darbo É, Debled M, Brouste V, Vélasco V, Pinard C, Larmonier N, Pellegrin I, Tarricone A, Arnedos M, Commeny J, Bonnefoi H, Larmonier C, MacGrogan G |
ESMO Open | 2022 |
|
TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, preventive, and personalized medicine
Zhang S, Wan X, Lv M, Li C, Chu Q, Wang G |
The EPMA Journal | 2022 |
|
Deep learning reveals cuproptosis features assist in predict prognosis and guide immunotherapy in lung adenocarcinoma
Li G, Luo Q, Wang X, Zeng F, Feng G, Che G |
Frontiers in Endocrinology | 2022 |
|
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Yap TA, Gainor JF, Callahan MK, Falchook GS, Pachynski RK, LoRusso P, Kummar S, Gibney GT, Burris HA, Tykodi SS, Rahma OE, Seiwert TY, Papadopoulos KP, Blum Murphy M, Park H, Hanson A, Hashambhoy-Ramsay Y, McGrath L, Hooper E, Xiao X, Cohen H, Fan M, Felitsky D, Hart C, McComb R, Brown K, Sepahi A, Jimenez J, Zhang W, Baeck J, Laken H, Murray R, Trehu E, Harvey CJ |
Clinical cancer research | 2022 |
|
Development and validation of a novel fibroblast scoring model for lung adenocarcinoma
Wei S, Gu X, Zhang W |
Frontiers in Oncology | 2022 |
|
NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets.
Indini A, Fiorilla I, Ponzone L, Calautti E, Audrito V |
International journal of molecular sciences | 2022 |
|
Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
Kim SY, Yin J, Bohlman S, Walker P, Dacic S, Kim C, Khan H, Liu SV, Ma PC, Nagasaka M, Reckamp KL, Abraham J, Uprety D, Wang F, Xiu J, Zhang J, Cheng H, Halmos B |
2022 | |
|
CXCL10-armed oncolytic adenovirus promotes tumor-infiltrating T-cell chemotaxis to enhance anti-PD-1 therapy
Li X, Lu M, Yuan M, Ye J, Zhang W, Xu L, Wu X, Hui B, Yang Y, Wei B, Guo C, Wei M, Dong J, Wu X, Gu Y |
OncoImmunology | 2022 |
|
Glutathione peroxidase 2 is a metabolic driver of the tumor immune microenvironment and immune checkpoint inhibitor response.
Ahmed KM, Veeramachaneni R, Deng D, Putluri N, Putluri V, Cardenas MF, Wheeler DA, Decker WK, Frederick AI, Kazi S, Sikora AG, Sandulache VC, Frederick MJ |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.
Ellingsen EB, Bounova G, Kerzeli I, Anzar I, Simnica D, Aamdal E, Guren T, Clancy T, Mezheyeuski A, Inderberg EM, Mangsbo SM, Binder M, Hovig E, Gaudernack G |
Journal of Translational Medicine | 2022 |
|
An immunotherapy response prediction model derived from proliferative CD4+ T cells and antigen-presenting monocytes in ccRCC.
Zheng K, Gao L, Hao J, Zou X, Hu X |
Frontiers in immunology | 2022 |
|
Pericyte mediates the infiltration, migration, and polarization of macrophages by CD163/MCAM axis in glioblastoma.
Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Liang X, Zhang L, Peng Y, Luo P, Zhang J, Liu Z, Cheng Q, Liu Z |
iScience | 2022 |
|
Biomarkers for immune checkpoint inhibitors in solid tumors.
Kapoor V, Kelly WJ |
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | 2022 |
|
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma
Denize T, Hou Y, Pignon JC, Walton E, West DJ, Freeman GJ, Braun DA, Wu CJ, Gupta S, Motzer RJ, Atkins MB, McDermott D, Choueiri TK, Shukla SA, Signoretti S |
Clinical cancer research | 2022 |
|
CXCR2 inhibition enables NASH-HCC immunotherapy
Leslie J, Mackey JB, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, Clark W, Gilroy K, Hedley A, Nixon C, Luli S, Laszczewska M, Pinyol R, Esteban-Fabró R, Willoughby CE, Haber PK, Andreu-Oller C, Rahbari M, Fan C, Pfister D, Raman S, Wilson N, Müller M, Collins A, Geh D, Fuller A, McDonald D, Hulme G, Filby A, Cortes-Lavaud X, Mohamed NE, Ford CA, Raffo Iraolagoitia XL, McFarlane AJ, McCain MV, Ridgway RA, Roberts EW, Barry ST, Graham GJ, Heikenwälder M, Reeves HL, Llovet JM, Carlin LM, Bird TG, Sansom OJ, Mann DA |
Gut | 2022 |
|
Cuproptosis scoring model predicts overall survival and assists in immunotherapeutic decision making in pancreatic carcinoma
Liu T, Liu Q, Wang Y, Yang R, Tian F |
Frontiers in Genetics | 2022 |
|
Identification of a novel necroptosis-related classifier to predict prognosis and guide immunotherapy in breast invasive carcinoma
Zhou Q, Xu Y, Shen L, Yang X, Wang L |
Frontiers in Oncology | 2022 |
|
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
Zhang C, Chen HF, Yan S, Wu L, Yan LX, Yan XL, Yue DS, Xu CW, Zheng M, Li JS, Liu SY, Yang LL, Jiang BY, Ou QX, Qiu ZB, Shao Y, Wu YL, Zhong WZ |
npj Precision Oncology | 2022 |
|
Development and verification of an immune-related gene prognostic index for gastric cancer
Zhang C, Liu T, Wang J, Zhang J |
Scientific Reports | 2022 |
|
The expression pattern of immune-related genes and characterization of tumor immune microenvironment: predicting prognosis and immunotherapeutic effects in cutaneous melanoma.
Dong D, Wang W, Wang H, Chen L, Liu T |
World journal of surgical oncology | 2022 |
|
In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.
Dubrot J, Du PP, Lane-Reticker SK, Kessler EA, Muscato AJ, Mehta A, Freeman SS, Allen PM, Olander KE, Ockerman KM, Wolfe CH, Wiesmann F, Knudsen NH, Tsao HW, Iracheta-Vellve A, Schneider EM, Rivera-Rosario AN, Kohnle IC, Pope HW, Ayer A, Mishra G, Zimmer MD, Kim SY, Mahapatra A, Ebrahimi-Nik H, Frederick DT, Boland GM, Haining WN, Root DE, Doench JG, Hacohen N, Yates KB, Manguso RT |
Nature Immunology | 2022 |
|
Leveraging the Dynamic Immune Environment Triad in Patients with Breast Cancer: Tumour, Lymph Node, and Peripheral Blood
Wall I, Boulat V, Shah A, Blenman KR, Wu Y, Alberts E, Calado DP, Salgado R, Grigoriadis A |
Cancers | 2022 |
|
Immunotherapy in soft tissue and bone sarcoma: unraveling the barriers to effectiveness
Panagi M, Pilavaki P, Constantinidou A, Stylianopoulos T |
Theranostics | 2022 |
|
Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study
Evrard D, Dumont C, Gatineau M, Delord JP, Fayette J, Dreyer C, Tijeras-Raballand A, de Gramont A, Delattre JF, Granier M, Aissat N, Garcia-Larnicol ML, Slimane K, Chibaudel B, Raymond E, Le Tourneau C, Faivre S |
Cancers | 2022 |
|
Identification of an immune-related gene prognostic index for predicting survival and immunotherapy efficacy in papillary renal cell carcinoma
Chen D, Zhang C, Zang Y, Wang W, Zhang J |
Frontiers in Genetics | 2022 |
|
Rutaecarpine prevents the malignant biological properties of breast cancer cells by the miR-149-3p/S100A4 axis
Xiong Y, Xiong C, Li P, Shan X |
Annals of translational medicine | 2022 |
|
Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction
Ji H, Liu Z, Wang F, Sun H, Wang N, Liu Y, Hu S, You C |
Frontiers in immunology | 2022 |
|
Analysis of genomes and transcriptomes of clear cell renal cell carcinomas identifies mutations and gene expression changes in the TGF-beta pathway
Che X, Li J, Xu Y, Wang Q, Wu G |
Frontiers in Genetics | 2022 |
|
Landscape of prognosis and immunotherapy responsiveness under tumor glycosylation-related lncRNA patterns in breast cancer
Lv W, Tan Y, Zhou X, Zhang Q, Zhang J, Wu Y |
Frontiers in immunology | 2022 |
|
Immune-related 3-lncRNA signature with prognostic connotation in a multi-cancer setting
Sherif S, Mall R, Almeer H, Naik A, Al Homaid A, Thomas R, Roelands J, Narayanan S, Mohamed MG, Bedri S, Al-Bader SB, Junejo K, Bedognetti D, Hendrickx W, Decock J |
Journal of Translational Medicine | 2022 |
|
Precision combination therapies based on recurrent oncogenic co-alterations
Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilié PG, Yap TA, Kopetz S, Sander C, Korkut A |
Cancer Discovery | 2022 |
|
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
Atkins MB, Abu-Sbeih H, Ascierto PA, Bishop MR, Chen DS, Dhodapkar M, Emens LA, Ernstoff MS, Ferris RL, Greten TF, Gulley JL, Herbst RS, Humphrey RW, Larkin J, Margolin KA, Mazzarella L, Ramalingam SS, Regan MM, Rini BI, Sznol M |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies
Bailey SR, Vatsa S, Larson RC, Bouffard AA, Scarfò I, Kann MC, Berger TR, Leick MB, Wehrli M, Schmidts A, Silva H, Lindell KA, Demato A, Gallagher KM, Frigault MJ, Maus MV |
2022 | |
|
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
Casarrubios M, Provencio M, Nadal E, Insa A, del Rosario García-Campelo M, Lázaro-Quintela M, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé R, Viñolas N, Barneto Aranda I, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernández-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermúdez A |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Lipid metabolic features of T cells in the Tumor Microenvironment
Lou W, Gong C, Ye Z, Hu Y, Zhu M, Fang Z, Xu H |
Lipids in Health and Disease | 2022 |
|
Machine learning reveals two heterogeneous subtypes to assist immune therapy based on lipid metabolism in lung adenocarcinoma
Gu X, Wei S, Li Z, Xu H |
Frontiers in immunology | 2022 |
|
Identification of four immune subtypes in locally advanced rectal cancer treated with neoadjuvant chemotherapy for predicting the efficacy of subsequent immune checkpoint blockade
He L, Jin M, Jian D, Yang B, Dai N, Feng Y, Xiao H, Wang D |
Frontiers in immunology | 2022 |
|
CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
Boudin L, de Nonneville A, Finetti P, Mescam L, Le Cesne A, Italiano A, Blay JY, Birnbaum D, Mamessier E, Bertucci F |
Journal of Translational Medicine | 2022 |
|
Anlotinib Benefits the αPDL1 Immunotherapy by Activating ROS/JNK/AP-1 Pathway to Upregulate PDL1 Expression in Colorectal Cancer
Luo B, Zhang S, Tan D, Yu X, Lin J, Wang M |
Oxidative medicine and cellular longevity | 2022 |
|
Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti–PD-L1 Immune Checkpoint Therapy
You S, Kim M, Hoi XP, Lee YC, Wang L, Spetzler D, Abraham J, Magee D, Jain P, Galsky MD, Chan KS, Theodorescu D |
JNCI Journal of the National Cancer Institute | 2022 |
|
miR-aculous new avenues for cancer immunotherapy
Tang WW, Bauer KM, Barba C, Ekiz HA, O\u2019Connell RM |
Frontiers in immunology | 2022 |
|
Development and validation of a combined glycolysis and immune prognostic signature for lung squamous cell carcinoma
Huang Q, Yang S, Yan H, Chen H, Wang Y, Wang Y |
Frontiers in Genetics | 2022 |
|
Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
Shklovskaya E, Pedersen B, Stewart A, Simpson JO, Ming Z, Irvine M, Scolyer RA, Long GV, Rizos H |
Cancers | 2022 |
|
Prognostic Value of UBE2T and Its Correlation with Immune Infiltrates in Lung Adenocarcinoma
Xu F, Xiong N, Yuan Y, Liu J |
Journal of Oncology | 2022 |
|
Artificial Intelligence Meets Whole Slide Images: Deep Learning Model Shapes an Immune-Hot Tumor and Guides Precision Therapy in Bladder Cancer
Jiang Y, Huang S, Zhu X, Cheng L, Liu W, Chen Q, Yang D |
Journal of Oncology | 2022 |
|
A novel signature of combing cuproptosis- with ferroptosis-related genes for prediction of prognosis, immunologic therapy responses and drug sensitivity in hepatocellular carcinoma
Zhao C, Zhang Z, Jing T |
Frontiers in Oncology | 2022 |
|
An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer
Cavalieri S, Serafini MS, Carenzo A, Canevari S, Lenoci D, Pistore F, Miceli R, Vecchio S, Ferrari D, Moro C, Sponghini A, Caldara A, Rocca MC, Secondino S, Moretti G, Denaro N, Caponigro F, Vaccher E, Rinaldi G, Ferraù F, Bossi P, Licitra L, De Cecco L |
Cells | 2022 |
|
Tumor-Intrinsic Nuclear β-Catenin Associates with an Immune Ignorance Phenotype and a Poorer Prognosis in Head and Neck Squamous Cell Carcinomas
Sánchez-Canteli M, Juesas L, Garmendia I, Otero-Rosales M, Calvo A, Alvarez-Fernández M, Astudillo A, Montuenga LM, García-Pedrero JM, Rodrigo JP |
International journal of molecular sciences | 2022 |
|
Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer
Su GH, Xiao Y, Jiang L, Zheng RC, Wang H, Chen Y, Gu YJ, You C, Shao ZM |
Journal of Translational Medicine | 2022 |
|
Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer
Zhu C, Wang S, Du Y, Dai Y, Huai Q, Li X, Du Y, Dai H, Yuan W, Yin S, Wang H |
BMC Gastroenterology | 2022 |
|
The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors.
Gueble SE, Vasquez JC, Bindra RS |
Current Treatment Options in Oncology | 2022 |
|
Distinct responses of newly identified monocyte subsets to advanced gastrointestinal cancer and COVID-19
Rigamonti A, Castagna A, Viatore M, Colombo FS, Terzoli S, Peano C, Marchesi F, Locati M |
Frontiers in immunology | 2022 |
|
Chitinase-3 like-protein-1 promotes glioma progression via the NF-κB signaling pathway and tumor microenvironment reprogramming
Zhao T, Zeng J, Xu Y, Su Z, Chong Y, Ling T, Xu H, Shi H, Zhu M, Mo Q, Huang X, Li Y, Zhang X, Ni H, You Q |
Theranostics | 2022 |
|
Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer
Waks AG, Keenan TE, Li T, Tayob N, Wulf GM, Richardson ET III, Attaya V, Anderson L, Mittendorf EA, Overmoyer B, Winer EP, Krop IE, Agudo J, Van Allen EM, Tolaney SM |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Immunotherapies catering to the unmet medical need of cold colorectal cancer
Yuan J, Li J, Gao C, Jiang C, Xiang Z, Wu J |
Frontiers in immunology | 2022 |
|
Gene set-based identification of two immune subtypes of diffuse large B cell lymphoma for guiding immune checkpoint blocking therapy
Li Z, Duan Y, Ke Q, Wang M, Cen H, Zhu X |
Frontiers in Genetics | 2022 |
|
Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer.
Hyung J, Cho EJ, Kim J, Kim JH, Kim JE, Hong YS, Kim TW, Sung CO, Kim SY |
Cancer Research and Treatment | 2022 |
|
Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia.
Vasquez EG, Nasreddin N, Valbuena GN, Mulholland EJ, Belnoue-Davis HL, Eggington HR, Schenck RO, Wouters VM, Wirapati P, Gilroy K, Lannagan TRM, Flanagan DJ, Najumudeen AK, Omwenga S, McCorry AMB, Easton A, Koelzer VH, East JE, Morton D, Trusolino L, Maughan T, Campbell AD, Loughrey MB, Dunne PD, Tsantoulis P, Huels DJ, Tejpar S, Sansom OJ, Leedham SJ |
Cell Stem Cell | 2022 |
|
Tumor-Infiltrating Neutrophils after Neoadjuvant Therapy are Associated with Poor Prognosis in Esophageal Cancer.
Cabalag CS, Prall OWJ, Ciciulla J, Galea LA, Thio N, Jayawardana M, Leong TYM, Milne JV, Fujihara KM, Chong L, Hii MW, Arnau GM, Neeson PJ, Phillips WA, Duong CP, Clemons NJ |
Annals of Surgical Oncology | 2022 |
|
Angiotensin-converting enzyme 2 identifies immuno-hot tumors suggesting angiotensin-(1-7) as a sensitizer for chemotherapy and immunotherapy in breast cancer.
Mei J, Cai Y, Xu R, Yu X, Han X, Weng M, Chen L, Ma T, Gao T, Gao F, Xia T, Zhu Y, Zhang Y |
Biological Procedures Online | 2022 |
|
How Risk Factors Affect Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Immune Microenvironment (TIME): Their Influence on Immune Escape Mechanisms and Immunotherapy Strategy.
Galizia D, Minei S, Maldi E, Chilà G, Polidori A, Merlano MC |
Biomedicines | 2022 |
|
A Novel Ferroptosis-Related Signature for Prediction of Prognosis, Immune Profiles and Drug Sensitivity in Hepatocellular Carcinoma Patients.
Zhao C, Zhang Z, Tao J |
Current oncology (Toronto, Ont.) | 2022 |
|
State-of-the-Art Advances of Nanomedicine for Diagnosis and Treatment of Bladder Cancer.
Kong C, Zhang S, Lei Q, Wu S |
Biosensors | 2022 |
|
Dissecting the Immunological Profiles in NSD3-Amplified LUSC through Integrative Multi-Scale Analyses.
Xu D, Liu S, Wu X, Marti TM, Dorn P, Schmid RA, Peng RW, Shu Y |
Cancers | 2022 |
|
A Metabolism-Related Gene Prognostic Index for Prediction of Response to Immunotherapy in Lung Adenocarcinoma.
Tang B, Hu L, Jiang T, Li Y, Xu H, Zhou H, Lan M, Xu K, Yin J, Su C, Zhou C, Xu C |
International journal of molecular sciences | 2022 |
|
Seven Fatty Acid Metabolism-Related Genes as Potential Biomarkers for Predicting the Prognosis and Immunotherapy Responses in Patients with Esophageal Cancer.
Guo Y, Pan S, Ke Y, Pan J, Li Y, Ma H |
Human vaccines | 2022 |
|
Integrative genomic analysis facilitates precision strategies for glioblastoma treatment.
Chen D, Liu Z, Wang J, Yang C, Pan C, Tang Y, Zhang P, Liu N, Li G, Li Y, Wu Z, Xia F, Zhang C, Nie H, Tang Z |
iScience | 2022 |
|
Multi-omics analysis: Paving the path toward achieving precision medicine in cancer treatment and immuno-oncology.
Raufaste-Cazavieille V, Santiago R, Droit A |
Frontiers in Molecular Biosciences | 2022 |
|
Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors.
Chen Z, John J, Wang JH |
Frontiers in Oncology | 2022 |
|
The identification of TCF1+ progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade.
Tabanelli V, Melle F, Motta G, Mazzara S, Fabbri M, Agostinelli C, Calleri A, Del Corvo M, Fiori S, Lorenzini D, Cesano A, Chiappella A, Vitolo U, Derenzini E, Griffin GK, Rodig SJ, Vanazzi A, Sabattini E, Tarella C, Sapienza MR, Pileri SA |
Blood Advances | 2022 |
|
Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer
Damrauer JS, Beckabir W, Klomp J, Zhou M, Plimack ER, Galsky MD, Grivas P, Hahn NM, O\u2019Donnell PH, Iyer G, Quinn DI, Vincent BG, Quale DZ, Wobker SE, Hoadley KA, Kim WY, Milowsky MI |
Nature Communications | 2022 |
|
CXCR6 expressing T cells: Functions and role in the control of tumors.
Mabrouk N, Tran T, Sam I, Pourmir I, Gruel N, Granier C, Pineau J, Gey A, Kobold S, Fabre E, Tartour E |
Frontiers in immunology | 2022 |
|
Mining of immunological and prognostic-related biomarker for cervical cancer based on immune cell signatures.
Wang N, Nanding A, Jia X, Wang Y, Yang C, Fan J, Dong A, Zheng G, Ma J, Shi X, Yang Y |
Frontiers in immunology | 2022 |
|
Amino acid metabolism-based molecular classification of colon adenocarcinomavia in silico analysis.
Xie Y, Chen H, Fang JY |
Frontiers in immunology | 2022 |
|
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers.
Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan NL, Blenman K, Holtrich U, Kalinsky K, Meric-Bernstam F, Pusztai L |
npj Breast Cancer | 2022 |
|
Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden
Georgoulias G, Zaravinos A |
Frontiers in immunology | 2022 |
|
Immunometabolism in the tumor microenvironment and its related research progress
Zhang Z, Hu Y, Chen Y, Chen Z, Zhu Y, Chen M, Xia J, Sun Y, Xu W |
Frontiers in Oncology | 2022 |
|
Vessel state and immune infiltration of the angiogenesis subgroup and construction of a prediction model in osteosarcoma
Wu J, Jin Z, Lin J, Fu Y, Wang J, Shen Y |
Frontiers in immunology | 2022 |
|
[Tumor-infiltrating natural killer and T cells in melanoma].
Tietze JK |
2022 | |
|
Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
Ballot E, Galland L, Mananet H, Boidot R, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S |
Breast Cancer Research | 2022 |
|
Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction.
Zhang S, Li M, Tan Y, Zhang J, Liu Y, Jiang W, Li X, Qi H, Tang L, Ji R, Zhao W, Gu Y, Qi L |
Journal of Molecular Medicine | 2022 |
|
SMO mutation predicts the effect of immune checkpoint inhibitor: From NSCLC to multiple cancers.
Ji W, Niu X, Yu Y, Li Z, Gu L, Lu S |
Frontiers in immunology | 2022 |
|
Characterization of the Immune Microenvironmental Landscape of Lung Squamous Cell Carcinoma with Immune Cell Infiltration
Chen C, Tang D, Gu C, Wang B, Yao Y, Wang R, Zhang H, Gao W |
Disease Markers | 2022 |
|
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
Lai GG, Yeo JC, Jain A, Zhou S, Pang M, Alvarez JJ, Sim NL, Tan AC, Suteja L, Lim TW, Guo YA, Shen M, Saw SP, Rohatgi N, Yeong JP, Takano A, Lim KH, Gogna A, Too CW, Da Zhuang K, Tan WL, Kanesvaran R, Ng QS, Ang MK, Rajasekaran T, Wang L, Toh CK, Lim WT, Tam WL, Tan SH, Skanderup AM, Tan EH, Tan DS |
2022 | |
|
CD8+ T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types
Zheng X, Jiang K, Xiao W, Zeng D, Peng W, Bai J, Chen X, Li P, Zhang L, Zheng X, Miao Q, Wang H, Wu S, Xu Y, Xu H, Li C, Li L, Gao X, Zheng S, Li J, Wang D, Zhou Z, Xia X, Yang S, Li Y, Cui Z, Zhang Q, Chen L, Lin X, Lin G |
Frontiers in immunology | 2022 |
|
EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico Analysis.
Du TQ, Liu R, Zhang Q, Luo H, Liu Z, Sun S, Wang X |
Biomolecules | 2022 |
|
Tumor Microenvironment Characterization in Breast Cancer Identifies Prognostic Pathway Signatures.
Li J, Qiu J, Han J, Li X, Jiang Y |
Genes & development | 2022 |
|
Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity.
Svensson-Arvelund J, Cuadrado-Castano S, Pantsulaia G, Kim K, Aleynick M, Hammerich L, Upadhyay R, Yellin M, Marsh H, Oreper D, Jhunjhunwala S, Moussion C, Merad M, Brown BD, García-Sastre A, Brody JD |
Nature Communications | 2022 |
|
Integrated Analysis of Single-Cell and Bulk RNA-Sequencing Reveals a Tissue-Resident Macrophage-Related Signature for Predicting Immunotherapy Response in Breast Cancer Patients
Xia ZA, Zhou Y, Li J, He J |
Cancers | 2022 |
|
Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma
Koh YW, Han JH, Haam S, Lee HW |
Frontiers in Oncology | 2022 |
|
Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer
Liu C, Xiao H, Cui L, Fang L, Han S, Ruan Y, Zhao W, Zhang Y |
Frontiers in immunology | 2022 |
|
The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance
Canar J, Darling K, Dadey R, Gamero AM |
Cytokine | 2022 |
|
CD4+ CTLs Act as a Key Effector Population for Allograft Rejection of MSCs in a Donor MHC-II Dependent Manner in Injured Liver
Shen S, Li Y, Jin M, Fan D, Pan R, Lin A, Chen Y, Xiang L, Zhao RC, Shao J |
Aging and disease | 2022 |
|
Low expression of INMT is associated with poor prognosis but favorable immunotherapy response in lung adenocarcinoma
Zhou X, Zou B, Wang J, Wu L, Tan Q, Ji C |
Frontiers in Genetics | 2022 |
|
Transcriptional Profiling Reveals Mesenchymal Subtypes of Small Cell Lung Cancer with Activation of the Epithelial-to-Mesenchymal Transition and Worse Clinical Outcomes
Cho HJ, Hong SA, Ryu D, Hong SH, Kim TM |
Cancers | 2022 |
|
Polygenic Risk Scores Associated with Tumor Immune Infiltration in Common Cancers
Choi J, Kim JS, Sung HJ, Chen YW, Chen Z, Wen W, Shu XO, Guo X |
Cancers | 2022 |
|
A Transcriptome and Methylome Study Comparing Tissues of Early and Late Onset Colorectal Carcinoma
Kibriya MG, Raza M, Quinn A, Kamal M, Ahsan H, Jasmine F |
International journal of molecular sciences | 2022 |
|
FMNL3 is Overexpressed in Tumor Tissues and Predicts an Immuno-Hot Phenotype in Pancreatic Cancer
Zhang Q, Nie H, Pan J, Xu H, Zhan Q |
International journal of general medicine | 2022 |
|
Identification and validation of a genomic mutation signature as a predictor for immunotherapy in NSCLC
Wang Z, Ge Y, Li H, Fei G, Wang S, Wei P |
Bioscience Reports | 2022 |
|
Somatic 9p24.1 alterations in HPV– head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity
Zhao X, Cohen EE, William WN Jr, Bianchi JJ, Abraham JP, Magee D, Spetzler DB, Gutkind JS, Alexandrov LB, Cavenee WK, Lippman SM, Davoli T |
Proceedings of the National Academy of Sciences | 2022 |
|
IL-2 delivery by engineered mesenchymal stem cells re-invigorates CD8(+) T cells to overcome immunotherapy resistance in cancer.
Bae J, Liu L, Moore C, Hsu E, Zhang A, Ren Z, Sun Z, Wang X, Zhu J, Shen J, Qiao J, Fu YX |
Nature Cell Biology | 2022 |
|
Immunogenomic correlates of immune-related adverse events for anti–programmed cell death 1 therapy
Zhang L, Shi Y, Han X |
Frontiers in immunology | 2022 |
|
Programmed Cell Death-Ligand 1 in Head and Neck Squamous Cell Carcinoma: Molecular Insights, Preclinical and Clinical Data, and Therapies
Meliante PG, Barbato C, Zoccali F, Ralli M, Greco A, de Vincentiis M, Colizza A, Petrella C, Ferraguti G, Minni A, Fiore M |
International journal of molecular sciences | 2022 |
|
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial.
Røssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T, Mathiesen RR, Lømo J, Garred Ø, Chauhan SK, Lereim RR, Dunn C, Naume B, Kyte JA |
Nature Medicine | 2022 |
|
Therapy sculpts the complex interplay between cancer and the immune system during tumour evolution
Thol K, Pawlik P, McGranahan N |
Genome Medicine | 2022 |
|
Adjuvant Immunotherapy in Patients with Early-Stage Non-small Cell Lung Cancer and Future Directions.
Saw SP, Ang MK, Tan DS |
Current Treatment Options in Oncology | 2022 |
|
IL-33/ST2 signaling promotes constitutive and inductive PD-L1 expression and immune escape in oral squamous cell carcinoma.
Zhao M, He Y, Zhu N, Song Y, Hu Q, Wang Z, Ni Y, Ding L |
British Journal of Cancer | 2022 |
|
Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer
Li Z, Wang X, Yang Y, Shi F, Zhang W, Wang Q, Wang S |
Cells | 2022 |
|
Vanadyl sulfate-enhanced oncolytic virus immunotherapy mediates the antitumor immune response by upregulating the secretion of pro-inflammatory cytokines and chemokines
Alluqmani N, Jirovec A, Taha Z, Varette O, Chen A, Serrano D, Maznyi G, Khan S, Forbes NE, Arulanandam R, Auer RC, Diallo JS |
Frontiers in immunology | 2022 |
|
Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy
Xu T, Liu Z, Huang L, Jing J, Liu X |
Frontiers in immunology | 2022 |
|
Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma
Wang Y, Zhang X, Xu C, Nan Y, Fan J, Zeng X, Kwon BS, Ju D |
Frontiers in immunology | 2022 |
|
TGFβ signaling activation correlates with immune-inflamed tumor microenvironment across human cancers and predicts response to immunotherapy.
Xia J, Zhang Q, Luan J, Min P, Zhang H, Chen G, Ji C, Song N |
Cell cycle (Georgetown, Tex.) | 2022 |
|
Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives.
Bai R, Li W, Cui J |
Cancer biology & medicine | 2022 |
|
Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.
Wu F, Jiang T, Chen G, Huang Y, Zhou J, Lin L, Feng J, Wang Z, Shu Y, Shi J, Hu Y, Wang Q, Cheng Y, Chen J, Lin X, Wang Y, Huang J, Cui J, Cao L, Liu Y, Zhang Y, Pan Y, Zhao J, Wang L, Chang J, Chen Q, Ren X, Zhang W, Fan Y, He Z, Fang J, Gu K, Dong X, Zhang T, Shi W, Zou J, Bai X, Ren S, Zhou C |
2022 | |
|
Baseline gene expression profiling determines long-term benefit to programmed cell death protein 1 axis blockade.
Vathiotis IA, Salichos L, Martinez-Morilla S, Gavrielatou N, Aung TN, Shafi S, Wong PF, Jessel S, Kluger HM, Syrigos KN, Warren S, Gerstein M, Rimm DL |
npj Precision Oncology | 2022 |
|
SPATA2 and CYLD inhibit T cell infiltration into colorectal cancer via regulation of IFN-γ/STAT1 axis.
Tan TG, Zybina Y, McKenna C, Olow A, Rukmini SJ, Wong MT, Sadekova S, Chackerian A, Bauché D |
Frontiers in Oncology | 2022 |
|
Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis
Li D, Wu X, Song W, Cheng C, Hao L, Zhang W |
Annals of translational medicine | 2022 |
|
Systematic Evaluation of the Predictive Gene Expression Signatures of Immune Checkpoint Inhibitors in Metastatic Melanoma
Coleman S, Xie M, Tarhini AA, Tan AC |
Molecular Carcinogenesis | 2022 |
|
Tumor immune microenvironment and immunotherapy efficacy in BRAF mutation non-small-cell lung cancer
Li H, Zhang Y, Xu Y, Huang Z, Cheng G, Xie M, Zhou Z, Yu Y, Xi W, Fan Y |
Cell Death and Disease | 2022 |
|
Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice
Küçükköse E, Heesters BA, Villaudy J, Verheem A, Cercel M, van Hal S, Boj SF, Borel Rinkes IH, Punt CJ, Roodhart JM, Laoukili J, Koopman M, Spits H, Kranenburg O |
Journal for ImmunoTherapy of Cancer | 2022 |
|
Identification of comutation in signaling pathways to predict the clinical outcomes of immunotherapy
Qiu J, Li X, He Y, Wang Q, Li J, Wu J, Jiang Y, Han J |
Journal of Translational Medicine | 2022 |
|
Integrated molecular analyses of an interferon-γ based subtype with regard to outcome, immune characteristics, and immunotherapy in bladder cancer and experimental verification.
Wang J, Chen S, Wang H, Cao J, Fan X, Man J, Li Q, Yang L |
Heliyon | 2022 |
|
PSME2 identifies immune-hot tumors in breast cancer and associates with well therapeutic response to immunotherapy.
Wu C, Zhong R, Sun X, Shi J |
Frontiers in Genetics | 2022 |
|
Remodeling of the tumor microenvironment through PAK4 inhibition sensitizes tumors to immune checkpoint blockade
Abril-Rodríguez G, Torrejon DY, Karin D, Campbell KM, Medina E, Saco JD, Galvez M, Champhekar AS, Perez-Garcilazo I, Baselga-Carretero I, Singh J, Comin-Anduix B, Puig-Saus C, Ribas A |
2022 | |
|
miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response
Cuttano R, Colangelo T, Guarize J, Dama E, Cocomazzi MP, Mazzarelli F, Melocchi V, Palumbo O, Marino E, Belloni E, Montani F, Vecchi M, Barberis M, Graziano P, Pasquier A, Sanz-Ortega J, Montuenga LM, Carbonelli C, Spaggiari L, Bianchi F |
Journal of Hematology & Oncology | 2022 |
|
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy.
Davar D, Zarour HM |
Clinical cancer research | 2022 |
|
Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates
Seyhan AA, Carini C |
International journal of molecular sciences | 2022 |
|
Boosting Antitumor Immunity with an Expanded Neoepitope Landscape.
Nagel R, Pataskar A, Champagne J, Agami R |
Cancer research | 2022 |
|
Coming of Age: Human Genomics and the Cancer-Immune Set Point.
Hammer C, Mellman I |
Cancer immunology research | 2022 |
|
Safety and Activity of PolyPEPI1018 Combined with Maintenance Therapy in Metastatic Colorectal Cancer: an Open-Label, Multicenter, Phase Ib Study.
Hubbard JM, Tőke ER, Moretto R, Graham RP, Youssoufian H, Lőrincz O, Molnár L, Csiszovszki Z, Mitchell JL, Wessling J, Tóth J, Cremolini C |
Clinical cancer research | 2022 |
|
Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets.
Kocher F, Puccini A, Untergasser G, Martowicz A, Zimmer K, Pircher A, Baca Y, Xiu J, Haybaeck J, Tymoszuk P, Goldberg RM, Petrillo A, Shields AF, Salem ME, Marshall JL, Hall M, Korn WM, Nabhan C, Battaglin F, Lenz HJ, Lou E, Choo SP, Toh CK, Gasteiger S, Pichler R, Wolf D, Seeber A |
Clinical cancer research | 2022 |
|
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types.
Cristescu R, Nebozhyn M, Zhang C, Albright A, Kobie J, Huang L, Zhao Q, Wang A, Ma H, Alexander Cao Z, Morrissey M, Ribas A, Grivas P, Cescon DW, McClanahan TK, Snyder A, Ayers M, Lunceford J, Loboda A |
Clinical cancer research | 2022 |
|
Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models.
Georgiev P, Muise ES, Linn DE, Hinton MC, Wang Y, Cai M, Cadzow L, Wilson DC, Sukumar S, Caniga M, Chen L, Xiao H, Yearley JH, Sriram V, Nebozhyn M, Sathe M, Blumenschein WM, Kerr KS, Hirsch HA, Javaid S, Olow AK, Moy LY, Chiang DY, Loboda A, Cristescu R, Sadekova S, Long BJ, McClanahan TK, Pinheiro EM |
Molecular cancer therapeutics | 2022 |
|
Transcriptomic Profiling of MSI-H/dMMR Gastrointestinal Tumors to Identify Determinants of Responsiveness to Anti-PD-1 Therapy.
Chida K, Kawazoe A, Suzuki T, Kawazu M, Ueno T, Takenouchi K, Nakamura Y, Kuboki Y, Kotani D, Kojima T, Bando H, Mishima S, Kuwata T, Sakamoto N, Watanabe J, Mano H, Ikeda M, Shitara K, Endo I, Nakatsura T, Yoshino T |
Clinical cancer research | 2022 |
|
Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor.
Koblish HK, Wu L, Wang LS, Liu PCC, Wynn R, Rios-Doria J, Spitz S, Liu H, Volgina A, Zolotarjova N, Kapilashrami K, Behshad E, Covington M, Yang YO, Li J, Diamond S, Soloviev M, O'Hayer K, Rubin S, Kanellopoulou C, Yang G, Rupar M, DiMatteo D, Lin L, Stevens C, Zhang Y, Thekkat P, Geschwindt R, Marando C, Yeleswaram S, Jackson J, Scherle P, Huber R, Yao W, Hollis G |
Cancer Discovery | 2022 |
|
Intrinsic and Extrinsic Transcriptional Profiles That Affect the Clinical Response to PD-1 Inhibitors in Patients with Non–Small Cell Lung Cancer
Byeon HE, Haam S, Han JH, Lee HW, Koh YW |
Cancers | 2022 |
|
Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma
Wen T, Sun G, Jiang W, He X, Shi Y, Ma F, Liu P |
EBioMedicine | 2022 |
|
A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer
Garralda E, Sukari A, Lakhani NJ, Patnaik A, Lou Y, Im SA, Golan T, Geva R, Wermke M, de Miguel M, Palcza J, Jha S, Chaney M, Abraham AK, Healy J, Falchook GS |
ESMO Open | 2022 |
|
Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy.
Anagnostou V, Landon BV, Medina JE, Forde P, Velculescu VE |
Science Translational Medicine | 2022 |
|
Genes Modulating Butyrate Metabolism for Assessing Clinical Prognosis and Responses to Systematic Therapies in Hepatocellular Carcinoma
Chuanbing Z, Zhengle Z, Ruili D, Kongfan Z, Jing T |
Biomolecules | 2022 |
|
The characteristics and clinical relevance of tumor fusion burden in head and neck squamous cell carcinoma
He L, Ren D, Lv G, Mao B, Wu L, Liu X, Gong L, Liu P |
Cancer Medicine | 2022 |
|
Characterization of rare histological subtypes of ovarian cancer based on molecular profiling
Takahashi N, Hatakeyama K, Nagashima T, Ohshima K, Urakami K, Yamaguchi K, Hirashima Y |
Cancer Medicine | 2022 |
|
Y90-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers
Rivoltini L, Bhoori S, Camisaschi C, Bergamaschi L, Lalli L, Frati P, Citterio D, Castelli C, Mazzaferro V |
Gut | 2022 |
|
Axin1 Protects Colon Carcinogenesis by an Immune-Mediated Effect
Sanson R, Lazzara SL, Cune D, Pitasi CL, Trentesaux C, Fraudeau M, Letourneur F, Saintpierre B, Le Gall M, Bossard P, Terris B, Finetti P, Bertucci F, Mamessier E, Romagnolo B, Perret C |
Cellular and Molecular Gastroenterology and Hepatology | 2022 |
|
Cancer immunotherapies transition endothelial cells into high-endothelial venules that generate TCF1+ T lymphocyte niches through a feed-forward loop
Hua Y, Vella G, Rambow F, Allen E, Martinez AA, Duhamel M, Takeda A, Jalkanen S, Junius S, Smeets A, Nittner D, Dimmeler S, Hehlgans T, Liston A, Bosisio FM, Floris G, Laoui D, Hollmén M, Lambrechts D, Merchiers P, Marine JC, Schlenner S, Bergers G |
Cancer Cell | 2022 |
|
IFN-γ and TGF-β, Crucial Players in Immune Responses: A Tribute to Howard Young
Gauthier T, Chen W |
Journal of Interferon & Cytokine Research | 2022 |
|
Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC
Garassino MC, Gadgeel S, Novello S, Halmos B, Felip E, Speranza G, Hui R, Garon EB, Horinouchi H, Sugawara S, Rodriguez-Abreu D, Reck M, Cristescu R, Aurora-Garg D, Loboda A, Lunceford J, Kobie J, Ayers M, Piperdi B, Pietanza MC, Paz-Ares L |
2022 | |
|
Breast cancer cells survive chemotherapy by activating targetable immune modulatory programs characterized by either PD-L1 or CD80
Shahbandi A, Chiu FY, Ungerleider NA, Kvadas R, Mheidly Z, Sun MJ, Tian D, Waizman DA, Anderson AY, Machado HL, Pursell ZF, Rao SG, Jackson JG |
2022 | |
|
Identification of a pyroptosis-based model for predicting clinical outcomes from immunotherapy in patients with metastatic melanoma.
Wu G, Chen B, Jiang J, Chen Y, Chen Y, Wang H |
Cancer Medicine | 2022 |
|
The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models
Phillips C, Bhamra I, Eagle C, Flanagan E, Armer R, Jones CD, Bingham M, Calcraft P, Edmenson Cook A, Thompson B, Woodcock SA |
2022 | |
|
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC
Negrao MV, Papadimitrakopoulou VA, Price AC, Tam AL, Furqan M, Laroia ST, Massarelli E, Pacheco J, Heymach JV, Tsao AS, Walker GV, Vora L, Mauro D, Kelley H, Wooldridge JE, Krieg AM, Niu J |
2022 | |
|
Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.
Andtbacka RHI, Wang Y, Pierce RH, Campbell JS, Yushak M, Milhem M, Ross M, Niland K, Arbeit RD, Parasuraman S, Bickley K, Yeung CC, Aicher LD, Smythe KS, Gan L |
2022 | |
|
Classifying cGAS-STING Activity Links Chromosomal Instability with Immunotherapy Response in Metastatic Bladder Cancer.
Sokač M, Ahrenfeldt J, Litchfield K, Watkins TBK, Knudsen M, Dyrskjøt L, Jakobsen MR, Birkbak NJ |
2022 | |
|
Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.
Dinstag G, Shulman ED, Elis E, Ben-Zvi DS, Tirosh O, Maimon E, Meilijson I, Elalouf E, Temkin B, Vitkovsky P, Schiff E, Hoang DT, Sinha S, Nair NU, Lee JS, Schäffer AA, Ronai Z, Juric D, Apolo AB, Dahut WL, Lipkowitz S, Berger R, Kurzrock R, Papanicolau-Sengos A, Karzai F, Gilbert MR, Aldape K, Rajagopal PS, Beker T, Ruppin E, Aharonov R |
2022 | |
|
Mass Transport Model of Radiation Response: Calibration and Application to Chemoradiation for Pancreatic Cancer
Wang CX, Elganainy D, Zaid MM, Butner JD, Agrawal A, Nizzero S, Minsky BD, Holliday EB, Taniguchi CM, Smith GL, Koong AC, Herman JM, Das P, Maitra A, Wang H, Wolff RA, Katz MH, Crane CH, Cristini V, Koay EJ |
International journal of radiation oncology, biology, physics | 2022 |
|
Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma
Park S, Cha H, Kim HS, Lee B, Kim S, Kim TM, Jung HA, Sun J, Ahn JS, Ahn M, Park K, Park W, Lee S |
Cancer Medicine | 2022 |
|
Biomarkers predictive of response to pembrolizumab in head and neck cancer
Pfister DG, Haddad RI, Worden FP, Weiss J, Mehra R, Chow LQ, Liu SV, Kang H, Saba NF, Wirth LJ, Sukari A, Massarelli E, Ayers M, Albright A, Webber AL, Mogg R, Lunceford J, Huang L, Cristescu R, Cheng J, Seiwert TY, Bauml JM |
Cancer Medicine | 2022 |
|
T cell‐inflamed gene expression profile is associated with favorable disease‐specific survival in non‐hypermutated microsatellite‐stable colorectal cancer patients
Yin H, Harrison TA, Thomas SS, Sather CL, Koehne AL, Malen RC, Reedy AM, Wurscher MA, Hsu L, Phipps AI, Zaidi SH, Newcomb PA, Peters U, Huyghe JR |
Cancer Medicine | 2022 |
|
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia
Kirkey DC, Loeb AM, Castro S, McKay CN, Perkins L, Pardo L, Leonti AR, Tang TT, Loken MR, Brodersen LE, Loeb KR, Scheinberg DA, Le Q, Meshinchi S |
Blood Advances | 2022 |
|
Chemoradiation therapy alters the PD-L1 score in locoregional recurrent squamous cell carcinomas of the head and neck
Park BJ, Mattox AK, Clayburgh D, Patel M, Bell RB, Yueh B, Leidner R, Xiao H, Couey M, Li S, Qin T, Sartor MA, Cairns B, MacDonough T, Halliwill K, Deschler D, Lin DT, Faquin WC, Sadow PM, Pai SI |
Oral Oncology | 2022 |
|
Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration
Wilde DC, Castro PD, Bera K, Lai S, Madabhushi A, Corredor G, Koyuncu C, Lewis JS Jr, Lu C, Frederick MJ, Frederick AM, Haugen AE, Zevallos JP, Sturgis EM, Shi J, Huang AT, Hernandez DJ, Skinner HD, Kemnade JO, Yu W, Sikora AG, Sandulache VC |
Modern Pathology | 2022 |
|
TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource
Chen Z, Luo Z, Zhang D, Li H, Liu X, Zhu K, Zhang H, Wang Z, Zhou P, Ren J, Zhao A, Zuo Z |
Genomics, Proteomics & Bioinformatics | 2022 |
|
HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade
Shao XM, Huang J, Niknafs N, Balan A, Cherry C, White J, Velculescu VE, Anagnostou V, Karchin R |
2022 | |
|
Comprehensive analysis of the prognostic impact and immune implication of KIAA1429 in lung adenocarcinoma
Guo L, Huai Q, Zhou B, Ying J, Guo W |
2022 | |
|
Selective glutamine metabolism inhibition in tumor cells improves anti-tumor T lymphocyte activity in triple-negative breast cancer
Deanna N. Edwards, Verra M. Ngwa, Ariel L. Raybuck, Shan Wang, Yoonha Hwang, Laura C. Kim, Sung Hoon Cho, Yeeun Paik, Qingfei Wang, Siyuan Zhang, H. Charles Manning, Jeffrey C. Rathmell, Rebecca S. Cook, Mark R. Boothby, Jin Chen |
Journal of Clinical Investigation | 2021 |
|
Melanoma dedifferentiation induced by interferon-gamma epigenetic remodeling in response to anti-PD-1 therapy
Yeon Joo Kim, Katherine M. Sheu, Jennifer Tsoi, Gabriel Abril-Rodriguez, Egmidio Medina, Catherine S Grasso, Davis Y. Torrejon, Ameya Champhekar, Kevin Litchfield, Charles Swanton, Daniel E. Speiser, Philip O. Scumpia, Alexander Hoffmann, Thomas G Graeber, Cristina Puig-Saus, Antoni Ribas |
Journal of Clinical Investigation | 2021 |
|
FOXA1 overexpression suppresses interferon signaling and immune response in cancer
Yundong He, Liguo Wang, Ting Wei, Yu-Tian Xiao, Haoyue Sheng, Hengchuan Su, Daniel Hollern, Xiaoling zhang, Jian Ma, Simeng Wen, Hongyan Xie, Yuqian Yan, Yunqian Pan, Xiaonan Hou, Xiaojia Tang, Vera J Suman, Jodi M. Carter, Richard Weinshilboum, Liewei Wang, Krishna R. Kalari, Saravut J. Weroha, Alan H. Bryce, Judy C. Boughey, Haidong Dong, Charles M. Perou, Dingwei Ye, Matthew P Goetz, Shancheng Ren, Haojie Huang |
Journal of Clinical Investigation | 2021 |
|
Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response
Michelle von Locquenghien, Catalina Rozalen, Toni Celià-Terrassa |
Journal of Clinical Investigation | 2021 |
|
Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy
N Ioannou, PR Hagner, M Stokes, AK Gandhi, B Apollonio, M Fanous, D Papazoglou, LA Sutton, R Rosenquist, RM Amini, H Chiu, A Lopez-Girona, P Janardhanan, FT Awan, J Jones, NE Kay, TD Shanafelt, MS Tallman, K Stamatopoulos, PE Patten, A Vardi, AG Ramsay |
Blood | 2021 |
|
Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
CL Hsu, DL Ou, LY Bai, CW Chen, L Lin, SF Huang, AL Cheng, YM Jeng, C Hsu |
Liver Cancer | 2021 |
|
Radiosensitivity index emerges as a potential biomarker for combined radiotherapy and immunotherapy
YH Dai, YF Wang, PC Shen, CH Lo, JF Yang, CS Lin, HL Chao, WY Huang |
npj Genomic Medicine | 2021 |
|
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
MY Lee, Y Robbins, C Sievers, J Friedman, HA Sater, PE Clavijo, N Judd, E Tsong, C Silvin, P Soon-Shiong, MR Padget, J Schlom, J Hodge, C Hinrichs, C Allen |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy
SM Poznanski, TM Ritchie, IY Fan, A El-Sayes, AL Portillo, R Ben-Avi, EA Rojas, MV Chew, Y Shargall, AA Ashkar |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma
K Du, S Wei, Z Wei, DT Frederick, B Miao, T Moll, T Tian, E Sugarman, DI Gabrilovich, RJ Sullivan, L Liu, KT Flaherty, GM Boland, M Herlyn, G Zhang |
Nature Communications | 2021 |
|
Remodeling chondroitin-6-sulfate-mediated immune exclusion enhances anti-PD-1 response in colorectal cancer with microsatellite stability
Qijing Wu, Qiong Huang, Yu Jiang, Fei Sun, Bishan Liang, Jiao Wang, Xingbin Hu, Mengting Sun, Zhenfeng Ma, Yulu Shi, Yanxiao Liang, Yujing Tan, Dongqiang Zeng, Fangzhen Yao, Xin Xu, Zhiqi Yao, Xiaoxiang Rong, Na Huang, Li Sun, Wangjun Liao, Min Shi |
Cancer immunology research | 2021 |
|
Mutational burden and chromosomal aneuploidy synergistically predict survival from radiotherapy in non-small cell lung cancer
Q Jia, Q Chu, A Zhang, J Yu, F Liu, K Qian, Y Xiao, X Wang, Y Yang, Y Zhao, J He, G Li, YY Wan, C Xie, B Zhu |
Communications biology | 2021 |
|
SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers
Q Zhang, L Cheng, Y Qin, L Kong, X Shi, J Hu, L Li, Z Ding, T Wang, J Shen, Y Yang, L Yu, B Liu, C Liu, X Qian |
IBMS BoneKEy | 2021 |
|
Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry
S Martinez-Morilla, F Villarroel-Espindola, PF Wong, MI Toki, TN Aung, V Pelekanou, B Bourke-Martin, KA Schalper, HM Kluger, DL Rimm |
Clinical cancer research | 2021 |
|
Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues
TW Fan, RM Higashi, H Song, S Daneshmandi, AL Mahan, MS Purdom, TJ Bocklage, TA Pittman, D He, C Wang, AN Lane |
eLife | 2021 |
|
Targeting the spectrum of immune checkpoints in prostate cancer
LA Sena, SR Denmeade, ES Antonarakis |
Expert Review of Clinical Pharmacology | 2021 |
|
Associations of immune cell homing gene signatures and infiltrates of lymphocyte subsets in human melanomas: discordance with CD163+ myeloid cell infiltrates
M Kwak, G Erdag, KM Leick, S Bekiranov, VH Engelhard, CL Slingluff |
Journal of Translational Medicine | 2021 |
|
Early memory differentiation and cell death resistance in T cells predicts melanoma response to sequential anti-CTLA4 and anti-PD1 immunotherapy
I Vanmeerbeek, DM Borras, J Sprooten, O Bechter, S Tejpar, AD Garg |
Genes and Immunity | 2021 |
|
Advancing to the era of cancer immunotherapy
Y Wang, M Wang, HX Wu, RH Xu |
2021 | |
|
Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression
JD Armitage, HV Newnes, A McDonnell, A Bosco, J Waithman |
Cells | 2021 |
|
T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options
L Gehrcken, T Sauerer, N Schaft, J Dörrie |
International journal of molecular sciences | 2021 |
|
Ratio of the interferon-γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma
C Cui, C Xu, W Yang, Z Chi, X Sheng, L Si, Y Xie, J Yu, S Wang, R Yu, J Guo, Y Kong |
npj Genomic Medicine | 2021 |
|
Synergy between Toxoplasma gondii type I Δ GRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
YC Zhu, HM Elsheikha, JH Wang, S Fang, JJ He, XQ Zhu, J Chen |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma
D Liu, X Yang, X Wu |
Frontiers in immunology | 2021 |
|
Microenvironmental regulation of tumour immunity and response to immunotherapy
MM Kockx, M McCleland, H Koeppen |
The Journal of Pathology | 2021 |
|
Clinical, molecular, metabolic, and immune features associated with oxidative phosphorylation in melanoma brain metastases
GM Fischer, RA Guerrieri, Q Hu, AY Joon, S Kumar, LE Haydu, JL McQuade, YN Gopal, B Knighton, W Deng, CW Hudgens, AJ Lazar, MT Tetzlaff, MA Davies |
2021 | |
|
Signal pathways of melanoma and targeted therapy
W Guo, H Wang, C Li |
Signal Transduction and Targeted Therapy | 2021 |
|
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
E Shklovskaya, H Rizos |
International journal of molecular sciences | 2021 |
|
Molecular Markers and Targets in Melanoma
C Teixido, P Castillo, C Martinez-Vila, A Arance, L Alos |
Cells | 2021 |
|
Defining Immunogenic and Radioimmunogenic Tumors
TR Medler, TC Blair, MR Crittenden, MJ Gough |
Frontiers in Oncology | 2021 |
|
IFN-γ-induced ER stress impairs autophagy and triggers apoptosis in lung cancer cells
C Fang, T Weng, S Hu, Z Yuan, H Xiong, B Huang, Y Cai, L Li, X Fu |
OncoImmunology | 2021 |
|
Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies
J Chantharasamee, JJ Adashek, K Wong, MA Eckardt, B Chmielowski, S Dry, FC Eilber, AS Singh |
Current Treatment Options in Oncology | 2021 |
|
Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors
MR Dugage, RL Jones, J Trent, S Champiat, S Dumont |
Frontiers in immunology | 2021 |
|
Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma
AA Strait, RA Woolaver, SC Hall, CD Young, SD Karam, A Jimeno, Y Lan, D Raben, JH Wang, XJ Wang |
2021 | |
|
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
SH Chen, PK Dominik, J Stanfield, S Ding, W Yang, N Kurd, R Llewellyn, J Heyen, C Wang, Z Melton, TV Blarcom, KC Lindquist, J Chaparro-Riggers, S Salek-Ardakani |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Explant Modeling of the Immune Environment of Head and Neck Cancer
S Sharon, T Duhen, S Bambina, J Baird, R Leidner, B Bell, N Casap, M Crittenden, S Vasudevan, M Jubran, N Kravchenko-Balasha, M Gough |
Frontiers in Oncology | 2021 |
|
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
G Morad, B Helmink, P Sharma, J Wargo |
Cell | 2021 |
|
Antitumour immunity regulated by aberrant ERBB family signalling
S Kumagai, S Koyama, H Nishikawa |
Nature Reviews Cancer | 2021 |
|
Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
LV dos Santos, CM Abrahão, WN William |
Frontiers in Oncology | 2021 |
|
Classification of Non-Small Cell Lung Cancer’s Tumor Immune Micro-Environment and Strategies to Augment Its Response to Immune Checkpoint Blockade
A Chi, X He, L Hou, NP Nguyen, G Zhu, RB Cameron, JM Lee |
Cancers | 2021 |
|
Using CRISPR to enhance T cell effector function for therapeutic applications
JJ Heeren |
2021 | |
|
Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy
S Baglivo, F Bianconi, G Metro, A Gili, FR Tofanetti, G Bellezza, B Ricciuti, M Mandarano, V Teti, A Siggillino, MS Reda, R Chiari, L Pistola, A Sidoni, V Minotti, F Roila, V Ludovini |
Genes & development | 2021 |
|
Interpretable systems biomarkers predict response to immune-checkpoint inhibitors
Ó Lapuente-Santana, M van Genderen, PA Hilbers, F Finotello, F Eduati |
2021 | |
|
Spatially organized multicellular immune hubs in human colorectal cancer
K Pelka, M Hofree, JH Chen, S Sarkizova, JD Pirl, V Jorgji, A Bejnood, D Dionne, WH Ge, KH Xu, SX Chao, DR Zollinger, DJ Lieb, JW Reeves, CA Fuhrman, ML Hoang, T Delorey, LT Nguyen, J Waldman, M Klapholz, I Wakiro, O Cohen, J Albers, CS Smillie, MS Cuoco, J Wu, M Su, J Yeung, B Vijaykumar, AM Magnuson, N Asinovski, T Moll, MN Goder-Reiser, AS Applebaum, LK Brais, LK DelloStritto, SL Denning, ST Phillips, EK Hill, JK Meehan, DT Frederick, T Sharova, A Kanodia, EZ Todres, J Jané-Valbuena, M Biton, B Izar, CD Lambden, TE Clancy, R Bleday, N Melnitchouk, J Irani, H Kunitake, DL Berger, A Srivastava, JL Hornick, S Ogino, A Rotem, S Vigneau, BE Johnson, RB Corcoran, AH Sharpe, VK Kuchroo, K Ng, M Giannakis, LT Nieman, GM Boland, AJ Aguirre, AC Anderson, O Rozenblatt-Rosen, A Regev, N Hacohen |
Cell | 2021 |
|
IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS
H Lin, BP Scull, BR Goldberg, HA Abhyankar, OE Eckstein, DJ Zinn, J Lubega, J Agrusa, NE Mallawaney, N Gulati, L Forbes, I Chinn, R Chakraborty, J Velasquez, J Goldman, D Bashir, F Lam, E Muscal, MM Henry, JN Greenberg, S Ladisch, ML Hermiston, LK Meyer, M Jeng, A Naqvi, K McClain, T Nguyen, H Wong, TK Man, MB Jordan, CE Allen |
Blood Advances | 2021 |
|
Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy
A Wang, H Chu, Z Jin, Q Jia, B Zhu, J Mei |
Disease Markers | 2021 |
|
Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma
JL Chao, M Korzinkin, A Zhavoronkov, IV Ozerov, MT Walker, K Higgins, MW Lingen, E Izumchenko, PA Savage |
Reproduction | 2021 |
|
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer
LA Emens, S Adams, A Cimino-Mathews, ML Disis, ME Gatti-Mays, AY Ho, K Kalinsky, HL McArthur, EA Mittendorf, R Nanda, DB Page, HS Rugo, KM Rubin, H Soliman, PA Spears, SM Tolaney, JK Litton |
Journal for ImmunoTherapy of Cancer | 2021 |
|
The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer
A Goncalves, P Finetti, D Birnbaum, F Bertucci |
npj Breast Cancer | 2021 |
|
Breast Cancer Consensus Subtypes: A system for subtyping breast cancer tumors based on gene expression
C Horr, SA Buechler |
npj Breast Cancer | 2021 |
|
Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors
F Bertucci, L Boudin, P Finetti, CV Berckelaer, PV Dam, L Dirix, P Viens, A Gonçalves, NT Ueno, SV Laere, D Birnbaum, E Mamessier |
OncoImmunology | 2021 |
|
A Tumor Progression Related 7-Gene Signature Indicates Prognosis and Tumor Immune Characteristics of Gastric Cancer
F Liu, Z Yang, L Zheng, W Shao, X Cui, Y Wang, J Jia, Y Fu |
Frontiers in Oncology | 2021 |
|
Identified lung adenocarcinoma metabolic phenotypes and their association with tumor immune microenvironment
XN Wu, D Su, YD Mei, MQ Xu, H Zhang, ZY Wang, LL Li, L Peng, JY Jiang, JY Yang, DJ Li, H Cao, ZW Xia, WJ Zeng, Q Cheng, N Zhang |
Cancer Immunology, Immunotherapy | 2021 |
|
Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer
L Wang, H Yang, P Dorn, S Berezowska, F Blank, C Wotzkow, TM Marti, RW Peng, N Harrer, W Sommergruber, GJ Kocher, RA Schmid, SR Hall |
EBioMedicine | 2021 |
|
Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients
K Jin, Y Cao, Y Gu, H Fang, Y Fei, J Wang, X Liu, K Lv, X He, C Lin, H Liu, H Li, H He, R Li, H Zhang, J Xu |
OncoImmunology | 2021 |
|
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
D Phillips, M Matusiak, BR Gutierrez, SS Bhate, GL Barlow, S Jiang, J Demeter, KS Smythe, RH Pierce, SP Fling, N Ramchurren, MA Cheever, Y Goltsev, RB West, MS Khodadoust, YH Kim, CM Schürch, GP Nolan |
Nature Communications | 2021 |
|
Immune evasion by cancer stem cells
H Tsuchiya, G Shiota |
Regenerative Therapy | 2021 |
|
Intratumoral Plasmid IL12 Expands CD8 + T Cells and Induces a CXCR3 Gene Signature in Triple-negative Breast Tumors that Sensitizes Patients to Anti–PD-1 Therapy
ML Telli, H Nagata, I Wapnir, CR Acharya, K Zablotsky, BA Fox, CB Bifulco, SM Jensen, C Ballesteros-Merino, MH Le, RH Pierce, E Browning, R Hermiz, L Svenson, D Bannavong, K Jaffe, J Sell, KM Foerter, DA Canton, CG Twitty, T Osada, HK Lyerly, EJ Crosby |
Clinical cancer research | 2021 |
|
Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma
CM Csizmar, SM Ansell |
International journal of molecular sciences | 2021 |
|
Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity
T Aoki, N Nishida, M Kudo |
Journal of Histochemistry & Cytochemistry | 2021 |
|
Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice
F Veglia, A Hashimoto, H Dweep, E Sanseviero, AD Leo, E Tcyganov, A Kossenkov, C Mulligan, B Nam, G Masters, J Patel, V Bhargava, P Wilkinson, D Smirnov, MA Sepulveda, S Singhal, EB Eruslanov, R Cristescu, A Loboda, Y Nefedova, DI Gabrilovich |
Journal of Experimental Medicine | 2021 |
|
Hypoxia and the phenomenon of immune exclusion
V Pietrobon, FM Marincola |
Journal of Translational Medicine | 2021 |
|
Comprehensive omic characterization of breast cancer in Mexican-Hispanic women
SL Romero-Cordoba, I Salido-Guadarrama, R Rebollar-Vega, V Bautista-Piña, C Dominguez-Reyes, A Tenorio-Torres, F Villegas-Carlos, JC Fernández-López, L Uribe-Figueroa, L Alfaro-Ruiz, A Hidalgo-Miranda |
Nature Communications | 2021 |
|
Immune-Related Mutational Landscape and Gene Signatures: Prognostic Value and Therapeutic Impact for Head and Neck Cancer
B Feng, J Hess |
Cancers | 2021 |
|
PDIA5 is Correlated With Immune Infiltration and Predicts Poor Prognosis in Gliomas
H Zhang, J He, Z Dai, Z Wang, X Liang, F He, Z Xia, S Feng, H Cao, L Zhang, Q Cheng |
Frontiers in immunology | 2021 |
|
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy
B Apollonio, N Ioannou, D Papazoglou, AG Ramsay |
Frontiers in Oncology | 2021 |
|
Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers
DJ McGrail, PG Pilié, H Dai, TN Lam, Y Liang, L Voorwerk, M Kok, XH Zhang, JM Rosen, AB Heimberger, CB Peterson, E Jonasch, SY Lin |
Science Translational Medicine | 2021 |
|
Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises
MM Pham, NY Ngoi, G Peng, DS Tan, TA Yap |
Trends in Cancer | 2021 |
|
Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Bladder Cancer
M Huang, L Liu, J Zhu, T Jin, Y Chen, L Xu, W Cheng, X Ruan, L Su, J Meng, X Lu, F Yan |
Frontiers in Cell and Developmental Biology | 2021 |
|
Integration of tumor inflammation, cell proliferation, and traditional biomarkers improves prediction of immunotherapy resistance and response
S Pabla, RJ Seager, EV Roey, S Gao, C Hoefer, MK Nesline, P DePietro, B Burgher, J Andreas, V Giamo, Y Wang, FL Lenzo, M Schoenborn, S Zhang, R Klein, ST Glenn, JM Conroy |
Biomarker Research | 2021 |
|
Advanced Melanoma
AM Haugh, AK Salama, DB Johnson |
Hematology/Oncology Clinics of North America | 2021 |
|
Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy
J McAuliffe, HF Chan, L Noblecourt, RA Ramirez-Valdez, V Pereira-Almeida, Y Zhou, E Pollock, F Cappuccini, I Redchenko, AV Hill, CS Leung, BJ den Eynde |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Chemokines and the immune response to cancer
AJ Ozga, MT Chow, AD Luster |
Immunity | 2021 |
|
Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES)
PK Lau, B Feran, L Smith, A Lasocki, R Molania, K Smith, A Weppler, C Angel, D Kee, P Bhave, B Lee, RJ Young, A Iravani, HA Yeang, IA Vergara, D Kok, K Drummond, PJ Neeson, KE Sheppard, T Papenfuss, BJ Solomon, S Sandhu, GA McArthur |
Journal for ImmunoTherapy of Cancer | 2021 |
|
The Abscopal Effect in the Era of Checkpoint Inhibitors
O Kodet, K Němejcova, K Strnadová, A Havlínová, P Dundr, I Krajsová, J Štork, K Smetana, L Lacina |
International journal of molecular sciences | 2021 |
|
Radiation-induced eosinophils improve cytotoxic T lymphocyte recruitment and response to immunotherapy
JN Cheng, W Luo, C Sun, Z Jin, X Zeng, PB Alexander, Z Gong, X Xia, X Ding, S Xu, P Zou, YY Wan, Q Jia, QJ Li, B Zhu |
Science Advances | 2021 |
|
Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study
R Liu, F Yang, JY Yin, YZ Liu, W Zhang, HH Zhou |
Frontiers in immunology | 2021 |
|
Metformin generates profound alterations in systemic and tumor immunity with associated antitumor effects
R Veeramachaneni, W Yu, JM Newton, JO Kemnade, HD Skinner, AG Sikora, VC Sandulache |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer
Y Zhang, K Mi, Z Li, L Qiang, M Lv, Y Wu, L Yuan, S Jin |
Frontiers in Oncology | 2021 |
|
The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes
D Salas-Benito, E Conde, I Tamayo-Uria, U Mancheño, E Elizalde, D Garcia-Ros, JM Aramendia, JC Muruzabal, J Alcaide, F Guillen-Grima, JA Minguez, J Amores-Tirado, A Gonzalez-Martin, P Sarobe, JJ Lasarte, M Ponz-Sarvise, CE Andrea, S Hervas-Stubbs |
British Journal of Cancer | 2021 |
|
Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers
J Han, R Yu, J Duan, J Li, W Zhao, G Feng, H Bai, Y Wang, X Zhang, R Wan, J Xu, X Wang, Y Guan, X Xia, Z Yao, K Fei, DP Carbone, Z Wang, J Wang |
Science Advances | 2021 |
|
Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes
W Wu, Y Liu, S Zeng, Y Han, H Shen |
Journal of Hematology & Oncology | 2021 |
|
Immune landscape and subtypes in primary resectable oral squamous cell carcinoma: prognostic significance and predictive of therapeutic response
P Diao, Y Jiang, Y Li, X Wu, J Li, C Zhou, L Jiang, W Zhang, E Yan, P Zhang, X Ding, H Wu, H Yuan, J Ye, X Song, L Wan, Y Wu, H Jiang, Y Wang, J Cheng |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer
A Kumar, R Watkins, AE Vilgelm |
Frontiers in immunology | 2021 |
|
Identification and Targeting of Mutant Peptide Neoantigens in Cancer Immunotherapy
DJ Verdon, MR Jenkins |
Cancers | 2021 |
|
Models that combine transcriptomic with spatial protein information exceed the predictive value for either single modality
IA Vathiotis, Z Yang, J Reeves, M Toki, TN Aung, PF Wong, H Kluger, KN Syrigos, S Warren, DL Rimm |
npj Precision Oncology | 2021 |
|
Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma
S Liu, HM Knochelmann, SH Lomeli, A Hong, M Richardson, Z Yang, RJ Lim, Y Wang, C Dumitras, K Krysan, C Timmers, MJ Romeo, C Krieg, EC OQuinn, JD Horton, SM Dubinett, CM Paulos, DM Neskey, RS Lo |
Cell reports. Medicine | 2021 |
|
Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?
N Principe, J Kidman, RA Lake, WJ Lesterhuis, AK Nowak, AM McDonnell, J Chee |
Frontiers in Oncology | 2021 |
|
Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer
T Kinoshita, H Terai, T Yaguchi |
Life Sciences | 2021 |
|
Immune Aging and Immunotherapy in Cancer
M Kaiser, MD Semeraro, M Herrmann, G Absenger, A Gerger, W Renner |
International journal of molecular sciences | 2021 |
|
Recent Advancements in Nanomedicine for ‘Cold’ Tumor Immunotherapy
Q Chen, T Sun, C Jiang |
Nano-Micro Letters | 2021 |
|
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
M Niu, M Yi, N Li, S Luo, K Wu |
Experimental Hematology and Oncology | 2021 |
|
A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer
Z Liu, Q Tang, T Qi, B Othmane, Z Yang, J Chen, J Hu, X Zu |
Frontiers in immunology | 2021 |
|
A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer
J Xiao, W Li, Y Huang, M Huang, S Li, X Zhai, J Zhao, C Gao, W Xie, H Qin, S Cai, Y Bai, P Lan, Y Zou |
BMC Cancer | 2021 |
|
Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort
W Zhang, L Zhang, H Jiang, Y Li, S Wang, Q Wang |
Aging | 2021 |
|
Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges
F Yang, J Wang, Y Wang, B Liu, J Molina |
Cancers | 2021 |
|
Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
N García-Sancha, R Corchado-Cobos, L Bellido-Hernández, C Román-Curto, E Cardeñoso-Álvarez, J Pérez-Losada, A Orfao, J Cañueto |
Cancers | 2021 |
|
Molecular predictors of response to pembrolizumab in thymic carcinoma
Y He, A Ramesh, Y Gusev, K Bhuvaneshwar, G Giaccone |
Reproduction | 2021 |
|
Find the Flame: Predictive Biomarkers for Immunotherapy in Melanoma
M Garutti, S Bonin, S Buriolla, E Bertoli, MA Pizzichetta, I Zalaudek, F Puglisi |
Cancers | 2021 |
|
CTLA-4 blockade and interferon-α induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma
A Khunger, E Piazza, S Warren, TH Smith, X Ren, A White, N Elliott, A Cesano, JM Beechem, JM Kirkwood, AA Tarhini, PK Singh |
PloS one | 2021 |
|
Boiling histotripsy and in-situ CD40 stimulation improve the checkpoint blockade therapy of poorly immunogenic tumors
MP Singh, SN Sethuraman, C Miller, J Malayer, A Ranjan |
Theranostics | 2021 |
|
Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation
J Duraiswamy, R Turrini, A Minasyan, D Barras, I Crespo, A Grimm, J Casado, R Genolet, F Benedetti, A Wicky, K Ioannidou, W Castro, C Neal, A Moriot, S Renaud-Tissot, V Anstett, N Fahr, J Tanyi, M Eiva, C Jacobson, K Montone, M Westergaard, I Svane, L Kandalaft, M Delorenzi, P Sorger, A Färkkilä, O Michielin, V Zoete, S Carmona, P Foukas, D Powell, S Rusakiewicz, M Doucey, D Laniti, G Coukos |
Cancer Cell | 2021 |
|
Identification of prognostic biomarkers related to the tumor microenvironment in thyroid carcinoma
J Du, G Li, Y Li, X Qiu |
Scientific Reports | 2021 |
|
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
J Budczies, M Kirchner, K Kluck, D Kazdal, J Glade, M Allgäuer, M Kriegsmann, CP Heußel, FJ Herth, H Winter, M Meister, T Muley, S Fröhling, S Peters, B Seliger, P Schirmacher, M Thomas, P Christopoulos, A Stenzinger |
OncoImmunology | 2021 |
|
Immunologically programming the tumor microenvironment induces the pattern recognition receptor NLRC4-dependent antitumor immunity
X Yu, W Liu, S Chen, X Cheng, PA Paez, T Sun, F Yuan, C Wei, JW Landry, AS Poklepovic, HD Bear, JR Subjeck, E Repasky, C Guo, XY Wang |
Journal for ImmunoTherapy of Cancer | 2021 |
|
An Integrated Fibrosis Signature for Predicting Survival and Immunotherapy Efficacy of Patients With Hepatocellular Carcinoma
L Liu, Z Liu, L Meng, L Li, J Gao, S Yu, B Hu, H Yang, W Guo, S Zhang |
Frontiers in Molecular Biosciences | 2021 |
|
An Update on Glioblastoma Biology, Genetics, and Current Therapies: Novel Inhibitors of the G Protein-Coupled Receptor CCR5
TL Turnšek, X Jiao, M Novak, S Jammula, G Cicero, AW Ashton, D Joyce, RG Pestell |
International journal of molecular sciences | 2021 |
|
A High Epigenetic Risk Score Shapes the Non-Inflamed Tumor Microenvironment in Breast Cancer
D Zhang, Y Wang, Q Yang |
Frontiers in Molecular Biosciences | 2021 |
|
Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
Y Lei, X Li, Q Huang, X Zheng, M Liu |
Frontiers in Oncology | 2021 |
|
EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer
KL Morel, AV Sheahan, DL Burkhart, SC Baca, N Boufaied, Y Liu, X Qiu, I Cañadas, K Roehle, M Heckler, C Calagua, H Ye, C Pantelidou, P Galbo, S Panja, A Mitrofanova, S Wilkinson, NC Whitlock, SY Trostel, AA Hamid, AS Kibel, DA Barbie, AD Choudhury, MM Pomerantz, CJ Sweeney, HW Long, DJ Einstein, GI Shapiro, SK Dougan, AG Sowalsky, HH He, ML Freedman, SP Balk, M Loda, DP Labbé, BM Olson, L Ellis |
2021 | |
|
Hypoxia, oxidative stress, and immune evasion: a trinity of the trichothecenes T-2 toxin and deoxynivalenol (DON)
L You, Y Zhao, K Kuca, X Wang, P Oleksak, Z Chrienova, E Nepovimova, V Jaćević, Q Wu, W Wu |
Archives of Toxicology | 2021 |
|
Monitoring T Cells Responses Mounted by Therapeutic Cancer Vaccines
KP Lim, NS Zainal |
Frontiers in Molecular Biosciences | 2021 |
|
PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity
S Qu, Z Jiao, G Lu, B Yao, T Wang, W Rong, J Xu, T Fan, X Sun, R Yang, J Wang, Y Yao, G Xu, X Yan, T Wang, H Liang, K Zen |
Genome biology | 2021 |
|
Characterization of the Immune Cell Infiltration Profile in Pancreatic Carcinoma to Aid in Immunotherapy
D Luo, F Kuang, J Du, M Zhou, F Peng, Y Gan, C Fang, X Yang, B Li, S Su |
Frontiers in Oncology | 2021 |
|
Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma
EF Simonds, ED Lu, O Badillo, S Karimi, EV Liu, W Tamaki, C Rancan, KM Downey, J Stultz, M Sinha, LK McHenry, NM Nasholm, P Chuntova, A Sundström, V Genoud, SA Shahani, LD Wang, CE Brown, PR Walker, FJ Swartling, L Fong, H Okada, WA Weiss, M Hellström |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Immunotherapy Strategies for Gastrointestinal Stromal Tumor
J Arshad, PA Costa, P Barreto-Coelho, BN Valdes, JC Trent |
Cancers | 2021 |
|
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
RP Bissonnette, RM Cesario, B Goodenow, F Shojaei, M Gillings |
BMC Cancer | 2021 |
|
Tumor Immunometabolism Characterization in Ovarian Cancer With Prognostic and Therapeutic Implications
M Yang, G Chen, K Gao, Y Wang |
Frontiers in Oncology | 2021 |
|
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab
Y Koguchi, N Iwamoto, T Shimada, SC Chang, J Cha, BD Curti, WJ Urba, BD Piening, WL Redmond |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Immune Cell Infiltration-Based Characterization of Triple-Negative Breast Cancer Predicts Prognosis and Chemotherapy Response Markers
Y Lv, D Lv, X Lv, P Xing, J Zhang, Y Zhang |
Frontiers in Genetics | 2021 |
|
Tumor-Infiltrating PD-1hiCD8+-T-Cell Signature as an Effective Biomarker for Immune Checkpoint Inhibitor Therapy Response Across Multiple Cancers
Z Yang, Y Deng, J Cheng, S Wei, H Luo, L Liu |
Frontiers in Oncology | 2021 |
|
Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile
RH Younis, I Ghita, M Elnaggar, R Chaisuparat, VI Theofilou, D Dyalram, RA Ord, E Davila, LJ Tallon, JC Papadimitriou, TJ Webb, SM Bentzen, JE Lubek |
Frontiers in immunology | 2021 |
|
Neutrophils Extracellular Traps Inhibition Improves PD-1 Blockade Immunotherapy in Colorectal Cancer
H Zhang, Y Wang, A Onuma, J He, H Wang, Y Xia, R Lal, X Cheng, G Kasumova, Z Hu, M Deng, JD Beane, AC Kim, H Huang, A Tsung |
Cancers | 2021 |
|
Immune Monitoring in Melanoma and Urothelial Cancer Patients Treated with Anti-PD-1 Immunotherapy and SBRT Discloses Tumor Specific Immune Signatures
A Meireson, SJ Tavernier, SV Gassen, N Sundahl, A Demeyer, M Spaas, V Kruse, L Ferdinande, JV Dorpe, B Hennart, D Allorge, F Haerynck, K Decaestecker, S Rottey, Y Saeys, P Ost, L Brochez |
Cancers | 2021 |
|
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma
R Reschke, J Yu, BA Flood, EF Higgs, K Hatogai, TF Gajewski |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Comprehensive analysis of aberrant alternative splicing related to carcinogenesis and prognosis of papillary thyroid cancer
X Zheng, L Feng, Y Yin, C Yu, X He, J Zhu, M Zhang, J Yu, M Xu |
Aging | 2021 |
|
Immune Infiltrating Cells-Derived Risk Signature Based on Large-scale Analysis Defines Immune Landscape and Predicts Immunotherapy Responses in Glioma Tumor Microenvironment
N Zhang, H Zhang, Z Wang, Z Dai, X Zhang, Q Cheng, Z Liu |
Frontiers in immunology | 2021 |
|
Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy
H Ji, Y Ba, S Ma, K Hou, S Mi, X Gao, J Jin, Q Gong, T Liu, F Wang, Z Liu, S Li, J Du, S Hu |
Frontiers in immunology | 2021 |
|
Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
A Rohatgi, JM Kirkwood |
Frontiers in Oncology | 2021 |
|
PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients
Y Wang, H Chen, , L Wu, Y Yang, J Zhang, L Wu, C Liu, N Zhuo, S Li, J Gong, J Li, X Zhang, X Wang, Z Peng, C Qi, Z Wang, J Li, Y Li, Z Lu, H Zhang, L Shen |
Cancer Immunology, Immunotherapy | 2021 |
|
Association of RYR2 Mutation With Tumor Mutation Burden, Prognosis, and Antitumor Immunity in Patients With Esophageal Adenocarcinoma
Z Liu, L Liu, D Jiao, C Guo, L Wang, Z Li, Z Sun, Y Zhao, X Han |
Frontiers in Genetics | 2021 |
|
Improving Breast Cancer Responses to Immunotherapy—a Search for the Achilles Heel of the Tumor Microenvironment
S Jenkins, R Wesolowski, ME Gatti-Mays |
Current Oncology Reports | 2021 |
|
Biomarkers of immunotherapy response in breast cancer beyond PD-L1
N Chic, F Brasó-Maristany, A Prat |
Breast Cancer Research and Treatment | 2021 |
|
Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma
CY Fong, I Chau |
Pharmacogenomics | 2021 |
|
NOTCH3 is a Prognostic Factor and Is Correlated With Immune Tolerance in Gastric Cancer
Y Cui, Q Li, W Li, Y Wang, F Lv, X Shi, Z Tang, Z Shen, Y Hou, H Zhang, B Mao, T Liu |
Frontiers in Oncology | 2021 |
|
Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer
M Rakaee, TK Kilvaer, S Jamaly, T Berg, EE Paulsen, M Berglund, E Richardsen, S Andersen, S Al-Saad, M Poehl, F Pezzella, DJ Kwiatkowski, RM Bremnes, LT Busund, T Donnem |
British Journal of Cancer | 2021 |
|
COVID-19 in Children: Expressions of Type I/II/III Interferons, TRIM28, SETDB1, and Endogenous Retroviruses in Mild and Severe Cases
PA Tovo, S Garazzino, V Daprà, G Pruccoli, C Calvi, F Mignone, C Alliaudi, M Denina, C Scolfaro, M Zoppo, F Licciardi, U Ramenghi, I Galliano, M Bergallo |
International journal of molecular sciences | 2021 |
|
A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma
Y Mei, MJ Chen, H Liang, L Ma |
2021 | |
|
DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor
C Wang, NS Zainal, SJ Chai, J Dickie, CP Gan, N Zulaziz, BK Lye, RV Sutavani, CH Ottensmeier, EV King, MT Abraham, SM binti Ismail, SH Lau, TG Kallarakkal, KS Mun, R binti Zain, ZA Rahman, GJ Thomas, SC Cheong, N Savelyeva, KP Lim |
Frontiers in immunology | 2021 |
|
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
CM Gay, CA Stewart, EM Park, L Diao, SM Groves, S Heeke, BY Nabet, J Fujimoto, LM Solis, W Lu, , RJ Cardnell, Q Wang, G Fabbri, KR Cargill, NI Vokes, K Ramkumar, B Zhang, CM Corte, P Robson, SG Swisher, JA Roth, BS Glisson, DS Shames, II Wistuba, J Wang, V Quaranta, J Minna, JV Heymach, LA Byers |
Cancer Cell | 2021 |
|
Gene Expression Landscape of SDH-Deficient Gastrointestinal Stromal Tumors
V Indio, A Schipani, M Nannini, M Urbini, A Rizzo, AD Leo, A Altimari, VD Scioscio, D Messelodi, G Tarantino, A Astolfi, M Pantaleo |
Journal of Clinical Medicine | 2021 |
|
Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
S Jeong, E Park, HD Kim, E Sung, H Kim, J Jeon, Y Kim, U Jung, YG Son, Y Hong, H Lee, S Lee, Y Lim, J Won, M Jeon, S Hwang, L Fang, W Jiang, Z Wang, EC Shin, SH Park, J Jung |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Systemic inflammation and pro-inflammatory cytokine profile predict response to checkpoint inhibitor treatment in NSCLC: a prospective study
D Kauffmann-Guerrero, K Kahnert, R Kiefl, L Sellmer, J Walter, J Behr, A Tufman |
Scientific Reports | 2021 |
|
PPARγ induces PD-L1 expression in MSS+ colorectal cancer cells
T Gutting, V Hauber, J Pahl, K Klapproth, W Wu, I Dobrota, F Herweck, J Reichling, L Helm, T Schroeder, B Li, P Weidner, T Zhan, M Eckardt, J Betge, S Belle, C Sticht, T Gaiser, M Boutros, MP Ebert, A Cerwenka, E Burgermeister |
OncoImmunology | 2021 |
|
The Prognostic Value of a Tumor Microenvironment-Based Immune Cell Infiltration Score Model in Colon Cancer
X Tang, M Liu, X Luo, M Zhu, S Huang, X Pan |
Frontiers in Oncology | 2021 |
|
EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
DR Menon, Y Li, T Yamauchi, DG Osborne, PK Vaddi, MF Wempe, Z Zhai, M Fujita |
Pharmaceuticals (Basel, Switzerland) | 2021 |
|
Antigen and checkpoint receptor engagement recalibrates T cell receptor signal strength
TA Elliot, EK Jennings, DA Lecky, N Thawait, A Flores-Langarica, A Copland, KM Maslowski, DC Wraith, D Bending |
Immunity | 2021 |
|
Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification
A Alay, D Cordero, S Hijazo-Pechero, E Aliagas, A Lopez-Doriga, R Marín, R Palmero, R Llatjós, I Escobar, R Ramos, S Padrones, V Moreno, E Nadal, X Solé |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab
G Zheng, Z Guo, W Li, , B Zuo, R Zhang, W Wen, AG Yang, L Jia |
Signal Transduction and Targeted Therapy | 2021 |
|
Type I and II Interferons in the Anti-Tumor Immune Response
SE Fenton, D Saleiro, LC Platanias |
Cancers | 2021 |
|
Immune-Checkpoint Inhibitors in B-Cell Lymphoma
M Armengol, JC Santos, M Fernández-Serrano, N Profitós-Pelejà, ML Ribeiro, G Roué |
Cancers | 2021 |
|
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma
R Bao, S Spranger, K Hernandez, Y Zha, P Pytel, JJ Luke, TF Gajewski, SL Volchenboum, SL Cohn, AV Desai |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes
JA Ligon, W Choi, G Cojocaru, W Fu, EH Hsiue, TF Oke, N Siegel, MH Fong, B Ladle, CA Pratilas, CD Morris, A Levin, DS Rhee, CF Meyer, AJ Tam, R Blosser, ED Thompson, A Suru, D McConkey, F Housseau, R Anders, DM Pardoll, N Llosa |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Identification of KRAS G12V associated clonal neoantigens and immune microenvironment in long-term survival of pancreatic adenocarcinoma
C Wang, M Shi, L Zhang, J Ji, R Xie, C Wu, X Guo, Y Yang, W Zhou, C Peng, H Zhang, F Yuan, J Zhang |
Cancer Immunology, Immunotherapy | 2021 |
|
Tumor-Infiltrating Immune-Related Long Non-Coding RNAs Indicate Prognoses and Response to PD-1 Blockade in Head and Neck Squamous Cell Carcinoma
B Ma, H Jiang, Y Luo, T Liao, W Xu, X Wang, C Dong, Q Ji, Y Wang |
Frontiers in immunology | 2021 |
|
Tonsillar Cancer with High CD8+ T-Cell Infiltration Features Increased Levels of Dendritic Cells and Transcriptional Regulation Associated with an Inflamed Tumor Microenvironment
DG Jimenez, A Sobti, D Askmyr, C Sakellariou, SC Santos, S Swoboda, O Forslund, L Greiff, M Lindstedt |
Cancers | 2021 |
|
The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy
J Lee, B Lozano-Ruiz, FM Yang, DD Fan, L Shen, JM González-Navajas |
Frontiers in immunology | 2021 |
|
Research status on immunotherapy trials of gastric cancer
C Liang, HM Wu, WM Yu, W Chen |
World journal of clinical cases | 2021 |
|
Fundamental and Essential Knowledge for Pathologists Engaged in the Research and Practice of Immune Checkpoint Inhibitor-Based Cancer Immunotherapy
T Kubo, T Shinkawa, Y Kikuchi, K Murata, T Kanaseki, T Tsukahara, Y Hirohashi, T Torigoe |
Frontiers in Oncology | 2021 |
|
Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
D Zeng, J Wu, H Luo, Y Li, J Xiao, J Peng, Z Ye, R Zhou, Y Yu, G Wang, N Huang, J Wu, X Rong, L Sun, H Sun, W Qiu, Y Xue, J Bin, Y Liao, N Li, M Shi, KM Kim, W Liao |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges
M Krishnamoorthy, JG Lenehan, SM Vareki |
JNCI Journal of the National Cancer Institute | 2021 |
|
Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
RA Sloane, MG White, RG Witt, A Banerjee, MA Davies, G Han, E Burton, N Ajami, JM Simon, C Bernatchez, LE Haydu, HA Tawbi, JE Gershenwald, E Keung, M Ross, J McQuade, RN Amaria, K Wani, AJ Lazar, SE Woodman, L Wang, MC Andrews, JA Wargo |
Cancers | 2021 |
|
Loss of cancer cell STAT1 improves response to radiation therapy and promotes T cell activation in head and neck squamous cell carcinoma
MW Knitz, LB Darragh, TE Bickett, S Bhatia, S Bukkapatnam, J Gadwa, M Piper, S Corbo, D Nguyen, BV Court, A Oweida, SD Karam |
Cancer Immunology, Immunotherapy | 2021 |
|
Interferon-γ: teammate or opponent in the tumour microenvironment?
AM Gocher, CJ Workman, DA Vignali |
Nature Reviews Immunology | 2021 |
|
Systematic investigation of cytokine signaling activity at the tissue and single-cell levels
P Jiang, Y Zhang, B Ru, Y Yang, T Vu, R Paul, A Mirza, G Altan-Bonnet, L Liu, E Ruppin, L Wakefield, KW Wucherpfennig |
Nature Methods | 2021 |
|
A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer
NJ Gurule, CE McCoach, TK Hinz, DT Merrick, AV Bokhoven, J Kim, T Patil, J Calhoun, RA Nemenoff, AC Tan, RC Doebele, LE Heasley |
npj Precision Oncology | 2021 |
|
Clinical Significance and Inflammatory Landscape of aNovel Recurrence-Associated Immune Signature in Stage II/III Colorectal Cancer
Z Liu, T Lu, J Li, L Wang, K Xu, Q Dang, L Liu, C Guo, D Jiao, Z Sun, X Han |
Frontiers in immunology | 2021 |
|
The Role of Somatic Mutations on the Immune Response of the Tumor Microenvironment in Prostate Cancer
CM Melo, T Vidotto, LP Chaves, W Lautert-Dutra, RB dos Reis, JA Squire |
International journal of molecular sciences | 2021 |
|
Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy
VS Pelly, A Moeini, LM Roelofsen, E Bonavita, CR Bell, C Hutton, A Blanco-Gomez, A Banyard, CP Bromley, E Flanagan, SC Chiang, C Jørgensen, TN Schumacher, DS Thommen, S Zelenay |
Cancer Discovery | 2021 |
|
Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma
E Shiuan, A Reddy, SO Dudzinski, AR Lim, A Sugiura, R Hongo, K Young, XD Liu, CC Smith, J ONeal, KB Dahlman, R McAlister, B Chen, K Ruma, N Roscoe, J Bender, J Ward, JY Kim, C Vaupel, J Bordeaux, S Ganesan, TM Mayer, GM Riedlinger, BG Vincent, NB Davis, SM Haake, JC Rathmell, E Jonasch, BI Rini, WK Rathmell, KE Beckermann |
Cancers | 2021 |
|
Checkpoint Blockade: Not Yet NINJA Status in Ovarian Cancer
RL Porter, UA Matulonis |
Journal of Clinical Oncology | 2021 |
|
Comprehensive characterization and clinical relevance of the SWI/SNF copy number aberrations across human cancers
Z Xing, B Ma, W Sun, Y Sun, C Liu |
Hereditas | 2021 |
|
Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy
Y Liao, D He, F Wen |
Immunogenetics | 2021 |
|
Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases
SM Prakadan, CA Alvarez-Breckenridge, SC Markson, AE Kim, RH Klein, N Nayyar, AW Navia, BM Kuter, KE Kolb, I Bihun, JL Mora, MS Bertalan, B Shaw, M White, A Kaplan, JH Stocking, MH Wadsworth, EQ Lee, U Chukwueke, N Wang, M Subramanian, D Rotem, DP Cahill, VA Adalsteinsson, JW Miller, RJ Sullivan, SL Carter, PK Brastianos, AK Shalek |
Nature Communications | 2021 |
|
A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients
X Zhu, X Tian, L Ji, X Zhang, Y Cao, C Shen, Y Hu, JW Wong, JY Fang, J Hong, H Chen |
npj Precision Oncology | 2021 |
|
Analysis of Gastric Cancer Transcriptome Allows the Identification of Histotype Specific Molecular Signatures With Prognostic Potential
A Carino, L Graziosi, S Marchianò, M Biagioli, E Marino, V Sepe, A Zampella, E Distrutti, A Donini, S Fiorucci |
Frontiers in Oncology | 2021 |
|
Deep generative neural network for accurate drug response imputation
P Jia, R Hu, G Pei, Y Dai, YY Wang, Z Zhao |
Nature Communications | 2021 |
|
DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors
Y Song, J Huang, D Liang, Y Hu, B Mao, Q Li, H Sun, Y Yang, J Zhang, H Zhang, H Chen, H Liu, S Zhang |
Frontiers in Oncology | 2021 |
|
Transcriptomic signatures of tumors undergoing T cell attack
A Gokuldass, A Schina, M Lauss, K Harbst, CA Chamberlain, A Draghi, MC Westergaard, M Nielsen, K Papp, Z Sztupinszki, I Csabai, IM Svane, Z Szallasi, G Jönsson, M Donia |
Cancer Immunology, Immunotherapy | 2021 |
|
Tumour inflammation signature and expression of S100A12 and HLA class I improve survival in HPV-negative hypopharyngeal cancer
M Mints, D Landin, A Näsman, L Mirzaie, RG Ursu, M Zupancic, L Marklund, T Dalianis, E Munck-Wikland, T Ramqvist |
Scientific Reports | 2021 |
|
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancer
, X Wei, S Li, C Liu, H Chen, J Gong, J Li, X Zhang, X Wang, Z Peng, C Qi, Z Wang, Y Wang, Y Wang, N Zhuo, H Zhang, Z Lu, L Shen |
npj Precision Oncology | 2021 |
|
Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer
L Cai, H Liu, F Huang, J Fujimoto, L Girard, J Chen, Y Li, YA Zhang, D Deb, V Stastny, K Pozo, CS Kuo, G Jia, C Yang, W Zou, A Alomar, K Huffman, M Papari-Zareei, L Yang, B Drapkin, EA Akbay, DS Shames, II Wistuba, T Wang, JE Johnson, G Xiao, RJ DeBerardinis, JD Minna, Y Xie, AF Gazdar |
2021 | |
|
Immunotherapy response modeling by ex-vivo organ culture for lung cancer
I Kamer, E Bab-Dinitz, O Zadok, E Ofek, T Gottfried, I Daniel-Meshulam, G Hout-Siloni, AB Nun, I Barshack, A Onn, J Bar |
Cancer Immunology, Immunotherapy | 2021 |
|
CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas
D Li, W Hu, X Lin, J Zhang, Z He, S Zhong, X Wen, P Zhang, X Jiang, H Duan, C Guo, J Wang, J Zeng, Z Chen, Y Mou, K Sai |
Frontiers in Cell and Developmental Biology | 2021 |
|
Dissecting immune cell stat regulation network reveals biomarkers to predict ICB therapy responders in melanoma
J Wang, F Li, Y Xu, X Zheng, C Zhang, C Hu, Y Xu, W Mi, X Li, Y Zhang |
Journal of Translational Medicine | 2021 |
|
Gene Expression Profiling as a Potential Tool for Precision Oncology in Non-Small Cell Lung Cancer
S Hijazo-Pechero, A Alay, R Marín, N Vilariño, C Muñoz-Pinedo, A Villanueva, D Santamaría, E Nadal, X Solé |
Cancers | 2021 |
|
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
V Ludovini, F Bianconi, A Siggillino, J Vannucci, S Baglivo, V Berti, FR Tofanetti, MS Reda, G Bellezza, M Mandarano, ML Belladonna, G Metro, R Chiari, A Sidoni, F Puma, V Minotti, F Roila |
Genes & development | 2021 |
|
Integrative Transcriptomic Analysis Reveals Distinctive Molecular Traits and Novel Subtypes of Collecting Duct Carcinoma
C Gargiuli, P Sepe, A Tessari, T Sheetz, M Colecchia, FG de Braud, G Procopio, M Sensi, E Verzoni, M Dugo |
Cancers | 2021 |
|
Immunotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
RW Hsieh, S Borson, A Tsagianni, DP Zandberg |
Frontiers in Oncology | 2021 |
|
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
AM Sarshekeh, J Alshenaifi, J Roszik, GC Manyam, SM Advani, R Katkhuda, A Verma, M Lam, J Willis, JP Shen, J Morris, JS Davis, JM Loree, HM Lee, JA Ajani, DM Maru, MJ Overman, S Kopetz |
Clinical cancer research | 2021 |
|
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition
K Litchfield, JL Reading, C Puttick, K Thakkar, C Abbosh, R Bentham, TB Watkins, R Rosenthal, D Biswas, A Rowan, E Lim, MA Bakir, V Turati, JA Guerra-Assunção, L Conde, AJ Furness, SK Saini, SR Hadrup, J Herrero, SH Lee, PV Loo, T Enver, J Larkin, MD Hellmann, S Turajlic, SA Quezada, N McGranahan, C Swanton |
Cell | 2021 |
|
YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype
TK Owonikoko, B Dwivedi, Z Chen, C Zhang, B Barwick, V Ernani, G Zhang, M Gilbert-Ross, J Carlisle, FR Khuri, WJ Curran, AA Ivanov, H Fu, S Lonial, SS Ramalingam, SY Sun, EK Waller, GL Sica |
Journal of Thoracic Oncology | 2021 |
|
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer
SV Lindskrog, F Prip, P Lamy, A Taber, CS Groeneveld, K Birkenkamp-Demtröder, JB Jensen, T Strandgaard, I Nordentoft, E Christensen, M Sokac, NJ Birkbak, L Maretty, GG Hermann, AC Petersen, V Weyerer, MO Grimm, M Horstmann, G Sjödahl, M Höglund, T Steiniche, K Mogensen, A de Reyniès, R Nawroth, B Jordan, X Lin, D Dragicevic, DG Ward, A Goel, CD Hurst, JD Raman, JI Warrick, U Segersten, D Sikic, KE van Kessel, T Maurer, JJ Meeks, DJ DeGraff, RT Bryan, MA Knowles, T Simic, A Hartmann, EC Zwarthoff, PU Malmström, N Malats, FX Real, L Dyrskjøt |
Nature Communications | 2021 |
|
PTEN loss correlates with T cell exclusion across human cancers
Z Lin, L Huang, SL Li, J Gu, X Cui, Y Zhou |
BMC Cancer | 2021 |
|
Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T cells into mammary tumors
RV Uzhachenko, V Bharti, Z Ouyang, A Blevins, S Mont, N Saleh, HA Lawrence, C Shen, SC Chen, GD Ayers, DG DeNardo, C Arteaga, A Richmond, AE Vilgelm |
Cell Reports | 2021 |
|
Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma
F Veigas, YD Mahmoud, J Merlo, A Rinflerch, GA Rabinovich, MR Girotti |
Cancers | 2021 |
|
Immunotherapy for sarcomas: new frontiers and unveiled opportunities
HK Birdi, A Jirovec, S Cortés-Kaplan, J Werier, C Nessim, JS Diallo, M Ardolino |
Journal for ImmunoTherapy of Cancer | 2021 |
|
FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
Y Wang, Z Tong, W Zhang, W Zhang, A Buzdin, X Mu, Q Yan, X Zhao, HH Chang, M Duhon, X Zhou, G Zhao, H Chen, X Li |
Frontiers in Oncology | 2021 |
|
Cancer neoantigens as potential targets for immunotherapy
W Ma, B Pham, T Li |
Clinical & Experimental Metastasis | 2021 |
|
The HDAC Inhibitor Domatinostat Promotes Cell-Cycle Arrest, Induces Apoptosis, and Increases Immunogenicity of Merkel Cell Carcinoma Cells
L Song, AC Bretz, J Gravemeyer, I Spassova, S Muminova, T Gambichler, A Sriram, S Ferrone, JC Becker |
Journal of Investigative Dermatology | 2021 |
|
The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
L Meng, J Xu, Y Ye, Y Wang, S Luo, X Gong |
Frontiers in immunology | 2021 |
|
N-cadherin inhibitor creates a microenvironment that protect TILs from immune checkpoints and Treg cells
Y Sun, J Jing, H Xu, L Xu, H Hu, C Tang, S Liu, Q Wei, R Duan, J Guo, L Yang |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Functional characterization of PD1+TIM3+ tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 blockade
M Roussel, KS Le, C Granier, FL Gutierrez, E Foucher, SL Gallou, C Pangault, L Xerri, V Launay, T Lamy, E Tartour, D Olive, T Fest |
Blood Advances | 2021 |
|
Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell Immunity
A Fukaya-Shiba, K Otsuka, H Sasaki, M Shikano, R Wakao |
Frontiers in Medicine | 2021 |
|
Germline genetic contribution to the immune landscape of cancer
RW Sayaman, M Saad, V Thorsson, D Hu, W Hendrickx, J Roelands, E Porta-Pardo, Y Mokrab, F Farshidfar, T Kirchhoff, RF Sweis, OF Bathe, C Heimann, MJ Campbell, C Stretch, S Huntsman, RE Graff, N Syed, L Radvanyi, S Shelley, D Wolf, FM Marincola, M Ceccarelli, J Galon, E Ziv, D Bedognetti |
Immunity | 2021 |
|
The clinical and molecular significance associated with STING signaling in breast cancer
EE Parkes, MP Humphries, E Gilmore, FA Sidi, V Bingham, SM Phyu, S Craig, C Graham, J Miller, D Griffin, M Salto-Tellez, SF Madden, RD Kennedy, SF Bakhoum, S McQuaid, NE Buckley |
npj Breast Cancer | 2021 |
|
Characterization of m6A-Related Genes Landscape in Skin Cutaneous Melanoma to Aid Immunotherapy and Assess Prognosis
J Meng, X Huang, Y Qiu, M Yu, J Lu, J Yao |
International journal of general medicine | 2021 |
|
Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation
A Roberts, L Bentley, T Tang, F Stewart, C Pallini, J Juvvanapudi, GR Wallace, AJ Cooper, A Scott, D Thickett, ST Lugg, H Bancroft, B Hemming, C Ferris, G Langman, A Robinson, J Chapman, B Naidu, T Pinkney, GS Taylor, K Brock, Z Stamataki, CA Brady, SJ Curnow, J Gordon, O Qureshi, NM Barnes |
Scientific Reports | 2021 |
|
Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
W Chong, Z Wang, L Shang, S Jia, J Liu, Z Fang, F Du, H Wu, Y Liu, Y Chen, H Chen |
Molecular Therapy — Nucleic Acids | 2021 |
|
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy
KE Kortekaas, SJ Santegoets, L Tas, I Ehsan, P Charoentong, HC van Doorn, MI van Poelgeest, DA Mustafa, SH van der Burg |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer
J Isaacs, C Anders, H McArthur, J Force |
Current Treatment Options in Oncology | 2021 |
|
Engineered Cytokines for Cancer and Autoimmune Disease Immunotherapy
B Uricoli, LA Birnbaum, P Do, JM Kelvin, J Jain, E Costanza, A Chyong, CC Porter, S Rafiq, EC Dreaden |
Advanced Healthcare Materials | 2021 |
|
An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment
RA Khouzam, SP Rao, GH Venkatesh, NA Zeinelabdin, S Buart, M Meylan, M Nimmakayalu, S Terry, S Chouaib |
Frontiers in immunology | 2021 |
|
Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
Y He, M Lu, J Che, Q Chu, P Zhang, Y Chen |
Frontiers in Oncology | 2021 |
|
Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
BW Labadie, AV Balar, JJ Luke |
Cancers | 2021 |
|
Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma
MT Campbell, SF Matin, AL Tam, RA Sheth, K Ahrar, RS Tidwell, P Rao, JA Karam, CG Wood, NM Tannir, E Jonasch, J Gao, AJ Zurita, AY Shah, S Jindal, F Duan, S Basu, H Chen, AB Espejo, JP Allison, SS Yadav, P Sharma |
Nature Communications | 2021 |
|
Identification of Immune-Related Genes for Establishment of Prognostic Index in Hepatocellular Carcinoma
Y Li, L Zou, X Liu, J Luo, H Liu |
Frontiers in Cell and Developmental Biology | 2021 |
|
Activation of a cGAS-STING-mediated immune response predicts response to neoadjuvant chemotherapy in early breast cancer
EE Parkes, KI Savage, T Lioe, C Boyd, S Halliday, SM Walker, K Lowry, L Knight, NE Buckley, A Grogan, GE Logan, A Clayton, J Hurwitz, SJ Kirk, J Xu, FA Sidi, MP Humphries, V Bingham, M Ang, C Askin, L Bamford, R Boyd, M Buckley, J Clarke, L Darragh, E Davis, J Foreman, R Gallagher, J Gill, M Hanna, N Hill, G Irwin, P Mallon, S McAleer, J McAllister, M Morris, N Pierce, S Refsum, S Sloan, S Treanor, JA James, CR James, DP Harkin, RD Kennedy, SA McIntosh |
British Journal of Cancer | 2021 |
|
Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8 + T cell clone size and cytotoxicity
R Watson, O Tong, R Cooper, C Taylor, P Sharma, A de los Aires, E Mahé, H Ruffieux, I Nassiri, M Middleton, B Fairfax |
Science Immunology | 2021 |
|
Bridging Radiotherapy to Immunotherapy: The IFN–JAK–STAT Axis
LZ Shi, JA Bonner |
International journal of molecular sciences | 2021 |
|
Biomarkers of therapeutic response with immune checkpoint inhibitors
P Bindal, JE Gray, TA Boyle, V Florou, S Puri |
Annals of translational medicine | 2021 |
|
NKG7 is a T-cell intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy
T Wen, W Barham, Y Li, H Zhang, JK Gicobi, JB Hirdler, X Liu, H Ham, KE Martinez, F Lucien, RR Lavoie, H Li, C Correia, DD Monie, Z An, SM Harrington, X Wu, R Guo, RS Dronca, AS Mansfield, Y Yan, SN Markovic, SS Park, J Sun, H Qin, MC Liu, G Vasmatzis, DD Billadeau, H Dong |
Cancer immunology research | 2021 |
|
Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
B Duchemann, J Remon, M Naigeon, L Cassard, JM Jouniaux, L Boselli, J Grivel, E Auclin, A Desnoyer, B Besse, N Chaput |
Translational Lung Cancer Research | 2021 |
|
Construction of an HCC recurrence model based on the investigation of immune-related lncRNAs and related mechanisms
XX Wang, LH Wu, L Ai, W Pan, JY Ren, Q Zhang, HM Zhang |
Molecular Therapy — Nucleic Acids | 2021 |
|
Immune evasion in HPV − head and neck precancer–cancer transition is driven by an aneuploid switch involving chromosome 9p loss
WN William, X Zhao, JJ Bianchi, HY Lin, P Cheng, JJ Lee, H Carter, LB Alexandrov, JP Abraham, DB Spetzler, SM Dubinett, DW Cleveland, W Cavenee, T Davoli, SM Lippman |
Proceedings of the National Academy of Sciences | 2021 |
|
Prognostic Value of an Immune-Related Gene Signature in Oral Squamous Cell Carcinoma
C Zhu, L Gu, M Yao, J Li, C Fang |
Frontiers in Oncology | 2021 |
|
CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
N Klümper, DJ Ralser, R Zarbl, K Schlack, AJ Schrader, M Rehlinghaus, MJ Hoffmann, G Niegisch, A Uhlig, L Trojan, J Steinestel, K Steinestel, RM Wirtz, D Sikic, M Eckstein, G Kristiansen, M Toma, M Hölzel, M Ritter, S Strieth, J Ellinger, D Dietrich |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
W Zhang, F Shi, Y Kong, Y Li, C Sheng, S Wang, Q Wang |
Cancer Medicine | 2021 |
|
Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease
I Isola, F Brasó-Maristany, DF Moreno, MP Mena, A Oliver-Calders, L Paré, LG Rodríguez-Lobato, B Martin-Antonio, MT Cibeira, J Bladé, L Rosiñol, A Prat, E Lozano, CF de Larrea |
Frontiers in immunology | 2021 |
|
Pan‐cancer analyses reveal that increased Hedgehog activity correlates with tumor immunosuppression and resistance to immune checkpoint inhibitors
J Jiang, Y Ding, Y Chen, J Lu, Y Chen, G Wu, N Xu, H Wang, L Teng |
Cancer Medicine | 2021 |
|
Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
JC Baltussen, MJ Welters, EM Verdegaal, E Kapiteijn, AM Schrader, M Slingerland, GJ Liefers, SH van der Burg, JE Portielje, NA de Glas |
Cancers | 2021 |
|
Single-Molecule RNA Sequencing Reveals IFNγ-Induced Differential Expression of Immune Escape Genes in Merkel Cell Polyomavirus–Positive MCC Cell Lines
T Sauerer, C Lischer, A Weich, C Berking, J Vera, J Dörrie |
Frontiers in microbiology | 2021 |
|
5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer
J Hu, B Othmane, A Yu, H Li, Z Cai, X Chen, W Ren, J Chen, X Zu |
BMC Medicine | 2021 |
|
Downregulation of Interferon-γ Receptor Expression Endows Resistance to Anti–Programmed Death Protein 1 Therapy in Colorectal Cancer
Lv C, Yuan D, Cao Y |
The Journal of pharmacology and experimental therapeutics | 2021 |
|
Molecular profiling of long-term responders to immune checkpoint inhibitors in advanced non-small cell lung cancer.
Frigola J, Navarro A, Carbonell C, Callejo A, Iranzo P, Cedrés S, Martinez-Marti A, Pardo N, Saoudi-Gonzalez N, Martinez D, Jimenez J, Sansano I, Mancuso FM, Nuciforo P, Montuenga LM, Sánchez-Cespedes M, Prat A, Vivancos A, Felip E, Amat R |
Molecular Oncology | 2021 |
|
Beta-catenin activation and immunotherapy resistance in hepatocellular carcinoma: mechanisms and biomarkers.
Kwee SA, Tiirikainen M |
Hepatoma Research | 2021 |
|
Ubiquitin-Specific Protease 6 Functions as a Tumor Suppressor in Ewing Sarcoma through Immune Activation.
Henrich IC, Jain K, Young R, Quick L, Lindsay JM, Park DH, Oliveira AM, Blobel GA, Chou MM |
Cancer research | 2021 |
|
Integrating Patient-Specific Information into Logic Models of Complex Diseases: Application to Acute Myeloid Leukemia.
Palma A, Iannuccelli M, Rozzo I, Licata L, Perfetto L, Massacci G, Castagnoli L, Cesareni G, Sacco F |
Journal of Personalized Medicine | 2021 |
|
Analysis of extracellular vesicle mRNA derived from plasma using the nCounter platform.
Bracht JWP, Gimenez-Capitan A, Huang CY, Potie N, Pedraz-Valdunciel C, Warren S, Rosell R, Molina-Vila MA |
Scientific Reports | 2021 |
|
Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer.
Wilkins A, Fontana E, Nyamundanda G, Ragulan C, Patil Y, Mansfield D, Kingston J, Errington-Mais F, Bottomley D, von Loga K, Bye H, Carter P, Tinkler-Hundal E, Noshirwani A, Downs J, Dillon M, Demaria S, Sebag-Montefiore D, Harrington K, West N, Melcher A, Sadanandam A |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment.
Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, Martínez-Ricarte F, Escudero L, Cordero E, Cicuendez M, Ruiz S, Parra G, Nuciforo P, Gonzalez J, Pineda E, Sahuquillo J, Tabernero J, Heyn H, Seoane J |
Nature Communications | 2021 |
|
The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma.
Song LB, Luan JC, Zhang QJ, Chen L, Wang HY, Cao XC, Song NH, Lu Y |
Journal of Immunology Research | 2021 |
|
Type I T cells sensitize treatment refractory tumors to chemotherapy through inhibition of oncogenic signaling pathways.
Cecil D, Park KH, Curtis B, Corulli L, Disis MN |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Distinct genomic features across cytolytic subgroups in skin melanoma.
Roufas C, Georgakopoulos-Soares I, Zaravinos A |
Cancer Immunology, Immunotherapy | 2021 |
|
Immune Checkpoint Inhibitors in Urothelial Carcinoma: Recommendations for Practical Approaches to PD-L1 and Other Potential Predictive Biomarker Testing.
Lopez-Beltran A, López-Rios F, Montironi R, Wildsmith S, Eckstein M |
Cancers | 2021 |
|
A novel immune subtype classification of ER-positive, PR-negative and HER2-negative breast cancer based on the genomic and transcriptomic landscape.
Xie P, An R, Yu S, He J, Zhang H |
Journal of Translational Medicine | 2021 |
|
Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study.
Bordonaro R, Calvo A, Auriemma A, Hollebecque A, Rubovszky G, Saunders MP, Pápai Z, Prager G, Stein A, André T, Argilés G, Cubillo A, Dahan L, Edeline J, Leger C, Cattan V, Fougeray R, Amellal N, Tabernero J |
ESMO Open | 2021 |
|
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.
Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, He MX, Reardon B, Shannon E, Wulf G, Spring LM, Jeselsohn R, Krop I, Lin NU, Partridge A, Winer EP, Mittendorf EA, Liu D, Van Allen EM, Tolaney SM |
Nature Communications | 2021 |
|
FDG PET biomarkers for prediction of survival in metastatic melanoma prior to anti-PD1 immunotherapy.
Flaus A, Habouzit V, De Leiris N, Vuillez JP, Leccia MT, Perrot JL, Prevot N, Cachin F |
Scientific Reports | 2021 |
|
Low baseline plasma PCSK9 level is associated with good clinical outcomes of immune checkpoint inhibitors in advanced non-small cell lung cancer.
Xie M, Yu X, Chu X, Xie H, Zhou J, Zhao J, Su C |
Thoracic Cancer | 2021 |
|
A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
Liu Z, Qi T, Li X, Yao Y, Othmane B, Chen J, Zu X, Ou Z, Hu J |
Frontiers in immunology | 2021 |
|
The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens
Vredevoogd DW, Apriamashvili G, Peeper DS |
2021 | |
|
Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties
Van Braeckel-Budimir N, Dolina JS, Wei J, Wang X, Chen SH, Santiago P, Tu G, Micci L, Al-Khami AA, Pfister S, Ram S, Sundar P, Thomas G, Long H, Yang W, Potluri S, Salek-Ardakani S |
Journal for ImmunoTherapy of Cancer | 2021 |
|
RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG, Catalan-Latorre A, Brugarolas A |
BMC Cancer | 2021 |
|
[Predictive diagnostics for checkpoint inhibitors].
Schildhaus HU, Weichert W |
Der Pathologe | 2021 |
|
Exploration of the Associations of lncRNA Expression Patterns with Tumor Mutation Burden and Prognosis in Colon Cancer.
Ding C, Shan Z, Li M, Xia Y, Jin Z |
OncoTargets and therapy | 2021 |
|
Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma.
Sobol RE, Menander KB, Chada S, Wiederhold D, Sellman B, Talbott M, Nemunaitis JJ |
Frontiers in Oncology | 2021 |
|
PERFECT trial results: Combining neoadjuvant chemoradiotherapy with atezolizumab is feasible in resectable esophageal adenocarcinoma.
Zhang L |
Thoracic Cancer | 2021 |
|
The Value of Population Screening in Advancing Personalized Medicine in the Field of Lung Cancer.
Mogenet A, Greillier L, Tomasini P |
Pharmacogenomics and Personalized Medicine | 2021 |
|
Preview of "Interpretable systems biomarkers predict response to immune-checkpoint inhibitors".
Guinney J |
2021 | |
|
PD-1 inhibition in patient derived tissue cultures of human gastric and gastroesophageal adenocarcinoma.
Hußtegge M, Hoang NA, Rebstock J, Monecke A, Gockel I, Weimann A, Schumacher G, Bechmann I, Lordick F, Kallendrusch S, Körfer J |
OncoImmunology | 2021 |
|
EVI2B Is a New Prognostic Biomarker in Metastatic Melanoma with IFNgamma Associated Immune Infiltration.
Yonekura S, Ueda K |
Cancers | 2021 |
|
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
Madonna G, Masucci GV, Capone M, Mallardo D, Grimaldi AM, Simeone E, Vanella V, Festino L, Palla M, Scarpato L, Tuffanelli M, D'angelo G, Villabona L, Krakowski I, Eriksson H, Simao F, Lewensohn R, Ascierto PA |
Cancers | 2021 |
|
Long-Term Follow-Up of Gemogenovatucel-T (Vigil) Survival and Molecular Signals of Immune Response in Recurrent Ovarian Cancer.
Rocconi RP, Stanbery L, Madeira da Silva L, Barrington RA, Aaron P, Manning L, Horvath S, Wallraven G, Bognar E, Walter A, Nemunaitis J |
Human vaccines | 2021 |
|
APOBEC Mutagenesis Is Concordant between Tumor and Viral Genomes in HPV-Positive Head and Neck Squamous Cell Carcinoma.
Faden DL, Kuhs KAL, Lin M, Langenbucher A, Pinheiro M, Yeager M, Cullen M, Boland JF, Steinberg M, Bass S, Lewis JS, Lawrence MS, Ferris RL, Mirabello L |
Viruses | 2021 |
|
Interferon-Induced Transmembrane Protein 3 Shapes an Inflamed Tumor Microenvironment and Identifies Immuno-Hot Tumors.
Cai Y, Ji W, Sun C, Xu R, Chen X, Deng Y, Pan J, Yang J, Zhu H, Mei J |
Frontiers in immunology | 2021 |
|
Immunotherapeutic Advances for NSCLC.
Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M |
Biologics : targets & therapy | 2021 |
|
Transcriptomic Characterization of Postmolar Gestational Choriocarcinoma.
Collet C, Lopez J, Battail C, Allias F, Devouassoux-Shisheboran M, Patrier S, Lemaitre N, Hajri T, Massardier J, You B, Mallet F, Golfier F, Alfaidy N, Bolze PA |
Biomedicines | 2021 |
|
What Are the Biomarkers for Immunotherapy in SCLC?
Longo V, Catino A, Montrone M, Pizzutilo P, Annese T, Pesola F, Marech I, Cassiano S, Ribatti D, Galetta D |
International journal of molecular sciences | 2021 |
|
The effect of hypoxia on PD-L1 expression in bladder cancer.
Smith V, Mukherjee D, Lunj S, Choudhury A, Hoskin P, West C, Illidge T |
BMC Cancer | 2021 |
|
Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion.
D'Alise AM, Leoni G, De Lucia M, Langone F, Nocchi L, Tucci FG, Micarelli E, Cotugno G, Troise F, Garzia I, Vitale R, Bignone V, Di Matteo E, Bartolomeo R, Charych DH, Lahm A, Zalevsky J, Nicosia A, Scarselli E |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival.
Shah MA, Cunningham D, Metges JP, Van Cutsem E, Wainberg Z, Elboudwarej E, Lin KW, Turner S, Zavodovskaya M, Inzunza D, Liu J, Patterson SD, Zhou J, He J, Thai D, Bhargava P, Brachmann CB, Cantenacci DVT |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial.
Powles T, Sridhar SS, Loriot Y, Bellmunt J, Mu XJ, Ching KA, Pu J, Sternberg CN, Petrylak DP, Tambaro R, Dourthe LM, Alvarez-Fernandez C, Aarts M, di Pietro A, Grivas P, Davis CB |
Nature Medicine | 2021 |
|
Identification of a novel immune signature for optimizing prognosis and treatment prediction in colorectal cancer.
Li Y, Li Y, Xia Z, Zhang D, Chen X, Wang X, Liao J, Yi W, Chen J |
Aging | 2021 |
|
Predictable Roles of Peripheral IgM Memory B Cells for the Responses to Anti-PD-1 Monotherapy Against Advanced Non-Small Cell Lung Cancer.
Xia L, Guo L, Kang J, Yang Y, Yao Y, Xia W, Sun R, Zhang S, Li W, Gao Y, Chen H, Li Z, Yang J, Lu S, Wang Y |
Frontiers in immunology | 2021 |
|
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer.
Nam CH, Koh J, Ock CY, Kim M, Keam B, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS |
The Korean Journal of Internal Medicine | 2021 |
|
Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy.
Sun S, Xu L, Zhang X, Pang L, Long Z, Deng C, Zhu J, Zhou S, Wan L, Pang B, Xiao Y |
Cancers | 2021 |
|
Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond.
Park R, Da Silva LL, Saeed A |
Cancers | 2021 |
|
Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation.
Noblejas-López MDM, Baliu-Piqué M, Nieto-Jiménez C, Cimas FJ, Morafraile EC, Pandiella A, Corbi ÁL, Győrffy B, Ocaña A |
International journal of molecular sciences | 2021 |
|
The Current Landscape of Clinical Trials for Systemic Treatment of HCC.
Foerster F, Galle PR |
Cancers | 2021 |
|
Genomic Correlates of DNA Damage in Breast Cancer Subtypes.
Cabañas Morafraile E, Pérez-Peña J, Fuentes-Antrás J, Manzano A, Pérez-Segura P, Pandiella A, Galán-Moya EM, Ocaña A |
Cancers | 2021 |
|
MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer.
Sun L, Li M, Deng L, Niu Y, Tang Y, Wang Y, Guo L |
Frontiers in pharmacology | 2021 |
|
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.
Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ |
Journal of Clinical Oncology | 2021 |
|
Hepatitis B virus-associated follicular lymphoma presents T-cell inflamed phenotype and response to lenalidomide.
Wang N, Qin W, Zheng Z, Zhao M, Xiong J, Fang H, Sun R, Wang Y, Li C, Dong L, Sun X, Wang L, Xu P, Cheng S, Xu H, Zhang F, Zhao W |
2021 | |
|
Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.
Kim A, Lim SM, Kim JH, Seo JS |
Frontiers in immunology | 2021 |
|
A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer.
Liu C, Gong J, Yu H, Liu Q, Wang S, Wang J |
Frontiers in Oncology | 2021 |
|
Development and validation of a robust immune-related risk signature for hepatocellular carcinoma.
Liu Z, Jiao D, Liu L, Zhou X, Yao Y, Li Z, Li J, Chen J, Lei Q, Han X |
Medicine | 2021 |
|
Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study.
Ruiz-Bañobre J, Molina-Díaz A, Fernández-Calvo O, Fernández-Núñez N, Medina-Colmenero A, Santomé L, Lázaro-Quintela M, Mateos-González M, García-Cid N, López-López R, Vázquez S, Anido-Herranz U |
ESMO Open | 2021 |
|
Dermatologic infections in cancer patients treated with checkpoint inhibitors.
Do MH, Barrios DM, Phillips GS, Postow MA, Warner AB, Rosenberg JE, Noor SJ, Markova A, Lacouture ME |
Journal of the American Academy of Dermatology | 2021 |
|
Characterizing the molecular and immune landscape of canine bladder cancer.
Cronise KE, Das S, Hernandez BG, Regan DP, Dailey DD, McGeachan RI, Lana SE, Page RL, Gustafson DL, Duval DL |
Veterinary and Comparative Oncology | 2021 |
|
Identification of immune subtypes of cervical squamous cell carcinoma predicting prognosis and immunotherapy responses.
Li Y, Lu S, Wang S, Peng X, Lang J |
Journal of Translational Medicine | 2021 |
|
Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancer.
Pereira B, Chen CT, Goyal L, Walmsley C, Pinto CJ, Baiev I, Allen R, Henderson L, Saha S, Reyes S, Taylor MS, Fitzgerald DM, Broudo MW, Sahu A, Gao X, Winckler W, Brannon AR, Engelman JA, Leary R, Stone JR, Campbell CD, Juric D |
Nature Communications | 2021 |
|
Gene expression profiles of breast cancer metastasis according to organ site.
Brasó-Maristany F, Paré L, Chic N, Martínez-Sáez O, Pascual T, Mallafré-Larrosa M, Schettini F, González-Farré B, Sanfeliu E, Martínez D, Galván P, Barnadas E, Salinas B, Tolosa P, Ciruelos E, Carcelero E, Guillén C, Adamo B, Moreno R, Vidal M, Muñoz M, Prat A |
Molecular Oncology | 2021 |
|
The landscape of tumors-infiltrate immune cells in papillary thyroid carcinoma and its prognostic value.
Huang Y, Yi T, Liu Y, Yan M, Peng X, Lv Y |
PeerJ | 2021 |
|
Validation of the Combined Biomarker for Prediction of Response to Checkpoint Inhibitor in Patients with Advanced Cancer.
Kim JC, Heo YJ, Kang SY, Lee J, Kim KM |
Cancers | 2021 |
|
Prognostic Potential of Tumor-Infiltrating Immune Cells in Resectable Oral Squamous Cell Carcinoma.
Caruntu A, Moraru L, Lupu M, Vasilescu F, Dumitrescu M, Cioplea M, Popp C, Dragusin A, Caruntu C, Zurac S |
Cancers | 2021 |
|
B cell-related gene signature and cancer immunotherapy response.
Lundberg A, Li B, Li R |
British Journal of Cancer | 2021 |
|
High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition.
Ni Y, Soliman A, Joehlin-Price A, Rose PG, Vlad A, Edwards RP, Mahdi H |
npj Precision Oncology | 2021 |
|
Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer.
Liu Z, Guo C, Dang Q, Wang L, Liu L, Weng S, Xu H, Lu T, Sun Z, Han X |
EBioMedicine | 2021 |
|
Novel Biomarkers and Druggable Targets in Advanced Melanoma.
Ferrucci PF, Cocorocchio E |
Cancers | 2021 |
|
A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer.
Peng J, Zou D, Han L, Yin Z, Hu X |
Frontiers in immunology | 2021 |
|
Discovery of acquired molecular signature on immune checkpoint inhibitors in paired tumor tissues.
Yoo SH, Yun J, Keam B, Hong SP, Ock CY, Koh J, Kim S, Jeon YK, Jung KC, Kim M, Kim TM, Kim DW, Kim JI, Heo DS |
Cancer Immunology, Immunotherapy | 2021 |
|
Coexistence of Emphysema With Non-small-cell Lung Cancer Predicts the Therapeutic Efficacy of Immune Checkpoint Inhibitors.
Takayama Y, Nakamura T, Fukushiro Y, Mishima S, Masuda K, Shoda H |
In vivo (Athens, Greece) | 2021 |
|
Decoding Immune Heterogeneity of Melanoma and identifying immune-prognostic hub genes.
Zhang Y, Hao S, Gao Y, Sun W, Li Y |
Journal of Cancer | 2021 |
|
CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.
Rocha P, Salazar R, Zhang J, Ledesma D, Solorzano JL, Mino B, Villalobos P, Dejima H, Douse DY, Diao L, Mitchell KG, Le X, Zhang J, Weissferdt A, Parra-Cuentas E, Cascone T, Rice DC, Sepesi B, Kalhor N, Moran C, Vaporciyan A, Heymach J, Gibbons DL, Lee JJ, Kadara H, Wistuba I, Behrens C, Solis LM |
Cancer Immunology, Immunotherapy | 2021 |
|
Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC).
Chen HX, Song M, Maecker HT, Gnjatic S, Patton D, Lee JJ, Adam SJ, Moravec R, Liu XS, Cerami E, Lindsay J, Tang M, Hodi FS, Wu CJ, Wistuba II, Al-Atrash G, Bernatchez C, Bendall SC, Hewitt SM, Sharon E, Streicher H, Enos RA, Bowman MD, Tatard-Leitman VM, Sanchez-Espiridion B, Ranasinghe S, Pichavant M, Del Valle DM, Yu J, Janssens S, Peterson-Klaus J, Rowe C, Bongers G, Jenq RR, Chang CC, Abrams JS, Mooney M, Doroshow JH, Harris LN, Thurin M |
Clinical cancer research | 2021 |
|
Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape.
Song SG, Kim S, Koh J, Yim J, Han B, Kim YA, Jeon YK, Chung DH |
Cancer Immunology, Immunotherapy | 2021 |
|
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms.
Wang Y, Mohseni M, Grauel A, Diez JE, Guan W, Liang S, Choi JE, Pu M, Chen D, Laszewski T, Schwartz S, Gu J, Mansur L, Burks T, Brodeur L, Velazquez R, Kovats S, Pant B, Buruzula G, Deng E, Chen JT, Sari-Sarraf F, Dornelas C, Varadarajan M, Yu H, Liu C, Lim J, Hao HX, Jiang X, Malamas A, LaMarche MJ, Geyer FC, McLaughlin M, Costa C, Wagner J, Ruddy D, Jayaraman P, Kirkpatrick ND, Zhang P, Iartchouk O, Aardalen K, Cremasco V, Dranoff G, Engelman JA, Silver S, Wang H, Hastings WD, Goldoni S |
Scientific Reports | 2021 |
|
[Developments in Immunotherapy for Advanced Non-small Cell Lung Cancer].
Li H, Wang J |
Zhongguo fei ai za zhi = Chinese journal of lung cancer | 2021 |
|
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J, Yu A, Othmane B, Qiu D, Li H, Li C, Liu P, Ren W, Chen M, Gong G, Guo X, Zhang H, Chen J, Zu X |
Theranostics | 2021 |
|
Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring STK11 or KEAP1 mutation.
Nie W, Gan L, Wang X, Gu K, Qian FF, Hu MJ, Zhang D, Chen SQ, Lu J, Cao SH, Li JW, Wang Y, Zhang B, Wang SY, Li CH, Yang P, Xu MD, Zhang XY, Zhong H, Han BH |
OncoImmunology | 2021 |
|
Identification of gastric cancer subtypes based on pathway clustering.
Li L, Wang X |
npj Precision Oncology | 2021 |
|
Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC.
He Y, Chen L, Zhao L, Dang S, Liu G, Sasada S, Ma PC, van Zandwijk N, Rosell R, Popper HH, Wang H, Jiang M, Guo H, Liu X, Chen S, Zhang X, Xu M, Zhu B, Liu M, Zhou C |
Theranostics | 2021 |
|
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.
Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, Chmielowski B, Campbell KM, Bao R, Kelley H, Morris A, Mauro D, Wooldridge JE, Luke JJ, Weiner GJ, Krieg AM, Milhem MM |
Cancer Discovery | 2021 |
|
Transcriptomic Correlates of Immunologic Activation in Head and Neck and Cervical Cancer.
Saiz-Ladera C, Baliu-Piqué M, Cimas FJ, Manzano A, García-Barberán V, Camarero SC, Hinojal GF, Pandiella A, Győrffy B, Stewart D, Cruz-Hernández JJ, Pérez-Segura P, Ocana A |
Frontiers in Oncology | 2021 |
|
Prognostic significance of T-cell-inflamed gene expression profile and PD-L1 expression in patients with esophageal cancer.
Steiniche T, Rha SY, Chung HC, Georgsen JB, Ladekarl M, Nordsmark M, Jespersen ML, Kim HS, Kim H, Fein C, Tang LH, Wu T, Marton MJ, Peter S, Kelsen DP, Ku G |
Cancer Medicine | 2021 |
|
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration.
Hu-Lieskovan S, Braiteh F, Grilley-Olson JE, Wang X, Forgie A, Bonato V, Jacobs IA, Chou J, Johnson ML |
Targeted Oncology | 2021 |
|
Analysis of Sociodemographic, Clinical, and Genomic Factors Associated With Breast Cancer Mortality in the Linked Surveillance, Epidemiology, and End Results and Medicare Database.
Robinson TJ, Wilson LE, Marcom PK, Troester M, Lynch CF, Hernandez BY, Parrilla E, Brauer HA, Dinan MA |
2021 | |
|
Conditional Deletion of Pdcd1 Identifies the Cell-Intrinsic Action of PD-1 on Functional CD8 T Cell Subsets for Antitumor Efficacy.
Raghavan S, Tovbis-Shifrin N, Kochel C, Sawant A, Mello M, Sathe M, Blumenschein W, Muise ES, Chackerian A, Pinheiro EM, Rosahl TW, Luche H, de Waal Malefyt R |
Frontiers in immunology | 2021 |
|
A Multi-Omics Analysis of Metastatic Melanoma Identifies a Germinal Center-Like Tumor Microenvironment in HLA-DR-Positive Tumor Areas.
Gadeyne L, Van Herck Y, Milli G, Atak ZK, Bolognesi MM, Wouters J, Marcelis L, Minia A, Pliaka V, Roznac J, Alexopoulos LG, Cattoretti G, Bechter O, Oord JVD, De Smet F, Antoranz A, Bosisio FM |
Frontiers in Oncology | 2021 |
|
Elevated GAS2L3 Expression Correlates With Poor Prognosis in Patients With Glioma: A Study Based on Bioinformatics and Immunohistochemical Analysis.
Zhou Y, Zhang L, Song S, Xu L, Yan Y, Wu H, Tong X, Yan H |
Frontiers in Genetics | 2021 |
|
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study.
D'Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, Georges S, Ellers-Lenz B, Shah P, Güzel G, Nghiem P |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.
Isaacs J, Tan AC, Hanks BA, Wang X, Owzar K, Herndon JE 2nd, Antonia SJ, Piantadosi S, Khasraw M |
Clinical cancer research | 2021 |
|
Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R, He Y, Zhang H, Wang J, Liu X, Liu H, Wu H, Liang Z |
Frontiers in immunology | 2021 |
|
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification
Leader AM, Grout JA, Maier BB, Nabet BY, Park MD, Tabachnikova A, Chang C, Walker L, Lansky A, Le Berichel J, Troncoso L, Malissen N, Davila M, Martin JC, Magri G, Tuballes K, Zhao Z, Petralia F, Samstein R, D\u2019Amore NR, Thurston G, Kamphorst AO, Wolf A, Flores R, Wang P, Möller S, Mellman I, Beasley MB, Salmon H, Rahman AH, Marron TU, Kenigsberg E, Merad M |
Cancer Cell | 2021 |
|
HPV+ oropharyngeal squamous cell carcinomas from patients with two tumors display synchrony of viral genomes yet discordant mutational profiles and signatures.
Faden DL, Langenbucher A, Kuhs K, Lewis JS, Mirabello L, Yeager M, Boland JF, Bass S, Steinberg M, Cullen M, Lawrence MS, Ferris RL |
Carcinogenesis | 2021 |
|
Association Between Immune-Related Adverse Events and the Prognosis of Patients with Advanced Gastric Cancer Treated with Nivolumab.
Kono Y, Choda Y, Nakagawa M, Miyahara K, Ishida M, Kubota T, Seo K, Hirata T, Obayashi Y, Gotoda T, Moritou Y, Okikawa Y, Iwamoto Y, Okada H |
Targeted Oncology | 2021 |
|
Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma.
Yuan W, Tao R, Huang D, Yan W, Shen G, Ning Q |
Aging | 2021 |
|
Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS).
Rokni MB, Pointer KB, George J, Luke JJ, Chmura SJ, Redler G |
Journal of Applied Clinical Medical Physics | 2021 |
|
Baseline Modified Glasgow Prognostic Score Associated with Survival in Metastatic Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Brown JT, Liu Y, Shabto JM, Martini DJ, Ravindranathan D, Hitron EE, Russler GA, Caulfield S, Yantorni LB, Joshi SS, Kissick H, Ogan K, Harris WB, Carthon BC, Kucuk O, Master VA, Bilen MA |
The oncologist | 2021 |
|
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
Qu J, Mei Q, Liu L, Cheng T, Wang P, Chen L, Zhou J |
Therapeutic advances in medical oncology | 2021 |
|
LRP1B mutations are associated with favorable outcomes to immune checkpoint inhibitors across multiple cancer types.
Brown LC, Tucker MD, Sedhom R, Schwartz EB, Zhu J, Kao C, Labriola MK, Gupta RT, Marin D, Wu Y, Gupta S, Zhang T, Harrison MR, George DJ, Alva A, Antonarakis ES, Armstrong AJ |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
Ross-Macdonald P, Walsh AM, Chasalow SD, Ammar R, Papillon-Cavanagh S, Szabo PM, Choueiri TK, Sznol M, Wind-Rotolo M |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Upregulation of HOXC9 generates interferon-gamma resistance in gastric cancer by inhibiting the DAPK1/RIG1/STAT1 axis.
Tang Y, Wang T, Yu Y, Yan Y, Wu C |
Cancer Science | 2021 |
|
A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes.
Calagua C, Ficial M, Jansen CS, Hirz T, Del Balzo L, Wilkinson S, Lake R, Ku AT, Voznesensky O, Sykes DB, Saylor PJ, Ye H, Signoretti S, Kissick H, Sowalsky AG, Balk SP, Einstein DJ |
Clinical cancer research | 2021 |
|
Molecular determinants of response to PD-L1 blockade across tumor types.
Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, Maund S, Liu LF, Kadel E 3rd, Baldwin N, Jhunjhunwala S, Nickles D, Assaf ZJ, Bower D, Patil N, McCleland M, Shames D, Molinero L, Huseni M, Sanjabi S, Cummings C, Mellman I, Mariathasan S, Hegde P, Powles T |
Nature Communications | 2021 |
|
YKT6, as a potential predictor of prognosis and immunotherapy response for oral squamous cell carcinoma, is related to cell invasion, metastasis, and CD8+ T cell infiltration.
Yang Z, Yan G, Zheng L, Gu W, Liu F, Chen W, Cui X, Wang Y, Yang Y, Chen X, Fu Y, Xu X |
OncoImmunology | 2021 |
|
Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma.
Jia DD, Niu Y, Zhu H, Wang S, Ma T, Li T |
Frontiers in Oncology | 2021 |
|
Down-regulation of A20 promotes immune escape of lung adenocarcinomas.
Breitenecker K, Homolya M, Luca AC, Lang V, Trenk C, Petroczi G, Mohrherr J, Horvath J, Moritsch S, Haas L, Kurnaeva M, Eferl R, Stoiber D, Moriggl R, Bilban M, Obenauf AC, Ferran C, Dome B, Laszlo V, Győrffy B, Dezso K, Moldvay J, Casanova E, Moll HP |
Science Translational Medicine | 2021 |
|
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Diab A, Tykodi SS, Daniels GA, Maio M, Curti BD, Lewis KD, Jang S, Kalinka E, Puzanov I, Spira AI, Cho DC, Guan S, Puente E, Nguyen T, Hoch U, Currie SL, Lin W, Tagliaferri MA, Zalevsky J, Sznol M, Hurwitz ME |
Journal of Clinical Oncology | 2021 |
|
Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy.
Chen HZ, Bonneville R, Paruchuri A, Reeser JW, Wing MR, Samorodnitsky E, Krook MA, Smith AM, Dao T, Miya J, Wang W, Yu L, Freud AG, Allenby P, Cole S, Otterson G, Shields P, Carbone DP, Roychowdhury S |
2021 | |
|
Novel Immune Infiltrating Cell Signature Based on Cell Pair Algorithm Is a Prognostic Marker in Cancer.
Zhang H, Wang Z, Dai Z, Wu W, Cao H, Li S, Zhang N, Cheng Q |
Frontiers in immunology | 2021 |
|
Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer.
Brasó-Maristany F, Sansó M, Chic N, Martínez D, González-Farré B, Sanfeliu E, Ghiglione L, Carcelero E, Garcia-Corbacho J, Sánchez M, Soy D, Jares P, Peg V, Saura C, Muñoz M, Prat A, Vivancos A |
Frontiers in Oncology | 2021 |
|
Pan-Cancer Analysis Reveals That E1A Binding Protein p300 Mutations Increase Genome Instability and Antitumor Immunity.
Chen Z, Chen C, Li L, Zhang T, Wang X |
Frontiers in Cell and Developmental Biology | 2021 |
|
Computational Recognition and Clinical Verification of TGF-β-Derived miRNA Signature With Potential Implications in Prognosis and Immunotherapy of Intrahepatic Cholangiocarcinoma.
Liu Z, Weng S, Xu H, Wang L, Liu L, Zhang Y, Guo C, Dang Q, Xing Z, Lu T, Han X |
Frontiers in Oncology | 2021 |
|
Spatial Distribution of Immune Cells in Head and Neck Squamous Cell Carcinomas.
Idel C, Ribbat-Idel J, Klapper L, Krupar R, Bruchhage KL, Dreyer E, Rades D, Polasky C, Offermann A, Kirfel J, Perner S, Wollenberg B |
Frontiers in Oncology | 2021 |
|
A novel gene signature associated with poor response to chemoradiotherapy in patients with locally advanced cervical cancer.
Kim KH, Chang JS, Byun HK, Kim YB |
Journal of Gynecologic Oncology | 2021 |
|
Sex Disparities of Genomic Determinants in Response to Immune Checkpoint Inhibitors in Melanoma.
Shi F, Zhang W, Yang Y, Yang Y, Zhao J, Xie M, Sheng C, Wang S, Wang Q |
Frontiers in immunology | 2021 |
|
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, Lubeck Y, Seignette IM, Smit LA, Willems SM, van den Brekel MWM, Dirven R, Baris Karakullukcu M, Karssemakers L, Klop WMC, Lohuis PJFM, Schreuder WH, Smeele LE, van der Velden LA, Bing Tan I, Onderwater S, Jasperse B, Vogel WV, Al-Mamgani A, Keijser A, van der Noort V, Broeks A, Hooijberg E, Peeper DS, Schumacher TN, Blank CU, de Boer JP, Haanen JBAG, Zuur CL |
Nature Communications | 2021 |
|
CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment.
Guan X, Wang Y, Sun Y, Zhang C, Ma S, Zhang D, Li D, Jia W |
Journal of inflammation research | 2021 |
|
Identification of m6A Regulator-Associated Methylation Modification Clusters and Immune Profiles in Melanoma.
Du F, Li H, Li Y, Liu Y, Li X, Dang N, Chu Q, Yan J, Fang Z, Wu H, Zhang Z, Zhu X, Li X |
Frontiers in Cell and Developmental Biology | 2021 |
|
Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses.
Huang ZD, Liu ZZ, Liu YY, Fu YC, Lin LL, Hu C, Gu HY, Wei RX |
Frontiers in immunology | 2021 |
|
Stage-stratified molecular profiling of non-muscle-invasive bladder cancer enhances biological, clinical, and therapeutic insight.
Hurst CD, Cheng G, Platt FM, Castro MAA, Marzouka NS, Eriksson P, Black EVI, Alder O, Lawson ARJ, Lindskrog SV, Burns JE, Jain S, Roulson JA, Brown JC, Koster J, Robertson AG, Martincorena I, Dyrskjøt L, Höglund M, Knowles MA |
Cell reports. Medicine | 2021 |
|
Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings.
Dobriyan A, Gluck I, Alon E, Barshack I, Yahalom R, Vered M |
2021 | |
|
Novel non-terminal tumor sampling procedure using fine needle aspiration supports immuno-oncology biomarker discovery in preclinical mouse models.
Sitnikova SI, Munnings-Tomes S, Galvani E, Kentner S, Mulgrew K, Rands C, España Agustí J, Zhang T, Ilieva KM, Rosignoli G, Ghadially H, Robinson MJ, Slidel T, Wilkinson RW, Dovedi SJ |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Single-cell analysis of regions of interest (SCARI) using a photosensitive tag.
van der Leun AM, Hoekstra ME, Reinalda L, Scheele CLGJ, Toebes M, van de Graaff MJ, Chen LYY, Li H, Bercovich A, Lubling Y, David E, Thommen DS, Tanay A, van Rheenen J, Amit I, van Kasteren SI, Schumacher TN |
Nature Chemical Biology | 2021 |
|
Landscape of Immune Microenvironment Under Immune Cell Infiltration Pattern in Breast Cancer.
Xu Q, Chen S, Hu Y, Huang W |
Frontiers in immunology | 2021 |
|
CALD1 promotes the expression of PD-L1 in bladder cancer via the JAK/STAT signaling pathway.
Li C, Yang F, Wang R, Li W, Maskey N, Zhang W, Guo Y, Liu S, Wang H, Yao X |
Annals of translational medicine | 2021 |
|
Identification of Pathway-Based Biomarkers with Crosstalk Analysis for Overall Survival Risk Prediction in Breast Cancer.
Liu X, Su L, Li J, Ou G |
Frontiers in Genetics | 2021 |
|
Development of an immune-related signature for predicting survival outcome and immunotherapy response in osteosarcoma.
Wang Q, Zhang W, Guo Y, Li Y, Fu K |
Aging | 2021 |
|
Pyroptosis-related gene mediated modification patterns and immune cell infiltration landscapes in cutaneous melanoma to aid immunotherapy.
Meng J, Huang X, Qiu Y, Zheng X, Huang J, Wen Z, Yao J |
Aging | 2021 |
|
Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy.
Yang S, Cheng Y, Wang X, Wei P, Wang H, Tan S |
Frontiers in Genetics | 2021 |
|
Identification of immune subtypes of Ph-neg B-ALL with ferroptosis related genes and the potential implementation of Sorafenib.
Hong Y, Zhang L, Tian X, Xiang X, Yu Y, Zeng Z, Cao Y, Chen S, Sun A |
BMC Cancer | 2021 |
|
Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer
Poma AM, Bruno R, Pietrini I, Alì G, Pasquini G, Proietti A, Vasile E, Cappelli S, Chella A, Fontanini G |
Cancers | 2021 |
|
Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy
Reschke R, Gussek P, Boldt A, Sack U, Köhl U, Lordick F, Gora T, Kreuz M, Reiche K, Simon JC, Ziemer M, Kunz M |
International journal of molecular sciences | 2021 |
|
Refining patient selection for breast cancer immunotherapy: beyond PD-L1
Kossai M, Radosevic-Robin N, Penault-Llorca F |
ESMO Open | 2021 |
|
Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score
Liu SY, Sun H, Zhou JY, Zhang JT, Yin K, Chen ZH, Su J, Zhang XC, Yang JJ, Zhou Q, Tu HY, Wu YL |
Translational oncology | 2021 |
|
Tumor suppressor immune gene therapy to reverse immunotherapy resistance
Chada S, Wiederhold D, Menander KB, Sellman B, Talbott M, Nemunaitis JJ, Ahn HM, Jung BK, Yun CO, Sobol RE |
Cancer Gene Therapy | 2021 |
|
Synthetic lethality-mediated precision oncology via the tumor transcriptome
Lee JS, Nair NU, Dinstag G, Chapman L, Chung Y, Wang K, Sinha S, Cha H, Kim D, Schperberg AV, Srinivasan A, Lazar V, Rubin E, Hwang S, Berger R, Beker T, Ronai Z, Hannenhalli S, Gilbert MR, Kurzrock R, Lee SH, Aldape K, Ruppin E |
Cell | 2021 |
|
Bioreductive prodrug PR-104 improves the tumour distribution and titre of the nitroreductase-armed oncolytic adenovirus ONYX-411NTR leading to therapeutic benefit.
Singleton DC, Mowday AM, Guise CP, Syddall SP, Bai SY, Li D, Ashoorzadeh A, Smaill JB, Wilson WR, Patterson AV |
Cancer Gene Therapy | 2021 |
|
Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer
Wang Y, Jiao X, Li S, Chen H, Wei X, Liu C, Gong J, Zhang X, Wang X, Peng Z, Qi C, Wang Z, Wang Y, Zhuo N, Zou J, Zhang H, Li J, Shen L, Lu Z |
Cancer biology & medicine | 2021 |
|
Distinct biomarker profiles and TCR sequence diversity characterize the response to PD-L1 blockade in a mouse melanoma model
Meskini RE, Atkinson D, Kulaga A, Abdelmaksoud A, Gumprecht M, Pate N, Hayes S, Oberst M, Kaplan IM, Raber P, Dyke TV, Sharan SK, Hollingsworth R, Day CP, Merlino G, Ohler ZW |
Molecular cancer research : MCR | 2021 |
|
Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker
E Fountzilas, R Kurzrock, HH Vo, AM Tsimberidou |
JNCI Journal of the National Cancer Institute | 2021 |
|
B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
Miyamoto T, Murakami R, Hamanishi J, Tanigaki K, Hosoe Y, Mise N, Takamatsu S, Mise Y, Ukita M, Taki M, Yamanoi K, Horikawa N, Abiko K, Yamaguchi K, Baba T, Matsumura N, Mandai M |
Cancer immunology research | 2021 |
|
TMB and Inflammatory Gene Expression Associated with Clinical Outcomes following Immunotherapy in Advanced Melanoma.
Hodi FS, Wolchok JD, Schadendorf D, Larkin J, Long GV, Qian X, Saci A, Young TC, Srinivasan S, Chang H, Tang H, Wind-Rotolo M, Rizzo JI, Jackson DG, Ascierto PA |
Cancer immunology research | 2021 |
|
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnović Ž, Vasev N, Ma L, Richards DA, Wilks ST, Milenković D, Xiao J, Sorrentino J, Horton J, O'Shaughnessy J |
Clinical cancer research | 2021 |
|
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib.
Brase JC, Walter RFH, Savchenko A, Gusenleitner D, Garrett J, Schimming T, Varaljai R, Castelletti D, Kim J, Dakappagari N, Schultz K, Robert C, Long GV, Nathan PD, Ribas A, Flaherty KT, Karaszewska B, Schachter J, Sucker A, Schmid KW, Zimmer L, Livingstone E, Gasal E, Schadendorf D, Roesch A |
Clinical cancer research | 2021 |
|
Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity.
Zhou X, Singh M, Sanz Santos G, Guerlavais V, Carvajal LA, Aivado M, Zhan Y, Oliveira MMS, Westerberg LS, Annis DA, Johnsen JI, Selivanova G |
Cancer Discovery | 2021 |
|
First-in-Class Anti-immunoglobulin-like Transcript 4 Myeloid-Specific Antibody MK-4830 Abrogates a PD-1 Resistance Mechanism in Patients with Advanced Solid Tumors.
Siu LL, Wang D, Hilton J, Geva R, Rasco D, Perets R, Abraham AK, Wilson DC, Markensohn JF, Lunceford J, Suttner L, Siddiqi S, Altura RA, Maurice-Dror C |
Clinical cancer research | 2021 |
|
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Pusztai L, Yau C, Wolf DM, Han HS, Du L, Wallace AM, String-Reasor E, Boughey JC, Chien AJ, Elias AD, Beckwith H, Nanda R, Albain KS, Clark AS, Kemmer K, Kalinsky K, Isaacs C, Thomas A, Shatsky R, Helsten TL, Forero-Torres A, Liu MC, Brown-Swigart L, Petricoin EF, Wulfkuhle JD, Asare SM, Wilson A, Singhrao R, Sit L, Hirst GL, Berry S, Sanil A, Asare AL, Matthews JB, Perlmutter J, Melisko M, Rugo HS, Schwab RB, Symmans WF, Yee D, van \u2018t Veer LJ, Hylton NM, DeMichele AM, Berry DA, Esserman LJ |
Cancer Cell | 2021 |
|
Overcoming Intrinsic Resistance of Cancer Cells to CAR T-Cell Killing
Lemoine J, Ruella M, Houot R |
Clinical cancer research | 2021 |
|
DNA hyper-methylation during Tuberculosis dampens host immune responsiveness
Andrew DiNardo, Kimal Rajapakshe, Tomoki Nishiguchi, Godwin Mtetwa, Sandra L. Grimm, Qiniso Dlamini, Jaquiline Kahari, Sanjana Mahapatra, Alexander W. Kay, Gugu Maphalala, Emily M. Mace, George Makedonas, Jeffrey D. Cirillo, Mihai Netea, Reinout van Crevel, Cristian Coarfa, Anna M. Mandalakas |
Journal of Clinical Investigation | 2020 |
|
Multi-omic analysis and immunoprofiling reveals distinct subtypes of human angiosarcoma
Jason Yongsheng Chan, Jing Quan Lim, Joe Poh Sheng Yeong, Vinod Ravi, Peiyong Guan, Arnoud Boot, Timothy Kwang Yong Tay, Sathiyamoorthy Selvarajan, Nur Diyana Md Nasir, Jie Hua Loh, Choon Kiat Ong, Dachuan Huang, Jing Tan, Zhimei li, Cedric Chuan-Young Ng, Thuan Tong Tan, Mikio Masuzawa, Wing-Kin Sung, Mohamad Farid, Richard Hong Hui Quek, Ngian Chye Tan, Melissa Ching Ching Teo, Steven G. Rozen, Patrick Tan, Andrew FUTREAL, Bin Tean Teh, Khee Chee Soo |
Journal of Clinical Investigation | 2020 |
|
Immune profiling of pediatric solid tumors
Rachael L Terry, Deborah Meyran, David S. Ziegler, Michelle Haber, Paul G. Ekert, Joseph A Trapani, Paul J Neeson |
Journal of Clinical Investigation | 2020 |
|
Tumor genotype, location and malignant potential shape the immunogenicity of primary, untreated Gastrointestinal Stromal Tumors
Daniela Gasparotto, Marta Sbaraglia, Sabrina Rossi, Davide Baldazzi, Monica Brenca, Alessia Mondello, Federica Nardi, Dominga Racanelli, Matilde Cacciatore, Angelo Paolo Dei Tos, Roberta Maestro |
JCI Insight | 2020 |
|
The Capacity of the Ovarian Cancer Tumor Microenvironment to Integrate Inflammation Signaling Conveys a Shorter Disease-free Interval
KR Jordan, MJ Sikora, JE Slansky, A Minic, JK Richer, MR Moroney, J Hu, RJ Wolsky, ZL Watson, TM Yamamoto, JC Costello, A Clauset, K Behbakht, TR Kumar, BG Bitler |
Clinical cancer research | 2020 |
|
Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
Z Lu, H Chen, S Li, J Gong, J Li, J Zou, L Wu, J Yu, W Han, H Sun, , X Zhang, Z Peng, M Lu, Z Wang, H Zhang, L Shen |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
EJ Lampert, A Cimino-Mathews, JS Lee, J Nair, MJ Lee, A Yuno, D An, JB Trepel, E Ruppin, JM Lee |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer
D Zeng, Z Ye, J Wu, R Zhou, X Fan, G Wang, Y Huang, J Wu, H Sun, M Wang, J Bin, Y Liao, N Li, M Shi, W Liao |
Theranostics | 2020 |
|
Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft
JJ Morton, N Alzofon, SB Keysar, TS Chimed, J Reisinger, L Perrenoud, PN Le, C Nieto, K Gomez, B Miller, R Yeager, D Gao, AC Tan, H Somerset, T Medina, XJ Wang, JH Wang, W Robinson, DR Roop, R Gonzalez, A Jimeno |
Molecular cancer research : MCR | 2020 |
|
CD8 + T-cell–Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas
JR Kane, J Zhao, T Tsujiuchi, B Laffleur, VA Arrieta, A Mahajan, G Rao, A Mela, C Dmello, L Chen, DY Zhang, E González-Buendia, C Lee-Chang, T Xiao, G Rothschild, U Basu, C Horbinski, MS Lesniak, AB Heimberger, R Rabadan, P Canoll, AM Sonabend |
Clinical cancer research | 2020 |
|
PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
XD Liu, W Kong, CB Peterson, DJ McGrail, A Hoang, X Zhang, T Lam, PG Pilie, H Zhu, KE Beckermann, SM Haake, S Isgandrova, M Martinez-Moczygemba, N Sahni, NM Tannir, SY Lin, WK Rathmell, E Jonasch |
Nature Communications | 2020 |
|
Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin + cell abundance
Q Zhou, Z Wang, H Zeng, H Zhang, Z Liu, Q Huang, J Wang, Y Chang, Q Bai, L Liu, Y Zhu, L Xu, B Dai, J Guo, Y Xia, Y Wang, J Xu |
OncoImmunology | 2020 |
|
Comprehensive Immune Profiling of Medullary Thyroid Cancer
N Pozdeyev, TA Erickson, L Zhang, K Ellison, CJ Rivard, S Sams, FR Hirsch, BR Haugen, JD French |
Thyroid | 2020 |
|
Effective Anti-tumor Response by TIGIT Blockade Associated With FcγR Engagement and Myeloid Cell Activation
JH Han, M Cai, J Grein, S Perera, H Wang, M Bigler, R Ueda, TW Rosahl, E Pinheiro, D LaFace, W Seghezzi, SM Williams |
Frontiers in immunology | 2020 |
|
Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
V Petrova, I Arkhypov, R Weber, C Groth, P Altevogt, J Utikal, V Umansky |
International journal of molecular sciences | 2020 |
|
Real-time metabolic profiling of oesophageal tumours reveals an altered metabolic phenotype to different oxygen tensions and to treatment with Pyrazinib
AM Buckley, MR Dunne, ME Morrissey, SA Kennedy, A Nolan, M Davern, EK Foley, N Clarke, J Lysaght, N Ravi, D OToole, F MacCarthy, JV Reynolds, BN Kennedy, J OSullivan |
Scientific Reports | 2020 |
|
Natural killer cells in cancer biology and therapy
SY Wu, T Fu, YZ Jiang, ZM Shao |
Molecular Cancer | 2020 |
|
Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment
A Busse, LH Mochmann, C Spenke, R Arsenic, F Briest, K Jöhrens, H Lammert, B Sipos, AA Kühl, R Wirtz, M Pavel, M Hummel, D Kaemmerer, RP Baum, P Grabowski |
Cancers | 2020 |
|
Tailoring precision immunotherapy: coming to a clinic soon?
S Han, WH Shuen, WW Wang, E Nazim, HC Toh |
ESMO Open | 2020 |
|
Tumor immune microenvironment in head and neck cancers
SM Chen, AL Krinsky, RA Woolaver, X Wang, Z Chen, JH Wang |
Molecular Carcinogenesis | 2020 |
|
Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy
X Zhang, M Shi, T Chen, B Zhang |
Molecular Therapy — Nucleic Acids | 2020 |
|
Association of MSH2 Expression With Tumor Mutational Burden and the Immune Microenvironment in Lung Adenocarcinoma
M Jia, L Yao, Q Yang, T Chi |
Frontiers in Oncology | 2020 |
|
Why the Outcome of Anti‐Tumor Immune Responses is Heterogeneous: A Novel Idea in the Context of Immunological Heterogeneity in Cancers
JH Wang |
BioEssays : news and reviews in molecular, cellular and developmental biology | 2020 |
|
Tumor Microenvironments in Organs: From the Brain to the Skin – Part B
A Birbrair |
2020 | |
|
The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell–Mediated Immunotherapies
S Varghese, S Pramanik, LJ Williams, HR Hodges, CW Hudgens, GM Fischer, CK Luo, B Knighton, L Tan, PL Lorenzi, AL Mackinnon, JL McQuade, Y Hailemichael, J Roszik, W Peng, YN Gopal |
Molecular cancer therapeutics | 2020 |
|
Tumor Microenvironment
PP Lee, FM Marincola |
Tumor Microenvironment | 2020 |
|
Determinants of Resistance to Checkpoint Inhibitors
L Tran, D Theodorescu |
International journal of molecular sciences | 2020 |
|
Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment
A Titov, A Valiullina, E Zmievskaya, E Zaikova, A Petukhov, R Miftakhova, E Bulatov, A Rizvanov |
Cancers | 2020 |
|
Toll-Like Receptor 9 Agonists in Cancer L Karapetyan, JJ Luke, D Davar |
OncoTargets and therapy | 2020 |
|
Nanovaccine administration route is critical to obtain pertinent iNKt cell help for robust anti-tumor T and B cell responses
Y Dölen, M Valente, O Tagit, E Jäger, EA Dinther, NK van Riessen, M Hruby, U Gileadi, V Cerundolo, CG Figdor |
OncoImmunology | 2020 |
|
Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma
A Fröhlich, J Sirokay, S Fietz, TJ Vogt, J Dietrich, R Zarbl, M Florin, P Kuster, G Saavedra, SR Valladolid, F Hoffmann, L Flatz, SS Ring, C Golletz, T Pietsch, S Strieth, P Brossart, GH Gielen, G Kristiansen, F Bootz, J Landsberg, D Dietrich |
EBioMedicine | 2020 |
|
Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response
CS Garris, JJ Luke |
Clinical cancer research | 2020 |
|
Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
H Sun, SY Liu, JY Zhou, JT Xu, HK Zhang, HH Yan, JJ Huan, PP Dai, CR Xu, J Su, YF Guan, X Yi, RS Yu, WZ Zhong, YL Wu |
EBioMedicine | 2020 |
|
Roles of IFN-γ in tumor progression and regression: a review
D Jorgovanovic, M Song, L Wang, Y Zhang |
Biomarker Research | 2020 |
|
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia
J Vadakekolathu, MD Minden, T Hood, SE Church, S Reeder, H Altmann, AH Sullivan, EJ Viboch, T Patel, N Ibrahimova, SE Warren, A Arruda, Y Liang, TH Smith, GA Foulds, MD Bailey, J Gowen-MacDonald, J Muth, M Schmitz, A Cesano, AG Pockley, PJ Valk, B Löwenberg, M Bornhäuser, SK Tasian, MP Rettig, JK Davidson-Moncada, JF DiPersio, S Rutella |
Science Translational Medicine | 2020 |
|
Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort
KG Mitchell, L Diao, T Karpinets, MV Negrao, HT Tran, ER Parra, EM Corsini, A Reuben, L Federico, C Bernatchez, H Dejima, A Francisco-Cruz, J Wang, MB Antonoff, AA Vaporciyan, SG Swisher, T Cascone, II Wistuba, JV Heymach, DL Gibbons, J Zhang, CL Haymaker, B Sepesi |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy Response
S Cheng, EJ Cheadle, TM Illidge |
Cancers | 2020 |
|
Cancer immune control needs senescence induction by interferon-dependent cell cycle regulator pathways in tumours
E Brenner, BF Schörg, F Ahmetlić, T Wieder, FJ Hilke, N Simon, C Schroeder, G Demidov, T Riedel, B Fehrenbacher, M Schaller, A Forschner, T Eigentler, H Niessner, T Sinnberg, KS Böhm, N Hömberg, H Braumüller, D Dauch, S Zwirner, L Zender, D Sonanini, A Geishauser, J Bauer, M Eichner, KJ Jarick, A Beilhack, S Biskup, D Döcker, D Schadendorf, L Quintanilla-Martinez, BJ Pichler, M Kneilling, R Mocikat, M Röcken |
Nature Communications | 2020 |
|
Comprehensive Genomic Profile of Heterogeneous Long Follow-Up Triple-Negative Breast Cancer and Its Clinical Characteristics Shows DNA Repair Deficiency Has Better Prognostic
E Rojas-Jiménez, JC Mejía-Gómez, C Díaz-Velásquez, R Quezada-Urban, HM Gregorio, F Vallejo-Lecuona, A de la Cruz-Montoya, FI Reyes, VM Pérez-Sánchez, HA Maldonado-Martínez, M Robles-Estrada, E Bargalló-Rocha, P Cabrera-Galeana, M Ramos-Ramírez, YI Chirino, LA Herrera, LI Terrazas, J Oliver, C Frecha, S Perdomo, F Vaca-Paniagua |
Genes & development | 2020 |
|
Neoadjuvant Immune-Checkpoint Blockade in Triple-Negative Breast Cancer: Current Evidence and Literature-Based Meta-Analysis of Randomized Trials
D Marinelli, M Mazzotta, L Pizzuti, E Krasniqi, T Gamucci, C Natoli, A Grassadonia, N Tinari, S Tomao, I Sperduti, G Sanguineti, A Botticelli, A Fabbri, C Botti, G Ciliberto, M Barba, P Vici |
Cancers | 2020 |
|
Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
MG Navarrete-Bernal, MG Cervantes-Badillo, JF Martínez-Herrera, CO Lara-Torres, R Gerson-Cwilich, A Zentella-Dehesa, M de Jesús Ibarra-Sánchez, J Esparza-López, JJ Montesinos, VA Cortés-Morales, D Osorio-Pérez, DA Villegas-Osorno, E Reyes-Sánchez, P Salazar-Sojo, LF Tallabs-Utrilla, S Romero-Córdoba, L Rocha-Zavaleta |
Frontiers in Oncology | 2020 |
|
The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences
JW Pan, MM Zabidi, PS Ng, MY Meng, SN Hasan, B Sandey, SJ Sammut, CH Yip, P Rajadurai, OM Rueda, C Caldas, SF Chin, SH Teo |
Nature Communications | 2020 |
|
Hyperprogression: A novel response pattern under immunotherapy
X Han, A Alu, Y Xiao, Y Wei, X Wei |
Clinical and Translational Medicine | 2020 |
|
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis
S Kato, QY Weng, ML Insco, KY Chen, S Muralidhar, J Pozniak, JM Diaz, Y Drier, N Nguyen, JA Lo, E van Rooijen, LV Kemeny, Y Zhan, Y Feng, W Silkworth, CT Powell, BB Liau, Y Xiong, J Jin, J Newton-Bishop, LI Zon, BE Bernstein, DE Fisher |
Cancer Discovery | 2020 |
|
Eicosanoids in Cancer: New Roles in Immunoregulation
AM Johnson, EK Kleczko, RA Nemenoff |
Frontiers in pharmacology | 2020 |
|
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
AP Algazi, CG Twitty, KK Tsai, M Le, R Pierce, E Browning, R Hermiz, DA Canton, D Bannavong, A Oglesby, M Francisco, L Fong, MJ Pittet, SP Arlauckas, C Garris, LP Levine, C Bifulco, C Ballesteros-Merino, S Bhatia, S Gargosky, RH Andtbacka, BA Fox, MD Rosenblum, AI Daud |
Clinical cancer research | 2020 |
|
Collagen-binding IL-12 enhances tumour inflammation and drives the complete remission of established immunologically cold mouse tumours
A Mansurov, J Ishihara, P Hosseinchi, L Potin, TM Marchell, A Ishihara, JM Williford, AT Alpar, MM Raczy, LT Gray, MA Swartz, JA Hubbell |
Nature Biomedical Engineering | 2020 |
|
Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti–PD-1 antibody in patients with mesothelioma and mouse tumor models
Q Jiang, A Ghafoor, I Mian, D Rathkey, A Thomas, C Alewine, M Sengupta, MA Ahlman, J Zhang, B Morrow, SM Steinberg, I Pastan, R Hassan |
Science Translational Medicine | 2020 |
|
B cells and tertiary lymphoid structures promote immunotherapy response
BA Helmink, SM Reddy, J Gao, S Zhang, R Basar, R Thakur, K Yizhak, M Sade-Feldman, J Blando, G Han, V Gopalakrishnan, , H Zhao, RN Amaria, HA Tawbi, AP Cogdill, W Liu, VS LeBleu, FG Kugeratski, S Patel, MA Davies, P Hwu, JE Lee, JE Gershenwald, A Lucci, R Arora, S Woodman, EZ Keung, PO Gaudreau, A Reuben, CN Spencer, EM Burton, LE Haydu, AJ Lazar, R Zapassodi, CW Hudgens, DA Ledesma, SF Ong, M Bailey, S Warren, D Rao, O Krijgsman, EA Rozeman, D Peeper, CU Blank, TN Schumacher, LH Butterfield, MA Zelazowska, KM McBride, R Kalluri, J Allison, F Petitprez, WH Fridman, C Sautès-Fridman, N Hacohen, K Rezvani, P Sharma, MT Tetzlaff, L Wang, JA Wargo |
Nature | 2020 |
|
Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
M Ralli, A Botticelli, IC Visconti, D Angeletti, M Fiore, P Marchetti, A Lambiase, M de Vincentiis, A Greco |
Journal of Immunology Research | 2020 |
|
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
Z Lu, Z Peng, C Liu, Z Wang, Y Wang, , J Li, L Shen |
2020 | |
|
Immune Landscape in Tumor Microenvironment: Implications for Biomarker Development and Immunotherapy
K Pérez-Romero, RM Rodríguez, A Amedei, G Barceló-Coblijn, DH Lopez |
International journal of molecular sciences | 2020 |
|
The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment
K Hudson, N Cross, N Jordan-Mahy, R Leyland |
Frontiers in immunology | 2020 |
|
ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer
J Zhang, N Zhou, A Lin, P Luo, X Chen, H Deng, S Kang, L Guo, W Zhu, J Zhang |
Cancer Immunology, Immunotherapy | 2020 |
|
HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors
KH Song, SJ Oh, S Kim, H Cho, HJ Lee, JS Song, JY Chung, E Cho, J Lee, S Jeon, C Yee, KM Lee, SM Hewitt, JH Kim, SR Woo, TW Kim |
Nature Communications | 2020 |
|
Identification of an Immune-Related Gene Signature Based on Immunogenomic Landscape Analysis to Predict the Prognosis of Adult Acute Myeloid Leukemia Patients
R Zhu, H Tao, W Lin, L Tang, Y Hu |
Frontiers in Oncology | 2020 |
|
From single gene analysis to single cell profiling: a new era for precision medicine
MT Martino, S Meschini, K Scotlandi, C Riganti, ED Smaele, F Zazzeroni, M Donadelli, C Leonetti, M Caraglia |
Journal of Experimental & Clinical Cancer Research | 2020 |
|
Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors
M Dosset, EL Joseph, TR Vargas, L Apetoh |
Cells | 2020 |
|
A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival
T Turan, S Kongpachith, K Halliwill, J Roelands, W Hendricks, FM Marincola, TJ Hudson, HJ Jacob, D Bedognetti, J Samayoa, M Ceccarelli |
British Journal of Cancer | 2020 |
|
The Resistance Mechanisms of Lung Cancer Immunotherapy
F Wang, S Wang, Q Zhou |
Frontiers in Oncology | 2020 |
|
Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma
O Melaiu, M Chierici, V Lucarini, G Jurman, LA Conti, RD Vito, R Boldrini, L Cifaldi, A Castellano, C Furlanello, V Barnaba, F Locatelli, D Fruci |
Nature Communications | 2020 |
|
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
DY Oh, SS Kwek, SS Raju, T Li, E McCarthy, E Chow, D Aran, A Ilano, CC Pai, C Rancan, K Allaire, A Burra, Y Sun, MH Spitzer, S Mangul, S Porten, MV Meng, TW Friedlander, CJ Ye, L Fong |
Cell | 2020 |
|
Liver Cancer Immunity
S Rizvi, J Wang, AB ElKhoueiry |
Hepatology | 2020 |
|
The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation
SS Ng, FD Rivera, J Yan, D Corvino, I Das, P Zhang, R Kuns, SB Chauhan, J Hou, XY Li, TC Frame, BA McEnroe, E Moore, J Na, JA Engel, MS Soon, B Singh, AJ Kueh, MJ Herold, MM de Oca, SS Singh, PT Bunn, AR Aguilera, M Casey, M Braun, N Ghazanfari, S Wani, Y Wang, FH Amante, CL Edwards, A Haque, WC Dougall, OP Singh, AG Baxter, MW Teng, A Loukas, NL Daly, N Cloonan, MA Degli-Esposti, J Uzonna, WR Heath, T Bald, SK Tey, K Nakamura, GR Hill, R Kumar, S Sundar, MJ Smyth, CR Engwerda |
Nature Immunology | 2020 |
|
Improving the therapeutic index in adoptive cell therapy: key factors that impact efficacy
E Wang, A Cesano, LH Butterfield, F Marincola |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Characterizing heterogeneity of non‐small cell lung tumour microenvironment to identify signature prognostic genes
K Mi, F Chen, Z Qian, J Chen, D Lv, C Zhang, Y Xu, H Wang, Y Zhang, Y Jiang, D Shang |
Journal of Cellular and Molecular Medicine | 2020 |
|
Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy
JD Butner, D Elganainy, CX Wang, Z Wang, SH Chen, NF Esnaola, R Pasqualini, W Arap, DS Hong, J Welsh, EJ Koay, V Cristini |
Science Advances | 2020 |
|
Transcriptomic Features of T Cell-Barren Tumors Are Conserved Across Diverse Tumor Types
ED Routh, AK Pullikuth, G Jin, J Chifman, JW Chou, RB D'Agostino, K Seino, H Wada, CG Print, W Zhang, Y Lu, LD Miller |
Frontiers in immunology | 2020 |
|
Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient
G Rossi, A Russo, M Tagliamento, A Tuzi, O Nigro, G Vallome, C Sini, M Grassi, MG Bello, S Coco, L Longo, L Zullo, ET Tanda, C Dellepiane, P Pronzato, C Genova |
Cancers | 2020 |
|
Checkpoint inhibitor immunotherapy in kidney cancer
W Xu, MB Atkins, DF McDermott |
Nature Reviews Urology | 2020 |
|
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
K Choucair, S Morand, L Stanbery, G Edelman, L Dworkin, J Nemunaitis |
Cancer Gene Therapy | 2020 |
|
New biomarkers for checkpoint inhibitor therapy
N Burdett, J Desai |
ESMO Open | 2020 |
|
Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy
E Shklovskaya, H Rizos |
International journal of molecular sciences | 2020 |
|
Directing Traffic: How to Effectively Drive T Cells into Tumors
AJ Anandappa, CJ Wu, PA Ott |
Cancer Discovery | 2020 |
|
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma
P Mondello, S Tadros, M Teater, L Fontan, AY Chang, N Jain, H Yang, S Singh, HY Ying, CS Chu, MC Ma, E Toska, S Alig, M Durant, E de Stanchina, S Ghosh, A Mottok, L Nastoupil, SS Neelapu, O Weigert, G Inghirami, J Baselga, A Younes, C Yee, A Dogan, DA Scheinberg, RG Roeder, AM Melnick, MR Green |
Cancer Discovery | 2020 |
|
Progress Toward Identifying Exact Proxies for Predicting Response to Immunotherapies
A Filipovic, G Miller, J Bolen |
Frontiers in Cell and Developmental Biology | 2020 |
|
Predictive biomarkers of response to immune checkpoint inhibitors in melanoma
CA Nebhan, DB Johnson |
Expert Review of Anticancer Therapy | 2020 |
|
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
S Hu-Lieskovan, S Bhaumik, K Dhodapkar, JC Grivel, S Gupta, BA Hanks, S Janetzki, TO Kleen, Y Koguchi, AW Lund, C Maccalli, YD Mahnke, RD Novosiadly, SR Selvan, T Sims, Y Zhao, HT Maecker |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)
W You, B Shang, J Sun, X Liu, L Su, S Jiang |
Oncology reports | 2020 |
|
FIP200 Suppresses Immune Checkpoint Therapy Responses in Breast Cancers by Limiting AZI2/TBK1/IRF Signaling Independent of Its Canonical Autophagy Function
T Okamoto, SK Yeo, M Hao, MR Copley, MA Haas, S Chen, JL Guan |
Cancer research | 2020 |
|
The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
Y Tang, P Zhang, Y Wang, J Wang, M Su, Y Wang, L Zhou, J Zhou, W Xiong, Z Zeng, Y Zhou, S Nie, Q Liao |
Frontiers in immunology | 2020 |
|
Comprehensive investigation of T and B cell receptor repertoires in an MC38 tumor model following murine anti‑PD‑1 administration
L Zhang, IM Wang, N Solban, R Cristescu, G Zeng, B Long |
Molecular medicine reports | 2020 |
|
Anti-tumour immunity induces aberrant peptide presentation in melanoma
O Bartok, A Pataskar, R Nagel, M Laos, E Goldfarb, D Hayoun, R Levy, PR Körner, IZ Kreuger, J Champagne, EA Zaal, OB Bleijerveld, X Huang, J Kenski, J Wargo, A Brandis, Y Levin, O Mizrahi, M Alon, S Lebon, W Yang, MM Nielsen, N Stern-Ginossar, M Altelaar, CR Berkers, T Geiger, DS Peeper, J Olweus, Y Samuels, R Agami |
Nature | 2020 |
|
Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types
R Bao, D Stapor, JJ Luke |
Genome Medicine | 2020 |
|
A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response
D Xiong, Y Wang, M You |
Nature Communications | 2020 |
|
Deep neural network classification based on somatic mutations potentially predicts clinical benefit of immune checkpoint blockade in lung adenocarcinoma
J Peng, D Zou, W Gong, S Kang, L Han |
OncoImmunology | 2020 |
|
Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomes
T Lu, S Wang, L Xu, Q Zhou, N Singla, J Gao, S Manna, L Pop, Z Xie, M Chen, JJ Luke, J Brugarolas, R Hannan, T Wang |
Science Immunology | 2020 |
|
Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation
V Indio, G Ravegnini, A Astolfi, M Urbini, M Saponara, AD Leo, E Gruppioni, G Tarantino, S Angelini, A Pession, MA Pantaleo, M Nannini |
Frontiers in immunology | 2020 |
|
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
JH Lee, E Shklovskaya, SY Lim, MS Carlino, AM Menzies, A Stewart, B Pedersen, M Irvine, S Alavi, JY Yang, D Strbenac, RP Saw, JF Thompson, JS Wilmott, RA Scolyer, GV Long, RF Kefford, H Rizos |
Nature Communications | 2020 |
|
High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations
Q Wang, Y Yang, M Yang, X Li, K Chen |
Aging | 2020 |
|
Moving towards Personalized Medicine in Muscle-Invasive Bladder Cancer: Where Are We Now and Where Are We Going?
JC Pardo, VR de Porras, A Plaja, C Carrato, O Etxaniz, O Buisan, A Font |
International journal of molecular sciences | 2020 |
|
Toward Systems Biomarkers of Response to Immune Checkpoint Blockers
Ó Lapuente-Santana, F Eduati |
Frontiers in Oncology | 2020 |
|
Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
Y Jing, J Liu, Y Ye, L Pan, H Deng, Y Wang, Y Yang, L Diao, SH Lin, GB Mills, G Zhuang, X Xue, L Han |
Nature Communications | 2020 |
|
Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
EJ Crosby, CR Acharya, AF Haddad, CA Rabiola, G Lei, JP Wei, XY Yang, T Wang, CX Liu, KU Wagner, WJ Muller, LA Chodosh, G Broadwater, T Hyslop, JH Shepherd, DP Hollern, X He, CM Perou, S Chai, BK Ashby, BG Vincent, JC Snyder, J Force, MA Morse, HK Lyerly, ZC Hartman |
Clinical cancer research | 2020 |
|
Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma
A Gokuldass, A Draghi, K Papp, TH Borch, M Nielsen, MC Westergaard, R Andersen, A Schina, KF Bol, CA Chamberlain, M Presti, Ö Met, K Harbst, M Lauss, S Soraggi, I Csabai, Z Szállási, G Jönsson, IM Svane, M Donia |
Cancers | 2020 |
|
Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis
X Wang, Z Chai, Y Li, F Long, Y Hao, G Pan, M Liu, B Li |
Genes & development | 2020 |
|
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
J Vadakekolathu, C Lai, S Reeder, SE Church, T Hood, A Lourdusamy, MP Rettig, I Aldoss, AS Advani, J Godwin, MJ Wieduwilt, M Arellano, J Muth, TO Yau, F Ravandi, K Sweet, H Altmann, GA Foulds, F Stölzel, JM Middeke, M Ciciarello, A Curti, PJ Valk, B Löwenberg, I Gojo, M Bornhäuser, JF DiPersio, JK Davidson-Moncada, S Rutella |
Blood Advances | 2020 |
|
Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma—An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer
RU Wahl, M Leijs, A Araujo, A Rübben |
International journal of molecular sciences | 2020 |
|
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study
D Zamarin, RA Burger, MW Sill, DJ Powell, HA Lankes, MD Feldman, O Zivanovic, C Gunderson, E Ko, C Mathews, S Sharma, AR Hagemann, S Khleif, C Aghajanian |
Journal of Clinical Oncology | 2020 |
|
Human T cells employ conserved AU‐rich elements to fine‐tune IFN‐γ production
JJ Heeren, B Popović, A Guislain, MC Wolkers |
European Journal of Immunology | 2020 |
|
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
HH Ng, RY Lee, S Goh, IS Tay, X Lim, B Lee, V Chew, H Li, B Tan, S Lim, JC Lim, B Au, JJ Loh, S Saraf, JE Connolly, T Loh, WQ Leow, JJ Lee, HC Toh, F Malavasi, SY Lee, P Chow, EW Newell, SP Choo, D Tai, J Yeong, TK Lim |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer
E Crespo-Rodriguez, K Bergerhoff, G Bozhanova, S Foo, EC Patin, H Whittock, R Buus, S Haider, G Muirhead, K Thway, K Newbold, RS Coffin, RG Vile, D Kim, M McLaughlin, AA Melcher, KJ Harrington, M Pedersen |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Immuno-Oncology Biomarkers for Personalized Immunotherapy in Breast Cancer
V Vafaizadeh, Z Barekati |
Frontiers in Cell and Developmental Biology | 2020 |
|
Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy
MD Hellmann, PA Jänne, M Opyrchal, N Hafez, LE Raez, DI Gabrilovich, F Wang, JB Trepel, MJ Lee, A Yuno, S Lee, S Brouwer, S Sankoh, L Wang, D Tamang, EV Schmidt, ML Meyers, SS Ramalingam, E Shum, P Ordentlich |
Clinical cancer research | 2020 |
|
A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma
W Guo, J Ma, S Guo, H Wang, S Wang, Q Shi, L Liu, T Zhao, F Yang, S Chen, J Chen, J Zhao, C Yu, X Yi, Y Yang, J Ma, Q Ni, G Zhu, T Gao, C Li |
Journal for ImmunoTherapy of Cancer | 2020 |
|
The cutting-edge progress of immune-checkpoint blockade in lung cancer
F Zhou, M Qiao, C Zhou |
Cellular and Molecular Immunology | 2020 |
|
Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma
F Hoffmann, R Zarbl, D Niebel, J Sirokay, A Fröhlich, C Posch, TA Holderried, P Brossart, G Saavedra, P Kuster, S Strieth, GH Gielen, SS Ring, J Dietrich, T Pietsch, L Flatz, G Kristiansen, J Landsberg, D Dietrich |
Clinical Epigenetics | 2020 |
|
Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma
Y Yao, Z Yan, S Lian, L Wei, C Zhou, D Feng, Y Zhang, J Yang, M Li, Y Chen |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma
IG Zizzari, C Napoletano, AD Filippo, A Botticelli, A Gelibter, F Calabrò, E Rossi, G Schinzari, F Urbano, G Pomati, S Scagnoli, A Rughetti, S Caponnetto, P Marchetti, M Nuti |
Cancers | 2020 |
|
Tumor Infiltrating Effector Memory Antigen-Specific CD8+ T Cells Predict Response to Immune Checkpoint Therapy
N Principe, J Kidman, S Goh, CM Tilsed, SA Fisher, VS Fear, CA Forbes, RM Zemek, A Chopra, M Watson, IM Dick, L Boon, RA Holt, RA Lake, AK Nowak, WJ Lesterhuis, AM McDonnell, J Chee |
Frontiers in immunology | 2020 |
|
Characterization of tumors with ultralow tumor mutational burden in Japanese cancer patients
K Hatakeyama, T Nagashima, K Ohshima, S Ohnami, S Ohnami, Y Shimoda, A Naruoka, K Maruyama, A Iizuka, T Ashizawa, T Mochizuki, K Urakami, Y Akiyama, K Yamaguchi |
Cancer Science | 2020 |
|
Earlier-Phased Cancer Immunity Cycle Strongly Influences Cancer Immunity in Operable Never-Smoker Lung Adenocarcinoma
HK Kim, JG Joung, YL Choi, SH Lee, BJ Park, YS Choi, D Ryu, JY Nam, MS Lee, WY Park, S Hwang, H Cha, HS Kim, S Lee, Y Jung, JE Lee, J Doh, S Paik, JH Kang, J Lee, J Kim |
iScience | 2020 |
|
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study
EJ Lampert, A Zimmer, M Padget, A Cimino-Mathews, JR Nair, Y Liu, EM Swisher, JW Hodge, AB Nixon, E Nichols, MH Bagheri, E Levy, MR Radke, S Lipkowitz, CM Annunziata, JM Taube, SM Steinberg, JM Lee |
Clinical cancer research | 2020 |
|
Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy
JI Griffiths, P Wallet, LT Pflieger, D Stenehjem, X Liu, PA Cosgrove, NA Leggett, JA McQuerry, G Shrestha, M Rossetti, G Sunga, PJ Moos, FR Adler, JT Chang, S Sharma, AH Bild |
Proceedings of the National Academy of Sciences | 2020 |
|
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
B Sangro, I Melero, S Wadhawan, RS Finn, GK Abou-Alfa, AL Cheng, T Yau, J Furuse, JW Park, Z Boyd, HT Tang, Y Shen, M Tschaika, J Neely, A El-Khoueiry |
Journal of Hepatology | 2020 |
|
NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response
SM Swain, G Tang, HA Brauer, DS Goerlitz, PC Lucas, A Robidoux, BT Harris, H Bandos, Y Ren, CE Geyer, P Rastogi, EP Mamounas, N Wolmark |
Clinical cancer research | 2020 |
|
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype
CM Corte, T Sen, CM Gay, K Ramkumar, L Diao, RJ Cardnell, BL Rodriguez, CA Stewart, VA Papadimitrakopoulou, L Gibson, JJ Fradette, Q Wang, Y Fan, DH Peng, MV Negrao, II Wistuba, J Fujimoto, LM Soto, C Behrens, F Skoulidis, JV Heymach, J Wang, DL Gibbons, LA Byers |
Journal of Thoracic Oncology | 2020 |
|
Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy
W Zhai, X Zhou, M Zhai, W Li, Y Ran, Y Sun, J Du, W Zhao, L Xing, Y Qi, Y Gao |
Science China Life Sciences | 2020 |
|
Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy
CM Amato, JD Hintzsche, K Wells, A Applegate, NT Gorden, VM Vorwald, RP Tobin, K Nassar, YG Shellman, J Kim, TM Medina, M Rioth, KD Lewis, MD McCarter, R Gonzalez, AC Tan, WA Robinson |
Cancers | 2020 |
|
Enhancing antitumor immunity through checkpoint blockade as a therapeutic strategy in T-cell lymphomas
A Neuwelt, T Al-Juhaishi, E Davila, B Haverkos |
Blood Advances | 2020 |
|
Omics-wide quantitative B-cell infiltration analyses identify GPR18 for human cancer prognosis with superiority over CD20
Y Liu, L Wang, KW Lo, VW Lui |
2020 | |
|
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
R Montal, D Sia, C Montironi, WQ Leow, R Esteban-Fabró, R Pinyol, M Torres-Martin, L Bassaganyas, A Moeini, J Peix, L Cabellos, M Maeda, C Villacorta-Martin, P Tabrizian, L Rodriguez-Carunchio, G Castellano, C Sempoux, B Minguez, TM Pawlik, I Labgaa, LR Roberts, M Sole, MI Fiel, S Thung, J Fuster, S Roayaie, A Villanueva, M Schwartz, JM Llovet |
Journal of Hepatology | 2020 |
|
Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway
AW Chai, PS Yee, S Price, SM Yee, HM Lee, VK Tiong, E Gonçalves, FM Behan, J Bateson, J Gilbert, AC Tan, U McDermott, MJ Garnett, SC Cheong |
eLife | 2020 |
|
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
JC Thompson, C Davis, C Deshpande, WT Hwang, S Jeffries, A Huang, TC Mitchell, CJ Langer, SM Albelda |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
VC Kok |
Frontiers in Oncology | 2020 |
|
Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma
A Fröhlich, S Loick, EG Bawden, S Fietz, J Dietrich, E Diekmann, G Saavedra, H Fröhlich, D Niebel, J Sirokay, R Zarbl, GH Gielen, G Kristiansen, F Bootz, J Landsberg, D Dietrich |
EBioMedicine | 2020 |
|
Chloride intracellular channel protein 2: prognostic marker and correlation with PD-1/PD-L1 in breast cancer
T Xu, Z Wang, M Dong, D Wu, S Liao, X Li |
Aging | 2020 |
|
Integration of Omics Data Sources to Inform Mechanistic Modeling of Immune‐Oncology Therapies: A Tutorial for Clinical Pharmacologists
G Lazarou, V Chelliah, BG Small, M Walker, PH Graaf, AM Kierzek |
Clinical Pharmacology & Therapeutics | 2020 |
|
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
YH Park, S Lal, JE Lee, YL Choi, J Wen, S Ram, Y Ding, SH Lee, E Powell, SK Lee, JH Yu, KA Ching, JY Nam, SW Kim, SJ Nam, JY Kim, SY Cho, S Park, J Kim, S Hwang, YJ Kim, V Bonato, D Fernandez, S Deng, S Wang, H Shin, ES Kang, WY Park, PA Rejto, J Bienkowska, Z Kan |
Nature Communications | 2020 |
|
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
F Petitprez, M Meylan, A de Reyniès, C Sautès-Fridman, WH Fridman |
Frontiers in immunology | 2020 |
|
Prediction of immune checkpoint inhibition with immune oncology-related gene expression in gastrointestinal cancer using a machine learning classifier
Z Lu, H Chen, , W Zhou, W Han, S Li, C Liu, J Gong, J Li, X Zhang, X Wang, Z Peng, C Qi, Z Wang, Y Li, J Li, Y Li, M Brock, H Zhang, L Shen |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial
JJ Luke, BE Onderdonk, SR Bhave, T Karrison, JM Lemons, P Chang, Y Zha, T Carll, T Krausz, L Huang, C Martinez, LA Janisch, RD Hseu, JW Moroney, JD Patel, NN Khodarev, JK Salama, PA Ott, GF Fleming, TF Gajewski, RR Weichselbaum, SP Pitroda, SJ Chmura |
Clinical cancer research | 2020 |
|
Loss of ELF5–FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-γ signalling
S Singh, S Kumar, RK Srivastava, A Nandi, G Thacker, H Murali, S Kim, M Baldeon, J Tobias, MA Blanco, R Saffie, MR Zaidi, S Sinha, L Busino, SY Fuchs, R Chakrabarti |
Nature Cell Biology | 2020 |
|
Characterization of the immune profile of oral tongue squamous cell carcinomas with advancing disease
K Meehan, C Leslie, M Lucas, A Jacques, B Mirzai, J Lim, M Bulsara, Y Khan, NC Wong, B Solomon, C Sader, P Friedland, GM Arnau, T Semple, AM Lim |
Cancer Medicine | 2020 |
|
Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer
TR McCaw, N Goel, DJ Brooke, AA Katre, AI Londoño, HJ Smith, TD Randall, RC Arend |
Cancer Medicine | 2020 |
|
Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
L Nayak, AM Molinaro, K Peters, JL Clarke, JT Jordan, J de Groot, L Nghiemphu, T Kaley, H Colman, C McCluskey, S Gaffey, TR Smith, DJ Cote, M Severgnini, JH Yearley, Q Zhao, WM Blumenschein, DG Duda, A Muzikansky, RK Jain, PY Wen, DA Reardon |
Clinical cancer research | 2020 |
|
Comprehensive analysis of cutaneous and uveal melanoma liver metastases
EP Hoefsmit, EA Rozeman, TM Van, P Dimitriadis, O Krijgsman, JW Conway, IP da Silva, JE van der Wal, SL Ketelaars, K Bresser, A Broeks, RM Kerkhoven, JW Reeves, S Warren, P Kvistborg, RA Scolyer, EW Kapiteijn, DS Peeper, GV Long, TN Schumacher, CU Blank |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers
T OMeara, M Marczyk, T Qing, V Yaghoobi, K Blenman, K Cole, V Pelekanou, DL Rimm, L Pusztai |
JCO Precision Oncology | 2020 |
|
The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy
ME Ahmed, S Falasiri, A Hajiran, J Chahoud, PE Spiess |
Journal of Clinical Medicine | 2020 |
|
The landscape of CD28, CD80, CD86, CTLA4 , and ICOS DNA methylation in head and neck squamous cell carcinomas
L de Vos, I Grünwald, EG Bawden, J Dietrich, K Scheckenbach, C Wiek, R Zarbl, F Bootz, J Landsberg, D Dietrich |
Epigenetics : official journal of the DNA Methylation Society | 2020 |
|
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma
CS Grasso, J Tsoi, M Onyshchenko, G Abril-Rodriguez, P Ross-Macdonald, M Wind-Rotolo, A Champhekar, E Medina, DY Torrejon, DS Shin, P Tran, YJ Kim, C Puig-Saus, K Campbell, A Vega-Crespo, M Quist, C Martignier, JJ Luke, JD Wolchok, DB Johnson, B Chmielowski, FS Hodi, S Bhatia, W Sharfman, WJ Urba, CL Slingluff, A Diab, JB Haanen, SM Algarra, DM Pardoll, V Anagnostou, SL Topalian, VE Velculescu, DE Speiser, A Kalbasi, A Ribas |
Cancer Cell | 2020 |
|
Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
B He, D Dong, Y She, C Zhou, M Fang, Y Zhu, H Zhang, Z Huang, T Jiang, J Tian, C Chen |
Journal for ImmunoTherapy of Cancer | 2020 |
|
High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot
SP Keam, H Halse, T Nguyen, M Wang, NV Losio, C Mitchell, F Caramia, DJ Byrne, S Haupt, G Ryland, PK Darcy, S Sandhu, P Blombery, Y Haupt, SG Williams, PJ Neeson |
Journal for ImmunoTherapy of Cancer | 2020 |
|
HDAC9 deficiency promotes tumor progression by decreasing the CD8 + dendritic cell infiltration of the tumor microenvironment
Y Ning, J Ding, X Sun, Y Xie, M Su, C Ma, J Pan, J Chen, H Jiang, C Qi |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Pan-cancer methylation analysis reveals an inverse correlation of tumor immunogenicity with methylation aberrancy
C Park, K Jeong, J Park, S Jung, J Bae, K Kim, C Ock, M Kim, B Keam, T Kim, Y Jeon, S Lee, J Lee, D Kim, G Kang, D Chung, D Heo |
Cancer Immunology, Immunotherapy | 2020 |
|
MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling
HL Ngan, Y Liu, AY Fong, PH Poon, CK Yeung, SS Chan, A Lau, W Piao, H Li, JS Tse, KW Lo, SM Chan, YX Su, JY Chan, CW Lau, GB Mills, JR Grandis, VW Lui |
Life science alliance | 2020 |
|
Lipopolysaccharide-mediated chronic inflammation promotes tobacco carcinogen-induced lung cancer and determines the efficacy of immunotherapy
CH Liu, Z Chen, K Chen, FT Liao, CE Chung, X Liu, YC Lin, P Keohavong, GD Leikauf, YP Di |
Cancer research | 2020 |
|
Learning from clinical trials of neoadjuvant checkpoint blockade.
Versluis JM, Long GV, Blank CU |
Nature Medicine | 2020 |
|
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy.
Pérez-Guijarro E, Yang HH, Araya RE, El Meskini R, Michael HT, Vodnala SK, Marie KL, Smith C, Chin S, Lam KC, Thorkelsson A, Iacovelli AJ, Kulaga A, Fon A, Michalowski AM, Hugo W, Lo RS, Restifo NP, Sharan SK, Van Dyke T, Goldszmid RS, Weaver Ohler Z, Lee MP, Day CP, Merlino G |
Nature Medicine | 2020 |
|
Sex-associated molecular differences for cancer immunotherapy.
Ye Y, Jing Y, Li L, Mills GB, Diao L, Liu H, Han L |
Nature Communications | 2020 |
|
Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma.
Kuriyama K, Higuchi T, Yokobori T, Saito H, Yoshida T, Hara K, Suzuki S, Sakai M, Sohda M, Higuchi T, Tsushima Y, Asao T, Kaira K, Kuwano H, Shirabe K, Saeki H |
Cancer Science | 2020 |
|
Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
Sonpavde G, Manitz J, Gao C, Tayama D, Kaiser C, Hennessy D, Makari D, Gupta A, Abdullah SE, Niegisch G, Rosenberg JE, Bajorin DF, Grivas P, Apolo AB, Dreicer R, Hahn NM, Galsky MD, Necchi A, Srinivas S, Powles T, Choueiri TK, Pond GR |
The Journal of Urology | 2020 |
|
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours.
Young K, Lawlor RT, Ragulan C, Patil Y, Mafficini A, Bersani S, Antonello D, Mansfield D, Cingarlini S, Landoni L, Pea A, Luchini C, Piredda L, Kannan N, Nyamundanda G, Morganstein D, Chau I, Wiedenmann B, Milella M, Melcher A, Cunningham D, Starling N, Scarpa A, Sadanandam A |
Gut | 2020 |
|
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).
Ascierto PA, Puzanov I, Agarwala SS, Blank C, Carvajal RD, Demaria S, Dummer R, Ernstoff M, Ferrone S, Fox BA, Gajewski TF, Garbe C, Hwu P, Lo RS, Long GV, Luke JJ, Osman I, Postow MA, Sullivan RJ, Taube JM, Trinchieri G, Zarour HM, Caracò C, Thurin M |
Journal of Translational Medicine | 2020 |
|
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, Mu XJ, Ching KA, Uemura M, Pal SK, Alekseev B, Gravis G, Campbell MT, Penkov K, Lee JL, Hariharan S, Wang X, Zhang W, Wang J, Chudnovsky A, di Pietro A, Donahue AC, Choueiri TK |
Nature Medicine | 2020 |
|
Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors.
Papadopoulos KP, Autio K, Golan T, Dobrenkov K, Chartash E, Chen Q, Wnek R, Long GV |
Clinical cancer research | 2020 |
|
Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer.
Hwang S, Kwon AY, Jeong JY, Kim S, Kang H, Park J, Kim JH, Han OJ, Lim SM, An HJ |
Scientific Reports | 2020 |
|
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma.
Wagener-Ryczek S, Schoemmel M, Kraemer M, Bruns C, Schroeder W, Zander T, Gebauer F, Alakus H, Merkelbach-Bruse S, Buettner R, Loeser H, Thelen M, Schlößer HA, Quaas A |
Cancer Immunology, Immunotherapy | 2020 |
|
Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors.
Alcaraz-Sanabria A, Baliu-Piqué M, Saiz-Ladera C, Rojas K, Manzano A, Marquina G, Casado A, Cimas FJ, Pérez-Segura P, Pandiella A, Gyorffy B, Ocana A |
Frontiers in Oncology | 2020 |
|
Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment.
Shen R, Li P, Li B, Zhang B, Feng L, Cheng S |
Frontiers in Oncology | 2020 |
|
EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells.
Yu S, Sha H, Qin X, Chen Y, Li X, Shi M, Feng J |
Oncogene | 2020 |
|
Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment.
Botticelli A, Vernocchi P, Marini F, Quagliariello A, Cerbelli B, Reddel S, Del Chierico F, Di Pietro F, Giusti R, Tomassini A, Giampaoli O, Miccheli A, Zizzari IG, Nuti M, Putignani L, Marchetti P |
Journal of Translational Medicine | 2020 |
|
Genomic landscape of lung adenocarcinoma in East Asians.
Chen J, Yang H, Teo ASM, Amer LB, Sherbaf FG, Tan CQ, Alvarez JJS, Lu B, Lim JQ, Takano A, Nahar R, Lee YY, Phua CZJ, Chua KP, Suteja L, Chen PJ, Chang MM, Koh TPT, Ong BH, Anantham D, Hsu AAL, Gogna A, Too CW, Aung ZW, Lee YF, Wang L, Lim TKH, Wilm A, Choi PS, Ng PY, Toh CK, Lim WT, Ma S, Lim B, Liu J, Tam WL, Skanderup AJ, Yeong JPS, Tan EH, Creasy CL, Tan DSW, Hillmer AM, Zhai W |
Nature Genetics | 2020 |
|
Gene signatures based on therapy responsiveness provide guidance for combined radiotherapy and chemotherapy for lower grade glioma.
Li G, Jiang Y, Lyu X, Cai Y, Zhang M, Li G, Qiao Q |
Journal of Cellular and Molecular Medicine | 2020 |
|
Transcriptional Profiling of Advanced Urothelial Cancer Predicts Prognosis and Response to Immunotherapy.
Baek SW, Jang IH, Kim SK, Nam JK, Leem SH, Chu IS |
International journal of molecular sciences | 2020 |
|
Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.
Onuma AE, Zhang H, Huang H, Williams TM, Noonan A, Tsung A |
Gene expression | 2020 |
|
Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade.
Gstalder C, Liu D, Miao D, Lutterbach B, DeVine AL, Lin C, Shettigar M, Pancholi P, Buchbinder EI, Carter SL, Manos MP, Rojas-Rudilla V, Brennick R, Gjini E, Chen PH, Lako A, Rodig S, Yoon CH, Freeman GJ, Barbie DA, Hodi FS, Miles W, Van Allen EM, Haq R |
Cancer Discovery | 2020 |
|
High-dimensional analyses reveal a distinct role of T-cell subsets in the immune microenvironment of gastric cancer.
Wang M, Huang YK, Kong JC, Sun Y, Tantalo DG, Yeang HXA, Ying L, Yan F, Xu D, Halse H, Di Costanzo N, Gordon IR, Mitchell C, Mackay LK, Busuttil RA, Neeson PJ, Boussioutas A |
Clinical & Translational Immunology | 2020 |
|
STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy.
Arwert EN, Milford EL, Rullan A, Derzsi S, Hooper S, Kato T, Mansfield D, Melcher A, Harrington KJ, Sahai E |
Nature Cell Biology | 2020 |
|
Inflammatory Cytokines and ctDNA Are Biomarkers for Progression in Advanced-Stage Melanoma Patients Receiving Checkpoint Inhibitors.
Pedersen JG, Madsen AT, Gammelgaard KR, Aggerholm-Pedersen N, Sørensen BS, Øllegaard TH, Jakobsen MR |
Cancers | 2020 |
|
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers.
Sundar R, Smyth EC, Peng S, Yeong JPS, Tan P |
Frontiers in Oncology | 2020 |
|
Blocking IL1 Beta Promotes Tumor Regression and Remodeling of the Myeloid Compartment in a Renal Cell Carcinoma Model: Multidimensional Analyses.
Aggen DH, Ager CR, Obradovic AZ, Chowdhury N, Ghasemzadeh A, Mao W, Chaimowitz MG, Lopez-Bujanda ZA, Spina CS, Hawley JE, Dallos MC, Zhang C, Wang V, Li H, Guo XV, Drake CG |
Clinical cancer research | 2020 |
|
Circulating Tumour Cell Expression of Immune Markers as Prognostic and Therapeutic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis.
Payne K, Pugh M, Brooks J, Batis N, Taylor G, Nankivell P, Mehanna H |
International journal of molecular sciences | 2020 |
|
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
Wan C, Keany MP, Dong H, Al-Alem LF, Pandya UM, Lazo S, Boehnke K, Lynch KN, Xu R, Zarrella DT, Gu S, Cejas P, Lim K, Long HW, Elias KM, Horowitz NS, Feltmate CM, Muto MG, Worley MJ Jr, Berkowitz RS, Matulonis UA, Nucci MR, Crum CP, Rueda BR, Brown M, Liu XS, Hill SJ |
Cancer research | 2020 |
|
cDC1 dysregulation in cancer: An opportunity for intervention.
Gajewski TF, Cron KR |
Journal of Experimental Medicine | 2020 |
|
An Immunogram for an Individualized Assessment of the Antitumor Immune Response in Patients With Hepatocellular Carcinoma.
Hu Y, Sun H, Zhang H, Wang X |
Frontiers in Oncology | 2020 |
|
Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy.
Ballot E, Ladoire S, Routy B, Truntzer C, Ghiringhelli F |
Cancers | 2020 |
|
Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients.
Son SM, Woo CG, Kim DH, Yun HY, Kim H, Kim HK, Yang Y, Kwon J, Kwon M, Kim TY, Kim HD, Koh JY, Park SH, Shin EC, Han HS |
Scientific Reports | 2020 |
|
EPHA5 mutations predict survival after immunotherapy in lung adenocarcinoma.
Chen Z, Chen J, Ren D, Zhang J, Yang Y, Zhang H, Mao B, Ma H |
Aging | 2020 |
|
Retreatment with immune checkpoint inhibitors in solid tumors: a systematic review.
Yang K, Li J, Sun Z, Zhao L, Bai C |
Therapeutic advances in medical oncology | 2020 |
|
Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date.
Tacconi EMC, Tuthill M, Protheroe A |
OncoTargets and therapy | 2020 |
|
The mutational pattern of homologous recombination (HR)-associated genes and its relevance to the immunotherapeutic response in gastric cancer.
Fan Y, Ying H, Wu X, Chen H, Hu Y, Zhang H, Wu L, Yang Y, Mao B, Zheng L |
Cancer biology & medicine | 2020 |
|
The mutational pattern of homologous recombination-related (HRR) genes in Chinese colon cancer and its relevance to immunotherapy responses.
Zhou P, Wu X, Chen H, Hu Y, Zhang H, Wu L, Yang Y, Mao B, Wang H |
Aging | 2020 |
|
Neutrophil depletion enhances the therapeutic effect of PD-1 antibody on glioma
Wang PF, Zhang YX, Su J, Yao K, Li SW, Huang GR, Yan CX |
Aging | 2020 |
|
Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.
Rizk EM, Seffens AM, Trager MH, Moore MR, Geskin LJ, Gartrell-Corrado RD, Wong W, Saenger YM |
American Journal of Clinical Dermatology | 2020 |
|
The G protein coupled receptor CCR5 in cancer.
Upadhyaya C, Jiao X, Ashton A, Patel K, Kossenkov AV, Pestell RG |
Advances in cancer research | 2020 |
|
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Kunacheewa C, Manasanch EE |
Best practice & research. Clinical haematology | 2020 |
|
Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone.
Metovic J, Annaratone L, Linari A, Osella-Abate S, Musuraca C, Veneziano F, Vignale C, Bertero L, Cassoni P, Ratto N, Comandone A, Grignani G, Piana R, Papotti M |
Cancer Immunology, Immunotherapy | 2020 |
|
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.
Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, Walsh AM, Baxi V, Pandya D, Baradet T, Locke D, Wu Q, Reilly TP, Phillips P, Nagineni V, Gianino N, Gu J, Zhao H, Perez-Gracia JL, Sanmamed MF, Melero I |
Nature Medicine | 2020 |
|
HK3 is correlated with immune infiltrates and predicts response to immunotherapy in non-small cell lung cancer.
Tuo Z, Zheng X, Zong Y, Li J, Zou C, Lv Y, Liu J |
Clinical and Translational Medicine | 2020 |
|
Prognostic Significance of Interferon-γ and Its Signaling Pathway in Early Breast Cancer Depends on the Molecular Subtypes.
Heimes AS, Härtner F, Almstedt K, Krajnak S, Lebrecht A, Battista MJ, Edlund K, Brenner W, Hasenburg A, Sahin U, Gehrmann M, Hengstler JG, Schmidt M |
International journal of molecular sciences | 2020 |
|
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Lai AY, Sorrentino JA, Dragnev KH, Weiss JM, Owonikoko TK, Rytlewski JA, Hood J, Yang Z, Malik RK, Strum JC, Roberts PJ |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Immune checkpoint blockade and biomarkers of clinical response in non-small cell lung cancer.
Hallqvist A, Rohlin A, Raghavan S |
Scandinavian Journal of Immunology | 2020 |
|
Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer.
Aghajani MJ, Yang T, Schmitz U, James A, McCafferty CE, de Souza P, Niles N, Roberts TL |
Endocrine Connections | 2020 |
|
Id1 and PD-1 Combined Blockade Impairs Tumor Growth and Survival of KRAS-mutant Lung Cancer by Stimulating PD-L1 Expression and Tumor Infiltrating CD8+ T Cells.
Baraibar I, Roman M, Rodríguez-Remírez M, López I, Vilalta A, Guruceaga E, Ecay M, Collantes M, Lozano T, Alignani D, Puyalto A, Oliver A, Ortiz-Espinosa S, Moreno H, Torregrosa M, Rolfo C, Caglevic C, García-Ros D, Villalba-Esparza M, De Andrea C, Vicent S, Pío R, Lasarte JJ, Calvo A, Ajona D, Gil-Bazo I |
Cancers | 2020 |
|
A genomic signature for accurate classification and prediction of clinical outcomes in cancer patients treated with immune checkpoint blockade immunotherapy.
Lu M, Wu KH, Trudeau S, Jiang M, Zhao J, Fan E |
Scientific Reports | 2020 |
|
Immune checkpoint inhibitors for esophageal squamous cell carcinoma: a narrative review.
Zhang W, Wang P, Pang Q |
Annals of translational medicine | 2020 |
|
G Protein-Coupled receptors and heterotrimeric G proteins as cancer drivers.
Arang N, Gutkind JS |
FEBS Letters | 2020 |
|
Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
Medjebar S, Truntzer C, Perrichet A, Limagne E, Fumet JD, Richard C, Elkrief A, Routy B, Rébé C, Ghiringhelli F |
OncoImmunology | 2020 |
|
Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer.
Zucali PA, Cordua N, D'Antonio F, Borea F, Perrino M, De Vincenzo F, Santoro A |
Frontiers in Oncology | 2020 |
|
PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential.
Rotman J, den Otter LAS, Bleeker MCG, Samuels SS, Heeren AM, Roemer MGM, Kenter GG, Zijlmans HJMAA, van Trommel NE, de Gruijl TD, Jordanova ES |
Frontiers in immunology | 2020 |
|
M1-like TAMs are required for the efficacy of PD-L1/PD-1 blockades in gastric cancer.
Zhao R, Wan Q, Wang Y, Wu Y, Xiao S, Li Q, Shen X, Zhuang W, Zhou Y, Xia L, Song Y, Chen Y, Yang H, Wu X |
OncoImmunology | 2020 |
|
Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?
Poletajew S, Krajewski W, Kryst P |
Translational andrology and urology | 2020 |
|
Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer.
Chen H, Chong W, Yang X, Zhang Y, Sang S, Li X, Lu M |
OncoImmunology | 2020 |
|
Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
Park C, Na KJ, Choi H, Ock CY, Ha S, Kim M, Park S, Keam B, Kim TM, Paeng JC, Park IK, Kang CH, Kim DW, Cheon GJ, Kang KW, Kim YT, Heo DS |
Theranostics | 2020 |
|
Challenges of PD-L1 testing in non-small cell lung cancer and beyond.
Wang M, Wang S, Trapani JA, Neeson PJ |
Journal of Thoracic Disease | 2020 |
|
Gene expression profiling identified TP53MutPIK3CAWild as a potential biomarker for patients with triple-negative breast cancer treated with immune checkpoint inhibitors.
Cheng J, Ding X, Xu S, Zhu B, Jia Q |
Oncology Letters | 2020 |
|
Bilateral murine tumor models for characterizing the response to immune checkpoint blockade.
Zemek RM, Fear VS, Forbes C, de Jong E, Casey TH, Boon L, Lassmann T, Bosco A, Millward MJ, Nowak AK, Lake RA, Lesterhuis WJ |
Nature Protocols | 2020 |
|
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
Chalabi M, Fanchi LF, Dijkstra KK, Van den Berg JG, Aalbers AG, Sikorska K, Lopez-Yurda M, Grootscholten C, Beets GL, Snaebjornsson P, Maas M, Mertz M, Veninga V, Bounova G, Broeks A, Beets-Tan RG, de Wijkerslooth TR, van Lent AU, Marsman HA, Nuijten E, Kok NF, Kuiper M, Verbeek WH, Kok M, Van Leerdam ME, Schumacher TN, Voest EE, Haanen JB |
Nature Medicine | 2020 |
|
Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer.
Kang BW, Chau I |
ESMO Open | 2020 |
|
Peripheral Cytokine Levels Differ by HPV Status and Change Treatment-Dependently in Patients with Head and Neck Squamous Cell Carcinoma.
Mytilineos D, Ezić J, von Witzleben A, Mytilineos J, Lotfi R, Fürst D, Tsamadou C, Theodoraki MN, Oster A, Völkel G, Kestler HA, Brunner C, Schuler PJ, Doescher J, Hoffmann TK, Laban S |
International journal of molecular sciences | 2020 |
|
Distinct Mutation Patterns Reveal Melanoma Subtypes and Influence Immunotherapy Response in Advanced Melanoma Patients.
Hilke FJ, Sinnberg T, Gschwind A, Niessner H, Demidov G, Amaral T, Ossowski S, Bonzheim I, Röcken M, Riess O, Garbe C, Schroeder C, Forschner A |
Cancers | 2020 |
|
Personalized Immuno-Oncology.
Jain KK |
2020 | |
|
Rationalizing the pathway to personalized neoadjuvant immunotherapy: the Lombard Street Approach.
Versluis JM, Thommen DS, Blank CU |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.
Chau I, Penel N, Soriano AO, Arkenau HT, Cultrera J, Santana-Davila R, Calvo E, Le Tourneau C, Zender L, Bendell JC, Mi G, Gao L, McNeely SC, Oliveira JM, Ferry D, Herbst RS, Fuchs CS |
Cancers | 2020 |
|
Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state.
Cerezo-Wallis D, Contreras-Alcalde M, Troulé K, Catena X, Mucientes C, Calvo TG, Cañón E, Tejedo C, Pennacchi PC, Hogan S, Kölblinger P, Tejero H, Chen AX, Ibarz N, Graña-Castro O, Martinez L, Muñoz J, Ortiz-Romero P, Rodriguez-Peralto JL, Gómez-López G, Al-Shahrour F, Rabadán R, Levesque MP, Olmeda D, Soengas MS |
Nature Medicine | 2020 |
|
Immune Phenotypes of Nasopharyngeal Cancer.
Nilsson JS, Sobti A, Swoboda S, Erjefält JS, Forslund O, Lindstedt M, Greiff L |
Cancers | 2020 |
|
Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade.
Bonavita E, Bromley CP, Jonsson G, Pelly VS, Sahoo S, Walwyn-Brown K, Mensurado S, Moeini A, Flanagan E, Bell CR, Chiang SC, Chikkanna-Gowda CP, Rogers N, Silva-Santos B, Jaillon S, Mantovani A, Reis e Sousa C, Guerra N, Davis DM, Zelenay S |
Immunity | 2020 |
|
The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies".
Strub T, Ballotti R, Bertolotto C |
Theranostics | 2020 |
|
Skeletal muscle mass predicts the outcome of nivolumab treatment for non-small cell lung cancer.
Tsukagoshi M, Yokobori T, Yajima T, Maeno T, Shimizu K, Mogi A, Araki K, Harimoto N, Shirabe K, Kaira K |
Medicine | 2020 |
|
Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma.
Galvani E, Mundra PA, Valpione S, Garcia-Martinez P, Smith M, Greenall J, Thakur R, Helmink B, Andrews MC, Boon L, Chester C, Gremel G, Hogan K, Mandal A, Zeng K, Banyard A, Ashton G, Cook M, Lorigan P, Wargo JA, Dhomen N, Marais R |
Nature Communications | 2020 |
|
Immunotherapeutic approaches for small-cell lung cancer.
Iams WT, Porter J, Horn L |
Nature reviews. Clinical oncology | 2020 |
|
Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing.
Bosisio FM, Antoranz A, van Herck Y, Bolognesi MM, Marcelis L, Chinello C, Wouters J, Magni F, Alexopoulos L, Stas M, Boecxstaens V, Bechter O, Cattoretti G, van den Oord J |
eLife | 2020 |
|
Lung metastases share common immune features regardless of primary tumor origin.
García-Mulero S, Alonso MH, Pardo J, Santos C, Sanjuan X, Salazar R, Moreno V, Piulats JM, Sanz-Pamplona R |
Journal for ImmunoTherapy of Cancer | 2020 |
|
Homologous repair deficiency score for identifying breast cancers with defective DNA damage response
Min A, Kim K, Jeong K, Choi S, Kim S, Suh KJ, Lee KH, Kim S, Im SA |
Scientific Reports | 2020 |
|
MethylResolver—a method for deconvoluting bulk DNA methylation profiles into known and unknown cell contents
Arneson D, Yang X, Wang K |
2020 | |
|
“To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers
Garutti M, Buriolla S, Bertoli E, Vitale MG, Rossi E, Schinzari G, Minisini AM, Puglisi F |
Cancers | 2020 |
|
Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1/PD-L1
Cimas FJ, Manzano A, Baliu-Piqué M, García-Gil E, Pérez-Segura P, Nagy Á, Pandiella A, Győrffy B, Ocana A |
Cancers | 2020 |
|
Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis
Chen C, An L, Cheng Y, Luo X, Li Z, Liu X |
Frontiers in Oncology | 2020 |
|
m6A RNA methyltransferases METTL3/14 regulate immune responses to anti‐PD‐1 therapy
Wang L, Hui H, Agrawal K, Kang Y, Li N, Tang R, Yuan J, Rana TM |
The EMBO Journal | 2020 |
|
The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures
Chen L, Oke T, Siegel N, Cojocaru G, Tam AJ, Blosser RL, Swailes J, Ligon JA, Lebid A, Morris C, Levin A, Rhee DS, Johnston FM, Greer JB, Meyer CF, Ladle BH, Thompson ED, Montgomery EA, Choi W, McConkey DJ, Anders RA, Pardoll DM, Llosa NJ |
Clinical cancer research | 2020 |
|
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts
Fumet JD, Truntzer C, Yarchoan M, Ghiringhelli F |
European Journal of Cancer | 2020 |
|
Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer.
Nakayama Y, Mimura K, Kua LF, Okayama H, Min AKT, Saito K, Hanayama H, Watanabe Y, Saito M, Momma T, Saze Z, Ohki S, Suzuki Y, Ichikawa D, Yong WP, Kono K |
2020 | |
|
Tumor immune microenvironment in cancer patients with leukocytosis
Kim KH, Sim NS, Chang JS, Kim YB |
Cancer Immunology, Immunotherapy | 2020 |
|
Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer
Zhang F, Bai H, Gao R, Fei K, Duan J, Zhang Z, Wang J, Hu X |
Cancer Immunology, Immunotherapy | 2020 |
|
A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases
Jansen Y, Kruse V, Corthals J, Schats K, van Dam PJ, Seremet T, Heirman C, Brochez L, Kockx M, Thielemans K, Neyns B |
Cancer Immunology, Immunotherapy | 2020 |
|
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
Qingzhu Jia, Jun Wang, Ning He, Ji He, Bo Zhu |
JCI Insight | 2019 |
|
cGAS/STING axis mediates a Topoisomerase II inhibitor-induced tumor immunogenicity
Zining Wang, Jiemin Chen, Jie Hu, Hongxia Zhang, Feifei Xu, Wenzhuo He, xiaojuan Wang, Mengyun Li, Wenhua Lu, Gucheng Zeng, Penghui Zhou, Peng Huang, Siyu Chen, Wende Li, Liangping Xia, Xiaojun Xia |
Journal of Clinical Investigation | 2019 |
|
Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
Julia Kargl, Xiaodong Zhu, Huajia Zhang, grace hy yang, Travis J Friesen, melissa shipley, Dean Y. Maeda, John A. Zebala, Jill McKay-Fleisch, Gavin Meredith, Afshin Mashadi-Hossein, Christina Baik, Robert H. Pierce, Mary W Redman, Jeffrey C. Thompson, Steven M Albelda, Hamid Bolouri, A McGarry Houghton |
JCI Insight | 2019 |
|
Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer
AS Hamy, L Derosa, C Valdelièvre, S Yonekura, P Opolon, M Priour, J Guerin, JY Pierga, B Asselain, DD Croze, A Pinheiro, M Lae, LS Talagrand, E Laas, L Darrigues, B Grandal, E Marangoni, E Montaudon, G Kroemer, L Zitvogel, F Reyal |
OncoImmunology | 2019 |
|
Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients
CL Ihle, MD Provera, DM Straign, EE Smith, SM Edgerton, AV Bokhoven, MS Lucia, P Owens |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies
E Hays, B Bonavida |
Antioxidants | 2019 |
|
Biomarkers for Immunotherapy of Cancer: Methods and Protocols
M Thurin, A Cesano, FM Marincola |
2019 | |
|
Pro-inflammatory Cytokines Alter the Immunopeptidome Landscape by Modulation of HLA-B Expression
A Javitt, E Barnea, MP Kramer, H Wolf-Levy, Y Levin, A Admon, Y Merbl |
Frontiers in immunology | 2019 |
|
PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
TV Larsen, D Hussmann, AL Nielsen |
2019 | |
|
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)
L Incorvaia, D Fanale, G Badalamenti, N Barraco, M Bono, LR Corsini, A Galvano, V Gristina, A Listì, S Vieni, S Gori, V Bazan, A Russo |
Advances in Therapy | 2019 |
|
Prostate cancer research: The next generation; report from the 2019 Coffey‐Holden Prostate Cancer Academy Meeting
AK Miyahira, A Sharp, L Ellis, J Jones, S Kaochar, HB Larman, DA Quigley, H Ye, JW Simons, KJ Pienta, HR Soule |
The Prostate | 2019 |
|
Neutrophils Driving Unconventional T Cells Mediate Resistance against Murine Sarcomas and Selected Human Tumors
A Ponzetta, R Carriero, S Carnevale, M Barbagallo, M Molgora, C Perucchini, E Magrini, F Gianni, P Kunderfranco, N Polentarutti, F Pasqualini, SD Marco, D Supino, C Peano, F Cananzi, P Colombo, S Pilotti, SY Alomar, E Bonavita, MR Galdiero, C Garlanda, A Mantovani, S Jaillon |
Cell | 2019 |
|
Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades
H Chen, W Chong, Q Wu, Y Yao, M Mao, X Wang |
Frontiers in immunology | 2019 |
|
The Outcome of TGFβ Antagonism in Metastatic Breast Cancer Models In Vivo Reflects a Complex Balance between Tumor-Suppressive and Proprogression Activities of TGFβ
Y Yang, HH Yang, B Tang, AM Wu, KC Flanders, N Moshkovich, DS Weinberg, MA Welsh, J Weng, HJ Ochoa, TY Hu, MA Herrmann, J Chen, EF Edmondson, RM Simpson, F Liu, H Liu, MP Lee, LM Wakefield |
Clinical cancer research | 2019 |
|
The evolving role of immuno-oncology for the treatment of head and neck cancer: I-O and Head and Neck Cancer
AL Strome, X Zhang, SE Strome |
Laryngoscope Investigative Otolaryngology | 2019 |
|
Strategies for developing and optimizing cancer vaccines
HM Maeng, JA Berzofsky |
F1000Research | 2019 |
|
Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response
MA Pantaleo, G Tarantino, C Agostinelli, M Urbini, M Nannini, M Saponara, C Castelli, S Stacchiotti, E Fumagalli, L Gatto, D Santini, AD Leo, T Marafioti, A Akarca, E Sabattini, A Pession, A Ardizzoni, V Indio, A Astolfi |
OncoImmunology | 2019 |
|
HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma
N Malissen, N Macagno, S Granjeaud, C Granier, V Moutardier, C Gaudy-Marqueste, N Habel, M Mandavit, B Guillot, C Pasero, E Tartour, R Ballotti, JJ Grob, D Olive |
OncoImmunology | 2019 |
|
MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment
DD Fang, Q Tang, Y Kong, Q Wang, J Gu, X Fang, P Zou, T Rong, J Wang, D Yang, Y Zhai |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy
EM Rizk, RD Gartrell, LW Barker, CL Esancy, GG Finkel, DD Bordbar, YM Saenger |
Hematology/Oncology Clinics of North America | 2019 |
|
The T-cell-inflamed tumor microenvironment as a paradigm for immunotherapy drug development
DJ Olson, JJ Luke |
Immunotherapy | 2019 |
|
Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma
JV de la Iglesia, RJ Slebos, L Martin-Gomez, X Wang, JK Teer, AC Tan, TA Gerke, G Aden-Buie, T van Veen, J Masannat, R Chaudhary, F Song, M Fournier, EM Siegel, MB Schabath, JT Wadsworth, J Caudell, L Harrison, BM Wenig, J Conejo-Garcia, JC Hernandez-Prera, CH Chung |
Clinical cancer research | 2019 |
|
The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status
E Ott, L Bilonda, D Dansette, C Deleine, E Duchalais, J Podevin, C Volteau, J Bennouna, Y Touchefeu, P Fourquier, WE Thomas, J Chetritt, S Bezieau, M Denis, C Toquet, JF Mosnier, A Jarry, C Bossard |
OncoImmunology | 2019 |
|
The Immune Microenvironment in Hormone Receptor–Positive Breast Cancer Before and After Preoperative Chemotherapy
AG Waks, DG Stover, JL Guerriero, D Dillon, WT Barry, E Gjini, C Hartl, W Lo, J Savoie, J Brock, R Wesolowski, Z Li, A Damicis, AV Philips, Y Wu, F Yang, A Sullivan, P Danaher, HA Brauer, W Osmani, M Lipschitz, KA Hoadley, M Goldberg, CM Perou, S Rodig, EP Winer, IE Krop, EA Mittendorf, SM Tolaney |
Clinical cancer research | 2019 |
|
Targeting STAT3 and STAT5 in Tumor-Associated Immune Cells to Improve Immunotherapy
G Verdeil, T Lawrence, AM Schmitt-Verhulst, N Auphan-Anezin |
Cancers | 2019 |
|
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
J Griss, W Bauer, C Wagner, M Simon, M Chen, K Grabmeier-Pfistershammer, M Maurer-Granofszky, F Roka, T Penz, C Bock, G Zhang, M Herlyn, K Glatz, H Läubli, KD Mertz, P Petzelbauer, T Wiesner, M Hartl, WF Pickl, R Somasundaram, P Steinberger, SN Wagner |
Nature Communications | 2019 |
|
The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial
DT Weed, S Zilio, IM Reis, Z Sargi, M Abouyared, CR Gomez-Fernandez, FJ Civantos, CP Rodriguez, P Serafini |
Frontiers in immunology | 2019 |
|
Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis, and Response to Immunotherapy
AE Vilgelm, A Richmond |
Frontiers in immunology | 2019 |
|
Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts
KE Hutchinson, SE Yost, CW Chang, RM Johnson, AR Carr, PR McAdam, DL Halligan, CC Chang, D Schmolze, J Liang, Y Yuan |
Clinical cancer research | 2019 |
|
Interferon Signaling Is Diminished with Age and Is Associated with Immune Checkpoint Blockade Efficacy in Triple-Negative Breast Cancer
J Sceneay, GJ Goreczny, K Wilson, S Morrow, MJ DeCristo, JM Ubellacker, Y Qin, T Laszewski, DG Stover, V Barrera, JN Hutchinson, RA Freedman, EA Mittendorf, SS McAllister |
Cancer Discovery | 2019 |
|
WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment
X Li, Y Xiang, F Li, C Yin, B Li, X Ke |
Frontiers in immunology | 2019 |
|
Decoding Immune Heterogeneity of Triple Negative Breast Cancer and Its Association with Systemic Inflammation
RC, Meneghini, Sant, Iorio, Sfondrini, Paolini, Agresti, Tagliabue, Bianchi |
Cancers | 2019 |
|
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
JJ Havel, D Chowell, TA Chan |
Nature Reviews Cancer | 2019 |
|
Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies
TJ Harryvan, EM Verdegaal, JC Hardwick, LJ Hawinkels, SH van der Burg |
Journal of Clinical Medicine | 2019 |
|
Paclitaxel Response Can Be Predicted With Interpretable Multi-Variate Classifiers Exploiting DNA-Methylation and miRNA Data
A Bomane, A Gonçalves, PJ Ballester |
Frontiers in Genetics | 2019 |
|
Tumour-intrinsic resistance to immune checkpoint blockade
A Kalbasi, A Ribas |
Nature Reviews Immunology | 2019 |
|
Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers
F Pagni, E Guerini-Rocco, AM Schultheis, G Grazia, E Rijavec, M Ghidini, G Lopez, K Venetis, GA Croci, U Malapelle, N Fusco |
International journal of molecular sciences | 2019 |
|
Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer
J Yeong, JC Lim, B Lee, H Li, CC Ong, AA Thike, WH Yeap, Y Yang, AY Lim, TK Tay, J Liu, SC Wong, J Chen, EH Lim, J Iqbal, R Dent, EW Newell, PH Tan |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Targeted transcriptional profiling of the tumor microenvironment reveals lymphocyte exclusion and vascular dysfunction in metastatic osteosarcoma
L Sorenson, Y Fu, T Hood, S Warren, TA McEachron |
OncoImmunology | 2019 |
|
Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells
J Friedman, M Padget, J Lee, J Schlom, J Hodge, C Allen |
Oral Oncology | 2019 |
|
Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
J Roelands, W Hendrickx, G Zoppoli, R Mall, M Saad, K Halliwill, G Curigliano, D Rinchai, J Decock, LG Delogu, T Turan, J Samayoa, L Chouchane, A Ballestrero, E Wang, P Finetti, F Bertucci, LD Miller, J Galon, FM Marincola, PJ Kuppen, M Ceccarelli, D Bedognetti |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non–Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis
I Datar, MF Sanmamed, J Wang, BS Henick, J Choi, T Badri, W Dong, N Mani, M Toki, LD Mejías, MD Lozano, JL Perez-Gracia, V Velcheti, MD Hellmann, JF Gainor, K McEachern, D Jenkins, K Syrigos, K Politi, S Gettinger, DL Rimm, RS Herbst, I Melero, L Chen, KA Schalper |
Clinical cancer research | 2019 |
|
Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV+ oral cancer
S Dorta-Estremera, VL Hegde, RB Slay, R Sun, AV Yanamandra, C Nicholas, S Nookala, G Sierra, MA Curran, KJ Sastry |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Microsatellite instability in endometrial cancer: New purpose for an old test
KC Kurnit, SN Westin, RL Coleman |
Cancer | 2019 |
|
Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors
PA Ott, CJ Wu |
Cancer Discovery | 2019 |
|
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
S Fenton, J Sosman, S Chandra |
2019 | |
|
Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma
H Yu, Z Chen, KV Ballman, MA Watson, R Govindan, I Lanc, DG Beer, R Bueno, LR Chirieac, MH Chui, G Chen, WA Franklin, DR Gandara, C Genova, KA Brovsky, MB Joshi, DT Merrick, WG Richards, CJ Rivard, DH Harpole, MS Tsao, A van Bokhoven, FA Shepherd, FR Hirsch |
Journal of Thoracic Oncology | 2019 |
|
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
AC Huang, RJ Orlowski, X Xu, R Mick, SM George, PK Yan, S Manne, AA Kraya, B Wubbenhorst, L Dorfman, K DAndrea, BM Wenz, S Liu, L Chilukuri, A Kozlov, M Carberry, L Giles, MW Kier, F Quagliarello, S McGettigan, K Kreider, L Annamalai, Q Zhao, R Mogg, W Xu, WM Blumenschein, JH Yearley, GP Linette, RK Amaravadi, LM Schuchter, RS Herati, B Bengsch, KL Nathanson, MD Farwell, GC Karakousis, EJ Wherry, TC Mitchell |
Nature Medicine | 2019 |
|
Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs
HY Yang, CC Yang, CY Wu, LJ Wang, KL Lu |
International journal of molecular sciences | 2019 |
|
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th–1 December 1st, 2018, Naples, Italy)
PA Ascierto, SS Agarwala, G Botti, A Budillon, MA Davies, R Dummer, M Ernstoff, S Ferrone, S Formenti, TF Gajewski, C Garbe, O Hamid, RS Lo, JJ Luke, O Michielin, G Palmieri, L Zitvogel, FM Marincola, G Masucci, C Caracò, M Thurin, I Puzanov |
Journal of Translational Medicine | 2019 |
|
Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies
A Naing, J Infante, S Goel, H Burris, C Black, S Marshall, I Achour, S Barbee, R May, C Morehouse, K Pollizzi, X Song, K Steele, N Elgeioushi, F Walcott, J Karakunnel, P LoRusso, A Weise, J Eder, B Curti, M Oberst |
Journal for ImmunoTherapy of Cancer | 2019 |
|
4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8 + T cells in Hepatocellular Carcinoma
HD Kim, S Park, S Jeong, YJ Lee, H Lee, CG Kim, KH Kim, SM Hong, JY Lee, S Kim, HK Kim, BS Min, JH Chang, YS Ju, EC Shin, GW Song, S Hwang, SH Park |
Hepatology | 2019 |
|
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
ZM Jilkova, C Aspord, T Decaens |
Cancers | 2019 |
|
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma
V Cristina, RG Herrera-Gómez, P Szturz, V Espeli, M Siano |
International journal of molecular sciences | 2019 |
|
Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer
JH Newman, CB Chesson, NL Herzog, PK Bommareddy, SM Aspromonte, R Pepe, R Estupinian, MM Aboelatta, S Buddhadev, S Tarabichi, M Lee, S Li, DJ Medina, EF Giurini, KH Gupta, G Guevara-Aleman, M Rossi, C Nowicki, A Abed, JW Goldufsky, JR Broucek, RE Redondo, D Rotter, SR Jhawar, SJ Wang, FJ Kohlhapp, HL Kaufman, PG Thomas, V Gupta, TM Kuzel, J Reiser, J Paras, MP Kane, EA Singer, J Malhotra, LK Denzin, DB SantAngelo, AB Rabson, LY Lee, A Lasfar, J Langenfeld, JM Schenkel, MJ Fidler, ES Ruiz, AL Marzo, JS Rudra, AW Silk, A Zloza |
Proceedings of the National Academy of Sciences | 2019 |
|
Emerging therapeutic agents for genitourinary cancers
K Zarrabi, A Paroya, S Wu |
Journal of Hematology & Oncology | 2019 |
|
Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade
JL Benci, LR Johnson, R Choa, Y Xu, J Qiu, Z Zhou, B Xu, D Ye, KL Nathanson, CH June, EJ Wherry, NR Zhang, H Ishwaran, MD Hellmann, JD Wolchok, T Kambayashi, AJ Minn |
Cell | 2019 |
|
The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival
J Zhang, FP Caruso, JK Sa, S Justesen, DH Nam, P Sims, M Ceccarelli, A Lasorella, A Iavarone |
2019 | |
|
Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
I Nederlof, DD Bortoli, Y Bareche, B Nguyen, M de Maaker, GK Hooijer, L Buisseret, M Kok, M Smid, GG den Eynden, AB Brinkman, J Hudecek, J Koster, C Sotiriou, D Larsimont, JW Martens, MJ van de Vijver, HM Horlings, R Salgado, E Biganzoli, C Desmedt |
Breast Cancer Research | 2019 |
|
IL-27 confers a protumorigenic activity of regulatory T cells via CD39
YJ Park, H Ryu, G Choi, BS Kim, ES Hwang, HS Kim, Y Chung |
Proceedings of the National Academy of Sciences | 2019 |
|
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women
T OMeara, A Safonov, D Casadevall, T Qing, A Silber, B Killelea, C Hatzis, L Pusztai |
Breast Cancer Research and Treatment | 2019 |
|
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
TF Cloughesy, AY Mochizuki, JR Orpilla, W Hugo, AH Lee, TB Davidson, AC Wang, BM Ellingson, JA Rytlewski, CM Sanders, ES Kawaguchi, L Du, G Li, WH Yong, SC Gaffey, AL Cohen, IK Mellinghoff, EQ Lee, DA Reardon, BJ OBrien, NA Butowski, PL Nghiemphu, JL Clarke, IC Arrillaga-Romany, H Colman, TJ Kaley, JF de Groot, LM Liau, PY Wen, RM Prins |
Nature Medicine | 2019 |
|
A gene expression assay for simultaneous measurement of microsatellite instability and anti-tumor immune activity
P Danaher, S Warren, SF Ong, N Elliott, A Cesano, S Ferree |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors
JM Conroy, S Pabla, MK Nesline, ST Glenn, A Papanicolau-Sengos, B Burgher, J Andreas, V Giamo, Y Wang, FL Lenzo, W Bshara, M Khalil, GK Dy, KG Madden, K Shirai, K Dragnev, LJ Tafe, J Zhu, M Labriola, D Marin, SJ McCall, J Clarke, DJ George, T Zhang, M Zibelman, P Ghatalia, I Araujo-Fernandez, L de la Cruz-Merino, A Singavi, B George, AC MacKinnon, J Thompson, R Singh, R Jacob, D Kasuganti, N Shah, R Day, L Galluzzi, M Gardner, C Morrison |
Journal for ImmunoTherapy of Cancer | 2019 |
|
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
C Kaderbhaï, Z Tharin, F Ghiringhelli |
Cancers | 2019 |
|
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O Hamid, C Robert, A Daud, FS Hodi, WJ Hwu, R Kefford, JD Wolchok, P Hersey, R Joseph, JS Weber, R Dronca, TC Mitchell, A Patnaik, HM Zarour, AM Joshua, Q Zhao, E Jensen, S Ahsan, N Ibrahim, A Ribas |
Annals of Oncology | 2019 |
|
Response to Anti–PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis
DB Johnson, R Bao, KK Ancell, AB Daniels, D Wallace, JA Sosman, JJ Luke |
Journal of the National Comprehensive Cancer Network : JNCCN | 2019 |
|
Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors
S Rapisuwon, B Izar, C Batenchuk, A Avila, S Mei, P Sorger, JM Parks, SJ Cooper, D Wagner, JC Zeck, AJ Charabaty, MB Atkins |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Genomic correlates of response to immune checkpoint blockade
TE Keenan, KP Burke, EM Allen |
Nature Medicine | 2019 |
|
How patients with an intact immune system develop head and neck cancer
S Greene, P Patel, CT Allen |
Oral Oncology | 2019 |
|
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
JJ Luke, R Bao, RF Sweis, S Spranger, TF Gajewski |
Clinical cancer research | 2019 |
|
Combinations of immuno-checkpoint inhibitors predictive biomarkers only marginally improve their individual accuracy
M Pallocca, D Angeli, F Palombo, F Sperati, M Milella, F Goeman, FD Nicola, M Fanciulli, P Nisticò, C Quintarelli, G Ciliberto |
Journal of Translational Medicine | 2019 |
|
Characterization of the tumor immune micromilieu and its interference with outcome after concurrent chemoradiation in patients with oropharyngeal carcinomas
AK Hess, K Jöhrens, A Zakarneh, P Balermpas, JV Grün, C Rödel, W Weichert, M Hummel, U Keilholz, V Budach, I Tinhofer |
OncoImmunology | 2019 |
|
Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
D Bedognetti, M Ceccarelli, L Galluzzi, R Lu, K Palucka, J Samayoa, S Spranger, S Warren, KK Wong, E Ziv, D Chowell, LM Coussens, DD Carvalho, DG DeNardo, J Galon, HL Kaufman, T Kirchhoff, MT Lotze, JJ Luke, AJ Minn, K Politi, LD Shultz, R Simon, V Thórsson, JB Weidhaas, ML Ascierto, PA Ascierto, JM Barnes, V Barsan, PK Bommareddy, A Bot, SE Church, G Ciliberto, AD Maria, D Draganov, WS Ho, HM McGee, A Monette, JF Murphy, P Nisticò, W Park, M Patel, M Quigley, L Radvanyi, H Raftopoulos, NP Rudqvist, A Snyder, RF Sweis, S Valpione, LH Butterfield, ML Disis, BA Fox, A Cesano, FM Marincola |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Case report: reinitiating pembrolizumab treatment after small bowel perforation
TN Beck, AE Kudinov, E Dulaimi, Y Boumber |
BMC Cancer | 2019 |
|
Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology
K Peskov, I Azarov, L Chu, V Voronova, Y Kosinsky, G Helmlinger |
Frontiers in immunology | 2019 |
|
Association of BRCA1- and BRCA2-deficiency with mutation burden, expression of PD-L1/PD-1, immune infiltrates, and T cell-inflamed signature in breast cancer
WX Wen, CO Leong, P Fei |
PloS one | 2019 |
|
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers
S Trebeschi, SG Drago, NJ Birkbak, I Kurilova, AM Cǎlin, AD Pizzi, F Lalezari, DM Lambregts, MW Rohaan, C Parmar, EA Rozeman, KJ Hartemink, C Swanton, JB Haanen, CU Blank, EF Smit, RG Beets-Tan, HJ Aerts |
Annals of Oncology | 2019 |
|
Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti–PD-1 response in NSCLC
BL Bullock, AK Kimball, JM Poczobutt, AJ Neuwelt, HY Li, AM Johnson, JW Kwak, EK Kleczko, RE Kaspar, EK Wagner, K Hopp, EL Schenk, MC Weiser-Evans, ET Clambey, RA Nemenoff |
2019 | |
|
Immunotherapeutic effects of intratumoral nanoplexed poly I:C
MA Aznar, L Planelles, M Perez-Olivares, C Molina, S Garasa, I Etxeberría, G Perez, I Rodriguez, E Bolaños, P Lopez-Casas, ME Rodriguez-Ruiz, JL Perez-Gracia, I Marquez-Rodas, A Teijeira, M Quintero, I Melero |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
PK Bommareddy, A Zloza, SD Rabkin, HL Kaufman |
OncoImmunology | 2019 |
|
Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis
CT Allen, S Lee, SM Norberg, D Kovalovsky, H Ye, PE Clavijo, S Hu-Lieskovan, R Schlegel, J Schlom, J Strauss, JL Gulley, J Trepel, CS Hinrichs |
Journal for ImmunoTherapy of Cancer | 2019 |
|
irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial
JC Pignon, O Jegede, SA Shukla, DA Braun, CE Horak, M Wind-Rotolo, Y Ishii, PJ Catalano, J Grosha, A Flaifel, JS Novak, KM Mahoney, GJ Freeman, AH Sharpe, FS Hodi, RJ Motzer, TK Choueiri, CJ Wu, MB Atkins, DF McDermott, S Signoretti |
Clinical cancer research | 2019 |
|
Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma
AM Melo, AM O'Brien, JJ Phelan, SA Kennedy, NA Wood, N Veerapen, GS Besra, NE Clarke, EK Foley, A Ravi, F MacCarthy, D O'Toole, N Ravi, JV Reynolds, MJ Conroy, AE Hogan, J O'Sullivan, MR Dunne |
Frontiers in immunology | 2019 |
|
Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
DB Doroshow, MF Sanmamed, K Hastings, K Politi, DL Rimm, L Chen, I Melero, KA Schalper, RS Herbst |
Clinical cancer research | 2019 |
|
Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy
V Wu, H Yeerna, N Nohata, J Chiou, O Harismendy, F Raimondi, A Inoue, RB Russell, P Tamayo, JS Gutkind |
The Journal of biological chemistry | 2019 |
|
Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
AM DAlise, G Leoni, G Cotugno, F Troise, F Langone, I Fichera, MD Lucia, L Avalle, R Vitale, A Leuzzi, V Bignone, ED Matteo, FG Tucci, V Poli, A Lahm, MT Catanese, A Folgori, S Colloca, A Nicosia, E Scarselli |
Nature Communications | 2019 |
|
Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod
M Rozenblit, W Hendrickx, A Heguy, L Chiriboga, C Loomis, K Ray, F Darvishian, M Egeblad, S Demaria, FM Marincola, D Bedognetti, S Adams |
Scientific Reports | 2019 |
|
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data P du Rusquec, O de Calbiac, M Robert, M Campone, JS Frenel |
Cancer management and research | 2019 |
|
Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses
P Poudel, G Nyamundanda, Y Patil, MC Cheang, A Sadanandam |
npj Breast Cancer | 2019 |
|
Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies
O Butters, K Young, D Cunningham, I Chau, N Starling |
Frontiers in Oncology | 2019 |
|
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysis
S Lu, JE Stein, DL Rimm, DW Wang, JM Bell, DB Johnson, JA Sosman, KA Schalper, RA Anders, H Wang, C Hoyt, DM Pardoll, L Danilova, JM Taube |
JAMA Oncology | 2019 |
|
Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes
C Lu, JD Klement, ML Ibrahim, W Xiao, PS Redd, A Nayak-Kapoor, G Zhou, K Liu |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Analysis of the transcriptomic features of microsatellite instability subtype colon cancer
H Wang, X Wang, L Xu, J Zhang, H Cao |
BMC Cancer | 2019 |
|
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
EE Cohen, RB Bell, CB Bifulco, B Burtness, ML Gillison, KJ Harrington, QT Le, NY Lee, R Leidner, RL Lewis, L Licitra, H Mehanna, LK Mell, A Raben, AG Sikora, R Uppaluri, F Whitworth, DP Zandberg, RL Ferris |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
A Woolston, K Khan, G Spain, LJ Barber, B Griffiths, R Gonzalez-Exposito, L Hornsteiner, M Punta, Y Patil, A Newey, S Mansukhani, MN Davies, A Furness, F Sclafani, C Peckitt, M Jiménez, K Kouvelakis, R Ranftl, R Begum, I Rana, J Thomas, A Bryant, S Quezada, A Wotherspoon, N Khan, N Fotiadis, T Marafioti, T Powles, S Lise, F Calvo, S Guettler, K von Loga, S Rao, D Watkins, N Starling, I Chau, A Sadanandam, D Cunningham, M Gerlinger |
Cancer Cell | 2019 |
|
Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial
S Zhang, K Kohli, RG Black, L Yao, SM Spadinger, Q He, VG Pillarisetty, LD Cranmer, BA Tine, C Yee, RH Pierce, SR Riddell, RL Jones, SM Pollack |
Cancer immunology research | 2019 |
|
Phospho‑STAT1 expression as a potential biomarker for anti‑PD‑1/anti‑PD‑L1 immunotherapy for breast cancer
Y Nakayama, K Mimura, T Tamaki, K Shiraishi, LF Kua, V Koh, M Ohmori, A Kimura, S Inoue, H Okayama, Y Suzuki, T Nakazawa, D Ichikawa, K Kono |
International journal of oncology | 2019 |
|
Clinical Correlates of Response to Anti-PD-1–based Therapy in Patients With Metastatic Melanoma:
EJ Davis, MC Perez, N Ayoubi, S Zhao, F Ye, DY Wang, JA Sosman, RN Al-Rohil, Z Eroglu, DB Johnson |
Journal of immunotherapy (Hagerstown, Md. : 1997) | 2019 |
|
The immune subtypes and landscape of squamous cell carcinoma
B Li, Y Cui, DK Nambiar, JB Sunwoo, R Li |
Clinical cancer research | 2019 |
|
Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II–III Melanoma
RD Gartrell, DK Marks, EM Rizk, M Bogardus, CL Gérard, LW Barker, Y Fu, CL Esancy, Li, J Ji, S Rui, MS Ernstoff, B Taback, S Pabla, R Chang, SJ Lee, JJ Krolewski, C Morrison, BA Horst, YM Saenger |
Clinical cancer research | 2019 |
|
A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis
EE Manasanch, G Han, R Mathur, Y Qing, Z Zhang, H Lee, DM Weber, B Amini, Z Berkova, K Eterovic, S Zhang, J Zhang, X Song, X Mao, M Morgan, L Feng, V Baladandayuthapani, A Futreal, L Wang, SS Neelapu, RZ Orlowski |
Blood Advances | 2019 |
|
Molecular Basis of Tumor Heterogeneity in Endometrial Carcinosarcoma
Leskela, PM, RR, Cristobal, Biscuola, PB, Ong, Guia, Palacios |
Cancers | 2019 |
|
First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells
BR Minev, E Lander, JF Feller, M Berman, BM Greenwood, I Minev, AF Santidrian, D Nguyen, D Draganov, MO Killinc, A Vyalkova, S Kesari, E McClay, G Carabulea, FM Marincola, LH Butterfield, AA Szalay |
Journal of Translational Medicine | 2019 |
|
The Tumor Microenvironment in Colorectal Cancer Therapy
L Pedrosa, F Esposito, TM Thomson, J Maurel |
Cancers | 2019 |
|
Human Tumor-Infiltrating Dendritic Cells: From in Situ Visualization to High-Dimensional Analyses
Hubert, Gobbini, BV, Caux, VG |
Cancers | 2019 |
|
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
T Seremet, Y Jansen, S Planken, H Njimi, M Delaunoy, HE Housni, G Awada, JK Schwarze, M Keyaerts, H Everaert, D Lienard, VD Marmol, P Heimann, B Neyns |
Journal of Translational Medicine | 2019 |
|
Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer
PP Yu, O Eton, LP Garrison |
Journal for ImmunoTherapy of Cancer | 2019 |
|
High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling
MI Toki, CR Merritt, PF Wong, JW Smithy, HM Kluger, KN Syrigos, GT Ong, SE Warren, JM Beechem, DL Rimm |
Clinical cancer research | 2019 |
|
Clinical and immune profiling for cancer of unknown primary site
K Haratani, H Hayashi, T Takahama, Y Nakamura, S Tomida, T Yoshida, Y Chiba, T Sawada, K Sakai, Y Fujita, Y Togashi, J Tanizaki, H Kawakami, A Ito, K Nishio, K Nakagawa |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma
S Gupta, L McCann, YG Chan, EW Lai, W Wei, PF Wong, JW Smithy, J Weidler, B Rhees, M Bates, HM Kluger, DL Rimm |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
B Adamo, M Bellet, L Paré, T Pascual, M Vidal, JA Fidalgo, S Blanch, N Martinez, L Murillo, P Gómez-Pardo, A López-González, K Amillano, J Canes, P Galván, B González-Farré, X González, P Villagrasa, E Ciruelos, A Prat |
Breast Cancer Research | 2019 |
|
HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
J Wang, H Sun, Q Zeng, XJ Guo, H Wang, HH Liu, ZY Dong |
Scientific Reports | 2019 |
|
Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy
S Wang, LA Cowley, XS Liu |
Molecules (Basel, Switzerland) | 2019 |
|
The Highly Pure Neem Leaf Extract, SCNE, Inhibits Tumorigenesis in Oral Squamous Cell Carcinoma via Disruption of Pro-tumor Inflammatory Cytokines and Cell Signaling
J Morris, CB Gonzales, JJ Chapa, AB Cabang, C Fountzilas, M Patel, S Orozco, MJ Wargovich |
Frontiers in Oncology | 2019 |
|
New insights in predictive determinants of the tumor immune microenvironment for immune checkpoint inhibition: a never ending story?
M Eckstein, S Gupta |
Annals of translational medicine | 2019 |
|
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
S Arora, R Velichinskii, RW Lesh, U Ali, M Kubiak, P Bansal, H Borghaei, MJ Edelman, Y Boumber |
Advances in Therapy | 2019 |
|
Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas
D Verver, V Poirier-Colame, G Tomasic, K Cherif-Rebai, DJ Grunhagen, C Verhoef, S Suciu, C Robert, L Zitvogel, AM Eggermont |
OncoImmunology | 2019 |
|
Recent Advances Targeting CCR5 for Cancer and Its Role in Immuno-Oncology
X Jiao, O Nawab, T Patel, AV Kossenkov, N Halama, D Jaeger, RG Pestell |
Cancer research | 2019 |
|
STING pathway agonism as a cancer therapeutic
BA Flood, EF Higgs, S Li, JJ Luke, TF Gajewski |
Immunological Reviews | 2019 |
|
Expression of MHC class I, HLA-A and HLA-B identifies immune-activated breast tumors with favorable outcome
M del Mar Noblejas-López, C Nieto-Jiménez, SM García, J Pérez-Peña, M Nuncia-Cantarero, F Andrés-Pretel, EM Galán-Moya, E Amir, A Pandiella, B Győrffy, A Ocana |
OncoImmunology | 2019 |
|
Targeted and novel therapy in advanced gastric cancer
JH Selim, S Shaheen, WC Sheu, CT Hsueh |
Experimental Hematology and Oncology | 2019 |
|
Clinicopathologic Characteristics of Epstein–Barr Virus-Associated Gastric Cancer Over the Past Decade in Japan
Yanagi, Nishikawa, Shimokuri, Shuto, Takagi, Takagi, Kobayashi, Yamamoto, Miura, Yanai, Suehiro, Yamasaki, Yoshiyama, Sakaida |
Microorganisms | 2019 |
|
The tumor inflammation signature (TIS) is associated with anti-PD-1 treatment benefit in the CERTIM pan-cancer cohort
D Damotte, S Warren, J Arrondeau, P Boudou-Rouquette, A Mansuet-Lupo, J Biton, H Ouakrim, M Alifano, C Gervais, A Bellesoeur, N Kramkimel, C Tlemsani, B Burroni, A Duche, F Letourneur, H Si, R Halpin, T Creasy, R Herbst, X Ren, P Morel, A Cesano, F Goldwasser, K Leroy |
Journal of Translational Medicine | 2019 |
|
Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma
JA Trujillo, JJ Luke, Y Zha, JP Segal, LL Ritterhouse, S Spranger, K Matijevich, TF Gajewski |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Role of CXCR3 signaling in response to anti-PD-1 therapy
X Han, Y Wang, J Sun, T Tan, X Cai, P Lin, Y Tan, B Zheng, B Wang, J Wang, L Xu, Z Yu, Q Xu, X Wu, Y Gu |
EBioMedicine | 2019 |
|
Domatinostat favors the immunotherapy response by modulating the tumor immune microenvironment (TIME)
AC Bretz, U Parnitzke, K Kronthaler, T Dreker, R Bartz, F Hermann, A Ammendola, T Wulff, S Hamm |
Journal for ImmunoTherapy of Cancer | 2019 |
|
DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients’ survival, immune cell infiltrates, mutational load, and interferon γ signature
V Sailer, U Sailer, EG Bawden, R Zarbl, C Wiek, TJ Vogt, J Dietrich, S Loick, I Grünwald, M Toma, C Golletz, A Gerstner, G Kristiansen, F Bootz, K Scheckenbach, J Landsberg, D Dietrich |
EBioMedicine | 2019 |
|
Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches
AJ Franke, WP Skelton, JS Starr, H Parekh, JJ Lee, MJ Overman, C Allegra, TJ George |
JNCI Journal of the National Cancer Institute | 2019 |
|
Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer
YM Li, JM Yu, ZY Liu, HJ Yang, J Tang, ZN Chen |
International journal of molecular sciences | 2019 |
|
Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
S Wang, Z He, X Wang, H Li, XS Liu |
eLife | 2019 |
|
BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma
BW Labadie, P Liu, R Bao, M Crist, R Fernandes, L Ferreira, S Graupner, AS Poklepovic, I Duran, SM Vareki, AV Balar, JJ Luke |
Journal of Translational Medicine | 2019 |
|
Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1
TR McCaw, M Li, D Starenki, M Liu, SJ Cooper, RC Arend, A Forero, DJ Buchsbaum, TD Randall |
Cancer Immunology, Immunotherapy | 2019 |
|
Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy
M Friedrich, S Jasinski-Bergner, MF Lazaridou, K Subbarayan, C Massa, S Tretbar, A Mueller, D Handke, K Biehl, J Bukur, M Donia, O Mandelboim, B Seliger |
Cancer Immunology, Immunotherapy | 2019 |
|
IFN-γ: A cytokine at the right time, is in the right place
JD Burke, HA Young |
Seminars in Immunology | 2019 |
|
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
H Shen, ES Yang, M Conry, J Fiveash, C Contreras, JA Bonner, LZ Shi |
Genes & Diseases | 2019 |
|
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
D Tai, SP Choo, V Chew |
Cancers | 2019 |
|
Tissue Site and the Cancer Immunity Cycle
BL Horton, TB Fessenden, S Spranger |
Trends in Cancer | 2019 |
|
The Roles of CD38 and CD157 in the Solid Tumor Microenvironment and Cancer Immunotherapy
YJ Wo, AS Gan, X Lim, IS Tay, S Lim, JC Lim, JP Yeong |
Cells | 2019 |
|
The dynamics of the inflammatory response during BBN-induced bladder carcinogenesis in mice
M Degoricija, J Korac-Prlic, K Vilovic, T Ivanisevic, B Haupt, V Palada, M Petkovic, I Karaman, J Terzic |
Journal of Translational Medicine | 2019 |
|
Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms
AJ Neuwelt, AK Kimball, AM Johnson, BW Arnold, BL Bullock, RE Kaspar, EK Kleczko, JW Kwak, MH Wu, LE Heasley, RC Doebele, HY Li, RA Nemenoff, ET Clambey |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Biomarkers for immunotherapy for treatment of glioblastoma
JP Lynes, AK Nwankwo, HP Sur, VE Sanchez, KA Sarpong, OI Ariyo, GA Dominah, EK Nduom |
Journal for ImmunoTherapy of Cancer | 2019 |
|
A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
J Pérez-Pena, JT Fekete, R Páez, M Baliu-Piqué, JÁ García-Saenz, V García-Barberán, A Manzano, P Pérez-Segura, A Esparis-Ogando, A Pandiella, B Gyorffy, A Ocana |
Frontiers in immunology | 2019 |
|
Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10
C Bergamaschi, H Pandit, BA Nagy, D Stellas, SM Jensen, J Bear, M Cam, A Valentin, BA Fox, BK Felber, GN Pavlakis |
Journal for ImmunoTherapy of Cancer | 2019 |
|
APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma
DL Faden, F Ding, Y Lin, S Zhai, F Kuo, TA Chan, LG Morris, RL Ferris |
Oral Oncology | 2019 |
|
Master protocols in immuno-oncology: do novel drugs deserve novel designs?
L Mazzarella, S Morganti, A Marra, D Trapani, G Tini, P Pelicci, G Curigliano |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G 4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
X Sheng, X Yan, Z Chi, L Si, C Cui, B Tang, S Li, L Mao, B Lian, X Wang, X Bai, L Zhou, Y Kong, J Dai, K Wang, X Tang, H Zhou, H Wu, H Feng, S Yao, KT Flaherty, J Guo |
Journal of Clinical Oncology | 2019 |
|
Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence
M Harel, R Ortenberg, SK Varanasi, KC Mangalhara, M Mardamshina, E Markovits, EN Baruch, V Tripple, M Arama-Chayoth, E Greenberg, A Shenoy, R Ayasun, N Knafo, S Xu, L Anafi, G Yanovich-Arad, GD Barnabas, S Ashkenazi, MJ Besser, J Schachter, M Bosenberg, GS Shadel, I Barshack, SM Kaech, G Markel, T Geiger |
Cell | 2019 |
|
Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade
JC Osorio, KC Arbour, DT Le, JN Durham, AJ Plodkowski, DF Halpenny, MS Ginsberg, P Sawan, JG Crompton, HA Yu, A Namakydoust, BY Nabet, JE Chaft, GJ Riely, H Rizvi, LA Diaz, MD Hellmann |
Journal of Clinical Oncology | 2019 |
|
Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer
H Cardenas, G Jiang, JT Pepin, JB Parker, S Condello, KP Nephew, H Nakshatri, D Chakravarti, Y Liu, D Matei |
npj Precision Oncology | 2019 |
|
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
D Liu, B Schilling, D Liu, A Sucker, E Livingstone, L Jerby-Arnon, L Zimmer, R Gutzmer, I Satzger, C Loquai, S Grabbe, N Vokes, CA Margolis, J Conway, MX He, H Elmarakeby, F Dietlein, D Miao, A Tracy, H Gogas, SM Goldinger, J Utikal, CU Blank, R Rauschenberg, D von Bubnoff, A Krackhardt, B Weide, S Haferkamp, F Kiecker, B Izar, L Garraway, A Regev, K Flaherty, A Paschen, EM Allen, D Schadendorf |
Nature Medicine | 2019 |
|
Considering adjuvant therapy for stage II melanoma
AS Poklepovic, JJ Luke |
Cancer | 2019 |
|
Intranasal Neuropeptide Y Blunts Lipopolysaccharide-Evoked Sickness Behavior but Not the Immune Response in Mice
G Zenz, A Farzi, EE Fröhlich, F Reichmann, P Holzer |
Neurotherapeutics | 2019 |
|
PAK4 inhibition improves PD-1 blockade immunotherapy
G Abril-Rodriguez, DY Torrejon, W Liu, JM Zaretsky, TS Nowicki, J Tsoi, C Puig-Saus, I Baselga-Carretero, E Medina, MJ Quist, AJ Garcia, W Senapedis, E Baloglu, A Kalbasi, G Cheung-Lau, B Berent-Maoz, B Comin-Anduix, S Hu-Lieskovan, CY Wang, CS Grasso, A Ribas |
2019 | |
|
An innate-like Vδ1 + γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer
Y Wu, F Kyle-Cezar, RT Woolf, C Naceur-Lombardelli, J Owen, D Biswas, A Lorenc, P Vantourout, P Gazinska, A Grigoriadis, A Tutt, A Hayday |
Science Translational Medicine | 2019 |
|
LAG3 ( LAG-3 , CD223 ) DNA methylation correlates with LAG3 expression by tumor and immune cells, immune cell infiltration, and overall survival in clear cell renal cell carcinoma
N Klümper, DJ Ralser, EG Bawden, J Landsberg, R Zarbl, G Kristiansen, M Toma, M Ritter, M Hölzel, J Ellinger, D Dietrich |
Journal for ImmunoTherapy of Cancer | 2019 |
|
Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade.
Casadevall D, Li X, Powles RL, Wali VB, Buza N, Pelekanou V, Dhawan A, Foldi J, Szekely B, Lopez-Giraldez F, Hatzis C, Pusztai L |
JCO Precision Oncology | 2019 |
|
Neoantigen-directed immune escape in lung cancer evolution.
Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, Joshi K, Henry JY, Ghorani E, Wilson GA, Birkbak NJ, Jamal-Hanjani M, Veeriah S, Szallasi Z, Loi S, Hellmann MD, Feber A, Chain B, Herrero J, Quezada SA, Demeulemeester J, Van Loo P, Beck S, McGranahan N, Swanton C |
Nature | 2019 |
|
Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
Di Blasi D, Boldanova T, Mori L, Terracciano L, Heim MH, De Libero G |
Cellular and Molecular Gastroenterology and Hepatology | 2019 |
|
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
Khodadoust MS, Rook AH, Porcu P, Foss F, Moskowitz AJ, Shustov A, Shanbhag S, Sokol L, Fling SP, Ramchurren N, Pierce R, Davis A, Shine R, Li S, Fong S, Kim J, Yang Y, Blumenschein WM, Yearley JH, Das B, Patidar R, Datta V, Cantu E, McCutcheon JN, Karlovich C, Williams PM, Subrahmanyam PB, Maecker HT, Horwitz SM, Sharon E, Kohrt HE, Cheever MA, Kim YH |
Journal of Clinical Oncology | 2019 |
|
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.
Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, Castro MAA, Fontugne J, Eriksson P, Mo Q, Kardos J, Zlotta A, Hartmann A, Dinney CP, Bellmunt J, Powles T, Malats N, Chan KS, Kim WY, McConkey DJ, Black PC, Dyrskjøt L, Höglund M, Lerner SP, Real FX, Radvanyi F |
European Urology | 2019 |
|
Integrated genomic profiling expands clinical options for patients with cancer.
Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R, Bobe AM, Bush S, Chang AL, Hoskinson DC, Khan AA, Kudalkar E, Leibowitz BD, Lozachmeur A, Michuda J, Parsons J, Perera JF, Salahudeen A, Shah KP, Taxter T, Zhu W, White KP |
Nature Biotechnology | 2019 |
|
Exceptionally rapid response to pembrolizumab in a SMARCA4-deficient thoracic sarcoma overexpressing PD-L1: A case report.
Takada K, Sugita S, Murase K, Kikuchi T, Oomori G, Ito R, Hayasaka N, Miyanishi K, Iyama S, Ikeda H, Kobune M, Emori M, Kato J, Hasegawa T |
Thoracic Cancer | 2019 |
|
Methods to assess anticancer immune responses in orthotopic bladder carcinomas.
Sweis RF |
Methods in enzymology | 2019 |
|
Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
Tu MM, Ng TL, De Jong FC, Zuiverloon TC, Fazzari FG, Theodorescu D |
2019 | |
|
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM |
2019 | |
|
Folic acid supplementation regulates key immunity-associated genes and pathways during the periparturient period in dairy cows.
Khan MZ, Zhang Z, Liu L, Wang D, Mi S, Liu X, Liu G, Guo G, Li X, Wang Y, Yu Y |
Asian-Australasian Journal of Animal Sciences | 2019 |
|
[Predictive biomarkers in oncologic uropathology].
Reis H, Szarvas T, Grünwald V |
Der Pathologe | 2019 |
|
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma.
Ribas A, Lawrence D, Atkinson V, Agarwal S, Miller WH Jr, Carlino MS, Fisher R, Long GV, Hodi FS, Tsoi J, Grasso CS, Mookerjee B, Zhao Q, Ghori R, Moreno BH, Ibrahim N, Hamid O |
Nature Medicine | 2019 |
|
Determinants of immunological evasion and immunocheckpoint inhibition response in non-small cell lung cancer: the genetic front.
Saigi M, Alburquerque-Bejar JJ, Sanchez-Cespedes M |
Oncogene | 2019 |
|
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
Kelly RJ, Lee J, Bang YJ, Almhanna K, Blum-Murphy M, Catenacci DVT, Chung HC, Wainberg ZA, Gibson MK, Lee KW, Bendell JC, Denlinger CS, Chee CE, Omori T, Leidner R, Lenz HJ, Chao Y, Rebelatto MC, Brohawn PZ, He P, McDevitt J, Sheth S, Englert JM, Ku GY |
Clinical cancer research | 2019 |
|
Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
Thompson JC, Hwang WT, Davis C, Deshpande C, Jeffries S, Rajpurohit Y, Krishna V, Smirnov D, Verona R, Lorenzi MV, Langer CJ, Albelda SM |
Lung cancer (Amsterdam, Netherlands) | 2019 |
|
Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
Bodor JN, Boumber Y, Borghaei H |
Cancer | 2019 |
|
A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T, Mimura K, Okayama H, Nakayama Y, Saito K, Yamada L, Endo E, Sakamoto W, Fujita S, Endo H, Saito M, Momma T, Saze Z, Ohki S, Kono K |
Oncology Letters | 2019 |
|
Robust immunoscore model to predict the response to anti-PD1 therapy in melanoma.
Nie RC, Yuan SQ, Wang Y, Chen YB, Cai YY, Chen S, Li SM, Zhou J, Chen GM, Luo TQ, Zhou ZW, Li YF |
Aging | 2019 |
|
The host protecting the tumor from the host – targeting PD‑L1 expressed by host cells
David H. Munn |
Journal of Clinical Investigation | 2018 |
|
CD4+ T-Cells Induce Rejection of Urothelial Tumors after Immune Checkpoint Blockade
Yuji Sato, Jennifer Bolzenius, Abdallad Eteleeb, Xinming Su, Christopher Maher, Jennifer Sehn, Vivek Arora |
JCI Insight | 2018 |
|
Dinaciclib Induces Immunogenic Cell Death and Enhances Anti-PD-1-mediated Tumor Suppression
Dewan Hossain, Sarah Javaid, Mingmei Cai, Chunsheng Zhang, Anandi Sawant, Marlene Hinton, Manjiri Sathe, Jeff Grein, Wendy Blumenschein, Elaine Pinheiro, Alissa Chackerian |
Journal of Clinical Investigation | 2018 |
|
PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy
Dmitriy Zamarin, Jacob Ricca, Svetlana Sadekova, Anton Oseledchyk, Ying Yu, Wendy Blumenschein, Jerelyn Wong, Mathieu Gigoux, Taha Merghoub, Jedd Wolchok |
Journal of Clinical Investigation | 2018 |
|
β-catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas
Jeremie Nsengimana, Jon Laye, Anastasia Filia, Sally O'Shea, Sathya Muralidhar, Joanna Pozniak, Alastair Droop, May Chan, Christy Walker, Louise Parkinson, Joanne Gascoyne, Tracy Mell, Minttu Polso, Rosalyn Jewell, Juliette Randerson-Moor, Graham Cook, D Tim Bishop, Julia Newton-Bishop |
Journal of Clinical Investigation | 2018 |
|
DNA repair defects and implications for immunotherapy
Katherine Bever, Dung Le |
Journal of Clinical Investigation | 2018 |
|
RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade
S Ganesh, X Shui, KP Craig, J Park, W Wang, BD Brown, MT Abrams |
Molecular Therapy | 2018 |
|
Batf3 + DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy
J Liu, EA Rozeman, JS ODonnell, S Allen, L Fanchi, MJ Smyth, CU Blank, MW Teng |
OncoImmunology | 2018 |
|
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma
M Oliva, A Spreafico, M Taberna, L Alemany, B Coburn, R Mesia, LL Siu |
Annals of Oncology | 2018 |
|
New Development of Biomarkers for Gastrointestinal Cancers: From Neoplastic Cells to Tumor Microenvironment
J Zhang, S Quadri, C Wolfgang, L Zheng |
Biomedicines | 2018 |
|
Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
P Danaher, S Warren, R Lu, J Samayoa, A Sullivan, I Pekker, B Wallden, FM Marincola, A Cesano |
Journal for ImmunoTherapy of Cancer | 2018 |
|
Cancer immunoediting and resistance to T cell-based immunotherapy
J ODonnell, M Teng, M Smyth |
Nature Reviews Clinical Oncology | 2018 |
|
Alteration of Tumor Metabolism by CD4+ T Cells Leads to TNF-α-Dependent Intensification of Oxidative Stress and Tumor Cell Death
T Habtetsion, ZC Ding, W Pi, T Li, C Lu, T Chen, , H Spartz, K Liu, Z Hao, N Mivechi, Y Huo, BR Blazar, DH Munn, G Zhou |
Cell Metabolism | 2018 |
|
PD-L1 expression in medulloblastoma: an evaluation by subgroup
AM Martin, CJ Nirschl, MJ Polanczyk, WR Bell, TR Nirschl, S Harris-Bookman, J Phallen, J Hicks, D Martinez, A Ogurtsova, H Xu, LM Sullivan, AK Meeker, EH Raabe, KJ Cohen, CG Eberhart, PC Burger, M Santi, JM Taube, DM Pardoll, CG Drake, M Lim |
Oncotarget | 2018 |
|
T Cell–Inflamed versus Non-T Cell–Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
JA Trujillo, RF Sweis, R Bao, JJ Luke |
Cancer immunology research | 2018 |
|
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies
R Zappasodi, T Merghoub, JD Wolchok |
Cancer Cell | 2018 |
|
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
F Castro, AP Cardoso, RM Gonçalves, K Serre, MJ Oliveira |
Frontiers in immunology | 2018 |
|
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial
R Pinyol, R Montal, L Bassaganyas, D Sia, T Takayama, GY Chau, V Mazzaferro, S Roayaie, HC Lee, N Kokudo, Z Zhang, S Torrecilla, A Moeini, L Rodriguez-Carunchio, E Gane, C Verslype, AE Croitoru, U Cillo, M de la Mata, L Lupo, S Strasser, JW Park, J Camps, M Solé, SN Thung, A Villanueva, C Pena, G Meinhardt, J Bruix, JM Llovet |
Gut | 2018 |
|
Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer
JJ Lee, E Chu |
Clinical Colorectal Cancer | 2018 |
|
Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy
DH Munn, MD Sharma, TS Johnson |
Cancer research | 2018 |
|
Epstein-Barr Virus-Positive Cancers Show Altered B-Cell Clonality
SR Selitsky, D Marron, LE Mose, JS Parker, DP Dittmer, DM Knipe |
mSystems | 2018 |
|
IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin
RS Lane, J Femel, AP Breazeale, CP Loo, G Thibault, A Kaempf, M Mori, T Tsujikawa, YH Chang, AW Lund |
Journal of Experimental Medicine | 2018 |
|
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration
A Oweida, MK Hararah, A Phan, D Binder, S Bhatia, S Lennon, S Bukkapatnam, BV Court, N Uyanga, L Darragh, HM Kim, D Raben, AC Tan, L Heasley, E Clambey, R Nemenoff, SD Karam |
Clinical cancer research | 2018 |
|
Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms
SY Lim, H Rizos |
Mammalian Genome | 2018 |
|
Regulation and Function of the PD-L1 Checkpoint
C Sun, R Mezzadra, TN Schumacher |
Immunity | 2018 |
|
Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges
J Duan, Y Wang, S Jiao |
Cancer Medicine | 2018 |
|
Inhibitors of the PD-1 Pathway in Tumor Therapy
MW LaFleur, Y Muroyama, CG Drake, AH Sharpe |
Journal of immunology (Baltimore, Md. : 1950) | 2018 |
|
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
X Li, W Song, C Shao, Y Shi, W Han |
Cellular and Molecular Immunology | 2018 |
|
Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer
O Belzile, X Huang, J Gong, J Carlson, A Schroit, R Brekken, B Freimark |
ImmunoTargets and Therapy | 2018 |
|
Role of noninvasive molecular imaging in determining response
AE Marciscano, DL Thorek |
Advances in Radiation Oncology | 2018 |
|
Immune oncology, immune responsiveness and the theory of everything
T Turan, D Kannan, M Patel, JM Barnes, SG Tanlimco, R Lu, K Halliwill, S Kongpachith, DE Kline, W Hendrickx, A Cesano, LH Butterfield, HL Kaufman, TJ Hudson, D Bedognetti, F Marincola, J Samayoa |
Journal for ImmunoTherapy of Cancer | 2018 |
|
Immune Gene Expression Profile in Hepatocellular Carcinoma and Surrounding Tissue Predicts Time to Tumor Recurrence
C Carone, A Olivani, RD Valle, R Manuguerra, EM Silini, T Trenti, G Missale, E Cariani |
Liver Cancer | 2018 |
|
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
P Jiang, S Gu, D Pan, J Fu, A Sahu, X Hu, Z Li, N Traugh, X Bu, B Li, J Liu, GJ Freeman, MA Brown, KW Wucherpfennig, XS Liu |
Nature Medicine | 2018 |
|
Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis
BW Labadie, R Bao, JJ Luke |
Clinical cancer research | 2018 |
|
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)
PA Ascierto, I Puzanov, SS Agarwala, C Bifulco, G Botti, C Caracò, G Ciliberto, MA Davies, R Dummer, S Ferrone, TF Gajewski, C Garbe, JJ Luke, FM Marincola, G Masucci, JM Mehnert, N Mozzillo, G Palmieri, MA Postow, SP Schoenberger, E Wang, M Thurin |
Journal of Translational Medicine | 2018 |
|
Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy
E García-Martínez, M Smith, A Buqué, F Aranda, FA de la Peña, A Ivars, MS Cánovas, MA Conesa, J Fucikova, R Spisek, L Zitvogel, G Kroemer, L Galluzzi |
OncoImmunology | 2018 |
|
MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation
PK Bommareddy, S Aspromonte, A Zloza, SD Rabkin, HL Kaufman |
Science Translational Medicine | 2018 |
|
Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy
H Läubli, S Dirnhofer, A Zippelius |
Virchows Archiv | 2018 |
|
Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond
J Zhu, AJ Armstrong, TW Friedlander, W Kim, SK Pal, DJ George, T Zhang |
Journal for ImmunoTherapy of Cancer | 2018 |
|
Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer
V Stühler, JM Maas, J Bochem, IA da Costa, T Todenhöfer, A Stenzl, J Bedke |
World Journal of Urology | 2018 |
|
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
M Sade-Feldman, K Yizhak, SL Bjorgaard, JP Ray, CG de Boer, RW Jenkins, DJ Lieb, JH Chen, DT Frederick, M Barzily-Rokni, SS Freeman, A Reuben, PJ Hoover, AC Villani, E Ivanova, A Portell, PH Lizotte, AR Aref, JP Eliane, MR Hammond, H Vitzthum, SM Blackmon, B Li, V Gopalakrishnan, SM Reddy, ZA Cooper, CP Paweletz, DA Barbie, A Stemmer-Rachamimov, KT Flaherty, JA Wargo, GM Boland, RJ Sullivan, G Getz, N Hacohen |
Cell | 2018 |
|
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma
DB Johnson, JM Bordeaux, JY Kim, CA Vaupel, DL Rimm, TH Ho, RW Joseph, AI Daud, RM Conry, EM Gaughan, LF Hernandez-Aya, A Dimou, P Funchain, JW Smithy, JS Witte, SB McKee, J Ko, J Wrangle, B Dabbas, S Tangri, J Lameh, JM Hall, J Markowitz, JM Balko, NK Dakappagari |
Clinical cancer research | 2018 |
|
Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer
JA Bridge, JC Lee, A Daud, JW Wells, JA Bluestone |
Frontiers in Medicine | 2018 |
|
The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy
A Anichini, E Tassi, G Grazia, R Mortarini |
Cancer Immunology, Immunotherapy | 2018 |
|
Common Mechanisms Linking Chronic Obstructive Pulmonary Disease and Lung Cancer
AM Houghton |
Annals of the American Thoracic Society | 2018 |
|
T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin
C Bauer, AA Pari, V Umansky, J Utikal, P Boukamp, HG Augustin, S Goerdt, C Géraud, M Felcht |
Cancer Immunology, Immunotherapy | 2018 |
|
Impact of oncogenic pathways on evasion of antitumour immune responses
S Spranger, TF Gajewski |
Nature Reviews Cancer | 2018 |
|
Dissecting the Immune Landscape of Acute Myeloid Leukemia
J Davidson-Moncada, E Viboch, S Church, S Warren, S Rutella |
Biomedicines | 2018 |
|
Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
JD Duarte, S Parakh, MC Andrews, K Woods, A Pasam, C Tutuka, S Ostrouska, JM Blackburn, A Behren, J Cebon |
Frontiers in immunology | 2018 |
|
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0
RJ Sullivan, MB Atkins, JM Kirkwood, SS Agarwala, JI Clark, MS Ernstoff, L Fecher, TF Gajewski, B Gastman, DH Lawson, J Lutzky, DF McDermott, KA Margolin, JM Mehnert, AC Pavlick, JM Richards, KM Rubin, W Sharfman, S Silverstein, CL Slingluff, VK Sondak, AA Tarhini, JA Thompson, WJ Urba, RL White, ED Whitman, FS Hodi, HL Kaufman |
Journal for ImmunoTherapy of Cancer | 2018 |
|
An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors
T Wang, R Lu, P Kapur, BS Jaiswal, R Hannan, Z Zhang, I Pedrosa, JJ Luke, H Zhang, LD Goldstein, Q Yousuf, YF Gu, T McKenzie, A Joyce, MS Kim, X Wang, D Luo, O Onabolu, C Stevens, Z Xie, M Chen, A Filatenkov, J Torrealba, X Luo, W Guo, J He, E Stawiski, Z Modrusan, S Durinck, S Seshagiri, J Brugarolas |
Cancer Discovery | 2018 |
|
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
N Auslander, G Zhang, JS Lee, DT Frederick, B Miao, T Moll, T Tian, Z Wei, S Madan, RJ Sullivan, G Boland, K Flaherty, M Herlyn, E Ruppin |
Nature Medicine | 2018 |
|
Checkpoint Inhibitors, Palliative Care, or Hospice
MP Davis, R Panikkar |
Current Oncology Reports | 2018 |
|
PD-1/PD-L1 Axis in Lung Cancer:
FC Santini, MD Hellmann |
The Cancer Journal | 2018 |
|
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients
N Karachaliou, M Gonzalez-Cao, G Crespo, A Drozdowskyj, E Aldeguer, A Gimenez-Capitan, C Teixido, MA Molina-Vila, S Viteri, MD Gil, SM Algarra, E Perez-Ruiz, I Marquez-Rodas, D Rodriguez-Abreu, R Blanco, T Puertolas, MA Royo, R Rosell |
Therapeutic advances in medical oncology | 2018 |
|
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
L Derosa, MD Hellmann, M Spaziano, D Halpenny, M Fidelle, H Rizvi, N Long, AJ Plodkowski, KC Arbour, JE Chaft, JA Rouche, L Zitvogel, G Zalcman, L Albiges, B Escudier, B Routy |
Annals of Oncology | 2018 |
|
Combination Immunotherapy in Non-small Cell Lung Cancer
ME Marmarelis, C Aggarwal |
Current Oncology Reports | 2018 |
|
PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy:
TR Cottrell, JM Taube |
The Cancer Journal | 2018 |
|
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
V Matson, J Fessler, R Bao, T Chongsuwat, Y Zha, ML Alegre, JJ Luke, TF Gajewski |
Science | 2018 |
|
Molekulare Prädiktoren in der Immunonkologie
W Weichert |
Der Pathologe | 2018 |
|
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
G Giaccone, C Kim, J Thompson, C McGuire, B Kallakury, JJ Chahine, M Manning, R Mogg, WM Blumenschein, MT Tan, DS Subramaniam, SV Liu, IM Kaplan, JN McCutcheon |
The Lancet Oncology | 2018 |
|
The Transcriptomic Landscape of Gastric Cancer: Insights into Epstein-Barr Virus Infected and Microsatellite Unstable Tumors
I Gullo, J Carvalho, D Martins, D Lemos, A Monteiro, M Ferreira, K Das, P Tan, C Oliveira, F Carneiro, P Oliveira |
International journal of molecular sciences | 2018 |
|
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment
JM Clarke, DJ George, S Lisi, AK Salama |
Targeted Oncology | 2018 |
|
Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma
D Saha, RL Martuza, SD Rabkin |
Immunotherapy | 2018 |
|
Tobacco Smoking-Associated Alterations in the Immune Microenvironment of Squamous Cell Carcinomas
A Desrichard, F Kuo, D Chowell, KW Lee, N Riaz, RJ Wong, TA Chan, LG Morris |
JNCI Journal of the National Cancer Institute | 2018 |
|
Immunoadjuvant therapy in sepsis: novel strategies for immunosuppressive sepsis coming down the pike
E Watanabe, LK Thampy, RS Hotchkiss |
Acute Medicine & Surgery | 2018 |
|
Emerging Biomarkers in Cutaneous Melanoma
A Eisenstein, EC Gonzalez, R Raghunathan, , M Wu, EO McLean, J McGee, B Ryu, RM Alani |
Molecular diagnosis & therapy | 2018 |
|
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
R Mehra, TY Seiwert, S Gupta, J Weiss, I Gluck, JP Eder, B Burtness, M Tahara, B Keam, H Kang, K Muro, R Geva, HC Chung, CC Lin, D Aurora-Garg, A Ray, K Pathiraja, J Cheng, LQ Chow, R Haddad |
British Journal of Cancer | 2018 |
|
Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
P Ghatalia, M Zibelman, DM Geynisman, E Plimack |
Therapeutic advances in medical oncology | 2018 |
|
The molecular basis of JAK/STAT inhibition by SOCS1
NP Liau, A Laktyushin, IS Lucet, JM Murphy, S Yao, E Whitlock, K Callaghan, NA Nicola, NJ Kershaw, JJ Babon |
Nature Communications | 2018 |
|
Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, A Plodkowski, N Long, JL Sauter, N Rekhtman, T Hollmann, KA Schalper, JF Gainor, R Shen, A Ni, KC Arbour, T Merghoub, J Wolchok, A Snyder, JE Chaft, MG Kris, CM Rudin, ND Socci, MF Berger, BS Taylor, A Zehir, DB Solit, ME Arcila, M Ladanyi, GJ Riely, N Schultz, MD Hellmann |
Journal of Clinical Oncology | 2018 |
|
Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade
P Jelinic, J Ricca, EV Oudenhove, N Olvera, T Merghoub, DA Levine, D Zamarin |
JNCI Journal of the National Cancer Institute | 2018 |
|
Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer
DE Meyers, PM Bryan, S Banerji, DG Morris |
Current Oncology | 2018 |
|
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
D Gopalakrishnan, VS Koshkin, MC Ornstein, A Papatsoris, P Grivas |
Therapeutics and Clinical Risk Management | 2018 |
|
Are we ready for routine precision medicine? Highlights from the Milan Summit on Precision Medicine, Milan, Italy, 8–9 February 2018
L Mazzarella |
ecancermedicalscience | 2018 |
|
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial
CS Fuchs, T Doi, RW Jang, K Muro, T Satoh, M Machado, W Sun, SI Jalal, MA Shah, JP Metges, M Garrido, T Golan, M Mandala, ZA Wainberg, DV Catenacci, A Ohtsu, K Shitara, R Geva, J Bleeker, AH Ko, G Ku, P Philip, PC Enzinger, YJ Bang, D Levitan, J Wang, M Rosales, RP Dalal, HH Yoon |
JAMA Oncology | 2018 |
|
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy
JD Fumet, C Richard, F Ledys, Q Klopfenstein, P Joubert, B Routy, C Truntzer, A Gagné, MA Hamel, CF Guimaraes, B Coudert, L Arnould, L Favier, A Lagrange, S Ladoire, P Saintigny, S Ortiz-Cuaran, M Perol, P Foucher, P Hofman, M Ilie, S Chevrier, R Boidot, V Derangere, F Ghiringhelli |
British Journal of Cancer | 2018 |
|
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
R Cristescu, R Mogg, M Ayers, A Albright, E Murphy, J Yearley, X Sher, XQ Liu, H Lu, M Nebozhyn, C Zhang, JK Lunceford, A Joe, J Cheng, AL Webber, N Ibrahim, ER Plimack, PA Ott, TY Seiwert, A Ribas, TK McClanahan, JE Tomassini, A Loboda, D Kaufman |
Science | 2018 |
|
Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28–29 2017, Doha, Qatar)
S Deola, BS Guerrouahen, H Sidahmed, A Al-Mohannadi, M Elnaggar, R Elsadig, EM Abdelalim, G Petrovski, M Gadina, A Thrasher, WS Wels, SP Hunger, E Wang, FM Marincola, C Maccalli, C Cugno |
Journal of Translational Medicine | 2018 |
|
RNA Oncoimmune Phenotyping of HPV-Positive p16-Positive Oropharyngeal Squamous Cell Carcinomas by Nodal Status
WH Stepp, D Farquhar, S Sheth, A Mazul, M Mamdani, TG Hackman, DN Hayes, JP Zevallos |
JAMA OTOLARYNGOL | 2018 |
|
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
D Davar, H Wang, JM Chauvin, O Pagliano, JJ Fourcade, M Ka, C Menna, A Rose, C Sander, AA Borhani, A Karunamurthy, AA Tarhini, HA Tawbi, Q Zhao, BH Moreno, S Ebbinghaus, N Ibrahim, JM Kirkwood, HM Zarour |
Journal of Clinical Oncology | 2018 |
|
TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure
A Chakravarthy, L Khan, NP Bensler, P Bose, DD Carvalho |
Nature Communications | 2018 |
|
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
L Jerby-Arnon, P Shah, MS Cuoco, C Rodman, MJ Su, JC Melms, R Leeson, A Kanodia, S Mei, JR Lin, S Wang, B Rabasha, D Liu, G Zhang, C Margolais, O Ashenberg, PA Ott, EI Buchbinder, R Haq, FS Hodi, GM Boland, RJ Sullivan, DT Frederick, B Miao, T Moll, KT Flaherty, M Herlyn, RW Jenkins, R Thummalapalli, MS Kowalczyk, I Cañadas, B Schilling, AN Cartwright, AM Luoma, S Malu, P Hwu, C Bernatchez, MA Forget, DA Barbie, AK Shalek, I Tirosh, PK Sorger, K Wucherpfennig, EM Allen, D Schadendorf, BE Johnson, A Rotem, O Rozenblatt-Rosen, LA Garraway, CH Yoon, B Izar, A Regev |
Cell | 2018 |
|
IFNL4 -ΔG Allele Is Associated with an Interferon Signature in Tumors and Survival of African-American Men with Prostate Cancer
W Tang, TA Wallace, M Yi, C Magi-Galluzzi, TH Dorsey, OO Onabajo, A Obajemu, SV Jordan, CA Loffredo, RM Stephens, RH Silverman, GR Stark, EA Klein, L Prokunina-Olsson, S Ambs |
Clinical cancer research | 2018 |
|
Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model
T Kimura, Y Kato, Y Ozawa, K Kodama, J Ito, K Ichikawa, K Yamada, Y Hori, K Tabata, K Takase, J Matsui, Y Funahashi, K Nomoto |
Cancer Science | 2018 |
|
Schweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunity
KM Kokolus, JS Haley, EJ Koubek, R Gowda, SS Dinavahi, A Sharma, DF Claxton, KF Helm, JJ Drabick, GP Robertson, JD Neighbors, RJ Hohl, TD Schell |
OncoImmunology | 2018 |
|
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
CS Garris, SP Arlauckas, RH Kohler, MP Trefny, S Garren, C Piot, C Engblom, C Pfirschke, M Siwicki, J Gungabeesoon, GJ Freeman, SE Warren, SF Ong, E Browning, CG Twitty, RH Pierce, MH Le, AP Algazi, AI Daud, SI Pai, A Zippelius, R Weissleder, MJ Pittet |
Immunity | 2018 |
|
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
JL Boland, Q Zhou, M Martin, MK Callahan, J Konner, RE O'Cearbhaill, CF Friedman, W Tew, V Makker, RN Grisham, ML Hensley, N Zecca, AE Iasonos, A Snyder, DM Hyman, P Sabbatini, C Aghajanian, KA Cadoo, D Zamarin |
Gynecologic Oncology | 2018 |
|
Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
JR Conway, E Kofman, SS Mo, H Elmarakeby, EV Allen |
Genome Medicine | 2018 |
|
Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers
DM Hyams, RW Cook, AC Buzaid |
Journal of Surgical Oncology | 2018 |
|
A Gene Expression Classifier from Whole Blood Distinguishes Benign from Malignant Lung Nodules Detected by Low-Dose CT
AV Kossenkov, R Qureshi, NB Dawany, J Wickramasinghe, Q Liu, RS Majumdar, C Chang, S Widura, T Kumar, WH Horng, E Konnisto, G Criner, JC Tsay, H Pass, S Yendamuri, A Vachani, T Bauer, B Nam, WN Rom, MK Showe, LC Showe |
Cancer research | 2018 |
|
DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers
J Ruiz-Bañobre, A Goel |
Gastroenterology | 2018 |
|
Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses
NJ Gurule, LE Heasley |
2018 | |
|
[Lichenoid drug reactions].
Merk HF, Vanstreels L, Megahed M |
2018 | |
|
Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic.
Cesano A, Warren S |
Biomedicines | 2018 |
|
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Tripathi A, Plimack ER |
Current Urology Reports | 2018 |
|
Review of diagnostic, prognostic, and predictive biomarkers in melanoma.
Ankeny JS, Labadie B, Luke J, Hsueh E, Messina J, Zager JS |
Clinical & Experimental Metastasis | 2018 |
|
EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions.
Sasaki S, Nishikawa J, Sakai K, Iizasa H, Yoshiyama H, Yanagihara M, Shuto T, Shimokuri K, Kanda T, Suehiro Y, Yamasaki T, Sakaida I |
2018 | |
|
Biomarkers for immune therapy in melanoma
Johnson DB, Chon J, Johnson MR, Balko JM |
Seminars in Cutaneous Medicine and Surgery | 2018 |
|
Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells
U Testa, G Castelli, E Pelosi |
Medical Sciences | 2017 |
|
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
M Łuksza, N Riaz, V Makarov, VP Balachandran, MD Hellmann, A Solovyov, NA Rizvi, T Merghoub, AJ Levine, TA Chan, JD Wolchok, BD Greenbaum |
Nature | 2017 |
|
The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy
FM Marincola, D Bedognetti, J Roelands, J Decock, E Wang, W Hendrickx |
Emerging Topics in Life Sciences | 2017 |
|
Cancer immune resistance: can theories converge?
FM Marincola, R Lu, T Turan, J Samayoa, FM Marincola |
Emerging Topics in Life Sciences | 2017 |
|
Biomarkers for immunotherapy in bladder cancer: a moving target
DH Aggen, CG Drake |
Journal for ImmunoTherapy of Cancer | 2017 |
|
TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
X Cao, Y Zhao, J Wang, B Dai, E Gentile, J Lin, X Pu, L Ji, S Wu, I Meraz, M Majidi, JA Roth |
Oncotarget | 2017 |
|
The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion
M Mojic, K Takeda, Y Hayakawa |
International journal of molecular sciences | 2017 |
|
Precision Medicine in Pediatric Neurooncology: A Review
AY Mochizuki, IM Frost, MB Mastrodimos, AS Plant, AC Wang, TB Moore, RM Prins, PS Weiss, SJ Jonas |
ACS Chemical Neuroscience | 2017 |
|
Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
S Shah, K Wood, B Labadie, B Won, R Brisson, T Karrison, T Hensing, M Kozloff, R Bao, JD Patel, JJ Luke |
Oncotarget | 2017 |
|
The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy
Z Hu |
Journal of Thoracic Disease | 2017 |
|
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd |
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology | 2009 |
|
DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers.
Pineda JMB, Bradley RK |
||
|
Functional status analysis of RNH1 in bladder cancer for predicting immunotherapy response.
Chen S, Ran J, Fan Z, Liu M, Wu L, Li Q, Peng J, Hu Z |
Scientific Reports | 2023 |
|
Molecular classification of urothelial bladder carcinoma.
Schwarzova L, Varchulova Novakova Z, Danisovic L, Ziaran S |
Molecular Biology Reports | 2023 |
|
T-cell derived extracellular vesicles prime macrophages for improved STING based cancer immunotherapy.
Hansen AS, Jensen LS, Gammelgaard KR, Ryttersgaard KG, Krapp C, Just J, Jønsson KL, Jensen PB, Boesen T, Johansen M, Etzerodt A, Deleuran BW, Jakobsen MR |
Journal of Extracellular Vesicles | 2023 |
|
ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression
Lavy M, Gauttier V, Dumont A, Chocteau F, Deshayes S, Fresquet J, Dehame V, Girault I, Trilleaud C, Neyton S, Mary C, Juin P, Poirier N, Barillé-Nion S, Blanquart C |
Frontiers in immunology | 2023 |
|
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2-negative breast cancer.
Bertucci F, De Nonneville A, Finetti P, Mamessier E |
2023 | |
|
Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors
Castiglioni A, Yang Y, Williams K, Gogineni A, Lane RS, Wang AW, Shyer JA, Zhang Z, Mittman S, Gutierrez A, Astarita JL, Thai M, Hung J, Yang YA, Pourmohamad T, Himmels P, De Simone M, Elstrott J, Capietto AH, Cubas R, Modrusan Z, Sandoval W, Ziai J, Gould SE, Fu W, Wang Y, Koerber JT, Sanjabi S, Mellman I, Turley SJ, Müller S |
Nature Communications | 2023 |
|
Biomarkers for Immune Checkpoint Inhibitors in Renal Cell Carcinoma
Martin SD, Bhuiyan I, Soleimani M, Wang G |
Journal of Clinical Medicine | 2023 |
|
Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers.
Romero JM, Titmuss E, Wang Y, Vafiadis J, Pacis A, Jang GH, Zhang A, Golesworthy B, Lenko T, Williamson LM, Grünwald B, O'Kane GM, Jones SJM, Marra MA, Wilson JM, Gallinger S, Laskin J, Zogopoulos G |
npj Precision Oncology | 2023 |
|
Cancer-Associated Fibroblasts Influence Survival in Pleural Mesothelioma: Digital Gene Expression Analysis and Supervised Machine Learning Model
Borchert S, Mathilakathu A, Nath A, Wessolly M, Mairinger E, Kreidt D, Steinborn J, Walter RF, Christoph DC, Kollmeier J, Wohlschlaeger J, Mairinger T, Brcic L, Mairinger FD |
International journal of molecular sciences | 2023 |
|
Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial
Ellingsen EB, O'Day S, Mezheyeuski A, Gromadka A, Clancy T, Kristedja TS, Milhem M, Zakharia Y |
Clinical cancer research | 2023 |
|
Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma.
Kaya NA, Tai D, Lim X, Lim JQ, Lau MC, Goh D, Phua CZJ, Wee FYT, Joseph CR, Lim JCT, Neo ZW, Ye J, Cheung L, Lee J, Loke KSH, Gogna A, Yao F, Lee MY, Shuen TWH, Toh HC, Hilmer A, Chan YS, Lim TK, Tam WL, Choo SP, Yeong J, Zhai W |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation?
Yiong CS, Lin TP, Lim VY, Toh TB, Yang VS |
Biomarker Research | 2023 |
|
Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
Lee J, Kim EH |
Frontiers in Oncology | 2023 |
|
Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
Schina A, Sztupinszki Z, Marie Svane I, Szallasi Z, Jönsson G, Donia M |
Journal for ImmunoTherapy of Cancer | 2023 |
|
A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8(+) T cells.
Chang YW, Hsiao HW, Chen JP, Tzeng SF, Tsai CH, Wu CY, Hsieh HH, Carmona SJ, Andreatta M, Di Conza G, Su MT, Koni PA, Ho PC, Chen HK, Yang MH |
Cell reports. Medicine | 2023 |
|
Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer.
O'Brien S, Butticello M, Thompson C, Wilson B, Wyce A, Mahajan V, Kruger R, Mohammad H, Fedoriw A |
BMC Cancer | 2023 |
|
Th1 cytokines in pediatric acute lymphoblastic leukemia.
Schober S, Rottenberger JM, Hilz J, Schmid E, Ebinger M, Feuchtinger T, Handgretinger R, Lang P, Queudeville M |
Cancer Immunology, Immunotherapy | 2023 |
|
Pan-cancer analysis of IFN-γ with possible immunotherapeutic significance: a verification of single-cell sequencing and bulk omics research.
Wei X, Ruan H, Zhang Y, Qin T, Zhang Y, Qin Y, Li W |
Frontiers in immunology | 2023 |
|
Eph receptor B6 shapes a cold immune microenvironment, inhibiting anti-cancer immunity and immunotherapy response in bladder cancer
Jia X, Zhang D, Zhou C, Yan Z, Jiang Z, Xie L, Jiang J |
Frontiers in Oncology | 2023 |
|
SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
An F, Zhang W, Guo Y, Shi F, Kong Y, Tang L, Han C, Wang Q |
Aging | 2023 |
|
Activin A-Mediated Polarization of Cancer-Associated Fibroblasts and Macrophages Confers Resistance to Checkpoint Immunotherapy in Skin Cancer.
Pich-Bavastro C, Yerly L, Di Domizio J, Tissot-Renaud S, Gilliet M, Kuonen F |
Clinical cancer research | 2023 |
|
A Comprehensive Benchmark of Transcriptomic Biomarkers for Immune Checkpoint Blockades.
Kang H, Zhu X, Cui Y, Xiong Z, Zong W, Bao Y, Jia P |
Cancers | 2023 |
|
Four types of adenine-related RNA modification writers -mediated molecular subtypes contribute to predicting clinical outcomes and treatment options in bladder cancer.
Zhang Y, Chen Y, Wen W |
Frontiers in immunology | 2023 |
|
Molecular biomarkers for facilitating genome‑directed precision medicine in gynecological cancer (Review)
Minaguchi T, Shikama A, Akiyama A, Satoh T |
Oncology Letters | 2023 |
|
Construction of an aging-related risk signature in high-grade serous ovarian cancer for predicting survival outcome and immunogenicity
Liu S, Liu Y, Ma J, Lv R, Wang F |
Medicine | 2023 |
|
S100A5 Attenuates Efficiency of Anti‐PD‐L1/PD‐1 Immunotherapy by Inhibiting CD8+ T Cell‐Mediated Anti‐Cancer Immunity in Bladder Carcinoma
Li H, Chen J, Li Z, Chen M, Ou Z, Mo M, Wang R, Tong S, Liu P, Cai Z, Zhang C, Liu Z, Deng D, Liu J, Cheng C, Hu J, Zu X |
Advanced Science | 2023 |
|
Spatial transformation of multi-omics data unlocks novel insights into cancer biology
Sokač M, Kjær A, Dyrskjøt L, Haibe-Kains B, JWL Aerts H, Birkbak NJ |
eLife | 2023 |
|
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma.
Cho BC, Penkov K, Bondarenko I, Kurochkin A, Pikiel J, Ahn HK, Korożan ME, Osipov M, Odintsova S, Braiteh F, Ribas A, Grilley-Olson JE, Lugowska I, Bonato V, Damore MA, Yang W, Jacobs IA, Bowers M, Li M, Johnson ML |
ESMO Open | 2023 |
|
Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial.
Ferreiro-Pantín M, Anido-Herranz U, Betancor YZ, Cebey-López V, León-Mateos L, García-González J, García-Acuña SM, Fernández-Díaz N, Tubio JMC, López-López R, Ruiz-Bañobre J |
ESMO Open | 2023 |
|
Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours.
Nabbi A, Beck P, Delaidelli A, Oldridge DA, Sudhaman S, Zhu K, Yang SYC, Mulder DT, Bruce JP, Paulson JN, Raman P, Zhu Y, Resnick AC, Sorensen PH, Sill M, Brabetz S, Lambo S, Malkin D, Johann PD, Kool M, Jones DTW, Pfister SM, Jäger N, Pugh TJ |
Genome Medicine | 2023 |
|
Translation of AI into oncology clinical practice.
El Naqa I, Karolak A, Luo Y, Folio L, Tarhini AA, Rollison D, Parodi K |
Oncogene | 2023 |
|
scGEM: Unveiling the Nested Tree-Structured Gene Co-Expressing Modules in Single Cell Transcriptome Data.
Zhang H, Lu X, Lu B, Chen L |
Cancers | 2023 |
|
Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy.
Li A, Luo L, Du W, Yu Z, He L, Fu S, Wang Y, Zhou Y, Yang C, Yang Y, Fang W, Zhang L, Hong S |
npj Precision Oncology | 2023 |
|
Construction and validation of a signature for T cell-positive regulators related to tumor microenvironment and heterogeneity of gastric cancer
Guo Y, Zhang Y, Cen K, Dai Y, Mai Y, Hong K |
Frontiers in immunology | 2023 |
|
Evolutionary patterns and research frontiers in neoadjuvant immunotherapy: a bibliometric analysis
Jiang S, Liu Y, Zheng H, Zhang L, Zhao H, Sang X, Xu Y, Lu X |
International journal of surgery (London, England) | 2023 |
|
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Alessi JV, Elkrief A, Ricciuti B, Wang X, Cortellini A, Vaz VR, Lamberti G, Frias RL, Venkatraman D, Fulgenzi CA, Pecci F, Recondo G, Federico AD, Barrichello A, Park H, Nishino M, Hambelton GM, Egger JV, Ladanyi M, Digumarthy S, Johnson BE, Christiani DC, Lin X, Gainor JF, Lin JJ, Pinato DJ, Schoenfeld AJ, Awad MM |
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023 |
|
Identification of angiogenesis‐related genes signature for predicting survival and its regulatory network in glioblastoma
Wan Z, Zuo X, Wang S, Zhou L, Wen X, Yao Y, Song J, Gu J, Wang Z, Liu R, Luo C |
Cancer Medicine | 2023 |
|
Guanylate‐binding proteins signature predicts favorable prognosis, immune‐hot microenvironment, and immunotherapy response in hepatocellular carcinoma
Ning Y, Fang S, Fang J, Lin K, Nie H, Xiong P, Qiu P, Zhao Q, Wang H, Wang F |
Cancer Medicine | 2023 |
|
Predicting lung adenocarcinoma prognosis, immune escape, and pharmacomic profile from arginine and proline-related genes
Wang Z, Zhang J, Shi S, Ma H, Wang D, Zuo C, Zhang Q, Lian C |
Scientific Reports | 2023 |
|
Trackable Intratumor Microdosing and Spatial Profiling Provide Early Insights into Activity of Investigational Agents in the Intact Tumor Microenvironment
Derry JM, Burns C, Frazier JP, Beirne E, Grenley M, DuFort CC, Killingbeck E, Leon M, Williams C, Gregory M, Houlton J, Clayburgh D, Swiecicki P, Huszar D, Berger A, Klinghoffer RA |
Clinical cancer research | 2023 |
|
Potential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review
Muscolino P, Granata B, Omero F, De Pasquale C, Campana S, Calabrò A, D\u2019Anna F, Drommi F, Pezzino G, Cavaliere R, Ferlazzo G, Silvestris N, Speranza D |
Frontiers in Oncology | 2023 |
|
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors.
Simpson RC, Shanahan ER, Scolyer RA, Long GV |
Nature reviews. Clinical oncology | 2023 |
|
Low level of ARID1A contributes to adaptive immune resistance and sensitizes triple-negative breast cancer to immune checkpoint inhibitors.
Chen XY, Li B, Wang Y, Jin J, Yang Y, Huang LH, Yang MD, Zhang J, Wang BY, Shao ZM, Ni T, Huang SL, Hu XC, Tao ZH |
2023 | |
|
CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity
Salehi-Rad R, Lim RJ, Du Y, Tran LM, Li R, Ong SL, Ling Huang Z, Dumitras C, Zhang T, Park SJ, Crosson W, Kahangi B, Abascal J, Seet C, Oh M, Shabihkhani M, Paul M, Krysan K, Lisberg AE, Garon EB, Liu B, Dubinett SM |
Journal for ImmunoTherapy of Cancer | 2023 |
|
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
Noviello TM, Di Giacomo AM, Caruso FP, Covre A, Mortarini R, Scala G, Costa MC, Coral S, Fridman WH, Sautès-Fridman C, Brich S, Pruneri G, Simonetti E, Lofiego MF, Tufano R, Bedognetti D, Anichini A, Maio M, Ceccarelli M |
Nature Communications | 2023 |
|
Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
Mogenet A, Finetti P, Denicolai E, Greillier L, Boudou-Rouquette P, Goldwasser F, Lumet G, Ceccarelli M, Birnbaum D, Bedognetti D, Mamessier E, Barlesi F, Bertucci F, Tomasini P |
Journal of Translational Medicine | 2023 |
|
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer.
Shirasawa M, Yoshida T, Shiraishi K, Goto N, Yagishita S, Imabayashi T, Matsumoto Y, Masuda K, Shinno Y, Okuma Y, Goto Y, Horinouchi H, Yotsukura M, Yoshida Y, Nakagawa K, Naoki K, Tsuchida T, Hamamoto R, Yamamoto N, Motoi N, Kohno T, Watanabe SI, Ohe Y |
British Journal of Cancer | 2023 |
|
Multi-omics analysis reveals the association between elevated KIF18B expression and unfavorable prognosis, immune evasion, and regulatory T cell activation in nasopharyngeal carcinoma
Tang S, Wu Z, Chen L, She L, Zuo W, Luo W, Zhang Y, Liang S, Liu G, He B, He J, Zhang N |
Frontiers in immunology | 2023 |
|
GBP5 Expression Predicted Prognosis of Immune Checkpoint Inhibitors in Small Cell Lung Cancer and Correlated with Tumor Immune Microenvironment
Tong Q, Li D, Yin Y, Cheng L, Ouyang S |
Journal of inflammation research | 2023 |
|
A clinically useful and biologically informative genomic classifier for papillary thyroid cancer
Craig S, Stretch C, Farshidfar F, Sheka D, Alabi N, Siddiqui A, Kopciuk K, Park YJ, Khalil M, Khan F, Harvey A, Bathe OF |
Frontiers in Endocrinology | 2023 |
|
GPX8 regulates pan-apoptosis in gliomas to promote microglial migration and mediate immunotherapy responses
Chen Z, Zheng D, Lin Z, Zhang C, Wei C, Deng X, Yan P, Zheng C, Lan C, Qin C, Wei X, Qin D, Wu Y, Peng J, Miao C, Lu L, Xia Y, Luo Q |
Frontiers in immunology | 2023 |
|
Machine learning-based integration develops a metabolism-derived consensus model for improving immunotherapy in pancreatic cancer
Guo Y, Wang R, Shi J, Yang C, Ma P, Min J, Zhao T, Hua L, Song Y, Li J, Su H |
Journal for ImmunoTherapy of Cancer | 2023 |
|
MTHFD2 promotes PD‐L1 expression via activation of the JAK/STAT signalling pathway in bladder cancer
Li L, Zhang Y, Hu W, Zou F, Ning J, Rao T, Ruan Y, Yu W, Cheng F |
Journal of Cellular and Molecular Medicine | 2023 |
|
The role of IFN-γ-signalling in response to immune checkpoint blockade therapy
Wong CW, Huang YY, Hurlstone A |
Essays in Biochemistry | 2023 |
|
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
Hermida-Prado F, Xie Y, Sherman S, Nagy Z, Russo D, Akhshi T, Chu Z, Feit A, Campisi M, Chen M, Nardone A, Guarducci C, Lim K, Font-Tello A, Lee I, García-Pedrero J, Cañadas I, Agudo J, Huang Y, Sella T, Jin Q, Tayob N, Mittendorf EA, Tolaney SM, Qiu X, Long H, Symmans WF, Lin JR, Santagata S, Bedrosian I, Yardley DA, Mayer IA, Richardson ET, Oliveira G, Wu CJ, Schuster EF, Dowsett M, Welm AL, Barbie D, Metzger O, Jeselsohn R |
Cancer research | 2023 |
|
Immune perturbation network identifies an EMT subtype with chromosomal instability and tumor immune-desert microenvironment
Xu H, Fu X, Liu B, Weng S, Guo C, Quan L, Liu L, Wang L, Xing Z, Cheng Q, Luo P, Chen K, Liu Z, Han X |
iScience | 2023 |
|
PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models
Wong CW, Evangelou C, Sefton KN, Leshem R, Zhang W, Gopalan V, Chattrakarn S, Fernandez Carro ML, Uzuner E, Mole H, Wilcock DJ, Smith MP, Sergiou K, Telfer BA, Isaac DT, Liu C, Perl NR, Marie K, Lorigan P, Williams KJ, Rao PE, Nagaraju RT, Niepel M, Hurlstone AF |
Nature Communications | 2023 |
|
Subsets of interferon signaling predict response to immune checkpoint blockade in melanoma patients
Horowitch B, Lee DY, Ding M, Martinez-Morilla S, Aung TN, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm DL, Ishizuka J |
Clinical cancer research | 2023 |
|
Gene Expressions and High Lymphocyte Count May Predict Durable Clinical Benefits in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
Mouritzen MT, Ladekarl M, Hager H, Mattesen TB, Lippert JB, Frank MS, Nøhr AK, Egendal IB, Carus A |
Cancers | 2023 |
|
Genomic and transcriptomic profiling indicates the prognosis significance of mutational signature for TMB-high subtype in Chinese patients with gastric cancer.
Cheng Y, Bu D, Zhang Q, Sun R, Lyle S, Zhao G, Dong L, Li H, Zhao Y, Yu J, Hao X |
Journal of Advanced Research | 2022 |
|
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit
Hayes DF, Herbst RS, Myles JL, Topalian SL, Yohe SL, Aronson N, Bellizzi AM, Basu Roy U, Bradshaw G, Edwards RH, El-Gabry EA, Elvin J, Gajewski TF, McShane LM, Oberley M, Philip R, Rimm DL, Rosenbaum JN, Rubin EH, Schlager L, Sherwood SW, Stewart M, Taube JM, Thurin M, Vasalos P, Laser J |
JCO Precision Oncology | 2022 |
|
TIGIT: a novel immunotherapy target moving from bench to bedside
Solomon BL, Garrido-Laguna I |
Cancer Immunology, Immunotherapy | 2018 |
|
Increased Tim-3(+) T cells in PBMCs during nivolumab therapy correlate with responses and prognosis of advanced esophageal squamous cell carcinoma patients.
Kato R, Yamasaki M, Urakawa S, Nishida K, Makino T, Morimoto-Okazawa A, Kawashima A, Iwahori K, Suzuki S, Ueda R, Mori M, Satoh T, Doki Y, Wada H |
Cancer Immunology, Immunotherapy | 2018 |
|
Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
Pistillo MP, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R, Banelli B, Ferrero F, Spano L, Tanda E, Ferrucci PF, Martinoli C, Cocorocchio E, Guida M, Tommasi S, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Quaglino P, Fava P, Osella-Abate S, Ascierto PA, Capone M, Simeone E, Romani M, Spagnolo F, Queirolo P |
Cancer Immunology, Immunotherapy | 2018 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)